<?xml version="1.0" encoding="UTF-8" standalone="no" ?><xml><records><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>8</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Naeser,P.</style></author><author><style face="normal" font="default"> Blomquist,E.</style></author><author><style face="normal" font="default"> Montelius,A.</style></author><author><style face="normal" font="default"> Thoumas,K.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophthalmology, Uppsala University, Sweden</style></auth-address><titles><title><style face="normal" font="default">Proton irradiation of malignant uveal melanoma. A five year follow-up of patients treated in Uppsala, Sweden</style></title><secondary-title><style face="normal" font="default">Upsala Journal of Medical Sciences.103.(3):203.-11,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Upsala Journal of Medical Sciences.103.(3):203.-11,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glaucoma</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Optic Nerve</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword></keywords><dates><year Day="0" Month="0" Year="1998">1998</year></dates><pub-location><style face="normal" font="default">SWEDEN</style></pub-location><isbn><style face="normal" font="default">0300-9734</style></isbn><abstract><style face="normal" font="default">Twenty patients with malignant uveal melanoma were treated at the The Svedbergh cyclotron in Uppsala from 1989 to 1991. Each tumour received a total dose of 54.6 Gy in four equal fractions on four following days. After treatment the melanoma in all eyes showed decrease in size combined with irradiation retinopathy. In eight patients the treatment was successful after five years. Nine eyes had to be enucleated, two due to recurrence and seven due to neovascular glaucoma. Three patients died, two from metastases and one from heart disease. In all patients the visual acuity was dependent on the distance between the irradiation field and the macula or optic nerve. Each patient suffered from transient post irradiation skin erythema and permanent loss of eyelashes and eyebrows when these were included in the irradiation field. The development of secondary glaucoma was positively correlated with tumour volume, but not to the age or sex of the patients. Histological examination of all the enucleated eyes revealed residual viable tumour without obvious radiation damage: mitotic figures were not identified. MRI examination, performed before and after treatment, demonstrated a marked shift in water binding properties after irradiation. The final visual acuity was dependent on the location of the tumour</style></abstract><notes><style face="normal" font="default">10052109wrg, 0332203IM0 (Protons)Journal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>38</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kent,D.</style></author><author><style face="normal" font="default"> Noonan,C.P.</style></author><author><style face="normal" font="default"> Damato,B.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">St Paul's Eye Unit, Royal Liverpool University Hospital, UK. dkent@liv.ac.uk</style></auth-address><titles><title><style face="normal" font="default">Management of Irish patients with intraocular melanoma referred to Liverpool, England</style></title><secondary-title><style face="normal" font="default">Acta Ophthalmologica Scandinavica.76.(5):584.-8.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Acta Ophthalmologica Scandinavica.76.(5):584.-8.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Brachytherapy</style></keyword><keyword><style face="normal" font="default"> Combined Modality Therapy</style></keyword><keyword><style face="normal" font="default"> England</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eye Enucleation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Ireland</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Melanoma/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Referral and Consultation</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Vision</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword></keywords><dates><year Day="0" Month="10" Year="1998">1998/10</year></dates><pub-location><style face="normal" font="default">DENMARK</style></pub-location><isbn><style face="normal" font="default">1395-3907</style></isbn><abstract><style face="normal" font="default">PURPOSE: This study reviews the results of patients referred from Ireland for treatment of an intraocular melanoma at the Ocular Oncology Service at St Paul's Eye Unit, Liverpool. PATIENTS AND METHODS: There were 57 patients with a median age of 55 years. Management included plaque radiotherapy (14), proton beam radiotherapy (17), local resection (10), endoresection (6), and enucleation (10). Fifty-two tumours involved the choroid. The tumours had a mean diameter of 11.4 mm and a mean thickness of 5.2 mm. RESULTS: The follow-up period had a median of 267 days. Retention of the eye was achieved in all 47 cases who underwent conservative management. Ninety percent of patients retained a vision of counting fingers, with an acuity of 6/12 or better in 50%. CONCLUSION: This group of patients gives an indication of the results that can be expected when uveal melanoma is managed by a variety of conservative techniques in a specialised ocular oncology service</style></abstract><notes><style face="normal" font="default">9826044cc4, 9507578IM0 (Protons)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>45</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Slater,J.D.</style></author><author><style face="normal" font="default"> Yonemoto,L.T.</style></author><author><style face="normal" font="default"> Rossi,C.J.,Jr.</style></author><author><style face="normal" font="default"> Reyes-Molyneux,N.J.</style></author><author><style face="normal" font="default"> Bush,D.A.</style></author><author><style face="normal" font="default"> Antoine,J.E.</style></author><author><style face="normal" font="default"> Loredo,L.N.</style></author><author><style face="normal" font="default"> Schulte,R.W.</style></author><author><style face="normal" font="default"> Teichman,S.L.</style></author><author><style face="normal" font="default"> Slater,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Medicine, Loma Linda University Medical Center, CA 92354, USA. jdslater@dominion.llumc.edu</style></auth-address><titles><title><style face="normal" font="default">Conformal proton therapy for prostate carcinoma</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.42.(2):299.-304.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.42.(2):299.-304.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Neoplasm Staging</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons</style></keyword><keyword><style face="normal" font="default"> Photons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Prostate</style></keyword><keyword><style face="normal" font="default"> Prostate-Specific Antigen</style></keyword><keyword><style face="normal" font="default"> Prostate-Specific Antigen/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Conformal</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treatment Failure</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="1" Month="9" Year="1998">1998/9/1</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">BACKGROUND: The role and optimum dose of radiation to eradicate prostate cancer continues to be evaluated. Protons offer an opportunity to increase the radiation dose to the prostate while minimizing treatment toxicity. METHODS: Six hundred forty-three patients with localized prostate cancer were treated with protons, with or without photons. Treatments were planned with a 3D planning system; patients received 74-75 CGE (Cobalt Gray Equivalent) at 1.8-2.0 CGE per fraction. Patients were evaluated for response to therapy and treatment-related toxicity. RESULTS: The overall clinical disease-free survival rate was 89% at 5 years. When post-treatment prostate-specific antigen (PSA) was used as an endpoint for disease control, the 4.5-year disease-free survival rate was 100% for patients with an initial PSA of &lt; 4.0 ng/ml, and 89%, 72%, and 53% for patients with initial PSA levels of 4.1-10.0, 10.1-20.0, and > 20.0, respectively. Patients in whom the post-treatment PSA nadir was below 0.5 ng/ml did significantly better than those whose nadir values were between 0.51-1.0 or > 1.0 ng/ml: the corresponding 5-year disease-free survival rates were 91%, 79%, and 40%, respectively. Minimal radiation proctitis was seen in 21% of patients; toxicity of greater severity was seen in less than 1%. CONCLUSION: Proton therapy to 74-75 CGE produced minimal treatment-related toxicity and excellent PSA normalization and disease-free survival in patients with low initial PSA levels. A prospective randomized dose-escalation trial is now underway to help define the optimum dose of radiation for patients with early stage prostate cancer</style></abstract><notes><style face="normal" font="default">9788407g97, 7603616IM0 (Protons)EC 3-4-21-77 (Prostate-Specific Antigen)Clinical TrialJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>69</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ravozzoni,L.</style></author><author><style face="normal" font="default"> Mosci,C.</style></author><author><style face="normal" font="default"> Polizzi,A.</style></author><author><style face="normal" font="default"> Schenome,M.</style></author><author><style face="normal" font="default"> Soldati,M.R.</style></author><author><style face="normal" font="default"> Buono,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">University Eye Clinic of Genova, Italy</style></auth-address><titles><title><style face="normal" font="default">Ultrasonographic follow-up of patients with choroidal melanoma following conservative treatment</style></title><secondary-title><style face="normal" font="default">Ophthalmologica.212.Suppl 1:77.-8.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ophthalmologica.212.Suppl 1:77.-8.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Brachytherapy</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="1998">1998</year></dates><pub-location><style face="normal" font="default">SWITZERLAND</style></pub-location><isbn><style face="normal" font="default">0030-3755</style></isbn><abstract><style face="normal" font="default">The authors assessed the regression of choroidal tumors, following irradiation treatment, by means of B scan sonography (Sonomed B 3000). Thirty-two patients were studied, 12 of whom underwent brachytherapy with 106Ru plaques and 20 of whom were treated with accelerated protons. After a follow-up period of 12 months, the following was observed: reduction of the thickness of the tumor (significantly greater in the tumors which underwent brachytherapy) and morphological and structural changes which consisted in a thinning of the tumor and an increased reflectivity</style></abstract><notes><style face="normal" font="default">9730759oig, 0054655IMComparative StudyJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>72</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Romani,A.</style></author><author><style face="normal" font="default"> Baldeschi,L.</style></author><author><style face="normal" font="default"> Genovesi-Ebert,F.</style></author><author><style face="normal" font="default"> Gremigni,E.</style></author><author><style face="normal" font="default"> Ragone,M.C.</style></author><author><style face="normal" font="default"> Rizzo,S.</style></author><author><style face="normal" font="default"> Nardi,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Section of Ophthalmology, Neurosciences Department of Pisa University, Italy</style></auth-address><titles><title><style face="normal" font="default">Ultrasonographic and angiographic follow-up of primary choroidal malignant melanoma after proton beam irradiation therapy</style></title><secondary-title><style face="normal" font="default">Ophthalmologica.212.Suppl 1:47.-9,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ophthalmologica.212.Suppl 1:47.-9,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Coloring Agents/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Fluorescein Angiography</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Fundus Oculi</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Image Enhancement</style></keyword><keyword><style face="normal" font="default"> Indocyanine Green/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mitosis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Ultrasonography</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Video Recording</style></keyword></keywords><dates><year Day="0" Month="0" Year="1998">1998</year></dates><pub-location><style face="normal" font="default">SWITZERLAND</style></pub-location><isbn><style face="normal" font="default">0030-3755</style></isbn><abstract><style face="normal" font="default">The aim of this study is to evaluate the reliability of the ultrasonographic and angiographic follow-up of primary choroidal malignant melanoma (PCMM) after proton beam irradiation therapy in a series of 14 patients. All patients underwent standardized A and B scan ultrasonography, fluorescein and indocyanine green videoangiography (FV, ICGV) before and after treatment with proton beam irradiation. The follow-up was carried out at 1, 3, 5, 8 months and then every 6 months. The mean follow-up was 26 months (range 6-46 months). The thickness of the tumors was demonstrated to be decreased and the internal reflectivity to be enhanced in 12 out of 14 cases from 8 months after treatment till the end of the follow-up period. In 2 eyes which were enucleated 5 months after treatment, histopathology confirmed that medium-low internal reflectivity corresponded to several areas of high cellularity and cellular mitosis. FV and ICGV were impossible because of opacities of dioptric media in 2 cases. From 8 months after treatment till the end of the follow-up period, in all the examined patients, FV demonstrated large hypofluorescent zones of the lesions which represented the destruction of the vascular tree of the tumor. From 8 months after treatment till the end of the follow-up period, ICGV demonstrated hypofluorescence of the lesions in 8 cases; mild hyperfluorescence and zones of colorant staining were present in late angiograms in 2 cases. The results of our study seem to confirm the reliability of standardized A and B scan ultrasonography in the follow-up of PCMM treated with proton beam irradiation; if ultrasonography is used together with FV and ICGV, the reliability of this combination is surely higher</style></abstract><notes><style face="normal" font="default">9730750oig, 0054655IM0 (Coloring Agents)0 (Protons)3599-32-4 (Indocyanine Green)Comparative StudyJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>119</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Satoh,H.</style></author><author><style face="normal" font="default"> Okumura,T.</style></author><author><style face="normal" font="default"> Yamashita,Y.T.</style></author><author><style face="normal" font="default"> Akine,Y.</style></author><author><style face="normal" font="default"> Hazegawa,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Proton irradiation for non-small cell lung cancer</style></title><secondary-title><style face="normal" font="default">Archives of Internal Medicine.158.(12):1379.-80.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Archives of Internal Medicine.158.(12):1379.-80.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Pulmonary Ventilation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="22" Month="6" Year="1998">1998/6/22</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0003-9926</style></isbn><notes><style face="normal" font="default">96458360372440, 7fsAIM, IM0 (Protons)LetterEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>142</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Santoni,R.</style></author><author><style face="normal" font="default"> Liebsch,N.</style></author><author><style face="normal" font="default"> Finkelstein,D.M.</style></author><author><style face="normal" font="default"> Hug,E.</style></author><author><style face="normal" font="default"> Hanssens,P.</style></author><author><style face="normal" font="default"> Goitein,M.</style></author><author><style face="normal" font="default"> Smith,A.R.</style></author><author><style face="normal" font="default"> O'Farrell,D.</style></author><author><style face="normal" font="default"> Efird,J.T.</style></author><author><style face="normal" font="default"> Fullerton,B.</style></author><author><style face="normal" font="default"> Munzenrider,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, Massachusetts General Hospital, Boston 02114, USA</style></auth-address><titles><title><style face="normal" font="default">Temporal lobe (TL) damage following surgery and high-dose photon and proton irradiation in 96 patients affected by chordomas and chondrosarcomas of the base of the skull</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.41.(1):59.-68,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.41.(1):59.-68,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Brain</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Combined Modality Therapy</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Photons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Temporal Lobe</style></keyword><keyword><style face="normal" font="default"> Temporal Lobe/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="1" Month="4" Year="1998">1998/4/1</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To determine the temporal lobe (TL) damage rate in 96 patients treated with high-dose proton and photon irradiation for chordomas and chondrosarcomas of the base of the skull. METHODS AND MATERIALS: The records of 96 consecutive patients treated at Massachusetts General Hospital (MGH) and Harvard Cyclotron Laboratory (HCL) between June 1984 and 1993, for chordomas and chondrosarcomas of the base of the skull were reviewed. All the patients had undergone some degree of resection of the tumor prior to radiation therapy. Seventy-five patients were classified as "primary tumors" and 21 as recurrent or regrowing tumors after one or more surgical procedures. All the patients were randomized to receive 66.6 or 72 cobalt Gray equivalent (CGE) on a prospective dose-searching study by proton and photon irradiation (Radiation Therapy Oncology Group #85-26) with conventional fractionation (1.8 CGE/day, 5 fractions/week). All treatments were planned using the three-dimensional (3D) planning system developed at the Massachusetts General Hospital, and the dose was delivered using opposed lateral fields for the photon component and a noncoplanar isocentric technique for the proton component. Clinical symptoms of TL damage were classified into 4 grades. Computerized tomography (CT) and magnetic resonance imaging (MRI) scans were evaluated for white matter changes. Abnormalities associated with persistent or recurrent tumor were distinguished from radiation-induced changes. TLs were delineated on the original scans of the 10 patients with damage and those of a group of 33 patients with no clinical or MRI evidence of injury. Dose distributions were calculated and dose-volume histograms were obtained for these patients. RESULTS: Of the patients, 10 developed TL damage, with bilateral injury in 2 and unilateral injury in 8. The cumulative TL damage incidence at 2 and 5 years was 7.6 and 13.2%, respectively. The MRI areas suggestive of TL damage were always separated from the tumor bed. Symptoms were severe to moderate in 8 patients. Several baseline factors, tumor- or host-related, were analyzed to evaluate their predictivity for TL damage: age, gender, tumor site, histology, type of presentation, type and number of surgical procedures, primary tumor volume, prescribed dose, normal tissue involvement, and volume of TL receiving doses ranging between 10 and 50 CGE or more. Only gender, in a univariate analysis (log rank) was a significant predictor of damage (0.0155), with male patients being at significantly higher risk of TL injury. In a stepwise Cox regression that included gender as a variable, no other baseline variable improved the prediction of damage. CONCLUSIONS: The 2- and 5-year cumulative TL damage rates were 7.6 and 13.2%, respectively. Despite the different TL damage rates related to age, tumor volume, number of surgical procedures prior to radiation therapy, and prescribed doses to the tumor, only gender was a significant predictor of damage (p = 0.0155) using a univariate (log rank) test. Chordomas and chondrosarcomas of the base of the skull may represent an interesting model to evaluate the TL damage rates because of their extradural origin, displacing the white matter instead of infiltrating it as gliomas do, because of their longer local recurrence-free survival other than gliomas and other brain tumors and because of the high doses of irradiation delivered to the target volume to obtain local control</style></abstract><notes><style face="normal" font="default">9588918g97, 7603616IM0 (Protons)Case ReportsClinical TrialJournal ArticleRandomized Controlled TrialEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>163</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Egan,K.M.</style></author><author><style face="normal" font="default"> Ryan,L.M.</style></author><author><style face="normal" font="default"> Gragoudas,E.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard University School of Medicine, Boston 02115, USA</style></auth-address><titles><title><style face="normal" font="default">Survival implications of enucleation after definitive radiotherapy for choroidal melanoma: an example of regression on time-dependent covariates</style></title><secondary-title><style face="normal" font="default">Archives of Ophthalmology.116.(3):366.-70.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Archives of Ophthalmology.116.(3):366.-70.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Ciliary Body</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Cobalt Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Cobalt Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eye Enucleation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Survivors</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Treatment Failure</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="1998">1998/3</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0003-9950</style></isbn><abstract><style face="normal" font="default">OBJECTIVE: To evaluate whether the removal of the eye after radiotherapy alters the rates of metastatic death in patients with melanoma of the choroid. PATIENTS AND METHODS: Using an extension of the Cox model, we based our analysis on a cohort of 1541 consecutive patients with unilateral choroidal or ciliary body melanoma treated with protons (70 cobalt-gray equivalent in 5 to 7 fractions) at the Harvard University (Boston, Mass) cyclotron between July 1, 1975, through December 31, 1993, and who were observed prospectively up to September 30, 1995. Patient survival and the status of the treated eye were updated annually. RESULTS: By September 1995 (median follow-up among survivors, 8 years), 137 patients underwent enucleation after radiotherapy for complications (n=103) or tumor regrowth (n=34). The overall 10-year rate of eye retention was 89% (95% confidence interval, 87%-91%). Of the 1541 patients, 300 died of tumor metastasis, 38 following enucleation of the affected eye (mean interval from enucleation to death, 25 months). The multivariate rate ratio for metastatic death associated with enucleation (modeled as a time-dependent covariate) was 0.9 (95% confidence interval, 0.6-1.4) for enucleation due to complications and 3.8 (95% confidence interval, 2.3-6.3) for enucleation associated with tumor regrowth. CONCLUSIONS: In the absence of tumor viability, enucleation after primary irradiation for choroidal melanoma has no deleterious effect on patients' survival. Enucleation concurrent with tumor regrowth is associated with high death rates; growth of the tumor in the eye may presage systemic recurrence and death from metastasis</style></abstract><notes><style face="normal" font="default">95144917706534, 830AIM, IM0 (Cobalt Radioisotopes)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>184</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gridley,D.S.</style></author><author><style face="normal" font="default"> Loredo,L.N.</style></author><author><style face="normal" font="default"> Slater,J.D.</style></author><author><style face="normal" font="default"> Archambeau,J.O.</style></author><author><style face="normal" font="default"> Bedros,A.A.</style></author><author><style face="normal" font="default"> Andres,M.L.</style></author><author><style face="normal" font="default"> Slater,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Microbiology &amp; Molecular Genetics, Loma Linda University/Independent Order of Foresters Cancer Research Laboratory, CA, USA</style></auth-address><titles><title><style face="normal" font="default">Pilot evaluation of cytokine levels in patients undergoing radiotherapy for brain tumor</style></title><secondary-title><style face="normal" font="default">Cancer Detection.&amp; Prevention.22.(1):20.-9,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cancer Detection.&amp; Prevention.22.(1):20.-9,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adenocarcinoma</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Brain</style></keyword><keyword><style face="normal" font="default"> Brain Neoplasms/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Brain Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Child,Preschool</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Cytokines/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glioblastoma</style></keyword><keyword><style face="normal" font="default"> Growth Substances/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Interleukin-1/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pilot Projects</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Tumor Necrosis Factor-alpha/me [Metabolism]</style></keyword></keywords><dates><year Day="0" Month="0" Year="1998">1998</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0361-090X</style></isbn><abstract><style face="normal" font="default">This study was undertaken to evaluate plasma levels of interleukin-1 beta (IL-1 beta), tumor necrosis factor-alpha (TNF-alpha) transforming growth factor-beta (TGF-beta), basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), and vascular endothelial growth factor (VEGF) in 3 pediatric and 14 adult patients receiving radiotherapy for brain tumor. Patients with glioblastoma, astrocytoma, chondrosarcoma, meningioma, schwannoma, and lung adenocarcinoma that had metastasized to the brain were included. Peripheral blood samples were collected before and after treatment with conventional photon and/or proton radiation; samples from healthy volunteers served as controls. Enzyme-linked immunosorbent assays were performed to quantitate the cytokines. Before irradiation, most patients had greater amounts of one or more of the cytokines compared with the mean obtained for control plasma. This was especially striking in patients with chondrosarcoma; the mean values for TGF-beta 1, TNF-alpha, bFGF, and EGF were 1458, 1289, 332, and 92% higher than in healthy subjects, respectively. After irradiation, bFGF and total TGF-beta 1 decreased in the majority of tested subjects. In contrast, IL-1 beta was detected only in pediatric patients (all with astrocytoma) and its levels after radiation were 33 to 67% higher than at pretreatment. EGF was found in four patients; post-treatment values were 125 to 608% higher in three of the individuals. These data show that cytokines are present at elevated concentrations in the blood circulation of patients with certain types of brain tumors and that changes in their levels can be detected after radiotherapy. Further investigations are warranted to determine whether these findings contribute to morbidity or therapeutic outcome</style></abstract><notes><style face="normal" font="default">9466045cnz, 7704778IM, S0 (Cytokines)0 (Growth Substances)0 (Interleukin-1)0 (Tumor Necrosis Factor-alpha)Journal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>190</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Char,D.H.</style></author><author><style face="normal" font="default"> Kroll,S.M.</style></author><author><style face="normal" font="default"> Castro,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophthalmology, University of California, San Francisco, USA</style></auth-address><titles><title><style face="normal" font="default">Ten-year follow-up of helium ion therapy for uveal melanoma</style></title><secondary-title><style face="normal" font="default">American Journal of Ophthalmology.125.(1):81.-9,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">American Journal of Ophthalmology.125.(1):81.-9,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eye Enucleation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Melanoma/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Optic Nerve</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Vision</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword><keyword><style face="normal" font="default"> Visual Acuity/ph [Physiology]</style></keyword></keywords><dates><year Day="0" Month="1" Year="1998">1998/1</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0002-9394</style></isbn><abstract><style face="normal" font="default">PURPOSE: To examine the results of helium ion irradiation in 218 patients with uveal melanoma treated more than 10 years ago. METHOD: A retrospective review was made of 218 patients (218 eyes) treated with helium ion radiation for uveal melanoma between 1978 and 1984. RESULTS: After helium ion irradiation, 208 (95.4%) of 218 eyes had local tumor control. Ten years after irradiation, 46 (22.4%) of 218 eyes had been enucleated; the majority of enucleations (37 of 46) resulted from anterior ocular segment complications. Ten years after radiation, 102 (46.8%) of the 218 patients were dead; 51 had non-melanoma-related deaths and 51 had died of metastatic melanoma. Best-corrected visual acuity after radiation was greater than 20/40 in 21 (23%) of 93 eyes of the patients who were alive and who had retained their eyes 10 or more years after treatment. In patients with tumors less than 6 mm in height and more than 3 mm distant from the nerve or the fovea, 13 (72%) of 18 retained visual acuity greater than 20/40. In contrast, only 11% of the patients with either thicker tumors or those close to the nerve or fovea retained that level of visual acuity. CONCLUSIONS: Helium ion irradiation of uveal melanoma is associated with good local tumor control and reasonable retention of the treated eye 10 years after treatment. In eyes with tumors less than 6 mm in thickness and more than 3 mm distant from the optic nerve and fovea, many retain excellent vision</style></abstract><notes><style face="normal" font="default">94373173oq, 0370500AIM, IM7440-59-7 (Helium)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>249</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Weber,D.C.</style></author><author><style face="normal" font="default"> Rutz,H.P.</style></author><author><style face="normal" font="default"> Bolsi,A.</style></author><author><style face="normal" font="default"> Pedroni,E.</style></author><author><style face="normal" font="default"> Coray,A.</style></author><author><style face="normal" font="default"> Jermann,M.</style></author><author><style face="normal" font="default"> Lomax,A.J.</style></author><author><style face="normal" font="default"> Hug,E.B.</style></author><author><style face="normal" font="default"> Goitein,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center for Proton Radiation Therapy, Paul Scherrer Institute, Villigen, Switzerland. damien.weber@hcuge.ch</style></auth-address><titles><title><style face="normal" font="default">Spot scanning proton therapy in the curative treatment of adult patients with sarcoma: the Paul Scherrer institute experience</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.69.(3):865.-71,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.69.(3):865.-71,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Kidney</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Planning,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Adjuvant/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Sarcoma</style></keyword><keyword><style face="normal" font="default"> Sarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Spinal Cord</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword></keywords><dates><year Day="1" Month="11" Year="2007">2007/11/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To assess the safety and efficacy of spot scanning proton beam therapy (PT) in the curative treatment of soft-tissue sarcoma (STS) in adults patients. PATIENTS AND METHODS: We identified 13 STS patients treated with PT between July 1998 and May 2005 in our institutional database. Tumor histology varied with the most common histologic subtypes including liposarcoma and peripheral nerve sheet tumor. All tumors were located in vicinity of critical structures, such as the spinal cord, optic apparatus, bowel, kidney, or bowel. Of the patients, 6 and 5 patients received PT either as adjuvant therapy for non-R0 resection or for recurrence, respectively. Two patients received radical PT for unresectable disease. The median prescribed dose was 69.4 CGE (CGE = proton Gy x 1.1)-Gy (range, 50.4-76.0) at 1.8 to 2 CGE-Gy (median, 1.9) per fraction. Pre-PT anthracycline-based chemotherapy was delivered to 3 patients only. No patient has been lost to follow-up (median 48.1 months, range, 19.1-100.7 months). RESULTS: Of the 13 patients, all but 2 patients were alive. Local recurrence developed in 3 (23%) patients. The administered dose to these patients was &lt; or =60 Gy-CGE. Distant control was achieved in all but 2 patients (lung metastasis), 1 of whom presented with a concomitant local recurrence. The 4-year local control and metastasis-free survival rates were 74.1% and 84.6%, respectively. Late grade > or =2 toxicity was observed in only 2 patients. CONCLUSIONS: Spot scanning PT is an effective and safe treatment for patient with STS in critical locations. The observed toxicity rate was acceptable</style></abstract><notes><style face="normal" font="default">17606333g97, 7603616IM0 (Protons)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>250</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hata,M.</style></author><author><style face="normal" font="default"> Tokuuye,K.</style></author><author><style face="normal" font="default"> Sugahara,S.</style></author><author><style face="normal" font="default"> Tohno,E.</style></author><author><style face="normal" font="default"> Nakayama,H.</style></author><author><style face="normal" font="default"> Fukumitsu,N.</style></author><author><style face="normal" font="default"> Mizumoto,M.</style></author><author><style face="normal" font="default"> Abei,M.</style></author><author><style face="normal" font="default"> Shoda,J.</style></author><author><style face="normal" font="default"> Minami,M.</style></author><author><style face="normal" font="default"> Akine,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Proton Medical Research Center, University of Tsukuba, Tsukuba, Ibaraki, Japan. mhata@syd.odn.ne.jp</style></auth-address><titles><title><style face="normal" font="default">Proton beam therapy for aged patients with hepatocellular carcinoma</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.69.(3):805.-12,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.69.(3):805.-12,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Treatment Failure</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="1" Month="11" Year="2007">2007/11/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To investigate the safety and efficacy of proton beam therapy for aged patients with hepatocellular carcinoma (HCC). METHODS AND MATERIALS: Twenty-one patients aged > or =80 years with HCC underwent proton beam therapy. At the time of irradiation, patient age ranged from 80 to 85 years (median, 81 years). Hepatic tumors were solitary in 17 patients and multiple in 4. Tumor size ranged from 10 to 135 mm (median, 40 mm) in maximum diameter. Ten, 5, and 6 patients received proton beam irradiation with total doses of 60 Gy in 10 fractions, 66 Gy in 22 fractions, and 70 Gy in 35 fractions, respectively, according to tumor location. RESULTS: All irradiated tumors were controlled during the follow-up period of 6-49 months (median, 16 months). Five patients showed new hepatic tumors outside the irradiated volume, 2-13 months after treatment, and 1 of them also had lung metastasis. The local progression-free and disease-free rates were 100% and 72% at 3 years, respectively. Of 21 patients, 7 died 6-49 months after treatment; 2 patients each died of trauma and old age, and 1 patient each died of HCC, pneumonia, and arrhythmia. The 3-year overall, cause-specific, and disease-free survival rates were 62%, 88%, and 51%, respectively. No therapy-related toxicity of Grade > or = 3 but thrombocytopenia in 2 patients was observed. CONCLUSIONS: Proton beam therapy seems to be tolerable, effective, and safe for aged patients with HCC. It may contribute to prolonged survival due to tumor control</style></abstract><notes><style face="normal" font="default">17524568g97, 7603616IM0 (Protons)Evaluation StudiesJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>256</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Miyamoto,T.</style></author><author><style face="normal" font="default"> Baba,M.</style></author><author><style face="normal" font="default"> Sugane,T.</style></author><author><style face="normal" font="default"> Nakajima,M.</style></author><author><style face="normal" font="default"> Yashiro,T.</style></author><author><style face="normal" font="default"> Kagei,K.</style></author><author><style face="normal" font="default"> Hirasawa,N.</style></author><author><style face="normal" font="default"> Sugawara,T.</style></author><author><style face="normal" font="default"> Yamamoto,N.</style></author><author><style face="normal" font="default"> Koto,M.</style></author><author><style face="normal" font="default"> Ezawa,H.</style></author><author><style face="normal" font="default"> Kadono,K.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author><author><style face="normal" font="default"> Mizoe,J.E.</style></author><author><style face="normal" font="default"> Yoshikawa,K.</style></author><author><style face="normal" font="default"> Kandatsu,S.</style></author><author><style face="normal" font="default"> Fujisawa,T.</style></author><author><style face="normal" font="default"> Working Group for Lung Cancer</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan. t_miyamt@nirs.go.jp</style></auth-address><titles><title><style face="normal" font="default">Carbon ion radiotherapy for stage I non-small cell lung cancer using a regimen of four fractions during 1 week.[see comment]</style></title><secondary-title><style face="normal" font="default">Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer.2(10):916.-26.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer.2(10):916.-26.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adenocarcinoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Adenocarcinoma/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Adenosquamous/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Adenosquamous/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Large Cell/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Large Cell/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Squamous Cell/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Squamous Cell/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Neoplasm Staging</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="10" Year="2007">2007/10</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><abstract><style face="normal" font="default">BACKGROUND: A phase I/II study was first conducted for the treatment of stage I non-small cell lung cancer (NSCLC) from 1994 to 1999 to determine the optimal dose. On the basis on the results, a phase II study using a regimen of four fractions during 1 week was performed. The purpose of the present study was to determine the local control and 5-year survival rates. METHODS: From December 2000 to November 2003, 79 patients with 80 primary lesions were treated. Using a fixed dose of 52.8 GyE for stage IA NSCLC and 60.0 GyE for stage IB NSCLC in four fractions during 1 week, the primary tumors were irradiated with carbon beams alone. The average age of the patients was 74.8 years. Sixty-two (78.5%) of these patients were medically inoperable. Local control and survival were determined using the Kaplan-Meier method. The data were statistically processed using the log-rank test. RESULTS: All patients were observed for a minimum of 3 years or until death, with a median follow-up time of 38.6 months, ranging from 2.5 to 72.2 months. The local control rate for all patients was 90% (T1: 98%, T2: 80%). The patients' 5-year lung cancer-specific survival rate was 68% (IA: 87%, IB: 42%). The overall survival was 45% (IA: 62%, IB: 25%). Half of the deaths were attributable to intercurrent diseases. No toxic reactions in the lung greater than grade 3 were detected. CONCLUSION: Carbon ion beam radiotherapy with a regimen of four fractions during 1 week has been proven as a valid alternative to surgery for stage I NSCLC and to offer particular benefits, especially for elderly and inoperable patients</style></abstract><notes><style face="normal" font="default">17909354101274235IM0 (Carbon Radioisotopes)Clinical Trial, Phase IIJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>268</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mayahara,H.</style></author><author><style face="normal" font="default"> Murakami,M.</style></author><author><style face="normal" font="default"> Kagawa,K.</style></author><author><style face="normal" font="default"> Kawaguchi,A.</style></author><author><style face="normal" font="default"> Oda,Y.</style></author><author><style face="normal" font="default"> Miyawaki,D.</style></author><author><style face="normal" font="default"> Sasaki,R.</style></author><author><style face="normal" font="default"> Sugimura,K.</style></author><author><style face="normal" font="default"> Hishikawa,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Hyogo Ion Beam Medical Center, Hyogo, Japan. hmayahar@ncc.go.jp</style></auth-address><titles><title><style face="normal" font="default">Acute morbidity of proton therapy for prostate cancer: the Hyogo Ion Beam Medical Center experience</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.69.(2):434.-43.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.69.(2):434.-43.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> Gastrointestinal Tract/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Hematuria/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prostate</style></keyword><keyword><style face="normal" font="default"> Prostate-Specific Antigen</style></keyword><keyword><style face="normal" font="default"> Prostate-Specific Antigen/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Planning,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Tumor Burden</style></keyword><keyword><style face="normal" font="default"> Urination Disorders/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Urogenital System/re [Radiation Effects]</style></keyword></keywords><dates><year Day="1" Month="10" Year="2007">2007/10/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To investigate the incidence and influencing factors of acute genitourinary (GU) and gastrointestinal morbidities in patients with prostate cancer treated with proton therapy. METHODS AND MATERIALS: A total of 287 patients with histologically proven Stage cT1-T4N0M0 prostate cancer were treated with proton therapy between 2003 and 2004. Of these, 204 (71%) received neoadjuvant androgen suppression therapy. The patients were treated with 190-230-MeV protons using lateral-opposed techniques to a dose of 74 GyE. Dose-volume histogram analyses were performed. The incidence of acute morbidity was evaluated using the National Cancer Institute Common Toxicity Criteria, version 2.0. Clinical factors, including age, clinical target volume, initial prostate-specific antigen level, T stage, presence of diabetes mellitus, and the use of androgen suppression therapy, were investigated to determine whether those affected the incidence of acute GU morbidity. RESULTS: None developed Grade 2 or higher acute gastrointestinal morbidity. In contrast, 111 (39%) and 4 (1%) patients experienced acute Grade 2 and Grade 3 GU morbidities, respectively. However, 87% of the patients were successfully relieved by the administration of a selective alpha-1 blocker. Multivariate analysis showed that a larger clinical target volume (p = 0.001) and the use of androgen suppression therapy (p = 0.017) were significant factors for the prediction of acute Grade 2-3 GU morbidity. CONCLUSION: In our experience with proton therapy, a low incidence of acute gastrointestinal morbidity was observed. In contrast, the incidence of acute GU morbidity was similar to that in other reports of photon radiotherapy. Additional follow-up is warranted to elucidate the long-term safety and efficacy of proton therapy for prostate cancer</style></abstract><notes><style face="normal" font="default">17482768g97, 7603616IM0 (Protons)EC 3-4-21-77 (Prostate-Specific Antigen)Journal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>269</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mizoe,J.E.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author><author><style face="normal" font="default"> Hasegawa,A.</style></author><author><style face="normal" font="default"> Yanagi,T.</style></author><author><style face="normal" font="default"> Takagi,R.</style></author><author><style face="normal" font="default"> Kamada,T.</style></author><author><style face="normal" font="default"> Tsuji,H.</style></author><author><style face="normal" font="default"> Takakura,K.</style></author><author><style face="normal" font="default"> Organizing Committee of the Central Nervous System Tumor Working Group</style></author></authors></contributors><auth-address><style face="normal" font="default">Hospital, Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan. j_mizoe@nirs.go.jp</style></auth-address><titles><title><style face="normal" font="default">Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.69.(2):390.-6,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.69.(2):390.-6,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> Antineoplastic Agents</style></keyword><keyword><style face="normal" font="default"> Antineoplastic Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Astrocytoma/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Astrocytoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Astrocytoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Brain</style></keyword><keyword><style face="normal" font="default"> Brain Neoplasms/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Brain Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Brain Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Combined Modality Therapy/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glioblastoma</style></keyword><keyword><style face="normal" font="default"> Glioblastoma/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Glioblastoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Glioblastoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Glioma/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Glioma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Glioma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Nimustine/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword></keywords><dates><year Day="1" Month="10" Year="2007">2007/10/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To report the results of a Phase I/II clinical trial for patients with malignant gliomas, treated with combined X-ray radiotherapy (XRT), chemotherapy, and carbon ion radiotherapy (CRT). METHODS AND MATERIALS: Between October 1994 and February 2002, 48 patients with histologically confirmed malignant gliomas (16 anaplastic astrocytoma (AA) and 32 glioblastoma multiforme (GBM) were enrolled in a Phase I/II clinical study. The treatment involved the application of 50 Gy/25 fractions/5 weeks of XRT, followed by CRT at 8 fractions/2 weeks. Nimustine hydrochloride (ACNU) were administered at a dose of 100 mg/m(2) concurrently in weeks 1, 4, or 5 of XRT. The carbon ion dose was increased from 16.8 to 24.8 Gray equivalent (GyE) in 10% incremental steps (16.8, 18.4, 20.0, 22.4, and 24.8 GyE, respectively). RESULTS: There was no Grade 3 or higher acute reaction in the brain. The late reactions included four cases of Grade 2 brain morbidity and four cases of Grade 2 brain reaction among 48 cases. The median survival time (MST) of AA patients was 35 months and that of GBM patients 17 months (p = 0.0035). The median progression-free survival and MST of GBM showed 4 and 7 months for the low-dose group, 7 and 19 months for the middle-dose group, and 14 and 26 months for the high-dose group. CONCLUSION: The results of combined therapy using XRT, ACNU chemotherapy, and CRT showed the potential efficacy of CRT for malignant gliomas in terms of the improved survival rate in those patients who received higher carbon doses</style></abstract><notes><style face="normal" font="default">17459607g97, 7603616IM0 (Antineoplastic Agents)0 (Carbon Radioisotopes)42471-28-3 (Nimustine)Clinical Trial, Phase IClinical Trial, Phase IIJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>325</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Boudinet,M.</style></author><author><style face="normal" font="default"> Berges,O.</style></author><author><style face="normal" font="default"> Le Huerou,J.Y.</style></author><author><style face="normal" font="default"> Lumbroso-Le,Rouic L.</style></author><author><style face="normal" font="default"> Desjardins,L.</style></author><author><style face="normal" font="default"> Laugier,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">CNRS, UMR7623 LIP, Paris, F-75006, France. michele.boudinet@lip.bhdc.jussieu.fr</style></auth-address><titles><title><style face="normal" font="default">Quantitative echography in the follow-up of patients treated with proton-beam irradiation for primary choroidal melanomas</style></title><secondary-title><style face="normal" font="default">Ultrasound in Medicine &amp; Biology.33(7.):1046.-56.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ultrasound in Medicine &amp; Biology.33(7.):1046.-56.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> Retinal Detachment/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Retinal Detachment/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Scattering,Radiation</style></keyword><keyword><style face="normal" font="default"> Spectrum Analysis</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="7" Year="2007">2007/7</year></dates><pub-location><style face="normal" font="default">England</style></pub-location><isbn><style face="normal" font="default">0301-5629</style></isbn><abstract><style face="normal" font="default">Quantitative ultrasonic characterization yields information that is correlated to the tissue microstructure and increases the diagnostic potential of ultrasound. The measurement of acoustic properties of melanomas in vivo has not yet been reported after proton-beam irradiation. This prospective study was conducted on a cohort of 50 patients diagnosed with primary malignant melanoma to assess in vivo the ability of quantitative echography to detect changes in choroidal malignant melanomas after proton-beam irradiation and to follow the ultrasonographic changes during 24 months posttreatment. Echographic evaluations of these patients were performed at diagnosis and repeated every 6 months after treatment over a 2-y period. The acoustic parameters included in this work are derived from the calibrated tissue backscatter spectra (spectral slope, spectral intercept and apparent integrated backscatter) of a selected tumor volume after correction of the apparatus transfer function and beam diffraction. Clinical parameters resulting from conventional echography were also quantified and included mainly tumor height, tumor vascularity and internal reflectivity. Spectral intercept and apparent integrated backscatter were found to be the most useful to evaluate changes in melanomas after treatment. Significant (p &lt; 0.05) differences of these parameter values were observed between pre- and postproton therapy. In particular, significant changes (compared with baseline) were observed for these parameters, even when the tumor size after treatment was not significantly different from baseline. The results suggest that quantitative spectrum analysis of frequency-dependent backscatter can provide information about the structural modifications of choroidal malignant melanomas as a result of proton-beam irradiation</style></abstract><notes><style face="normal" font="default">17448588wne, 0410553IM0 (Protons)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>342</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nishimura,H.</style></author><author><style face="normal" font="default"> Ogino,T.</style></author><author><style face="normal" font="default"> Kawashima,M.</style></author><author><style face="normal" font="default"> Nihei,K.</style></author><author><style face="normal" font="default"> Arahira,S.</style></author><author><style face="normal" font="default"> Onozawa,M.</style></author><author><style face="normal" font="default"> Katsuta,S.</style></author><author><style face="normal" font="default"> Nishio,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. westvill@med.kobe-u.ac.jp</style></auth-address><titles><title><style face="normal" font="default">Proton-beam therapy for olfactory neuroblastoma</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.68(3):758.-62.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.68(3):758.-62.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Esthesioneuroblastoma,Olfactory/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Esthesioneuroblastoma,Olfactory/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Nasal Cavity</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Nose Neoplasms/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Nose Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Base</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="1" Month="7" Year="2007">2007/7/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To analyze the feasibility and efficacy of proton-beam therapy (PBT) for olfactory neuroblastoma (ONB) as a definitive treatment, by reviewing our preliminary experience. Olfactory neuroblastoma is a rare disease, and a standard treatment strategy has not been established. Radiation therapy for ONB is challenging because of the proximity of ONBs to critical organs. Proton-beam therapy can provide better dose distribution compared with X-ray irradiation because of its physical characteristics, and is deemed to be a feasible treatment modality. METHODS AND MATERIALS: A retrospective review was performed on 14 patients who underwent PBT for ONB as definitive treatment at the National Cancer Center Hospital East (Kashiwa, Chiba, Japan) from November 1999 to February 2005. A total dose of PBT was 65 cobalt Gray equivalents (Gy(E)), with 2.5-Gy(E) once-daily fractionations. RESULTS: The median follow-up period for surviving patients was 40 months. One patient died from disseminated disease. There were two persistent diseases, one of which was successfully salvaged with surgery. The 5-year overall survival rate was 93%, the 5-year local progression-free survival rate was 84%, and the 5-year relapse-free survival rate was 71%. Liquorrhea was observed in one patient with Kadish's stage C disease (widely destroying the skull base). Most patients experienced Grade 1 to 2 dermatitis in the acute phase. No other adverse events of Grade 3 or greater were observed according to the RTOG/EORTC acute and late morbidity scoring system. CONCLUSIONS: Our preliminary results of PBT for ONB achieved excellent local control and survival outcomes without serious adverse effects. Proton-beam therapy is considered a safe and effective modality that warrants further study</style></abstract><notes><style face="normal" font="default">17398027g97, 7603616IM0 (Protons)Clinical TrialJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>343</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hata,M.</style></author><author><style face="normal" font="default"> Tokuuye,K.</style></author><author><style face="normal" font="default"> Kagei,K.</style></author><author><style face="normal" font="default"> Sugahara,S.</style></author><author><style face="normal" font="default"> Nakayama,H.</style></author><author><style face="normal" font="default"> Fukumitsu,N.</style></author><author><style face="normal" font="default"> Hashimoto,T.</style></author><author><style face="normal" font="default"> Mizumoto,M.</style></author><author><style face="normal" font="default"> Ohara,K.</style></author><author><style face="normal" font="default"> Akine,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Proton Medical Research Center, University of Tsukuba, Tsukuba, Ibaraki, Japan. mhata@syd.odn.ne.jp</style></auth-address><titles><title><style face="normal" font="default">Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.68(3):786.-93.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.68(3):786.-93.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adenocarcinoma</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Dose-Response Relationship,Radiation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Neoplasm Staging</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pilot Projects</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="1" Month="7" Year="2007">2007/7/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To present treatment outcomes of hypofractionated high-dose proton beam therapy for Stage I non-small-cell lung cancer (NSCLC). METHODS AND MATERIALS: Twenty-one patients with Stage I NSCLC (11 with Stage IA and 10 with Stage IB) underwent hypofractionated high-dose proton beam therapy. At the time of irradiation, patient age ranged from 51 to 85 years (median, 74 years). Nine patients were medically inoperable because of comorbidities, and 12 patients refused surgical resection. Histology was squamous cell carcinoma in 6 patients, adenocarcinoma in 14, and large cell carcinoma in 1. Tumor size ranged from 10 to 42 mm (median, 25 mm) in maximum diameter. Three and 18 patients received proton beam irradiation with total doses of 50 Gy and 60 Gy in 10 fractions, respectively, to primary tumor sites. RESULTS: Of 21 patients, 2 died of cancer and 2 died of pneumonia at a median follow-up period of 25 months. The 2-year overall and cause-specific survival rates were 74% and 86%, respectively. All but one of the irradiated tumors were controlled during the follow-up period. Five patients showed recurrences 6-29 months after treatment, including local progression and new lung lesions outside of the irradiated volume in 1 and 4 patients, respectively. The local progression-free and disease-free rates were 95% and 79% at 2 years, respectively. No therapy-related toxicity of Grade > or =3 was observed. CONCLUSIONS: Hypofractionated high-dose proton beam therapy seems feasible and effective for Stage I NSCLC. Proton beams may contribute to enhanced efficacy and lower toxicity in the treatment of patients with Stage I NSCLC</style></abstract><notes><style face="normal" font="default">17379439g97, 7603616IM0 (Protons)Clinical Trial, Phase IClinical Trial, Phase IIJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>369</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schulz-Ertner,D.</style></author><author><style face="normal" font="default"> Karger,C.P.</style></author><author><style face="normal" font="default"> Feuerhake,A.</style></author><author><style face="normal" font="default"> Nikoghosyan,A.</style></author><author><style face="normal" font="default"> Combs,S.E.</style></author><author><style face="normal" font="default"> Jakel,O.</style></author><author><style face="normal" font="default"> Edler,L.</style></author><author><style face="normal" font="default"> Scholz,M.</style></author><author><style face="normal" font="default"> Debus,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, University of Heidelberg, Heidelberg, Germany.Daniela.Ertner@med.uni-heidelberg.de</style></auth-address><titles><title><style face="normal" font="default">Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.68(2):449.-57.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.68(2):449.-57.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Child,Preschool</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Dose-Response Relationship,Radiation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local</style></keyword><keyword><style face="normal" font="default"> Neoplasm,Residual</style></keyword><keyword><style face="normal" font="default"> Optic Nerve</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Base</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Temporal Lobe</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="1" Month="6" Year="2007">2007/6/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: The aim of this study was to evaluate the effectiveness and toxicity of carbon ion radiotherapy in chordomas of the skull base. METHODS AND MATERIALS: Between November 1998 and July 2005, a total of 96 patients with chordomas of the skull base have been treated with carbon ion radiation therapy (RT) using the raster scan technique at the Gesellschaft fur Schwerionenforschung (GSI) in Darmstadt, Germany. All patients had gross residual tumors. Median total dose was 60 CGE (range, 60-70 CGE) delivered in 20 fractions within 3 weeks. Local control and overall survival rates were calculated using the Kaplan-Meier method. Toxicity was assessed according to the Common Terminology Criteria (CTCAE v.3.0) and the Radiation Therapy Oncology Group (RTOG) / European Organization for Research and Treatment of Cancer (EORTC) score. RESULTS: Mean follow-up was 31 months (range, 3-91 months). Fifteen patients developed local recurrences after carbon ion RT. The actuarial local control rates were 80.6% and 70.0% at 3 and 5 years, respectively. Target doses in excess of 60 CGE and primary tumor status were associated with higher local control rates. Overall survival was 91.8% and 88.5% at 3 and 5 years, respectively. Late toxicity consisted of optic nerve neuropathy RTOG/EORTC Grade 3 in 4.1% of the patients and necrosis of a fat plomb in 1 patient. Minor temporal lobe injury (RTOG/EORTC Grade 1-2) occurred in 7 patients (7.2%). CONCLUSIONS: Carbon ion RT offers an effective treatment option for skull-base chordomas with acceptable toxicity. Doses in excess of 75 CGE with 2 CGE per fraction are likely to increase local control probability</style></abstract><notes><style face="normal" font="default">17363188g97, 7603616IM0 (Carbon Radioisotopes)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>374</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bush,D.A.</style></author><author><style face="normal" font="default"> Slater,J.D.</style></author><author><style face="normal" font="default"> Garberoglio,C.</style></author><author><style face="normal" font="default"> Yuh,G.</style></author><author><style face="normal" font="default"> Hocko,J.M.</style></author><author><style face="normal" font="default"> Slater,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Medicine, Loma Linda University Medical Center, Loma Linda, CA 92354, USA. dbush@dominion.llumc.edu</style></auth-address><titles><title><style face="normal" font="default">A technique of partial breast irradiation utilizing proton beam radiotherapy: comparison with conformal x-ray therapy.[see comment]</style></title><secondary-title><style face="normal" font="default">Cancer Journal.13(2):114.-8.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cancer Journal.13(2):114.-8.,</style></abbr-1></periodical><pages end="Apr" start="">-Apr</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Breast</style></keyword><keyword><style face="normal" font="default"> Breast Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Breast/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Immobilization</style></keyword><keyword><style face="normal" font="default"> Immobilization/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Motion</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prone Position</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Planning,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Conformal</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vacuum</style></keyword><keyword><style face="normal" font="default"> X-Rays</style></keyword></keywords><dates><year Day="0" Month="3" Year="2007">2007/3</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">1528-9117</style></isbn><abstract><style face="normal" font="default">PURPOSE: To develop a breast immobilization system and clinical technique to deliver partial breast irradiation with a proton beam and compare dose distributions using proton therapy and conformal x-rays. METHODS: A clinical technique to provide reproducible breast immobilization was developed. Breast immobilization begins by fitting each patient with a treatment brassiere. Patients are placed prone in a cylindrical polyvinyl chloride shell with the upper and lower body being supported and immobilized with Vac-Lok foam bead cushions. The upper chest and breast areas are immobilized with two-part expandable foam. After a treatment planning computed tomography scan, the lumpectomy cavity is outlined, and a clinical target volume is generated by adding 1cm in all dimensions. A three-dimensional treatment plan is developed with treatment typically given with 2 to 4 separate proton beams. The dose administered is 40 cobalt Gray equivalents (CGE) delivered in 10 daily fractions of 4 CGE with multiple fields treated each day. Proton and conformal x-ray plans were compared using dose-volume histogram analysis to determine volumes of normal breast tissue and skin treated with each technique. RESULTS: An institutional review board-approved clinical trial was developed using this technique, and 20 patients have completed treatment. All subjects were able to undergo the immobilization procedure and daily treatments without significant discomfort, and no treatment interruptions were encountered. There was no evidence of respiratory motion identified on treatment planning CT images or on daily set-up radiographs. Acute toxicity has been limited to occasional radiation dermatitis (Radiation Therapy Oncology Group grade 1-2). Proton plans were compared with 2 methods of photon partial breast irradiation, including reduced tangential fields and five-field conformal techniques. Ten treatment plans with dose-volume histogram analysis revealed that the use of proton beams provided a significant reduction in doses to the ipsilateral breast and skin while eliminating doses to the heart and lung tissues. CONCLUSIONS: A simple immobilization procedure provides accurate and reproducible breast positioning while simultaneously eliminating respiratory motion. The procedure has been well tolerated by the first 20 patients. Protons can provide substantial normal tissue protection compared with the use of conformal x-rays when used for partial breast treatment. We plan to continue enrollment and analyze long-term toxicity, local control, and survival</style></abstract><notes><style face="normal" font="default">17476139100931981IM0 (Protons)Clinical TrialJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>439</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Miyamoto,T.</style></author><author><style face="normal" font="default"> Baba,M.</style></author><author><style face="normal" font="default"> Yamamoto,N.</style></author><author><style face="normal" font="default"> Koto,M.</style></author><author><style face="normal" font="default"> Sugawara,T.</style></author><author><style face="normal" font="default"> Yashiro,T.</style></author><author><style face="normal" font="default"> Kadono,K.</style></author><author><style face="normal" font="default"> Ezawa,H.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author><author><style face="normal" font="default"> Mizoe,J.E.</style></author><author><style face="normal" font="default"> Yoshikawa,K.</style></author><author><style face="normal" font="default"> Kandatsu,S.</style></author><author><style face="normal" font="default"> Fujisawa,T.</style></author><author><style face="normal" font="default"> Working Group for Lung Cancer</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences (NIRS), Chiba, Japan. t_miyamt@nirs.go.jp</style></auth-address><titles><title><style face="normal" font="default">Curative treatment of Stage I non-small-cell lung cancer with carbon ion beams using a hypofractionated regimen</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.67.(3):750.-8.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.67.(3):750.-8.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adenocarcinoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Adenocarcinoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Squamous Cell/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Squamous Cell/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword></keywords><dates><year Day="1" Month="3" Year="2007">2007/3/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: A phase I/II study on carbon ion radiotherapy for Stage I non-small-cell lung cancer (NSCLC) was first conducted between 1994 and 1999 and determined the optimal dose. Second, a Phase II study using the optimal dose was performed. The purpose of the present study was to clarify the local control and 5-year survival rates. METHODS AND MATERIALS: Between April 1999 and December 2000, 50 patients with 51 primary lesions were treated. Using a fixed dose of 72 GyE in nine fractions over 3 weeks, the primary tumors were irradiated with carbon ion beams alone. The average age of the patients was 74.5 years. Thirty-three (66%) of these were medically inoperable. Local control and survival were determined by using the Kaplan-Meier method and the data were statistically processed by using the log-rank test. RESULTS: All patients were observed for a minimum of 5 years or until death with a median follow-up time of 59.2 months (range, 6.0-83.0 months). The local control rate for all patients was 94.7%. The patients' 5-year cause-specific survival rate was 75.7% (IA: 89.4; IB: 55.1), and overall survival 50.0% (IA: 55.2; IB: 42.9). No toxic reactions in the lung greater than Grade 3 were detected. CONCLUSIONS: Carbon ion radiotherapy, a new treatment modality with superior benefits in terms of quality of life and activity of daily living, has been proven as a valid alternative to surgery for Stage I NSCLC and to offer particular benefits, especially for elderly and inoperable patients</style></abstract><notes><style face="normal" font="default">17293232g97, 7603616IM0 (Carbon Radioisotopes)Clinical Trial, Phase IIJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>440</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tsuji,H.</style></author><author><style face="normal" font="default"> Ishikawa,H.</style></author><author><style face="normal" font="default"> Yanagi,T.</style></author><author><style face="normal" font="default"> Hirasawa,N.</style></author><author><style face="normal" font="default"> Kamada,T.</style></author><author><style face="normal" font="default"> Mizoe,J.E.</style></author><author><style face="normal" font="default"> Kanai,T.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author><author><style face="normal" font="default"> Ohnishi,Y.</style></author><author><style face="normal" font="default"> Working Group for Ophthalmologic Tumors</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan. h_tsuji@nirs.go.jp</style></auth-address><titles><title><style face="normal" font="default">Carbon-ion radiotherapy for locally advanced or unfavorably located choroidal melanoma: a Phase I/II dose-escalation study</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.67.(3):857.-62.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.67.(3):857.-62.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Glaucoma</style></keyword><keyword><style face="normal" font="default"> Glaucoma,Neovascular/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Intraocular Pressure</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Melanoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pressure</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Relative Biological Effectiveness</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="1" Month="3" Year="2007">2007/3/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To evaluate the applicability of carbon ion beams for the treatment of choroidal melanoma with regard to normal tissue morbidity and local tumor control. METHODS AND MATERIALS: Between January 2001 and February 2006, 59 patients with locally advanced or unfavorably located choroidal melanoma were enrolled in a Phase I/II clinical trial of carbon-ion radiotherapy at the National Institute of Radiologic Sciences. The primary endpoint of this study was normal tissue morbidity, and secondary endpoints were local tumor control and patient survival. Of the 59 subjects enrolled, 57 were followed >6 months and analyzed. RESULTS: Twenty-three patients (40%) developed neovascular glaucoma, and three underwent enucleation for eye pain due to elevated intraocular pressure. Incidence of neovascular glaucoma was dependent on tumor size and site. Five patients had died at analysis, three of distant metastasis and two of concurrent disease. All but one patient, who developed marginal recurrence, were controlled locally. Six patients developed distant metastasis, five in the liver and one in the lung. Three-year overall survival, disease-free survival, and local control rates were 88.2%, 84.8%, and 97.4%, respectively. No apparent dose-response relationship was observed in either tumor control or normal tissue morbidity at the dose range applied. CONCLUSION: Carbon-ion radiotherapy can be applied to choroidal melanoma with an acceptable morbidity and sufficient antitumor effect, even with tumors of unfavorable size or site</style></abstract><notes><style face="normal" font="default">17161555g97, 7603616IM0 (Carbon Radioisotopes)Clinical Trial, Phase IClinical Trial, Phase IIJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>448</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hirasawa,N.</style></author><author><style face="normal" font="default"> Tsuji,H.</style></author><author><style face="normal" font="default"> Ishikawa,H.</style></author><author><style face="normal" font="default"> Koyama-Ito,H.</style></author><author><style face="normal" font="default"> Kamada,T.</style></author><author><style face="normal" font="default"> Mizoe,J.E.</style></author><author><style face="normal" font="default"> Ito,Y.</style></author><author><style face="normal" font="default"> Naganawa,S.</style></author><author><style face="normal" font="default"> Ohnishi,Y.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Center for Charged Particle Therapy, National Institute of Radiological Sciences (NIRS), Chiba, Japan. naoki_h@nirs.go.jp</style></auth-address><titles><title><style face="normal" font="default">Risk factors for neovascular glaucoma after carbon ion radiotherapy of choroidal melanoma using dose-volume histogram analysis</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.67.(2):538.-43.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.67.(2):538.-43.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glaucoma</style></keyword><keyword><style face="normal" font="default"> Glaucoma,Neovascular/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Optic Disk</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="1" Month="2" Year="2007">2007/2/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To determine the risk factors for neovascular glaucoma (NVG) after carbon ion radiotherapy (C-ion RT) of choroidal melanoma. METHODS AND MATERIALS: A total of 55 patients with choroidal melanoma were treated between 2001 and 2005 with C-ion RT based on computed tomography treatment planning. All patients had a tumor of large size or one located close to the optic disk. Univariate and multivariate analyses were performed to identify the risk factors of NVG for the following parameters; gender, age, dose-volumes of the iris-ciliary body and the wall of eyeball, and irradiation of the optic disk (ODI). RESULTS: Neovascular glaucoma occurred in 23 patients and the 3-year cumulative NVG rate was 42.6 +/- 6.8% (standard error), but enucleation from NVG was performed in only three eyes. Multivariate analysis revealed that the significant risk factors for NVG were V50IC (volume irradiated > or =50 GyE to iris-ciliary body) (p = 0.002) and ODI (p = 0.036). The 3-year NVG rate for patients with V50IC > or =0.127 mL and those with V50IC &lt;0.127 mL were 71.4 +/- 8.5% and 11.5 +/- 6.3%, respectively. The corresponding rate for the patients with and without ODI were 62.9 +/- 10.4% and 28.4 +/- 8.0%, respectively. CONCLUSION: Dose-volume histogram analysis with computed tomography indicated that V50IC and ODI were independent risk factors for NVG. An irradiation system that can reduce the dose to both the anterior segment and the optic disk might be worth adopting to investigate whether or not incidence of NVG can be decreased with it</style></abstract><notes><style face="normal" font="default">17141971g97, 7603616IM0 (Carbon Radioisotopes)Clinical Trial, Phase IClinical Trial, Phase IIJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>449</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Timmermann,B.</style></author><author><style face="normal" font="default"> Schuck,A.</style></author><author><style face="normal" font="default"> Niggli,F.</style></author><author><style face="normal" font="default"> Weiss,M.</style></author><author><style face="normal" font="default"> Lomax,A.J.</style></author><author><style face="normal" font="default"> Pedroni,E.</style></author><author><style face="normal" font="default"> Coray,A.</style></author><author><style face="normal" font="default"> Jermann,M.</style></author><author><style face="normal" font="default"> Rutz,H.P.</style></author><author><style face="normal" font="default"> Goitein,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Radiation Medicine, Proton Therapy, Paul Scherrer Institut, Villigen, Switzerland. beate.timmermann@psi.ch</style></auth-address><titles><title><style face="normal" font="default">Spot-scanning proton therapy for malignant soft tissue tumors in childhood: First experiences at the Paul Scherrer Institute</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.67.(2):497.-504.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.67.(2):497.-504.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Child,Preschool</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Feasibility Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> Head and Neck Neoplasms/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Head and Neck Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Head and Neck Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Meningeal Neoplasms/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Meningeal Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Meningeal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Rhabdomyosarcoma,Embryonal/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Rhabdomyosarcoma,Embryonal/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Rhabdomyosarcoma,Embryonal/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Sarcoma</style></keyword><keyword><style face="normal" font="default"> Sarcoma/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Sarcoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Sarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Survivors</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="1" Month="2" Year="2007">2007/2/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: Radiotherapy plays a major role in the treatment strategy of childhood sarcomas. Consequences of treatment are likely to affect the survivor's quality of life significantly. We investigated the feasibility of spot-scanning proton therapy (PT) for soft tissue tumors in childhood. METHODS AND MATERIALS: Sixteen children with soft tissue sarcomas were included. Median age at PT was 3.3 years. In 10 children the tumor histology was embryonal rhabdomyosarcoma. All tumors were located in the head or neck, parameningeal, or paraspinal, or pelvic region. In the majority of children, the tumor was initially unresectable (Intergroup Rhabdomyosarcoma Study [IRS] Group III in 75%). In 50% of children the tumors exceeded 5 cm. Fourteen children had chemotherapy before and during PT. Median total dose of radiotherapy was 50 cobalt Gray equivalent (CGE). All 16 children were treated with spot-scanning proton therapy at the Paul Scherrer Institute, and in 3 children the PT was intensity-modulated (IMPT). RESULTS: After median follow-up of 1.5 years, local control was achieved in 12 children. Four children failed locally, 1 at the border of the radiation field and 3 within the field. All 4 children died of tumor recurrence. All 4 showed unfavorable characteristic either of site or histopathology of the tumor. Acute toxicity was low, with Grade 3 or 4 side effects according to Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) criteria occurring in the bone marrow only. CONCLUSIONS: Proton therapy was feasible and well tolerated. Early local control rates are comparable to those being achieved after conventional radiotherapy. For investigations on late effect, longer follow-up is needed</style></abstract><notes><style face="normal" font="default">17084557g97, 7603616IM0 (Protons)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>450</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rutz,H.P.</style></author><author><style face="normal" font="default"> Weber,D.C.</style></author><author><style face="normal" font="default"> Sugahara,S.</style></author><author><style face="normal" font="default"> Timmermann,B.</style></author><author><style face="normal" font="default"> Lomax,A.J.</style></author><author><style face="normal" font="default"> Bolsi,A.</style></author><author><style face="normal" font="default"> Pedroni,E.</style></author><author><style face="normal" font="default"> Coray,A.</style></author><author><style face="normal" font="default"> Jermann,M.</style></author><author><style face="normal" font="default"> Goitein,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Radiation Medicine, Paul Scherrer Institute, Villigen, Switzerland. hanspeter.rutz@psi.ch</style></auth-address><titles><title><style face="normal" font="default">Extracranial chordoma: Outcome in patients treated with function-preserving surgery followed by spot-scanning proton beam irradiation</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.67.(2):512.-20.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.67.(2):512.-20.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Neoplasm,Residual</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="1" Month="2" Year="2007">2007/2/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To evaluate the use of postoperative proton therapy (PT) in extracranial chordoma. PATIENTS AND METHODS: Twenty-six patients were treated. Gross total resection was achieved in 18 patients. Nine patients had cervical, 2 had thoracic, 8 had lumbar, and 7 had sacro-coccygeal chordomas. Thirteen patients had implants. PT was administered after function-preserving surgery, using a gantry and spot scanning, without or with intensity modulation (IMPT; 6 patients), and/or photon-based radiotherapy (RT, 6 patients). Median total dose was 72 cobalt Gray equivalent (CGE; range, 59.4-74.4), with means of 70.5 and 73.2 CGE for patients with and without implants. Median follow-up time was 35 months (range, 13-73 months). Adverse events were scored using the Common Terminology Criteria for Adverse Events grading system (version 3.0). RESULTS: At 3 years, actuarial overall survival (OS) and progression-free survival (PFS) rates were 84% and 77%, respectively. One patient each died of local failure (LF), distant failure (DF), suicide, and secondary tumor. We observed 5 LFs and 3 DFs; 3-year LF-free and DF-free survival rates were 86%. We observed four radiation-induced late adverse events (Grade 2 sensory neuropathy; Grade 3 subcutaneous necrosis, and osteonecrosis; and Grade 5 secondary cancer). In univariate analysis, implants were associated with LF (p = 0.034). Gross residual tumor above 30 mL was negatively associated with OS (p = 0.013) and PFS (p = 0.025). CONCLUSIONS: Postoperative PT for extracranial chordomas delivered with spot scanning offers high local control rates. Toxicity was acceptable. Implants were significantly associated with LF. Residual tumor above 30 mL impacted negatively on OS and PFS</style></abstract><notes><style face="normal" font="default">17084540g97, 7603616IMEvaluation StudiesJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>460</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rundle,P.</style></author><author><style face="normal" font="default"> Singh,A.D.</style></author><author><style face="normal" font="default"> Rennie,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Ocular Oncology Clinic, Royal Hallamshire Hospital, Sheffield, UK. Paul.Rundle@sth.nhs.uk</style></auth-address><titles><title><style face="normal" font="default">Proton beam therapy for iris melanoma: a review of 15 cases</style></title><secondary-title><style face="normal" font="default">Eye.21(1):79.-82,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Eye.21(1):79.-82,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Cataract</style></keyword><keyword><style face="normal" font="default"> Cataract/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Glaucoma</style></keyword><keyword><style face="normal" font="default"> Glaucoma/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Iris Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Iris Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="1" Year="2007">2007/1</year></dates><pub-location><style face="normal" font="default">England</style></pub-location><isbn><style face="normal" font="default">0950-222X</style></isbn><abstract><style face="normal" font="default">AIM: To report results of proton beam therapy for iris melanoma. METHODS: A retrospective case series of 15 patients with nonresectable iris melanomas treated with proton beam therapy between August 1998 and August 2004. The main outcome measures were (1) local tumour control, (2) complications, and (3) eye retention. RESULTS: Of the 15 cases, 11 patients showed documented growth (including two cases of local recurrence following iridocyclectomy) while a further three cases were biopsy-proven melanoma. One patient presented with a newly acquired vascular nodule of the iris associated with angle seeding and glaucoma. Tumour control at mean follow-up of 34 months was 93% (14 of 15 eyes). Common complications included glaucoma in 53% (five patients had glaucoma prior to irradiation), dry eye (27%) and cataract in three patients (20%). Eye retention was possible in 80% (12 cases). CONCLUSION: Proton beam therapy is an effective treatment for cases of nonresectable iris melanoma. The major complications are cataract and glaucoma</style></abstract><notes><style face="normal" font="default">16410818eye, 8703986IM0 (Protons)Evaluation StudiesJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>495</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Weber,D.C.</style></author><author><style face="normal" font="default"> Chan,A.W.</style></author><author><style face="normal" font="default"> Lessell,S.</style></author><author><style face="normal" font="default"> McIntyre,J.F.</style></author><author><style face="normal" font="default"> Goldberg,S.I.</style></author><author><style face="normal" font="default"> Bussiere,M.R.</style></author><author><style face="normal" font="default"> Fitzek,M.M.</style></author><author><style face="normal" font="default"> Thornton,A.F.</style></author><author><style face="normal" font="default"> Delaney,T.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. damien.weber@hcuge.ch</style></auth-address><titles><title><style face="normal" font="default">Visual outcome of accelerated fractionated radiation for advanced sinonasal malignancies employing photons/protons</style></title><secondary-title><style face="normal" font="default">Radiotherapy &amp; Oncology.81.(3):243.-9,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Radiotherapy &amp; Oncology.81.(3):243.-9,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Squamous Cell/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Squamous Cell/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Transitional Cell/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Transitional Cell/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Cataract</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Eye Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Nasal Cavity</style></keyword><keyword><style face="normal" font="default"> Nasolacrimal Duct</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Paranasal Sinus Neoplasms/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Paranasal Sinus Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Planning,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Conformal</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="12" Year="2006">2006/12</year></dates><pub-location><style face="normal" font="default">Ireland</style></pub-location><isbn><style face="normal" font="default">0167-8140</style></isbn><abstract><style face="normal" font="default">PURPOSE: To investigate the visual outcomes of patients with advanced sinonasal malignancies treated with proton/photon accelerated fractionated radiation (AFR). PATIENTS AND METHODS: Between 1991 and 2001, AFR was used to treat 36 patients with advanced stage primary (n=33) or recurrent (n=3) nasal or paranasal malignant tumors. Full ophthalmologic follow-up was documented. The median dose to the gross tumor volume (GTV) was 69.6 CGE (range 60.8-77). Visual complications were graded according to the National Cancer Institute Common Toxicity Criteria (CTC) and the late effects of normal tissue (LENT) scoring systems. The median follow-up was 52.4 months (range 17-122.8). RESULTS: Thirteen patients developed late visual/ocular toxicity. Cataracts were LENT grade 1 and 3 in 2 patients and 1 patient, respectively. One LENT grade 1 vascular retinopathy and 1 optic neuropathy were also observed. Three and five patients presented with nasolacrimal duct stenosis (CTC grade 2, 2 patients; CTC grade 3, 1 patient) and dry-eye syndrome (CTC grade 1, 1 patient; CTC grade 2, 4 patients), respectively. The 3- and 5-year probability of LENT/CTC grade > or =2 visual toxicity were 15.8+/-6.7% and 20.7+/-7.8%, respectively. CONCLUSIONS: AFR for locally advanced nasal cavity and paranasal sinus tumors enables delivery of 70 CGE to the tumor with acceptable ophthalmologic complications</style></abstract><notes><style face="normal" font="default">17050017rae, 8407192IM0 (Protons)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>500</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hata,M.</style></author><author><style face="normal" font="default"> Tokuuye,K.</style></author><author><style face="normal" font="default"> Sugahara,S.</style></author><author><style face="normal" font="default"> Fukumitsu,N.</style></author><author><style face="normal" font="default"> Hashimoto,T.</style></author><author><style face="normal" font="default"> Ohnishi,K.</style></author><author><style face="normal" font="default"> Nemoto,K.</style></author><author><style face="normal" font="default"> Ohara,K.</style></author><author><style face="normal" font="default"> Matsuzaki,Y.</style></author><author><style face="normal" font="default"> Akine,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Proton Medical Research Center, University of Tsukuba, Tsukuba, Ibaraki, Japan</style></auth-address><titles><title><style face="normal" font="default">Proton beam therapy for hepatocellular carcinoma patients with severe cirrhosis</style></title><secondary-title><style face="normal" font="default">Strahlentherapie und Onkologie.182.(12):713.-20.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Strahlentherapie und Onkologie.182.(12):713.-20.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Cause of Death</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Liver Cirrhosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Liver Cirrhosis/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Liver Cirrhosis/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Liver Cirrhosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Liver Failure/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Liver Failure/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Staging</style></keyword><keyword><style face="normal" font="default"> Neoplasms,Multiple Primary/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Neoplasms,Multiple Primary/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Neoplasms,Multiple Primary/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Neoplasms,Multiple Primary/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Planning,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Synchrotrons</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="12" Year="2006">2006/12</year></dates><pub-location><style face="normal" font="default">Germany</style></pub-location><isbn><style face="normal" font="default">0179-7158</style></isbn><abstract><style face="normal" font="default">BACKGROUND AND PURPOSE: Hepatocellular carcinoma (HCC) patients with severe cirrhosis are usually treated with supportive care because of their poor prognosis. However, the survival of severe cirrhotic patients has recently improved due to advanced treatments. The aim of this study was to define the role of proton beam therapy for HCC patients with severe cirrhosis. PATIENTS AND METHODS: 19 HCC patients with Child-Pugh class C cirrhosis received proton beam therapy. The hepatic tumors were solitary in 14 patients and multiple in five, and the tumor size was 25-80 mm (median 40 mm) in maximum diameter. No patient had regional lymph node or distant metastasis. Total doses of 50-84 Gy (median 72 Gy) in ten to 24 fractions (median 16) were delivered to the tumors. RESULTS: Of the 19 patients, six, eight and four died of cancer, liver failure and intercurrent diseases, respectively, during the follow-up period of 3-63 months (median 17 months) after treatment. A remaining patient was alive with no evidence of disease 33 months after treatment. All but one of irradiated tumors were controlled during the follow-up period. Ten patients had new intrahepatic tumors outside the irradiated volume. The overall and progression-free survival rates were 53% and 47% at 1 year, respectively, and 42% each at 2 years. Performance status and Child-Pugh score were significant prognostic factors for survival. Therapy-related toxicity of grade 3 or more was not observed. CONCLUSION: Proton beam therapy for HCC patients with severe cirrhosis was tolerable. It may improve survival for patients with relatively good general condition and liver function</style></abstract><notes><style face="normal" font="default">17149578vcm, 8603469IM0 (Protons)Journal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>506</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ishikawa,H.</style></author><author><style face="normal" font="default"> Tsuji,H.</style></author><author><style face="normal" font="default"> Kamada,T.</style></author><author><style face="normal" font="default"> Hirasawa,N.</style></author><author><style face="normal" font="default"> Yanagi,T.</style></author><author><style face="normal" font="default"> Mizoe,J.E.</style></author><author><style face="normal" font="default"> Akakura,K.</style></author><author><style face="normal" font="default"> Suzuki,H.</style></author><author><style face="normal" font="default"> Shimazaki,J.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan</style></auth-address><titles><title><style face="normal" font="default">Risk factors of late rectal bleeding after carbon ion therapy for prostate cancer</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.66.(4):1084.-91.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.66.(4):1084.-91.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Gastrointestinal Hemorrhage/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Heavy Ions/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Japan/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prostate</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Rectal Diseases/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Rectum</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="15" Month="11" Year="2006">2006/11/15</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: The aim of this study was to determine the risk factors for late gastrointestinal (GI) morbidity after hypofractionated carbon ion radiotherapy (C-ion RT) for prostate cancer. METHODS AND MATERIALS: Between April 2000 and November 2003, a Phase II clinical trial of C-ion RT with a total dose of 66 GyE in 20 fractions was performed on 175 patients with prostate cancer, and the correlations of clinical and dosimetric parameters with the incidence of late GI toxicity in 172 patients who survived for more than 18 months were investigated. RESULTS: Although no Grade 3-4 late morbidities of the rectum were observed, Grade 1 and 2 morbidities developed in 23 (13%) and 4 (2%) patients, respectively. Dose-volume histogram analysis revealed that the percentage of rectal volume receiving 50% of the prescribed dose (V50) was significantly higher in patients with rectal toxicity than without toxicity (13.2 +/- 5.6% with toxicity; 11.4 +/- 4.0% without toxicity, p = 0.046). Multivariate analysis demonstrated that the use of anticoagulation therapy (p = 0.010) and rectal V50 (p = 0.012) were significant risk factors for the occurrence of Grade 1-2 late GI toxicity. CONCLUSIONS: Although C-ion RT with hypofractionation yielded favorable results regarding late GI complication, dosimetric parameter was a very important factor in the occurrence of rectal bleeding after C-ion RT as well as photon beam RT. Our results provide useful information for physicians applying charged particle RT in the treatment of prostate cancer</style></abstract><notes><style face="normal" font="default">16979840g97, 7603616IM0 (Carbon Radioisotopes)Clinical Trial, Phase IIJournal ArticleRandomized Controlled TrialResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>517</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pommier,P.</style></author><author><style face="normal" font="default"> Liebsch,N.J.</style></author><author><style face="normal" font="default"> Deschler,D.G.</style></author><author><style face="normal" font="default"> Lin,D.T.</style></author><author><style face="normal" font="default"> McIntyre,J.F.</style></author><author><style face="normal" font="default"> Barker,F.G.</style></author><author><style face="normal" font="default"> Adams,J.A.</style></author><author><style face="normal" font="default"> Lopes,V.V.</style></author><author><style face="normal" font="default"> Varvares,M.</style></author><author><style face="normal" font="default"> Loeffler,J.S.</style></author><author><style face="normal" font="default"> Chan,A.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA</style></auth-address><titles><title><style face="normal" font="default">Proton beam radiation therapy for skull base adenoid cystic carcinoma</style></title><secondary-title><style face="normal" font="default">Archives of Otolaryngology -- Head &amp; Neck Surgery.132.(11):1242.-9,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Archives of Otolaryngology -- Head &amp; Neck Surgery.132.(11):1242.-9,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Adenoid Cystic/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Adenoid Cystic/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Cavernous Sinus</style></keyword><keyword><style face="normal" font="default"> Cranial Fossa,Posterior</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Nasopharyngeal Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Neoplasm Metastasis</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local</style></keyword><keyword><style face="normal" font="default"> Neutrons</style></keyword><keyword><style face="normal" font="default"> Paranasal Sinus Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Salvage Therapy</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Base</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Sphenoid Sinus</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Vision</style></keyword></keywords><dates><year Day="0" Month="11" Year="2006">2006/11</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0886-4470</style></isbn><abstract><style face="normal" font="default">OBJECTIVE: To determine the treatment outcome and prognostic factors in patients with adenoid cystic carcinoma of the skull base treated with proton beam radiation therapy. DESIGN: Retrospective analysis. SETTING: Massachusetts General Hospital, Massachusetts Eye and Ear Infirmary, and Harvard Medical School, Boston. PATIENTS: From 1991 to 2002, 23 patients with newly diagnosed adenoid cystic carcinoma with skull base extension were treated with combined proton and photon radiotherapy. There was tumor involvement of the sphenoid sinus in 61% of patients (14), nasopharynx in 61% (14), clivus in 48% (11), and cavernous sinus in 74% (17). The extent of surgery was biopsy alone in 48% (11), partial resection in 39% (9), and gross total resection with positive margins in 13% (3). The median total dose to the primary site was 75.9 cobalt-gray equivalent. The median follow-up of all surviving patients was 64 months. MAIN OUTCOME MEASURES: Locoregional control and disease-free survival and overall survival rates. RESULTS: Tumors recurred locally in 2 patients at 33 and 68 months, respectively. No patients developed neck recurrence. Eight patients had distant metastasis as the first site of recurrence. The local control rate at 5 years was 93%. The rate of freedom from distant metastasis at 5 years was 62%. The disease-free and overall survival rates at 5 years were 56% and 77%, respectively. In multivariate analysis, significant adverse factors predictive for overall survival were change in vision at presentation (P = .02) and involvement of sphenoid sinus and clivus (P = .01). CONCLUSIONS: High-dose conformal proton beam radiation therapy results in a very encouraging local control rate in patients with adenoid cystic carcinoma of the skull base. Changes in vision at presentation and tumor involvement of the sphenoid sinus and clivus are important prognostic factors</style></abstract><notes><style face="normal" font="default">171168228603209, alqAIM, IM0 (Protons)7440-44-0 (Carbon)Comparative StudyJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>530</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lumbroso-Le,Rouic L.</style></author><author><style face="normal" font="default"> Delacroix,S.</style></author><author><style face="normal" font="default"> Dendale,R.</style></author><author><style face="normal" font="default"> Levy-Gabriel,C.</style></author><author><style face="normal" font="default"> Feuvret,L.</style></author><author><style face="normal" font="default"> Noel,G.</style></author><author><style face="normal" font="default"> Plancher,C.</style></author><author><style face="normal" font="default"> Nauraye,C.</style></author><author><style face="normal" font="default"> Garcia,P.</style></author><author><style face="normal" font="default"> Calugaru,V.</style></author><author><style face="normal" font="default"> Asselain,B.</style></author><author><style face="normal" font="default"> Desjardins,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of ophthalmology, Institut Curie, Paris, France. livia.lumbroso@ curie.net</style></auth-address><titles><title><style face="normal" font="default">Proton beam therapy for iris melanomas</style></title><secondary-title><style face="normal" font="default">Eye.</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Eye.</style></abbr-1></periodical><pages end="1305" start="1300">1300-1305</pages><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Cataract</style></keyword><keyword><style face="normal" font="default"> Cataract/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Ciliary Body</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Glaucoma</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Intraocular Pressure</style></keyword><keyword><style face="normal" font="default"> Iris Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Iris Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pressure</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="11" Year="1920">1920/11</year></dates><pub-location><style face="normal" font="default">England</style></pub-location><isbn><style face="normal" font="default">0950-222X</style></isbn><abstract><style face="normal" font="default">AIMS: To describe the results in terms of local control, eye preservation and systemic evolution of iris melanomas treated by proton beam irradiation. METHODS: Retrospective review of the charts of patients with iris melanoma treated by proton beam therapy between April 1998 and September 2002. Ciliary body melanomas with iris involvement or tumours with extrascleral invasion were excluded. Treatment consisted of 60 Gy of proton beam irradiation delivered in four fractions to the tumour volume. RESULTS: A total of 21 patients were treated, median follow-up of 33 months (8-72 months). 15 patients presented a lesion with documented growth. The median clinical diameter was 5 mm (2-8 mm), the median ultrasound diameter 4.8 mm (2-7.7 mm) The patients were 6% T1, 57.1% T2, and 14.3% T3 all N0M0. The iridocorneal angle was invaded by the tumour in 71.4% of patients. At the end of follow-up, all patients were alive with no proven metastatic disease except one patient with suspicious liver lesions. None of the patients showed tumour progression or ocular relapse. The tumour response at 2 years was a flat lesion for 6.3% of cases, partial regression in 75% and stable in 18.8%. None of the patients required secondary enucleation. The main complication was cataract (45% within 24 months of treatment). Raised intraocular pressure was observed in 15% of patients but no neovascular glaucoma. CONCLUSIONS: Proton beam therapy shows potential utility for selected cases of localised iris melanomas allowing excellent local tumour control and eye preservation. Further follow-up on larger series is needed to confirm these results</style></abstract><notes><style face="normal" font="default">16294207eye, 8703986IM0 (Protons)Evaluation StudiesJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>540</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ishikawa,H.</style></author><author><style face="normal" font="default"> Tsuji,H.</style></author><author><style face="normal" font="default"> Kamada,T.</style></author><author><style face="normal" font="default"> Yanagi,T.</style></author><author><style face="normal" font="default"> Mizoe,J.E.</style></author><author><style face="normal" font="default"> Kanai,T.</style></author><author><style face="normal" font="default"> Morita,S.</style></author><author><style face="normal" font="default"> Wakatsuki,M.</style></author><author><style face="normal" font="default"> Shimazaki,J.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author><author><style face="normal" font="default"> Working Group for Genitourinary Tumors</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Inage-ku, Chiba-city, Japan</style></auth-address><titles><title><style face="normal" font="default">Carbon ion radiation therapy for prostate cancer: results of a prospective phase II study</style></title><secondary-title><style face="normal" font="default">Radiotherapy &amp; Oncology.81.(1):57.-64.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Radiotherapy &amp; Oncology.81.(1):57.-64.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adenocarcinoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Adenocarcinoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Androgen Antagonists/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Feasibility Studies</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Prostate</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Rectum</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Statistics,Nonparametric</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="0" Month="10" Year="2006">2006/10</year></dates><pub-location><style face="normal" font="default">Ireland</style></pub-location><isbn><style face="normal" font="default">0167-8140</style></isbn><abstract><style face="normal" font="default">BACKGROUND AND PURPOSE: To determine the efficacy and feasibility of carbon ion radiotherapy (C-ion RT) for prostate cancer. PATIENTS AND METHODS: Between April 2000 and November 2003, 175 patients received C-ion RT using a recommended dose fractionation (66.0 GyE/20 fractions) established from prior studies. C-ion RT alone was performed for 33 patients constituting a low-risk group (Stage &lt; or =T2a and PSA &lt;20 ng/ml and Gleason score &lt; or =6); the remaining 142 high-risk patients received an additional androgen deprivation therapy (ADT). RESULTS: The 4-year overall survival and bNED rates were 91% and 87%, respectively. Local control was achieved in all but one patient. The 4-year bNED rates were 87% in the low-risk group and 88% in the high-risk group. In very advanced diseases (Stage > or= T3a or PSA > or= 20 ng/ml or Gleason score > or =8), there was significant difference in the bNED rate according to period of ADT administration (ADT > or =24 months: 93%, ADT &lt;24 months: 73%, p&lt;0.01). Grade 2 late toxicities developed in 4 patients (2%) for the rectum and 9 patients (5%) for the genitourinary system but no Grade 3 or higher toxicity was observed. CONCLUSIONS: The effectiveness of C-ion RT for prostate cancer has been well confirmed. Based on these results, new study of a C-ion RT modified for the administration strategy of ADT according to the patient risk has been started by dividing patients into 3 groups, high-risk, intermediate-risk, and low-risk</style></abstract><notes><style face="normal" font="default">16971008rae, 8407192IM0 (Androgen Antagonists)0 (Carbon Radioisotopes)Clinical Trial, Phase IIJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>556</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kozak,K.R.</style></author><author><style face="normal" font="default"> Smith,B.L.</style></author><author><style face="normal" font="default"> Adams,J.</style></author><author><style face="normal" font="default"> Kornmehl,E.</style></author><author><style face="normal" font="default"> Katz,A.</style></author><author><style face="normal" font="default"> Gadd,M.</style></author><author><style face="normal" font="default"> Specht,M.</style></author><author><style face="normal" font="default"> Hughes,K.</style></author><author><style face="normal" font="default"> Gioioso,V.</style></author><author><style face="normal" font="default"> Lu,H.M.</style></author><author><style face="normal" font="default"> Braaten,K.</style></author><author><style face="normal" font="default"> Recht,A.</style></author><author><style face="normal" font="default"> Powell,S.N.</style></author><author><style face="normal" font="default"> Delaney,T.F.</style></author><author><style face="normal" font="default"> Taghian,A.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA</style></auth-address><titles><title><style face="normal" font="default">Accelerated partial-breast irradiation using proton beams: initial clinical experience</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.66.(3):691.-8.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.66.(3):691.-8.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Breast</style></keyword><keyword><style face="normal" font="default"> Breast Neoplasms/px [Psychology]</style></keyword><keyword><style face="normal" font="default"> Breast Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Breast Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Breast/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Breast/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Color</style></keyword><keyword><style face="normal" font="default"> Esthetics</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Mastectomy,Segmental</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patient Satisfaction</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Conformal/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Conformal/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Telangiectasis/et [Etiology]</style></keyword></keywords><dates><year Day="1" Month="11" Year="2006">2006/11/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: We present our initial clinical experience with proton, three-dimensional, conformal, external beam, partial-breast irradiation (3D-CPBI). METHODS AND MATERIALS: Twenty patients with Stage I breast cancer were treated with proton 3D-CPBI in a Phase I/II clinical trial. Patients were followed at 3 to 4 weeks, 6 to 8 weeks, 6 months, and every 6 months thereafter for recurrent disease, cosmetic outcome, toxicity, and patient satisfaction. RESULTS: With a median follow-up of 12 months (range, 8-22 months), no recurrent disease has been detected. Global breast cosmesis was judged by physicians to be good or excellent in 89% and 100% of cases at 6 months and 12 months, respectively. Patients rated global breast cosmesis as good or excellent in 100% of cases at both 6 and 12 months. Proton 3D-CPBI produced significant acute skin toxicity with moderate to severe skin color changes in 79% of patients at 3 to 4 weeks and moderate to severe moist desquamation in 22% of patients at 6 to 8 weeks. Telangiectasia was noted in 3 patients. Three patients reported rib tenderness in the treated area, and one rib fracture was documented. At last follow-up, 95% of patients reported total satisfaction with proton 3D-CPBI. CONCLUSIONS: Based on our study results, proton 3D-CPBI offers good-to-excellent cosmetic outcomes in 89% to 100% of patients at 6-month and 12-month follow-up and nearly universal patient satisfaction. However, proton 3D-CPBI, as used in this study, does result in significant acute skin toxicity and may potentially be associated with late skin (telangiectasia) and rib toxicity. Because of the dosimetric advantages of proton 3D-CPBI, technique modifications are being explored to improve acute skin tolerance</style></abstract><notes><style face="normal" font="default">17011445g97, 7603616IM0 (Protons)Clinical Trial, Phase IClinical Trial, Phase IIJournal ArticleResearch Support, N.I.H., ExtramuralResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>559</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Desjardins,L.</style></author><author><style face="normal" font="default"> Lumbroso-Le,Rouic L.</style></author><author><style face="normal" font="default"> Levy-Gabriel,C.</style></author><author><style face="normal" font="default"> Dendale,R.</style></author><author><style face="normal" font="default"> Delacroix,S.</style></author><author><style face="normal" font="default"> Nauraye,C.</style></author><author><style face="normal" font="default"> Esteve,M.</style></author><author><style face="normal" font="default"> Plancher,C.</style></author><author><style face="normal" font="default"> Asselain,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institut Curie, Paris, France. laurence.desjardins@curie.net</style></auth-address><titles><title><style face="normal" font="default">Combined proton beam radiotherapy and transpupillary thermotherapy for large uveal melanomas: a randomized study of 151 patients.[see comment]</style></title><secondary-title><style face="normal" font="default">Ophthalmic Research.38.(5):255.-60,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ophthalmic Research.38.(5):255.-60,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Cobalt Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Cobalt Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Combined Modality Therapy</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Eye Enucleation/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Glaucoma</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperthermia,Induced</style></keyword><keyword><style face="normal" font="default"> Informed Consent</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pupil</style></keyword><keyword><style face="normal" font="default"> Radioisotope Teletherapy</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Retinal Detachment/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/th [Therapy]</style></keyword></keywords><dates><year Day="0" Month="0" Year="2006">2006</year></dates><pub-location><style face="normal" font="default">Switzerland</style></pub-location><isbn><style face="normal" font="default">0030-3747</style></isbn><abstract><style face="normal" font="default">INTRODUCTION: Exudation from the tumour scar and glaucoma can be major problems after proton beam irradiation of uveal melanoma and can sometimes lead to secondary enucleation. We conducted a randomized study to determine whether systematic transpupillary thermotherapy (TTT) after proton beam radiotherapy could have a beneficial effect. PATIENTS AND METHOD: Between February 1999 and April 2003, all the patients treated by proton beam radiotherapy for uveal melanomas >/=7 mm thick or >/=15 mm in diameter were included in this study after giving their informed consent. One half of the patients received proton beam radiotherapy alone (60 Gy in 4 fractions) and the other half received the same dose of proton beam radiotherapy followed by TTT at 1, 6 and 12 months. All the information concerning the initial tumour parameters, treatments and follow-up was recorded and a statistical analysis was performed. RESULTS: We randomized 151 patients. The median follow-up was 38 months. The 2 groups of patients were similar in terms of age, gender and tumour characteristics. The patients treated with TTT showed a greater reduction of tumour thickness (p = 0.06), less retinal detachment at the latest follow-up (p = 0.14) and a lower secondary enucleation rate (p = 0.02). DISCUSSION: The present study is the first randomized analysis to demonstrate a significant decrease in the secondary enucleation rate in patients treated with TTT after proton beam radiotherapy. Further studies should be performed to determine whether TTT could be beneficial to smaller tumours and to define its optimal dose. Copyright (c) 2006 S. Karger AG, Basel</style></abstract><notes><style face="normal" font="default">16888407oie, 0267442IM0 (Cobalt Radioisotopes)Journal ArticleRandomized Controlled TrialEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>582</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hata,M.</style></author><author><style face="normal" font="default"> Tokuuye,K.</style></author><author><style face="normal" font="default"> Sugahara,S.</style></author><author><style face="normal" font="default"> Fukumitsu,N.</style></author><author><style face="normal" font="default"> Hashimoto,T.</style></author><author><style face="normal" font="default"> Ohnishi,K.</style></author><author><style face="normal" font="default"> Nemoto,K.</style></author><author><style face="normal" font="default"> Ohara,K.</style></author><author><style face="normal" font="default"> Matsuzaki,Y.</style></author><author><style face="normal" font="default"> Akine,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Proton Medical Research Center, University of Tsukuba, Tsukuba, Ibaraki, Japan. mhata@syd.odn.ne.jp</style></auth-address><titles><title><style face="normal" font="default">Proton beam therapy for hepatocellular carcinoma with limited treatment options</style></title><secondary-title><style face="normal" font="default">Cancer.107.(3):591.-8.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cancer.107.(3):591.-8.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="1" Month="8" Year="2006">2006/8/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0008-543X</style></isbn><abstract><style face="normal" font="default">BACKGROUND: The authors conducted a retrospective review to define the usefulness of proton beam therapy for patients who had hepatocellular carcinoma (HCC) with limited treatment options. METHODS: Twenty-one patients with HCC for whom other treatment modalities either were contraindicative or were unfeasible because of coexisting diseases and unfavorable conditions received proton beam therapy. Four patients had renal failure, 2 patients had severe heart disease, 9 patients had severe cirrhosis, 1 patient had aplastic anemia, 1 patient had a dissecting abdominal aortic aneurysm before treatment, and 4 patients had bleeding tendency or unresectable tumors. Moreover, 2 of the latter 4 patients were allergic to iodine, and 2 other patients were unable to be catheterized for transcatheter arterial chemoembolization. Hepatic tumors were solitary in 14 patients and multiple in 7 patients, and the tumors ranged in greatest dimension from 25 mm to 100 mm (median, 40 mm). No patient had regional lymph node or distant metastasis. Total doses of 63 grays (Gy) to 84 Gy (median, 73 Gy) in 13 to 27 fractions (median, 18 fractions) were used for tumor treatments. RESULTS: All but 1 of the irradiated tumors were controlled at a median follow-up of 3.3 years. The objective response rate was 81%, and the primary site-control rate was 93% at 5 years. Eleven patients had intrahepatic recurrences, and 2 patients had distant metastases in the lungs. Four of 11 patients with intrahepatic recurrences received a second course of proton beam therapy, and all recurrent tumors were controlled. The overall and cause-specific survival rates were 62% and 82% at 2 years, respectively, and 33% and 67% at 5 years, respectively. Grade > or =3 therapy-related toxicities were not observed. CONCLUSIONS: Proton beam therapy was safe and effective for a variety of patients with HCC. The current results suggested that this method was tolerable and effective, even for patients with HCC who had limited treatment options. Copyright 2006 American Cancer Society</style></abstract><notes><style face="normal" font="default">168049310374236, clzAIM, IM0 (Protons)Journal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>612</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Murayama,S.</style></author><author><style face="normal" font="default"> Fuji,H.</style></author><author><style face="normal" font="default"> Yamashita,H.</style></author><author><style face="normal" font="default"> Futami,Y.</style></author><author><style face="normal" font="default"> Numano,M.</style></author><author><style face="normal" font="default"> Harada,H.</style></author><author><style face="normal" font="default"> Kamata,M.</style></author><author><style face="normal" font="default"> Nishimura,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Proton Therapy Division, Shizuoka Cancer Center Hospital</style></auth-address><titles><title><style face="normal" font="default">[Initial clinical experience of proton therapy at Shizuoka Cancer Center]. [Japanese]</style></title><secondary-title><style face="normal" font="default">Nippon Igaku Hoshasen Gakkai Zasshi - Nippon Acta Radiologica.65.(4):424.-31.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Nippon Igaku Hoshasen Gakkai Zasshi - Nippon Acta Radiologica.65.(4):424.-31.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Cancer Care Facilities</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> Head and Neck Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prostate</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="0" Month="10" Year="2005">2005/10</year></dates><pub-location><style face="normal" font="default">Japan</style></pub-location><isbn><style face="normal" font="default">0048-0428</style></isbn><abstract><style face="normal" font="default">PURPOSE: To present the initial experience and preliminary clinical results of patients treated mainly with proton irradiation at the newly developed proton therapy facility at Shizuoka Cancer Center. MATERIALS AND METHODS: We reviewed 125 patients who underwent proton therapy between July 2003 and December 2004. Of these 125 patients, 11 had head and neck malignancies, 15 non-small cell lung cancers, 22 hepatocellular carcinomas, 62 prostate cancers, and 15 other malignant tumors. RESULTS: Most patients experienced Grade 0-1 acute morbidities (NCI-CTC) in skin or mucosa, while a temporary Grade 2-3 reaction was observed in a high dose area. Response rates were 73% for H &amp; N malignancies, 100% for NSCLC, and 77% for HCC. PSA evaluation for patients with prostate cancer revealed a high rate of complete response. CONCLUSION: The efficacy and safety of proton therapy at Shizuoka Cancer Center was demonstrated for patients with early-stage cancer or locally advanced disease</style></abstract><notes><style face="normal" font="default">16334397o3g, 0413544IM0 (Protons)English AbstractJournal ArticleResearch Support, Non-U.S. Gov'tJapanese</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>638</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tsuji,H.</style></author><author><style face="normal" font="default"> Yanagi,T.</style></author><author><style face="normal" font="default"> Ishikawa,H.</style></author><author><style face="normal" font="default"> Kamada,T.</style></author><author><style face="normal" font="default"> Mizoe,J.E.</style></author><author><style face="normal" font="default"> Kanai,T.</style></author><author><style face="normal" font="default"> Morita,S.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author><author><style face="normal" font="default"> Working Group for Genitourinary Tumors</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan. h_tsuji@nirs.go.jp</style></auth-address><titles><title><style face="normal" font="default">Hypofractionated radiotherapy with carbon ion beams for prostate cancer</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.63(4):1153.-60,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.63(4):1153.-60,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adenocarcinoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Prostate</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Conformal/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Rectum</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="15" Month="11" Year="2005">2005/11/15</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: Analysis of the results of hypofractionated conformal carbon ion radiotherapy for localized prostate cancer was performed, with special regard to normal tissue morbidity and biochemical relapse-free rate (bNED). METHODS AND MATERIALS: Analysis was performed for 201 patients treated with the dose fractionation regimen established during three clinical trials performed between June 1995 and February 2004. Outcomes were measured in terms of toxicity, survival, freedom from local recurrence, and bNED. RESULTS: No Grade 3 or higher toxicities were observed in either the rectum or genitourinary system, and the incidences of Grade 2 rectum or genitourinary morbidity were only 1.0% and 6.0%, respectively. The overall 5-year biochemical relapse-free survival was 83.2% without any local recurrence. Gleason score, initial PSA, and T stage were all significant prognostic factors for bNED, which was 97.1% in patients with Gleason score &lt; or =7 and initial PSA &lt;20 ng/mL. CONCLUSION: Hypofractionated carbon ion radiotherapy with the established dose fractionation regimen yielded satisfactory bNED without local recurrence and with minimal morbidity. Long-term results are necessary to confirm the utility of carbon ion radiotherapy in the treatment of localized prostate cancer</style></abstract><notes><style face="normal" font="default">15990247g97, 7603616IM0 (Carbon Radioisotopes)Clinical Trial, Phase IClinical Trial, Phase IIJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>643</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hamrouni,Z.</style></author><author><style face="normal" font="default"> Levy,C.</style></author><author><style face="normal" font="default"> Lumbroso,L.</style></author><author><style face="normal" font="default"> D'Hermies,F.</style></author><author><style face="normal" font="default"> Frau,E.</style></author><author><style face="normal" font="default"> Mazal,A.</style></author><author><style face="normal" font="default"> Delacroix,S.</style></author><author><style face="normal" font="default"> Nauraye,C.</style></author><author><style face="normal" font="default"> Dendale,R.</style></author><author><style face="normal" font="default"> Schlienger,P.</style></author><author><style face="normal" font="default"> Desjardins,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Service d'Ophtalmologie, Institut Curie, Paris</style></auth-address><titles><title><style face="normal" font="default">[Results of treating uveal melanoma with proton beam radiation: 10-year follow-up]. [French]</style></title><secondary-title><style face="normal" font="default">Journal Francais.d.Opthalmologie.28.(8.):833.-9,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Journal Francais.d.Opthalmologie.28.(8.):833.-9,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fluorescein Angiography</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Glaucoma</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Optic Disk</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> radiography</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Retinal Detachment</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Ultrasonography</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword></keywords><dates><year Day="0" Month="10" Year="2005">2005/10</year></dates><pub-location><style face="normal" font="default">France</style></pub-location><abstract><style face="normal" font="default">PURPOSE: We analyzed the long-term results of uveal melanoma treatment with proton beam irradiation in a series of patients with a follow-up of at least 10 years. PATIENTS AND METHODS: The patients were treated with proton beam radiation between September 1991 and December 1992. They had an initial examination including visual acuity, funduscopy, A and B scan ultrasonography of the eye, fundus photographs and fluorescein angiography. General examination included chest radiography and B scan ultrasonography of the liver. All tumors received a total dose of 60 cobalt-Gray equivalents (applied in four daily fractions) at the Orsay proton therapy center. RESULTS: A total of 167 patients were treated with a median follow-up of 116 months. Their median age was 59 years. Thirteen tumors were anterior to the equator, 76 overlapped the equator and 78 were posterior to the equator. An initial retinal detachment was present in 41 cases. The optic disk was invaded in 10 cases. The median tumor diameter was 12 mm and the median tumor thickness was 5.8 mm. The mean initial acuity was 20/50. The survival rate was 62.93% at 10 years; 72.9% of deaths resulted from metastasis. Statistically significant risk factors for death identified in the multivariate analysis were tumor diameter greater than 12 mm (p=0.0004) and age over 60 years (p=0.0001). The metastasis rate at 10 years was 31%. The liver was affected in 97.8% of these patients. Risk factors for metastasis were the anterior site of the tumor, its volume greater than 0.4 cc and the presence of retinal detachment at diagnosis. The secondary enucleation rate at 10 years was 13.23%, mainly attributable to secondary neovascular glaucoma. The local recurrence rate was 6%. The visual acuity rate in 42.1% of patients was better than 20/100 at 10 years. Visual loss was mainly due to postradiation maculopathy and neuropathy. CONCLUSION: Our study confirms the long-term results found in the literature on proton beam radiation. This therapy allows good tumor control, an excellent eye retention rate, and good final visual acuity for approximately half of the patients</style></abstract><notes><style face="normal" font="default">16249762iae, 7804128IMEnglish AbstractJournal ArticleFrench</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>650</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Noel,G.</style></author><author><style face="normal" font="default"> Feuvret,L.</style></author><author><style face="normal" font="default"> Calugaru,V.</style></author><author><style face="normal" font="default"> Dhermain,F.</style></author><author><style face="normal" font="default"> Mammar,H.</style></author><author><style face="normal" font="default"> Haie-Meder,C.</style></author><author><style face="normal" font="default"> Ponvert,D.</style></author><author><style face="normal" font="default"> Hasboun,D.</style></author><author><style face="normal" font="default"> Ferrand,R.</style></author><author><style face="normal" font="default"> Nauraye,C.</style></author><author><style face="normal" font="default"> Boisserie,G.</style></author><author><style face="normal" font="default"> Beaudre,A.</style></author><author><style face="normal" font="default"> Gaboriaud,G.</style></author><author><style face="normal" font="default"> Mazal,A.</style></author><author><style face="normal" font="default"> Habrand,J.L.</style></author><author><style face="normal" font="default"> Mazeron,J.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institut Curie-CPO batiment 101, University Campus, 91898 Orsay, Cedex, France. noel@ipno.in2p3.fr</style></auth-address><titles><title><style face="normal" font="default">Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams</style></title><secondary-title><style face="normal" font="default">Acta Oncologica.44.(7.):700.-8.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Acta Oncologica.44.(7.):700.-8.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons</style></keyword><keyword><style face="normal" font="default"> Photons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Conformal/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2005">2005</year></dates><pub-location><style face="normal" font="default">Norway</style></pub-location><isbn><style face="normal" font="default">0284-186X</style></isbn><abstract><style face="normal" font="default">To define the prognostic factors for local control and overall survival among 100 consecutive patients with chordoma of the base of skull or upper cervical spine treated by fractionated irradiation combining proton and photon beams. Between December 1993 and August 2002, 100 patients (median age: 53 years [8 - 85], M/F sex ratio: 3/2) were treated by a combination of high-energy photons and protons. The proton component was delivered at the Centre de Protontherapie d'Orsay (CPO) by a 201 MeV beam. The median total dose delivered to the tumor volume was 67 GyECo. With a median follow-up of 31 months [range: 0 - 87], 25 tumours relapsed locally. The 2- and 4-year local control rates were 86.3% (+/-3.9%) and 53.8% (+/-7.5%), respectively. According to multivariate analysis, at least 95% of the tumor volume encompassed by the 95% isodose (p = 0.048; RR: 3.4 95%CI [1.01 - 11.8]) and a minimal dose delivered into the tumor volume &lt;56 GyECo (p = 0.042; RR: 2.3 95%CI [1.03 - 5.2]) were independent prognostic factors of local control. Ten patients died. The 2- and 5-year overall survival rates were 94.3% (+/-2.5%) and 80.5% (+/-7.2%), respectively. According to multivariate analysis, local tumor control (p = 0.005; RR: 21 95%CI [2.2 - 200]) was a prognostic factor of overall survival. For chordomas of the base of the skull and upper cervical spine treated by surgery and irradiation combining photons and protons, the quality of irradiation, reflected by homogeneity of the dose into the tumor volume, is a major factor of local control. Close attention must be paid to minimize the underdosed areas close to critical organs. The role of surgical resection remains paramount, and a trial of dose escalation would have to consider an increase in the dose to critical organs, especially as current results indicate the low toxicity of this treatment</style></abstract><notes><style face="normal" font="default">16227160aon, 8709065IM0 (Protons)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>674</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Weber,D.C.</style></author><author><style face="normal" font="default"> Rutz,H.P.</style></author><author><style face="normal" font="default"> Pedroni,E.S.</style></author><author><style face="normal" font="default"> Bolsi,A.</style></author><author><style face="normal" font="default"> Timmermann,B.</style></author><author><style face="normal" font="default"> Verwey,J.</style></author><author><style face="normal" font="default"> Lomax,A.J.</style></author><author><style face="normal" font="default"> Goitein,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Medicine, Proton Therapy Program, Paul Scherrer Institut, Villigen, Switzerland. damien.weber@hcuge.ch</style></auth-address><titles><title><style face="normal" font="default">Results of spot-scanning proton radiation therapy for chordoma and chondrosarcoma of the skull base: the Paul Scherrer Institut experience</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.63(2):401.-9,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.63(2):401.-9,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Base</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="1" Month="10" Year="2005">2005/10/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To assess the clinical results of spot scanning proton beam radiation therapy (PT) in the treatment of skull base chordomas and low-grade chondrosarcomas (CS). METHODS AND MATERIALS: Between October 1998 and October 2003, 29 patients (median age, 39 years) with chordomas (n = 18) and CS (n = 11) were treated at the Paul Scherrer Institut (PSI) with protons using the main 510-MeV cyclotron. Tumor conformal application of proton beams was realized by spot scanning technology. The median chordoma and CS dose was 74 and 68 cobalt Gy equivalent, respectively (cobalt Gy equivalent = proton Gy x 1.1). Median gross tumor volumes (GTV) were 16.4 mL (range, 1.8-48.1 mL) and 15.2 mL (range, 2.3-57.3 mL) for chordoma and CS, respectively. Late toxicity was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE, v3.0) grading system. The median follow-up time was 29 months (range, 6-68 months). RESULTS: Actuarial 3-year local control rates were 87.5% and 100% for chordoma and CS, respectively. We observed one surgical pathway and one marginal failure in patients with chordomas. No regional failure or distant metastasis was observed. At 3 years, actuarial PFS and OS for the entire cohort was 90% and 93.8%, respectively. Actuarial 3-year complication-free survival was 82.2%. Radiation-induced pituitary dysfunction was observed in 4 (14%) patients (CTCAE Grade 2). No patient presented with post-PT brainstem or optic pathways necrosis or dysfunction. In univariate analysis, age &lt; or =40 years at the time of PT affected favorably on PFS (p = 0.09). CONCLUSION: Spot-scanning PT offers high tumor control rates of skull base chordoma and CS. These results compare favorably to other combined proton-photon or carbon ion irradiation series. Observed toxicity was acceptable. Younger age (&lt; or =40 years) was a favorable prognostic factor of PFS. These preliminary results are encouraging but should be confirmed during a longer follow-up</style></abstract><notes><style face="normal" font="default">16168833g97, 7603616IM0 (Protons)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>683</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zietman,A.L.</style></author><author><style face="normal" font="default"> DeSilvio,M.L.</style></author><author><style face="normal" font="default"> Slater,J.D.</style></author><author><style face="normal" font="default"> Rossi,C.J.,Jr.</style></author><author><style face="normal" font="default"> Miller,D.W.</style></author><author><style face="normal" font="default"> Adams,J.A.</style></author><author><style face="normal" font="default"> Shipley,W.U.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. azietman@partners.org</style></auth-address><titles><title><style face="normal" font="default">Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.[see comment]</style></title><secondary-title><style face="normal" font="default">JAMA.294.(10):1233.-9,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">JAMA.294.(10):1233.-9,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adenocarcinoma</style></keyword><keyword><style face="normal" font="default"> Adenocarcinoma/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Adenocarcinoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prostate</style></keyword><keyword><style face="normal" font="default"> Prostate-Specific Antigen</style></keyword><keyword><style face="normal" font="default"> Prostate-Specific Antigen/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Conformal</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="14" Month="9" Year="2005">2005/9/14</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><abstract><style face="normal" font="default">CONTEXT: Clinically localized prostate cancer is very prevalent among US men, but recurrence after treatment with conventional radiation therapy is common. OBJECTIVE: To evaluate the hypothesis that increasing the radiation dose delivered to men with clinically localized prostate cancer improves disease outcome. DESIGN, SETTING, AND PATIENTS: Randomized controlled trial of 393 patients with stage T1b through T2b prostate cancer and prostate-specific antigen (PSA) levels less than 15 ng/mL randomized between January 1996 and December 1999 and treated at 2 US academic institutions. Median age was 67 years and median PSA level was 6.3 ng/mL. Median follow-up was 5.5 (range, 1.2-8.2) years. INTERVENTION: Patients were randomized to receive external beam radiation to a total dose of either 70.2 Gy (conventional dose) or 79.2 Gy (high dose). This was delivered using a combination of conformal photon and proton beams. MAIN OUTCOME MEASURE: Increasing PSA level (ie, biochemical failure) 5 years after treatment. RESULTS: The proportions of men free from biochemical failure at 5 years were 61.4% (95% confidence interval, 54.6%-68.3%) for conventional-dose and 80.4% (95% confidence interval, 74.7%-86.1%) for high-dose therapy (P&lt;.001), a 49% reduction in the risk of failure. The advantage to high-dose therapy was observed in both the low-risk and the higher-risk subgroups (risk reduction, 51% [P&lt;.001] and 44% [P = .03], respectively). There has been no significant difference in overall survival rates between the treatment groups. Only 1% of patients receiving conventional-dose and 2% receiving high-dose radiation experienced acute urinary or rectal morbidity of Radiation Therapy Oncology Group (RTOG) grade 3 or greater. So far, only 2% and 1%, respectively, have experienced late morbidity of RTOG grade 3 or greater. CONCLUSIONS: Men with clinically localized prostate cancer have a lower risk of biochemical failure if they receive high-dose rather than conventional-dose conformal radiation. This advantage was achieved without any associated increase in RTOG grade 3 acute or late urinary or rectal morbidity</style></abstract><notes><style face="normal" font="default">161601317501160AIM, IMEC 3-4-21-77 (Prostate-Specific Antigen)Clinical TrialComparative StudyJournal ArticleMulticenter StudyRandomized Controlled TrialResearch Support, N.I.H., ExtramuralResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>703</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hata,M.</style></author><author><style face="normal" font="default"> Tokuuye,K.</style></author><author><style face="normal" font="default"> Sugahara,S.</style></author><author><style face="normal" font="default"> Kagei,K.</style></author><author><style face="normal" font="default"> Igaki,H.</style></author><author><style face="normal" font="default"> Hashimoto,T.</style></author><author><style face="normal" font="default"> Ohara,K.</style></author><author><style face="normal" font="default"> Matsuzaki,Y.</style></author><author><style face="normal" font="default"> Tanaka,N.</style></author><author><style face="normal" font="default"> Akine,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Proton Medical Research Center, University of Tsukuba, Tsukuba, Japan. mhata@syd.odn.ne.jp</style></auth-address><titles><title><style face="normal" font="default">Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus</style></title><secondary-title><style face="normal" font="default">Cancer.104.(4):794.-801.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cancer.104.(4):794.-801.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Budd-Chiari Syndrome/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Budd-Chiari Syndrome/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Neoplasm Circulating Cells/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Portal Vein/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Thrombosis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Thrombosis/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="15" Month="8" Year="2005">2005/8/15</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0008-543X</style></isbn><abstract><style face="normal" font="default">BACKGROUND: Treatment modalities for patients with hepatocellular carcinoma (HCC) who have portal vein tumor thrombus (PVTT) are limited and controversial; furthermore, the prognosis for these patients is extremely poor. The authors conducted a retrospective review to determine the role of proton beam therapy in the treatment of patients who had HCC with PVTT. METHODS: Twelve patients with HCC who had tumor thrombus in the main trunk or major branches of the portal vein (clinical T3-T4N0M0) were treated with proton beam therapy. At the time they received proton beam irradiation, patients ranged in age from 42 years to 80 years (median, 62 years), and their tumors ranged in size from 40 mm to 110 mm (median, 60 mm) in greatest dimension. A total dose of 50-72 gray (Gy) (median, 55 Gy) in 10-22 fractions was delivered to the tumors, including PVTT. RESULTS: All tumors that were treated with proton beam therapy remained controlled at a median follow-up of 2.3 years (range, 0.3-7.3 years). Among 12 patients, 10 patients had new liver tumors outside the irradiated volume 0.1-2.4 years after proton beam therapy, and 3 patients also had distant metastases; consequently, 8 patients died of disease, and 2 patients were salvaged by further therapies. The remaining two patients were alive with no evidence of disease 4.3 years and 6.4 years after proton beam therapy. The progression-free survival rates were 67% at 2 years and 24% at 5 years. The median progression-free survival was 2.3 years. According to the Acute Radiation Morbidity Scoring Criteria (Radiation Therapy Oncology Group), therapy-related toxicity > or = Grade 3 was not observed. CONCLUSIONS: Proton beam therapy for patients with HCC who had PVTT was feasible and effective. It appeared to improve survival and local control significantly for these patients</style></abstract><notes><style face="normal" font="default">159812840374236, clzAIM, IM0 (Protons)Journal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>712</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Noel,G.</style></author><author><style face="normal" font="default"> Feuvret,L.</style></author><author><style face="normal" font="default"> Dhermain,F.</style></author><author><style face="normal" font="default"> Mammar,H.</style></author><author><style face="normal" font="default"> Haie-Meder,C.</style></author><author><style face="normal" font="default"> Ponvert,D.</style></author><author><style face="normal" font="default"> Hasboun,D.</style></author><author><style face="normal" font="default"> Ferrand,R.</style></author><author><style face="normal" font="default"> Nauraye,C.</style></author><author><style face="normal" font="default"> Boisserie,G.</style></author><author><style face="normal" font="default"> Beaudre,A.</style></author><author><style face="normal" font="default"> Gaboriaud,G.</style></author><author><style face="normal" font="default"> Mazal,A.</style></author><author><style face="normal" font="default"> Touboul,E.</style></author><author><style face="normal" font="default"> Habrand,J.L.</style></author><author><style face="normal" font="default"> Mazeron,J.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre de protontherapie d'Orsay, institut Curie, CPO batiment 101, campus universitaire, 91898 Orsay cedex, France. noel@ipno.in2p3.fr</style></auth-address><titles><title><style face="normal" font="default">[Chordomas of the base of the skull and upper cervical spine. 100 patients irradiated by a 3D conformal technique combining photon and proton beams]. [French]</style></title><secondary-title><style face="normal" font="default">Cancer Radiotherapie.9(3):161.-74.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cancer Radiotherapie.9(3):161.-74.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons</style></keyword><keyword><style face="normal" font="default"> Photons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiometry</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Base</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="5" Year="2005">2005/5</year></dates><pub-location><style face="normal" font="default">France</style></pub-location><isbn><style face="normal" font="default">1278-3218</style></isbn><abstract><style face="normal" font="default">OBJECTIVE: To define prognostic factors for local control and survival in 100 consecutive patients treated by fractionated photon and proton radiation for chordoma of the skull base and upper cervical spine. PATIENTS AND METHODS: Between December 1995 and August 2002, 100 patients (median age: 53 years, range: 8-85, M/F sex-ratio: 3/2), were treated by a combination of high-energy photons and protons. The proton component was delivered by the 201 MeV proton beam of the Centre de Protontherapie d'Orsay (CPO). The median total dose delivered to the gross tumour volume was 67 Cobalt Gray Equivalent (CGE) (range: 60-71). A complete surgery, incomplete surgery or a biopsy was performed before the radiotherapy in 16, 75 and 9 cases, respectively. RESULTS: With a median follow-up of 31 months (range: 1-87), 25 tumours failed locally. The 2 and 4-year local control rates were 86.3% (+/-3.9%) and 53.8% (+/-7.5%), respectively. According to multivariate analysis, less than 95% of the tumour volume encompassed by the 95% isodose line (P=0.048; RR: 3.4 IC95% [1.01-11.8]) and a minimal dose less than 56 CGE (p=0.042; RR: 2.3 IC95% [1.03-5.2]) were independent prognostic factors of local control. Ten patients died. The 2 and 5-year overall survival rates were 94.3% (+/-2.5%) and 80.5% (+/-7.2%). According to multivariate analysis, a controlled tumour (P=0.005; RR: 21 IC95% [2.2-200]) was the lonely independent favourable prognostic factor for overall survival. CONCLUSION: In chordomas of the skull base and upper cervical spine treated by surgical resection followed by high-dose photon and proton irradiation, local control is mainly dependent on the quality of radiation, especially dose-uniformity within the gross tumour volume. Special attention must be paid to minimise underdosed areas due to the close proximity of critical structures and possibly escalate dose-constraints to tumour targets in future studies, in view of the low toxicity observed to date</style></abstract><notes><style face="normal" font="default">15979920cqv, 9711272IM0 (Protons)Clinical TrialEnglish AbstractJournal ArticleFrench</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>721</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schulz-Ertner,D.</style></author><author><style face="normal" font="default"> Nikoghosyan,A.</style></author><author><style face="normal" font="default"> Didinger,B.</style></author><author><style face="normal" font="default"> Munter,M.</style></author><author><style face="normal" font="default"> Jakel,O.</style></author><author><style face="normal" font="default"> Karger,C.P.</style></author><author><style face="normal" font="default"> Debus,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, University of Heidelberg, Heidelberg, Germany. Daniela.Ertner@med.uni-heidelberg.de</style></auth-address><titles><title><style face="normal" font="default">Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniques</style></title><secondary-title><style face="normal" font="default">Cancer.104.(2):338.-44.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cancer.104.(2):338.-44.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Adenoid Cystic/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Orbital Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Orbital Neoplasms/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Base</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="15" Month="7" Year="2005">2005/7/15</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0008-543X</style></isbn><abstract><style face="normal" font="default">BACKGROUND: The authors evaluated whether modern photon techniques, such as stereotactic fractionated radiation therapy (FSRT) or intensity-modulated RT, outweighed the biologic advantages of high-linear-energy transfer RT in the treatment of patients with locally advanced adenoid cystic carcinomas (ACC) that infiltrated the skull base or the orbit. METHODS: Between June 1995 and December 2003, 63 patients with ACC were treated with modern RT techniques at the University of Heidelberg. The treatment results achieved with modern photon techniques alone were compared with the results achieved with combined photon RT and a carbon ion boost. Twenty-nine patients (Group A) were treated with a combination of photon RT and a carbon ion boost. Thirty-four patients (Group B) received photon RT alone. RESULTS: The median follow-up was 16 months for Group A and 24 months for Group B. Locoregional control rates at 2 years and 4 years were 77.5% and 77.5% for Group A and 72.2% and 24.6% for Group B, respectively (P = 0.08; log-rank test). Disease-free and overall survival rates at 2 years/4 years were 71.5%/53% and 86.6%/75.8% for Group A and 69.2%/23% and 77.9%/77.9% for Group B, respectively. Rates for severe late toxicity were &lt; 5% for both groups. CONCLUSIONS: Modern RT techniques allowed the safe delivery of high target doses to patients with locally advanced ACC. Late toxicity rates were kept lower compared with the historic neutron therapy data. A combination of modern photon RT and carbon ion RT seemed to be advantageous, with a trend toward higher locoregional control rates compared with modern photon RT alone</style></abstract><notes><style face="normal" font="default">159379070374236, clzAIM, IM0 (Carbon Radioisotopes)Evaluation StudiesJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>743</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chiba,T.</style></author><author><style face="normal" font="default"> Tokuuye,K.</style></author><author><style face="normal" font="default"> Matsuzaki,Y.</style></author><author><style face="normal" font="default"> Sugahara,S.</style></author><author><style face="normal" font="default"> Chuganji,Y.</style></author><author><style face="normal" font="default"> Kagei,K.</style></author><author><style face="normal" font="default"> Shoda,J.</style></author><author><style face="normal" font="default"> Hata,M.</style></author><author><style face="normal" font="default"> Abei,M.</style></author><author><style face="normal" font="default"> Igaki,H.</style></author><author><style face="normal" font="default"> Tanaka,N.</style></author><author><style face="normal" font="default"> Akine,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Gastroenterology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan</style></auth-address><titles><title><style face="normal" font="default">Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients</style></title><secondary-title><style face="normal" font="default">Clinical Cancer Research.11(10):3799.-805.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clinical Cancer Research.11(10):3799.-805.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Liver Cirrhosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Palliative Care</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="15" Month="5" Year="2005">2005/5/15</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">1078-0432</style></isbn><abstract><style face="normal" font="default">PURPOSE: We present results of patients with hepatocellular carcinoma (HCC) treated with proton beam therapy. EXPERIMENTAL DESIGN: We reviewed 162 patients having 192 HCCs treated from November 1985 to July 1998 by proton beam therapy with or without transarterial embolization and percutaneous ethanol injection. The patients in the present series were considered unsuitable for surgery for various reasons, including hepatic dysfunction, multiple tumors, recurrence after surgical resection, and concomitant illnesses. The median total dose of proton irradiation was 72 Gy in 16 fractions over 29 days. RESULTS: The overall survival rate for all of the 162 patients was 23.5% at 5 years. The local control rate at 5 years was 86.9% for all 192 tumors among the 162 patients. The degree of impairment of hepatic functions attributable to coexisting liver cirrhosis and the number of tumors in the liver significantly affected patient survival. For 50 patients having least impaired hepatic functions and a solitary tumor, the survival rate at 5 years was 53.5%. The patients had very few acute reactions to treatments and a few late sequelae during and after the treatments. CONCLUSIONS: Proton beam therapy for patients with HCC is effective, safe, well tolerable, and repeatable. It is the useful treatment mode for either cure or palliation for patients with HCC irrespective of tumor size, tumor location in the liver, insufficient feeding of the tumor with arteries, presence of vascular invasion, impaired hepatic functions, and coexisting intercurrent diseases</style></abstract><notes><style face="normal" font="default">15897579c2h, 9502500IM0 (Protons)Journal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>751</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Slater,J.D.</style></author><author><style face="normal" font="default"> Yonemoto,L.T.</style></author><author><style face="normal" font="default"> Mantik,D.W.</style></author><author><style face="normal" font="default"> Bush,D.A.</style></author><author><style face="normal" font="default"> Preston,W.</style></author><author><style face="normal" font="default"> Grove,R.I.</style></author><author><style face="normal" font="default"> Miller,D.W.</style></author><author><style face="normal" font="default"> Slater,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Medicine, Loma Linda University Medical Center, Loma Linda, CA 92354, USA. jdslater@dominion.llumc.edu</style></auth-address><titles><title><style face="normal" font="default">Proton radiation for treatment of cancer of the oropharynx: early experience at Loma Linda University Medical Center using a concomitant boost technique</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.62.(2):494.-500.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.62.(2):494.-500.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Carcinoma,Squamous Cell/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Squamous Cell/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Neoplasm Staging</style></keyword><keyword><style face="normal" font="default"> Oropharyngeal Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Oropharyngeal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons</style></keyword><keyword><style face="normal" font="default"> Photons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="1" Month="6" Year="2005">2005/6/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To assess accelerated fractionation using photon and proton radiation to improve local control and reduce complications in treating locally advanced oropharyngeal cancer. METHODS AND MATERIALS: Twenty-nine patients with localized Stage II-IV oropharyngeal cancer received accelerated photon and proton radiation, 75.9 GyE in 45 fractions/5.5 weeks, to the primary disease, involved lymph nodes, and potential areas of subclinical spread. Follow-up ranged from 2 to 96 months. RESULTS: Five-year actuarial control for local disease was 88%, and for neck node disease, 96%; yielding a 84% locoregional control rate at 5 years. Four patients developed distant metastases. The 5-year actuarial locoregional control rate was 84%. The actuarial 2-year disease-free survival rate was 81%; at 5 years, it was 65%. All patients completed the prescribed treatment; though aggressive nutritional and anesthetic support was necessary. Late Grade 3 toxicity was seen in 3 patients. CONCLUSIONS: Protons used as a concomitant boost with photons effectively delivered an accelerated time-dose schedule to the cancer with a more tolerable schedule to surrounding normal tissues. Preliminary results reveal increased locoregional control without increased toxicity. Future studies must evaluate the optimum time-dose schedule</style></abstract><notes><style face="normal" font="default">15890592g97, 7603616IM0 (Protons)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>765</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Niizawa,G.</style></author><author><style face="normal" font="default"> Ikegami,T.</style></author><author><style face="normal" font="default"> Matsuzaki,Y.</style></author><author><style face="normal" font="default"> Saida,Y.</style></author><author><style face="normal" font="default"> Tohno,E.</style></author><author><style face="normal" font="default"> Kurosawa,T.</style></author><author><style face="normal" font="default"> Saito,Y.</style></author><author><style face="normal" font="default"> Chiba,T.</style></author><author><style face="normal" font="default"> Kita,Y.</style></author><author><style face="normal" font="default"> Tokuuye,K.</style></author><author><style face="normal" font="default"> Akine,Y.</style></author><author><style face="normal" font="default"> Tanaka,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Gastroenterology and Hepatology, Institute of Clinical Medicine, Graduate School of Comprehensive Human Sciences and University Hospital, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, 305-8575, Japan</style></auth-address><titles><title><style face="normal" font="default">Monitoring of hepatocellular carcinoma, following proton radiotherapy, with contrast-enhanced color Doppler ultrasonography</style></title><secondary-title><style face="normal" font="default">Journal of Gastroenterology.40.(3):283.-90.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Journal of Gastroenterology.40.(3):283.-90.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Blood Flow Velocity</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Color</style></keyword><keyword><style face="normal" font="default"> Contrast Media</style></keyword><keyword><style face="normal" font="default"> Contrast Media/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Cyclotrons</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Injections,Intravenous</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/us [Ultrasonography]</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Polysaccharides/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Polysaccharides/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Ultrasonography</style></keyword><keyword><style face="normal" font="default"> Ultrasonography,Doppler,Color/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="2005">2005/3</year></dates><pub-location><style face="normal" font="default">Japan</style></pub-location><isbn><style face="normal" font="default">0944-1174</style></isbn><abstract><style face="normal" font="default">BACKGROUND: We have reported that proton radiotherapy for hepatocellular carcinoma (HCC) is a safe and effective therapeutic option. However, it is difficult to evaluate its effect in certain cases. Recently, it has been reported that the usage of contrast-enhanced color Doppler ultrasonography (CECDU) can improve diagnostic accuracy, both in terms of the presence of hepatic tumor and in the evaluation of treatment. The aim of this study was to determine the usefulness of CECDU in assessing the therapeutic response of HCC treated with proton radiotherapy. METHODS: Twenty-two patients treated with the proton radiotherapy were studied. We inspected HCC lesions by CECDU, before and after the irradiation, over time. The magnitude of blood flow in the HCC was quantified on still images by CECDU. The ratio of the number of color pixels against that of the total number of pixels in the tumor area was defined as the tumor blood flow ratio (TBFR). RESULTS: Immediately after the proton treatment, a transient increase of blood flow in the tumor was recognized in more than half of the patients, while the TBFR was unchanged or decreased in the remaining patients. At longer periods after irradiation, the TBFR in all HCCs gradually decreased, and this reduction of TBFR was statistically significant from 9 months after irradiation. These findings are consistent with those obtained previously by computed tomography (CT) as well as magnetic resonance imaging (MRI). CONCLUSIONS: We propose CECDU as a useful diagnostic option for the evaluation of HCC treated with proton radiotherapy</style></abstract><notes><style face="normal" font="default">15830288bwp, 9430794IM0 (Contrast Media)0 (Polysaccharides)0 (Protons)127279-08-7 (SHU 508)Comparative StudyJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>791</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kawashima,M.</style></author><author><style face="normal" font="default"> Furuse,J.</style></author><author><style face="normal" font="default"> Nishio,T.</style></author><author><style face="normal" font="default"> Konishi,M.</style></author><author><style face="normal" font="default"> Ishii,H.</style></author><author><style face="normal" font="default"> Kinoshita,T.</style></author><author><style face="normal" font="default"> Nagase,M.</style></author><author><style face="normal" font="default"> Nihei,K.</style></author><author><style face="normal" font="default"> Ogino,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Radiation Oncology, Hepatobiliary, and Pancreatic Medical Oncology, and Hepatobiliary Surgery, National Cancer Center Hospital East, Chiba, Japan. mkawashi@east.ncc.go.jp</style></auth-address><titles><title><style face="normal" font="default">Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma</style></title><secondary-title><style face="normal" font="default">Journal of Clinical Oncology.23(9):1839.-46,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Journal of Clinical Oncology.23(9):1839.-46,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Dose-Response Relationship,Radiation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Informed Consent</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Liver Cirrhosis/cl [Classification]</style></keyword><keyword><style face="normal" font="default"> Liver Cirrhosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patient Selection</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="0" Month="3" Year="2005">2005/3</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0732-183X</style></isbn><abstract><style face="normal" font="default">PURPOSE: To evaluate the safety and efficacy of proton beam radiotherapy (PRT) for hepatocellular carcinoma. PATIENTS AND METHODS: Eligibility criteria for this study were: solitary hepatocellular carcinoma (HCC); no indication for surgery or local ablation therapy; no ascites; age >/= 20 years; Zubrod performance status of 0 to 2; no serious comorbidities other than liver cirrhosis; written informed consent. PRT was administered in doses of 76 cobalt gray equivalent in 20 fractions for 5 weeks. No patients received transarterial chemoembolization or local ablation in combination with PRT. RESULTS: Thirty patients were enrolled between May 1999 and February 2003. There were 20 male and 10 female patients, with a median age of 70 years. Maximum tumor diameter ranged from 25 to 82 mm (median, 45 mm). All patients had liver cirrhosis, the degree of which was Child-Pugh class A in 20, and class B in 10 patients. Acute reactions of PRT were well tolerated, and PRT was completed as planned in all patients. Four patients died of hepatic insufficiency without tumor recurrence at 6 to 9 months. Three of these four patients had pretreatment indocyanine green retention rate at 15 minutes of more than 50%. After a median follow-up period of 31 months (16 to 54 months), only one patient experienced recurrence of the primary tumor, and 2-year actuarial local progression-free rate was 96% (95% CI, 88% to 100%). Actuarial overall survival rate at 2 years was 66% (48% to 84%). CONCLUSION: PRT showed excellent control of the primary tumor, with minimal acute toxicity. Further study is warranted to scrutinize adequate patient selection in order to maximize survival benefit of this promising modality</style></abstract><notes><style face="normal" font="default">15774777jco, 8309333IMClinical TrialClinical Trial, Phase IIJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>818</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tsina,E.K.</style></author><author><style face="normal" font="default"> Lane,A.M.</style></author><author><style face="normal" font="default"> Zacks,D.N.</style></author><author><style face="normal" font="default"> Munzenrider,J.E.</style></author><author><style face="normal" font="default"> Collier,J.M.</style></author><author><style face="normal" font="default"> Gragoudas,E.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Retina Service, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts 02114, USA</style></auth-address><titles><title><style face="normal" font="default">Treatment of metastatic tumors of the choroid with proton beam irradiation</style></title><secondary-title><style face="normal" font="default">Ophthalmology.112.(2):337.-43.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ophthalmology.112.(2):337.-43.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Cataract</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Cobalt Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Cobalt Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glaucoma</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Metastasis/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Relative Biological Effectiveness</style></keyword><keyword><style face="normal" font="default"> Retinal Detachment</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Ultrasonography</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword></keywords><dates><year Day="0" Month="2" Year="2005">2005/2</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><abstract><style face="normal" font="default">OBJECTIVE: To describe the clinical outcomes of patients treated by proton beam irradiation for choroidal metastatic tumors. DESIGN: Noncomparative case series. PARTICIPANTS: A retrospective chart review was performed on a series of 63 patients (76 eyes) with choroidal metastases treated with proton beam therapy between December 1989 and September 2000. METHODS: Patients were treated with 2 fractions of 14 cobalt gray equivalents (CGEs) (CGE = proton Gy x relative biological effectiveness 1.1), each using a nonoperative "light-field" technique. Ophthalmologic follow-up was available for 46 patients (55 eyes), with a mean follow-up time of 10 months. The medical record or the Social Security Death Index was used to obtain survival status, which was available in 94% of cases. MAIN OUTCOME MEASURES: Tumor regression, recurrence, treatment-associated complications, and visual acuity were evaluated by ophthalmologic examination and ultrasonography. Eye retention and length of survival also were assessed. RESULTS: At the time of ocular diagnosis, 49 patients reported a history of a primary cancer. Median survival time after ocular diagnosis was 16 months through May 2003. Most choroidal metastases were dome shaped (62%) and located at the posterior pole (95%). Mean tumor height was approximately 3.5 mm, and serous retinal detachment was seen in 63% of cases. Eighty-four percent of treated tumors regressed completely within 5 months of treatment, and none of these recurred. Retinal detachment resolved in 82% of patients within 3.8 months after treatment, and visual acuity was preserved or improved in 47% of the patients. Complications occurred in 56% of cases and included madarosis, keratitis, dry eye syndrome, cataract, neovascular glaucoma, chorioretinal atrophy, radiation papillopathy, and radiation maculopathy. None of the treated eyes required enucleation. CONCLUSIONS: Proton beam irradiation is a useful therapeutic approach for choroidal metastases; it allows retention of the globe, achieves a high probability of local tumor control, and helps to avoid pain and visual loss. Although complications occur in most cases, many of these are minor and are not associated with a change in function. This modality is accurate and efficient, because it only entails 2 treatment fractions and does not require surgery for tumor localization</style></abstract><notes><style face="normal" font="default">156915727802443IM0 (Cobalt Radioisotopes)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>826</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Delaney,T.F.</style></author><author><style face="normal" font="default"> Park,L.</style></author><author><style face="normal" font="default"> Goldberg,S.I.</style></author><author><style face="normal" font="default"> Hug,E.B.</style></author><author><style face="normal" font="default"> Liebsch,N.J.</style></author><author><style face="normal" font="default"> Munzenrider,J.E.</style></author><author><style face="normal" font="default"> Suit,H.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. tdelaney@partners.org</style></auth-address><titles><title><style face="normal" font="default">Radiotherapy for local control of osteosarcoma</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.61.(2):492.-8.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.61.(2):492.-8.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Bone Neoplasms/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Bone Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Bone Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Chemotherapy,Adjuvant</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Dose-Response Relationship,Radiation</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Osteosarcoma/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Osteosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Osteosarcoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Sarcoma</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword></keywords><dates><year Day="1" Month="2" Year="2005">2005/2/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: Local control of osteosarcoma in patients for whom a resection with satisfactory margins is not achieved can be difficult. This study evaluated the efficacy of radiotherapy (RT) in this setting. METHODS AND MATERIALS: We identified 41 patients in our sarcoma database with osteosarcomas that either were not resected or were excised with close or positive margins and who underwent RT with external beam photons and/or protons at our institution between 1980 and 2002. Patient charts were reviewed to assess local control, progression-free survival, metastasis-free survival, and overall survival. RESULTS: The anatomic sites treated were head/face/skull in 17, extremity in 8, spine in 8, pelvis in 7, and trunk in 1. Of the 41 patients, 27 (65.85%) had undergone gross total tumor resection, 9 (21.95%) subtotal resection, and 5 (12.2%) biopsy only. The radiation dose ranged from 10 to 80 Gy (median 66). Twenty-three patients (56.1%) received a portion of their RT with protons. Chemotherapy was given to 35 patients (85.4%). Of the 41 patients, 27 (65.85%) were treated for localized disease at primary presentation, 10 (24.4%) for local recurrence, and 4 (9.8%) for metastatic disease. The overall local control rate at 5 years was 68% +/- 8.3%. The local control rate according to the extent of resection was 78.4% +/- 8.6% for gross total resection 77.8% +/- 13.9% for subtotal resection, and 40% +/- 21.9% for biopsy only (p &lt; 0.01). The overall survival rate according to the extent of resection was 74.45% +/- 9.1% for gross total resection, 74.1% +/- 16.1% for subtotal resection, and 25% +/- 21.65% for biopsy only (p &lt; 0.001). Patients with either gross or subtotal resection had a greater rate of local control, survival, and disease-free survival compared with those who underwent biopsy only at 5 years (77.7% +/- 7.5% vs. 40% +/- 21% [p &lt;0.001], 73.9% +/- 8.1% vs. 25% +/- 21.6% [p &lt;0.001], and 51.9% +/- 9.1% vs. 25% +/- 21.6% [p &lt;0.01], respectively). Overall survival was better in patients treated at primary presentation (78.8% +/- 8.6% compared with 54% +/- 17.3% for recurrence) p &lt;0.05). No definitive dose-response relationship for local control of tumor was seen, although the local control rate was 71% +/- 9% for 32 patients receiving doses > or =55 Gy vs. 53.6% +/- 20.1% for 9 patients receiving &lt;55 Gy (p = 0.11). Of 15 patients with tumors >5.3 cm, 9 received doses > or =55 Gy and the local control rate was 80% +/- 17.9%, and 6 received doses &lt;55 Gy with a local control rate of only 50% +/- 25% at 5 years (p = 0.16). Among patients who underwent gross total resection, the local control rate was 77.5% +/- 9.95% in 22 patients with negative margins vs 66.7% +/- 27.2% in 3 patients with positive margins (p = 0.54). Two patients had unknown margin status. CONCLUSION: RT can help provide local control of osteosarcoma for patients in whom surgical resection with widely, negative margins is not possible. It appears to be more effective in situations in which microscopic or minimal residual disease is being treated</style></abstract><notes><style face="normal" font="default">15667972g97, 7603616IMEvaluation StudiesJournal ArticleResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>838</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sugahara,S.</style></author><author><style face="normal" font="default"> Tokuuye,K.</style></author><author><style face="normal" font="default"> Okumura,T.</style></author><author><style face="normal" font="default"> Nakahara,A.</style></author><author><style face="normal" font="default"> Saida,Y.</style></author><author><style face="normal" font="default"> Kagei,K.</style></author><author><style face="normal" font="default"> Ohara,K.</style></author><author><style face="normal" font="default"> Hata,M.</style></author><author><style face="normal" font="default"> Igaki,H.</style></author><author><style face="normal" font="default"> Akine,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, Institute of Clinical Medicine , University of Tsukuba, Tennodai, Tsukuba, Ibaraki, Japan. ssuga@md.tsukuba.ac.jp</style></auth-address><titles><title><style face="normal" font="default">Clinical results of proton beam therapy for cancer of the esophagus</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.61.(1):76.-84.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.61.(1):76.-84.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Squamous Cell/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Squamous Cell/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Esophageal Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Esophageal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Esophagus</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> X-Rays</style></keyword></keywords><dates><year Day="1" Month="1" Year="2005">2005/1/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To present the results of proton beam therapy for patients with esophageal cancer. METHODS AND MATERIALS: This study reviewed 46 patients with esophageal cancer who were treated between 1985 and 1998 using proton beams with or without X-rays. All patients had locoregionally confined disease; all but one had squamous cell carcinoma. Of the 46 patients, 40 received combinations of X-rays (median, 48 Gy) and protons (median, 31.7 Gy) as a boost. The median total dose of combined X-ray and proton radiation for the 40 patients was 76.0 Gy (range, 69.1-87.4 Gy). The remaining 6 patients received only proton beam therapy (median, 82.0 Gy; range, 75-89.5 Gy). RESULTS: The 5-year actuarial survival rate for the 46 patients, patients with T1 (n = 23), and those with T2-T4 (n = 23) was 34%, 55%, and 13%, respectively. The 5-year disease-specific survival rate for the 46 patients, those with T1, and those with T2-T4 was 67%, 95%, and 33%, respectively. The 5-year local control rate for patients with T1 and T2-T4 lesions was 83% and 29%, respectively. The site of the first relapse was locoregional for 16 patients and distant organs for 2 patients. CONCLUSION: The results suggest that proton beam therapy is an effective treatment for patients with locally confined esophageal cancer. Additional studies are required to determine the optimal total dose, fractionation schedule, and best combinations of protons and conventional X-rays with or without chemotherapy</style></abstract><notes><style face="normal" font="default">15629597g97, 7603616IM0 (Protons)Journal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>864</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schulz-Ertner,D.</style></author><author><style face="normal" font="default"> Nikoghosyan,A.</style></author><author><style face="normal" font="default"> Didinger,B.</style></author><author><style face="normal" font="default"> Debus,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dept. of Clinical Radiology, University of Heidelberg, Heidelberg, Germany. Daniela_Ertner@med.uni-heidelberg.de</style></auth-address><titles><title><style face="normal" font="default">Carbon ion radiation therapy for chordomas and low grade chondrosarcomas--current status of the clinical trials at GSI</style></title><secondary-title><style face="normal" font="default">Radiotherapy &amp; Oncology.73.Suppl 2:S53.-6,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Radiotherapy &amp; Oncology.73.Suppl 2:S53.-6,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Biophysics</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Heavy Ions/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Physics</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Base</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="12" Year="2004">2004/12</year></dates><pub-location><style face="normal" font="default">Ireland</style></pub-location><isbn><style face="normal" font="default">0167-8140</style></isbn><abstract><style face="normal" font="default">Carbon ion radiation therapy (RT) is available at the German Ion Research Center (GSI) in Darmstadt, Germany, since December 1997. Patient treatments within the pilot project are carried out by radiation oncologists of the University of Heidelberg in cooperation with the Department of Biophysics of GSI, the Division of Medical Physics of the German Cancer Research Center Heidelberg and the Research Center Rossendorf. Patients are treated within three beam time blocks of 20 days per year at the basic physics research center at GSI, the overall capacity per year being 45 to 50 patients. Main purpose of the pilot project was to investigate carbon ion radiation therapy for different tumor entities within clinical phase I/II trials. This manuscript updates the results of the clinical phase I/II trial of carbon ion RT in chordomas and low grade chondrosarcomas of the skull base and summarizes the current status of the ongoing phase I/II trial for extracranial chordomas and low grade chondrosarcomas</style></abstract><notes><style face="normal" font="default">15971310rae, 8407192IM7440-44-0 (Carbon)Clinical TrialClinical Trial, Phase IClinical Trial, Phase IIJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>906</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Noel,G.</style></author><author><style face="normal" font="default"> Feuvret,L.</style></author><author><style face="normal" font="default"> Ferrand,R.</style></author><author><style face="normal" font="default"> Boisserie,G.</style></author><author><style face="normal" font="default"> Mazeron,J.J.</style></author><author><style face="normal" font="default"> Habrand,J.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre de Protontherapie d'Orsay, Institut Curie, 91402 Orsay, France. noel@ipno.in2p3.fr</style></auth-address><titles><title><style face="normal" font="default">Radiotherapeutic factors in the management of cervical-basal chordomas and chondrosarcomas</style></title><secondary-title><style face="normal" font="default">Neurosurgery.55.(6):1252.-60; discussion.1260.-2,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Neurosurgery.55.(6):1252.-60; discussion.1260.-2,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword></keywords><dates><year Day="0" Month="12" Year="2004">2004/12</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><abstract><style face="normal" font="default">OBJECTIVE: To define prognostic factors for local control and survival in 90 consecutive patients treated by fractionated photon and proton radiation for chordoma or chondrosarcoma of the cranial base and upper cervical spine. METHODS: Between December 1995 and December 2000, 90 patients (median age, 51.3 yr; range, 10-85 yr; male/female ratio, 3:2) were treated by a combination of high-energy photons and protons. Sixty-four patients had a chordoma, and 26 had a chondrosarcoma. The proton component was delivered by the 201-MeV proton beam of the Centre de Protontherapie d'Orsay. The median total dose delivered to the gross tumor volume (GTV) was 67 cobalt Gray equivalents (range, 22-70 cobalt Gray equivalents). RESULTS: With a median follow-up of 34 months (range, 3-74 mo), treatment of 25 tumors failed locally. The 3-year local control rates were 69.2% (+/-6.0%) and 91.6% (+/-8.4%) for chordomas and chondrosarcomas, respectively. According to multivariate analysis, a small tumor volume excluded from the 95% isodose line (P = 0.032; relative risk [RR], 0.098; 95% confidence interval [CI], 0.01-0.81) and a controlled tumor (P = 0.049; RR, 0.19; 95% CI, 0.04-0.99) were independent favorable prognostic factors for overall survival. On multivariate analysis, a high minimum dose (P = 0.02; RR, 2.8; 95% CI, 1.2-6.6), a high tumor control probability (P = 0.02; RR, 3.8; 95% CI, 1.2-12.5), a high dose delivered to 95% of the GTV (P = 0.03; RR, 3.4; 95% CI, 1.15-10.2), a high GTV encompassed by the 90% isodose line (P = 0.01; RR, 3.29; 95% CI, 1.29-8.44), and a small GTV excluded from the 90% isodose line (P = 0.036; RR, 0.4; 95% CI, 0.1-0.9) were independent favorable prognostic factors for local control. CONCLUSION: In chordomas and chondrosarcomas of the cranial base and cervical spine treated by surgical resection and then by high-dose photon and proton irradiation, local control is mainly dependent on the quality of radiation, especially dose uniformity within the GTV. Special attention must be paid to minimize underdosed areas because of the close proximity of critical structures and to redefine and possibly escalate dose constraints to tumor targets in future studies in view of the low toxicity observed to date</style></abstract><notes><style face="normal" font="default">15574207nzl, 7802914IMJournal ArticleMulticenter StudyEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>920</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Igaki,H.</style></author><author><style face="normal" font="default"> Tokuuye,K.</style></author><author><style face="normal" font="default"> Okumura,T.</style></author><author><style face="normal" font="default"> Sugahara,S.</style></author><author><style face="normal" font="default"> Kagei,K.</style></author><author><style face="normal" font="default"> Hata,M.</style></author><author><style face="normal" font="default"> Ohara,K.</style></author><author><style face="normal" font="default"> Hashimoto,T.</style></author><author><style face="normal" font="default"> Tsuboi,K.</style></author><author><style face="normal" font="default"> Takano,S.</style></author><author><style face="normal" font="default"> Matsumura,A.</style></author><author><style face="normal" font="default"> Akine,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Proton Medical Research Center, University Hospital, University of Tsukuba, Ibaraki, Japan. igaki-tky@umin.ac.jp</style></auth-address><titles><title><style face="normal" font="default">Clinical results of proton beam therapy for skull base chordoma. [Review] [38 refs]</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.60(4):1120.-6,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.60(4):1120.-6,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Base</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> X-Rays</style></keyword></keywords><dates><year Day="15" Month="11" Year="2004">2004/11/15</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To evaluate clinical results of proton beam therapy for patients with skull base chordoma. METHODS AND MATERIALS: Thirteen patients with skull base chordoma who were treated with proton beams with or without X-rays at the University of Tsukuba between 1989 and 2000 were retrospectively reviewed. A median total tumor dose of 72.0 Gy (range, 63.0-95.0 Gy) was delivered. The patients were followed for a median period of 69.3 months (range, 14.6-123.4 months). RESULTS: The 5-year local control rate was 46.0%. Cause-specific, overall, and disease-free survival rates at 5 years were 72.2%, 66.7%, and 42.2%, respectively. The local control rate was higher, without statistical significance, for those with preoperative tumors &lt;30 mL. Partial or subtotal tumor removal did not yield better local control rates than for patients who underwent biopsy only as the latest surgery. CONCLUSION: Proton beam therapy is effective for patients with skull base chordoma, especially for those with small tumors. For a patient with a tumor of &lt;30 mL with no prior treatment, biopsy without tumor removal seems to be appropriate before proton beam therapy. [References: 38]</style></abstract><notes><style face="normal" font="default">15519783g97, 7603616IM0 (Protons)Journal ArticleResearch Support, Non-U.S. Gov'tReviewEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>923</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bush,D.A.</style></author><author><style face="normal" font="default"> Hillebrand,D.J.</style></author><author><style face="normal" font="default"> Slater,J.M.</style></author><author><style face="normal" font="default"> Slater,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Medicine, Loma Linda University Medical Center, 11234 Anderson Street, Loma Linda, California 92354, USA. dbush@dominion.llumc.edu</style></auth-address><titles><title><style face="normal" font="default">High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial</style></title><secondary-title><style face="normal" font="default">Gastroenterology.127.(5 Suppl 1):S189.-93.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Gastroenterology.127.(5 Suppl 1):S189.-93.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Bilirubin/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Liver Transplantation</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Serum Albumin</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="11" Year="2004">2004/11</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0016-5085</style></isbn><abstract><style face="normal" font="default">This phase II trial was undertaken to determine the efficacy and toxicity of proton beam radiotherapy for patients with locally unresectable hepatocellular carcinoma. Cirrhotic patients were eligible if they had a Child-Pugh score of 10 or less. Eligible patients included those with T 1 -T 3 hepatocellular carcinoma; selected T 4 patients also were eligible. Patients with lymph node or distant metastases were ineligible. Daily proton beam radiotherapy was directed to the liver tumor with an additional 1-2 cm margin. The total dose was 63 cobalt Gray equivalents, administered in 15 divided fractions over 3 weeks. Thirty-four patients have completed treatment and have been followed up for a minimum of 6 months, with a median follow-up period of 20 months. The mean age was 65 years, and average tumor size was 5.7 cm. Posttreatment toxicity included a small but significant decline in albumin levels and increased total bilirubin; 3 experienced duodenal or colonic bleeding when bowel was immediately adjacent to the treated tumor. Two-year actuarial data showed a 75% local tumor control rate and an overall survival rate of 55%. Of patients with an elevated pretreatment alpha-fetoprotein, 85% were found to have declining alpha-fetoprotein levels from a pretreatment mean of 1405 to 35 at 6 months after treatment. Six patients underwent liver transplantation between 6 and 16 months after completion of radiotherapy with 2 showing no evidence of residual carcinoma within the explanted liver. Overall the majority of patients responded to treatment, and the therapy was well tolerated</style></abstract><notes><style face="normal" font="default">15508084fh3, 0374630AIM, IM0 (Protons)0 (Serum Albumin)635-65-4 (Bilirubin)Clinical TrialClinical Trial, Phase IIJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>924</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rossi,C.J.,Jr.</style></author><author><style face="normal" font="default"> Slater,J.D.</style></author><author><style face="normal" font="default"> Yonemoto,L.T.</style></author><author><style face="normal" font="default"> Jabola,B.R.</style></author><author><style face="normal" font="default"> Bush,D.A.</style></author><author><style face="normal" font="default"> Levy,R.P.</style></author><author><style face="normal" font="default"> Grove,R.</style></author><author><style face="normal" font="default"> Slater,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Medicine, Loma Linda University Medical Center, Loma Linda, California 92354, USA</style></auth-address><titles><title><style face="normal" font="default">Influence of patient age on biochemical freedom from disease in patients undergoing conformal proton radiotherapy of organ-confined prostate cancer</style></title><secondary-title><style face="normal" font="default">Urology.64.(4):729.-32.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Urology.64.(4):729.-32.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adenocarcinoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Adenocarcinoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Adenocarcinoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Life Tables</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Prostate</style></keyword><keyword><style face="normal" font="default"> Prostate-Specific Antigen</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Conformal</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="10" Year="2004">2004/10</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><abstract><style face="normal" font="default">OBJECTIVES: To examine a large, single-institution series of patients to test the perception among clinicians that radiotherapy is preferred for "older" patients and surgery should be indicated for "younger" men. Both radiotherapy and surgery are used to control prostate cancer, and both yield similar results in terms of long-term biochemical disease-free (bNED) survival. METHODS: The bNED survival results from more than 1000 patients treated solely with conformal radiotherapy were analyzed to determine whether a difference in outcome supervened for patients younger than 60 years of age versus older patients. RESULTS: No statistically significant difference in bNED survival was found, in terms of patient age. Statistically significant predictors of outcome included pretreatment prostate-specific antigen level, clinical stage at diagnosis, and Gleason score. CONCLUSIONS: Patient age younger than 60 years versus older than 60 years at treatment did not influence bNED survival significantly. Patient age at treatment should not be used in and of itself to recommend one type of treatment over another</style></abstract><notes><style face="normal" font="default">15491710wsy, 0366151IMComparative StudyJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>925</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bush,D.A.</style></author><author><style face="normal" font="default"> Slater,J.D.</style></author><author><style face="normal" font="default"> Shin,B.B.</style></author><author><style face="normal" font="default"> Cheek,G.</style></author><author><style face="normal" font="default"> Miller,D.W.</style></author><author><style face="normal" font="default"> Slater,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Medicine, Loma Linda University Medical Center, 11234 Anderson Street, Loma Linda, CA 92354, USA. dbush@dominion.llumc.edu</style></auth-address><titles><title><style face="normal" font="default">Hypofractionated proton beam radiotherapy for stage I lung cancer</style></title><secondary-title><style face="normal" font="default">Chest.126.(4):1198.-203.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Chest.126.(4):1198.-203.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Motion</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="10" Year="2004">2004/10</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0012-3692</style></isbn><abstract><style face="normal" font="default">STUDY OBJECTIVES: To determine the efficacy and toxicity of high-dose hypofractionated proton beam radiotherapy for patients with clinical stage I lung cancer. DESIGN: A prospective phase 2 clinical trial. SETTING: Loma Linda University Medical Center. PATIENTS: Subjects with clinical stage I non-small cell lung cancer who were medically inoperable or refused surgery. INTERVENTIONS: All patients were treated with proton beam radiotherapy. The target included the gross tumor volume as seen on CT scan, with additional margin to allow for respiratory motion. A multibeam treatment plan was generated. Delivered treatment was 51 cobalt Gray equivalent (CGE) in 10 fractions over 2 weeks to the initial 22 patients; the subsequent 46 patients received 60 CGE in 10 fractions over 2 weeks. RESULTS: Sixty-eight patients were analyzed for this report, with a median follow-up time of 30 months. No cases of symptomatic radiation pneumonitis or late esophageal or cardiac toxicity were seen. The 3-year local control and disease-specific survival rates were 74%, and 72%, respectively. There was significant improvement in local tumor control in T1 vs T2 tumors (87% vs 49%), with a trend toward improved survival. Cox regression analysis revealed that patients with higher performance status, female gender, and smaller tumor sizes had significantly improved survival. CONCLUSION: High-dose hypofractionated proton beam radiotherapy can be administered safely, with minimal toxicity, to patients with stage I lung cancer. Local tumor control appears to be improved when compared to historical results utilizing conventional radiotherapy, with a good expectation of disease-specific survival 3 years following treatment</style></abstract><notes><style face="normal" font="default">154863830231335, d1cAIM, IMJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>926</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhang,H.</style></author><author><style face="normal" font="default"> Yoshikawa,K.</style></author><author><style face="normal" font="default"> Tamura,K.</style></author><author><style face="normal" font="default"> Sagou,K.</style></author><author><style face="normal" font="default"> Tian,M.</style></author><author><style face="normal" font="default"> Suhara,T.</style></author><author><style face="normal" font="default"> Kandatsu,S.</style></author><author><style face="normal" font="default"> Suzuki,K.</style></author><author><style face="normal" font="default"> Tanada,S.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medical Imaging, National Institute of Radiological Sciences, Chiba, Japan</style></auth-address><titles><title><style face="normal" font="default">Carbon-11-methionine positron emission tomography imaging of chordoma</style></title><secondary-title><style face="normal" font="default">Skeletal Radiology.33(9):524.-30.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Skeletal Radiology.33(9):524.-30.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Feasibility Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Positron-Emission Tomography</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Sacrum/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Sacrum/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword></keywords><dates><year Day="0" Month="9" Year="2004">2004/9</year></dates><pub-location><style face="normal" font="default">Germany</style></pub-location><isbn><style face="normal" font="default">0364-2348</style></isbn><abstract><style face="normal" font="default">OBJECTIVE: Chordoma is a rare malignant bone tumor that arises from notochord remnants. This is the first trial to investigate the utility of (11)C-methionine (MET) positron emission tomography (PET) in the imaging of chordoma before and after carbon-ion radiotherapy (CIRT). DESIGN AND PATIENTS: Fifteen patients with chordoma were investigated with MET-PET before and after CIRT and the findings analyzed visually and quantitatively. Tumor MET uptake was evaluated by tumor-to-nontumor ratio (T/N ratio). RESULTS: In 12 (80%) patients chordoma was clearly visible in the baseline MET-PET study with a mean T/N ratio of 3.3+/-1.7. The MET uptake decreased significantly to 2.3+/-1.4 after CIRT ( P&lt;0.05). A significant reduction in tumor MET uptake of 24% was observed after CIRT. Fourteen (93%) patients showed no local recurrence after CIRT with a median follow-up time of 20 months. CONCLUSION: This study has demonstrated that MET-PET is feasible for imaging of chordoma. MET-PET could provide important tumor metabolic information for the therapeutic monitoring of chordoma after CIRT</style></abstract><notes><style face="normal" font="default">15483754ute, 7701953IM0 (Carbon Radioisotopes)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>950</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mizoe,J.E.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author><author><style face="normal" font="default"> Kamada,T.</style></author><author><style face="normal" font="default"> Matsuoka,Y.</style></author><author><style face="normal" font="default"> Tsuji,H.</style></author><author><style face="normal" font="default"> Osaka,Y.</style></author><author><style face="normal" font="default"> Hasegawa,A.</style></author><author><style face="normal" font="default"> Yamamoto,N.</style></author><author><style face="normal" font="default"> Ebihara,S.</style></author><author><style face="normal" font="default"> Konno,A.</style></author><author><style face="normal" font="default"> Organizing Committee for the Working Group for Head-And-Neck Cancer</style></author></authors></contributors><auth-address><style face="normal" font="default">Hospital, Research Center of Charged Particle, National Institute of Radiological Sciences, Chiba, Japan</style></auth-address><titles><title><style face="normal" font="default">Dose escalation study of carbon ion radiotherapy for locally advanced head-and-neck cancer.[see comment]</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.60(2):358.-64.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.60(2):358.-64.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> Head and Neck Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Head and Neck Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Heavy Ions/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Ions</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation Tolerance/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword></keywords><dates><year Day="1" Month="10" Year="2004">2004/10/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To evaluate the toxicity and efficacy of carbon ion radiotherapy for head-and-neck cancer in a Phase I/II dose escalation clinical trial. METHODS AND MATERIALS: Between June 1994 and January 1997, 36 patients with locally advanced, histologically proven, and new or recurrent cancer of the head and neck were treated with carbon ions. A dose escalation study was conducted, delivering 18 fractions through 6 weeks for 17 patients (Group A) and 16 fractions through 4 weeks for 19 patients (Group B). Eligibility and ineligibility criteria were the same in both groups. The dosages were escalated in increments of 10% after careful observation of at least 3 patients treated with the same dosages. The endpoints of the study were a Grade 3 reaction of the skin and the mucous membrane or local control of the tumors. RESULTS: Follow-up time ranged from 77 to 108 months with a median of 90 months. Grade 3 acute reaction of the skin was detected in 1 of the 2 patients in Group A who were treated with 70.2 GyE/18 fractions/6 weeks. In Group B, Grade 3 acute skin reaction was detected in 20% (1/5), 27% (2/11), and 67% (2/3) patients treated with 52.8 GyE, 57.6 GyE, and 64.0 GyE through 16 fractions for 4 weeks, respectively. There was only 1 patient with a Grade 3 acute reaction of the mucous membrane. Only 1 patient developed a Grade 2 late reaction of the mucous membrane (superficial ulcer), which was located close to the tumor. No other Grade 2 or greater late reaction was noted until the time of analysis. Acute tumor reactions in 34 patients consisted of 10 patients of complete response 19 of partial response, 4 of no change, and 1 of progressive disease. Local control of 34 patients calculated by the Kaplan-Meier method was 75% at 5 years. Five years' local control of five malignant melanomas showed 100%, and that of 9 patients with adenoid cystic carcinoma was 90%. Also, local control of 8 patients of salivary glands and 4 patients of ears was 100% at 56 months and 5 years. CONCLUSIONS: The dose fractionation methods of 70.2 GyE through 18 fractions for 6 weeks and 64.0 GyE through 16 fractions for 4 weeks showed equal clinical outcome in terms of morbidity and local control. The outcome of carbon ion radiotherapy showed a specific effectiveness in local control of non-squamous cell carcinoma such as adenoid cystic carcinomas and malignant melanomas. From the results of this study, it can be concluded that carbon ion radiotherapy will deliver a high local control rate without unacceptable injuries to the surrounding normal tissues</style></abstract><notes><style face="normal" font="default">15380567g97, 7603616IM7440-44-0 (Carbon)Clinical TrialClinical Trial, Phase IClinical Trial, Phase IIJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>966</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Imai,R.</style></author><author><style face="normal" font="default"> Kamada,T.</style></author><author><style face="normal" font="default"> Tsuji,H.</style></author><author><style face="normal" font="default"> Yanagi,T.</style></author><author><style face="normal" font="default"> Baba,M.</style></author><author><style face="normal" font="default"> Miyamoto,T.</style></author><author><style face="normal" font="default"> Kato,S.</style></author><author><style face="normal" font="default"> Kandatsu,S.</style></author><author><style face="normal" font="default"> Mizoe,J.E.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author><author><style face="normal" font="default"> Tatezaki,S.</style></author><author><style face="normal" font="default"> Working Group for Bone,Soft Tissue Sarcomas</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba</style></auth-address><titles><title><style face="normal" font="default">Carbon ion radiotherapy for unresectable sacral chordomas</style></title><secondary-title><style face="normal" font="default">Clinical Cancer Research.10(17):5741.-6,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clinical Cancer Research.10(17):5741.-6,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Sacrum</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="1" Month="9" Year="2004">2004/9/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">1078-0432</style></isbn><abstract><style face="normal" font="default">PURPOSE: The purpose is to evaluate the efficacy and toxicity of carbon ion radiotherapy for unresectable sacral chordomas. EXPERIMENTAL DESIGN: We performed a retrospective analysis of 30 patients with unresectable sacral chordomas treated with carbon ion radiotherapy at the Heavy Ion Medical Accelerator in Chiba, Japan. Twenty-three patients presented with no prior treatment, and the remaining 7 patients had locally recurrent disease following previous surgical resection. The median clinical target volume was 546 cm(3). The applied carbon ion dose ranged from 52.8 to 73.6 GyE (gray equivalent, median 70.4) in 16 fixed fractions over 4 weeks. RESULTS: At median follow-up of 30 months (range, 9 to 87 months), 26 patients were still alive and 24 patients remained continuously disease-free. Overall and cause-specific survival rates at 5 years were 52 and 94%, respectively. The overall local control rate at 5 years was 96%. Two patients experienced severe skin/soft tissue complications requiring skin grafts. No other treatment-related surgical interventions, including colostomy or urinary diversion, were carried out. All patients have remained ambulatory and able to stay at home after carbon ion radiotherapy. CONCLUSIONS: Carbon ion radiotherapy is effective and safe in the management of patients with unresectable sacral chordomas and offers a promising alternative to surgery</style></abstract><notes><style face="normal" font="default">15355901c2h, 9502500IM0 (Carbon Radioisotopes)Clinical TrialClinical Trial, Phase IClinical Trial, Phase IIJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1010</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hara,I.</style></author><author><style face="normal" font="default"> Murakami,M.</style></author><author><style face="normal" font="default"> Kagawa,K.</style></author><author><style face="normal" font="default"> Sugimura,K.</style></author><author><style face="normal" font="default"> Kamidono,S.</style></author><author><style face="normal" font="default"> Hishikawa,Y.</style></author><author><style face="normal" font="default"> Abe,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. hara@med.kobe-u.ac.jp</style></auth-address><titles><title><style face="normal" font="default">Experience with conformal proton therapy for early prostate cancer</style></title><secondary-title><style face="normal" font="default">American Journal of Clinical Oncology.27.(4):323.-7.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">American Journal of Clinical Oncology.27.(4):323.-7.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prostate</style></keyword><keyword><style face="normal" font="default"> Prostate-Specific Antigen</style></keyword><keyword><style face="normal" font="default"> Prostate-Specific Antigen/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Conformal</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="8" Year="2004">2004/8</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><abstract><style face="normal" font="default">A study was conducted to evaluate the use of proton beam therapy for the treatment of organ-confined prostate cancer. This is a preliminary assessment of treatment-related morbidity and tumor response. Sixteen patients with T1-T2b prostate cancer underwent proton beam therapy. Acute and late toxicity was scored according to the National Cancer Institute Common Toxicity Criteria Grading System (version 2.0, April 1999) and to the Radiation Therapy Oncology Group grading system, respectively. Local control was assessed using magnetic resonance imaging (MRI) and prostate-specific antigen (PSA) values. Although skin toxicity and bladder irritability were commonly observed, none of the patients developed grade III or IV toxicity. Of 9 patients in whom the primary lesion was detected by MRI, partial response and no change (NC) was observed in 6 (66.7%) and 3 (33.3%) patients, respectively. Four patients presented normal PSA value before treatment due to the previous endocrine therapy. However, the other 12 patients with elevated PSA value before treatment showed complete response. No patients showed PSA failure within the median follow-up period of 11.9 months. Although longer follow-up is necessary, minimum toxicity and good short-term clinical responses were observed following proton beam therapy in T1-T2 prostate cancer patients</style></abstract><notes><style face="normal" font="default">152897223ez, 8207754IM0 (Protons)EC 3-4-21-77 (Prostate-Specific Antigen)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1015</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kato,H.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author><author><style face="normal" font="default"> Miyamoto,T.</style></author><author><style face="normal" font="default"> Mizoe,J.E.</style></author><author><style face="normal" font="default"> Kamada,T.</style></author><author><style face="normal" font="default"> Tsuji,H.</style></author><author><style face="normal" font="default"> Yamada,S.</style></author><author><style face="normal" font="default"> Kandatsu,S.</style></author><author><style face="normal" font="default"> Yoshikawa,K.</style></author><author><style face="normal" font="default"> Obata,T.</style></author><author><style face="normal" font="default"> Ezawa,H.</style></author><author><style face="normal" font="default"> Morita,S.</style></author><author><style face="normal" font="default"> Tomizawa,M.</style></author><author><style face="normal" font="default"> Morimoto,N.</style></author><author><style face="normal" font="default"> Fujita,J.</style></author><author><style face="normal" font="default"> Ohto,M.</style></author><author><style face="normal" font="default"> Liver Cancer Working Group</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba-shi 263-8555, Japan. h_kato@nirs.go.jp</style></auth-address><titles><title><style face="normal" font="default">Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.59.(5):1468.-76.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.59.(5):1468.-76.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heavy Ions/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Liver Cirrhosis/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Statistics,Nonparametric</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="1" Month="8" Year="2004">2004/8/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To evaluate the toxicity and antitumor effect of carbon ion radiotherapy for hepatocellular carcinoma within a Phase I-II trial. METHODS AND MATERIALS: Between June 1995 and February 1997, 24 patients with histopathologically proven hepatocellular carcinoma were treated to 15 fractions within 5 weeks in a step-wise dose-escalation study. The disease stage was Stage II in 10, IIIA in 6, and IVA in 8 patients. The Common Toxicity Criteria, Radiation Therapy Oncology Group/European Organization for the Research and Treatment of Cancer criteria, and Child-Pugh score were used to evaluate toxicity. The antitumor effect was evaluated by the tumor response, cumulative local control, and survival rates. RESULTS: During a median follow-up of 71 months (range, 63-83 months), no severe adverse effects and no treatment-related deaths occurred. The Child-Pugh score did not increase by >2 points after the start of therapy. In 78% and 75% of all patients, the score did not increase by >1 point in the early and late phase, respectively. The overall tumor response rate was 71%. The local control and overall survival rate was 92% and 92%, 81% and 50%, and 81% and 25% at 1, 3, and 5 years, respectively. CONCLUSION: Carbon ion radiotherapy appears safe and effective for patients with hepatocellular carcinoma. Additional clinical studies using a larger subject group are required to confirm the therapeutic efficacy</style></abstract><notes><style face="normal" font="default">15275734g97, 7603616IM7440-44-0 (Carbon)Clinical TrialClinical Trial, Phase IClinical Trial, Phase IIJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1026</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hocht,S.</style></author><author><style face="normal" font="default"> Bechrakis,N.E.</style></author><author><style face="normal" font="default"> Nausner,M.</style></author><author><style face="normal" font="default"> Kreusel,K.M.</style></author><author><style face="normal" font="default"> Kluge,H.</style></author><author><style face="normal" font="default"> Heese,J.</style></author><author><style face="normal" font="default"> Heufelder,J.</style></author><author><style face="normal" font="default"> Cordini,D.</style></author><author><style face="normal" font="default"> Homeyer,H.</style></author><author><style face="normal" font="default"> Fuchs,H.</style></author><author><style face="normal" font="default"> Martus,P.</style></author><author><style face="normal" font="default"> Foerster,M.H.</style></author><author><style face="normal" font="default"> Wiegel,T.</style></author><author><style face="normal" font="default"> Hinkelbein,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology and Radiotherapy, Charite-Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany. stefan.hoecht@charite.de</style></auth-address><titles><title><style face="normal" font="default">Proton therapy of uveal melanomas in Berlin. 5 years of experience at the Hahn-Meitner Institute.[see comment]</style></title><secondary-title><style face="normal" font="default">Strahlentherapie und Onkologie.180.(7.):419.-24.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Strahlentherapie und Onkologie.180.(7.):419.-24.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Berlin</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eye Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Glaucoma/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="0" Month="7" Year="2004">2004/7</year></dates><pub-location><style face="normal" font="default">Germany</style></pub-location><isbn><style face="normal" font="default">0179-7158</style></isbn><abstract><style face="normal" font="default">BACKGROUND AND PURPOSE: In June 1998, proton-beam therapy of ocular tumors started at the Hahn-Meitner Institute Berlin, Germany. The purpose of the present study is to evaluate treatment outcome for uveal melanomas. PATIENTS AND METHODS: 245 consecutive patients with primary melanoma of the uvea were treated from June 1998 to April 2003 with a 68-MeV proton beam. In 96.2% of all patients, a uniform fractionation scheme was applied: single dose 15 CGE (cobalt gray equivalent), total dose 60 CGE on 4 consecutive days. Follow-up is available in 229 patients. RESULTS: At the time of median follow-up (18.4 months), local control is 96.4% and 95.5% at 3 years. Eye retention rate is 92.6% at 20 months (median follow-up) and 87.5% at 3 years. CONCLUSION: Proton-beam irradiation of uveal melanomas at the Hahn-Meitner Institute after the first 5 years of its initiation reveals local tumor control and eye retention rates in the range of other centers with larger experience. Delivering high treatment quality in hadron therapy from the beginning has been achieved</style></abstract><notes><style face="normal" font="default">15241529vcm, 8603469IM0 (Protons)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1033</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kagei,K.</style></author><author><style face="normal" font="default"> Tokuuye,K.</style></author><author><style face="normal" font="default"> Sugahara,S.</style></author><author><style face="normal" font="default"> Hata,M.</style></author><author><style face="normal" font="default"> Igaki,H.</style></author><author><style face="normal" font="default"> Hashimoto,T.</style></author><author><style face="normal" font="default"> Ohara,K.</style></author><author><style face="normal" font="default"> Akine,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Proton Medical Research Center, Department of Radiation Oncology, University Hospital, University of Tsukuba</style></auth-address><titles><title><style face="normal" font="default">[Initial experience of proton beam therapy at the new facility of the University of Tsukuba]. [Japanese]</style></title><secondary-title><style face="normal" font="default">Nippon Igaku Hoshasen Gakkai Zasshi - Nippon Acta Radiologica.64.(4):225.-30.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Nippon Igaku Hoshasen Gakkai Zasshi - Nippon Acta Radiologica.64.(4):225.-30.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Cancer Care Facilities</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> Head and Neck Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prostate</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Conformal</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Relative Biological Effectiveness</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2004">2004/5</year></dates><pub-location><style face="normal" font="default">Japan</style></pub-location><isbn><style face="normal" font="default">0048-0428</style></isbn><abstract><style face="normal" font="default">PURPOSE: To present the initial experience with proton beam therapy at the new Proton Medical Research Center (PMRC) of the University of Tsukuba. MATERIALS AND METHODS: The new facility has a synchrotron with maximum energy of 250MeV and two rotational gantries. We treated 105 patients with 120 lesions with proton beams in the first year, beginning in September 2001. The most common lesion treated was primary liver cancer (40 lesions) followed by lung cancer, head and neck cancers, and prostate cancer. Concurrent X-ray radiotherapy was given for 38 of the 120 lesions. RESULTS: The median follow-up period was 11 months (range, 1-19 months). Of the 105 patients, 97% had Grade 0-2 RTOG/EORTC acute morbidities, while the remaining 3% had Grade 3. Tumor response after irradiation was CR for 35% of the lesions, PR for 25%, SD for 22%, PD for 9%, and not evaluated for 9%. CONCLUSION: The proton beam therapy conducted at the new facility of the University of Tsukuba was safe and effective</style></abstract><notes><style face="normal" font="default">15211886o3g, 0413544IM0 (Protons)English AbstractJournal ArticleJapanese</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1040</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kodjikian,L.</style></author><author><style face="normal" font="default"> Roy,P.</style></author><author><style face="normal" font="default"> Rouberol,F.</style></author><author><style face="normal" font="default"> Garweg,J.G.</style></author><author><style face="normal" font="default"> Chauvel,P.</style></author><author><style face="normal" font="default"> Manon,L.</style></author><author><style face="normal" font="default"> Jean-Louis,B.</style></author><author><style face="normal" font="default"> Little,R.E.</style></author><author><style face="normal" font="default"> Sasco,A.J.</style></author><author><style face="normal" font="default"> Grange,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophtalmology, Croix-Rousse Hospital, and Laboratory of Biomaterials and Matrix Remodelling, Claude Bernard University, Lyon, France. kodjikian.laurent@wanadoo.fr</style></auth-address><titles><title><style face="normal" font="default">Survival after proton-beam irradiation of uveal melanomas</style></title><secondary-title><style face="normal" font="default">American Journal of Ophthalmology.137.(6):1002.-10,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">American Journal of Ophthalmology.137.(6):1002.-10,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Cause of Death</style></keyword><keyword><style face="normal" font="default"> Ciliary Body</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Eye Enucleation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Metastasis</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="0" Month="6" Year="2004">2004/6</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0002-9394</style></isbn><abstract><style face="normal" font="default">PURPOSE: To evaluate the independent prognostic factors for survival, metastasis, local recurrence, and enucleation in patients who had undergone proton-beam therapy for posterior uveal melanomas. DESIGN: Interventional case series. METHODS: In this retrospective study, 224 consecutive incident cases were treated at the Biomedical Cyclotron Centre (Nice, France) from June 1991 to December 1997. Overall, metastasis-free, local recurrence-free, and enucleation-free survival rates were calculated according to the Kaplan-Meier method using the log-rank test. The multivariate prognostic analysis was performed using the Cox proportional hazards model. RESULTS: The 5-year overall survival rate was 78.1% (SE: 3.7%). A largest basal tumor diameter (LTD) below 10 mm and female sex were independently associated with a better prognosis. The 5-year metastasis-free survival rate was 75.6% (SE: 3.6%). Only an LTD above 10 mm and ciliary body involvement were independently associated with metastasis. Ten patients (4.5%) had a local recurrence, which was correlated with the risk of metastasis (P =.045). The 5-year enucleation-free survival rate was 69.6% (SE: 4.0%). Once again, an LTD below 10 mm and female sex were predictive of a better prognosis. CONCLUSION: Our results with proton-beam therapy correspond to those reported in the literature. This treatment strategy is safe and yields predictably good results. In addition to the two independent prognostic factors for survival and metastasis, namely LTD and ciliary body involvement, sex also had a significant impact in our case series, but the clinical relevance of this finding is unknown</style></abstract><notes><style face="normal" font="default">151837833oq, 0370500AIM, IMJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1063</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Marucci,L.</style></author><author><style face="normal" font="default"> Niemierko,A.</style></author><author><style face="normal" font="default"> Liebsch,N.J.</style></author><author><style face="normal" font="default"> Aboubaker,F.</style></author><author><style face="normal" font="default"> Liu,M.C.</style></author><author><style face="normal" font="default"> Munzenrider,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. marucci_laura@yahoo.com</style></auth-address><titles><title><style face="normal" font="default">Spinal cord tolerance to high-dose fractionated 3D conformal proton-photon irradiation as evaluated by equivalent uniform dose and dose volume histogram analysis</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.59.(2):551.-5,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.59.(2):551.-5,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Child,Preschool</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiation Tolerance</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Spinal Cord</style></keyword><keyword><style face="normal" font="default"> Spinal Cord/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="1" Month="6" Year="2004">2004/6/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To evaluate cervical spinal cord tolerance using equivalent uniform dose (EUD) and dose volume histogram (DVH) analysis after proton-photon radiotherapy. METHODS AND MATERIAL: The 3D dose distributions were analyzed in 85 patients with cervical vertebral tumors. Mean follow-up was 41.3 months. The mean prescribed dose was 76.3 Cobalt Gray Equivalent (CGE = proton dose x RBE 1.1). Dose constraints to the center and the surface of the cervical cord were 55-58 CGE and 67-70 CGE, respectively. Dose parameters, DVH and EUD, were calculated for each patient. The spinal cord toxicity was graded using the European Organization for Research and Treatment of Cancer (EORTC) and Radiation Therapy Oncology Group (RTOG) late effects scoring system. RESULTS: Thirteen patients experienced Grade 1-2 toxicity. Four patients had Grade 3 toxicity. For the dose range used in this study, none of the dosimetric parameters was found to be associated with the observed distribution of cord toxicities. The only factor significantly associated with cord toxicity was the number of surgeries before irradiation. CONCLUSION: The data and our analysis suggest that the integrity of the normal musculoskeletal supportive tissues and vascular supply may be important confounding factors of toxicity at these dose levels. The results also indicate that the cervical spinal cord dose constraints used in treating these patients are appropriate for conformal proton-photon radiotherapy</style></abstract><notes><style face="normal" font="default">15145175g97, 7603616IM0 (Protons)Clinical TrialJournal ArticleRandomized Controlled TrialResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1064</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Slater,J.D.</style></author><author><style face="normal" font="default"> Rossi,C.J.,Jr.</style></author><author><style face="normal" font="default"> Yonemoto,L.T.</style></author><author><style face="normal" font="default"> Bush,D.A.</style></author><author><style face="normal" font="default"> Jabola,B.R.</style></author><author><style face="normal" font="default"> Levy,R.P.</style></author><author><style face="normal" font="default"> Grove,R.I.</style></author><author><style face="normal" font="default"> Preston,W.</style></author><author><style face="normal" font="default"> Slater,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Medicine, Loma Linda University Medical Center, Loma Linda, CA, USA</style></auth-address><titles><title><style face="normal" font="default">Proton therapy for prostate cancer: the initial Loma Linda University experience</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.59.(2):348.-52,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.59.(2):348.-52,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Prostate</style></keyword><keyword><style face="normal" font="default"> Prostate-Specific Antigen</style></keyword><keyword><style face="normal" font="default"> Prostate-Specific Antigen/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Conformal</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="1" Month="6" Year="2004">2004/6/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: We analyzed results of conformal proton radiation therapy for localized prostate cancer, with emphasis on biochemical freedom from relapse. METHODS AND MATERIALS: Analyses were performed for 1255 patients treated between October 1991 and December 1997. Outcomes were measured on primarily in terms of biochemical relapse and toxicity. RESULTS: The overall biochemical disease-free survival rate was 73%, and was 90% in patients with initial PSA &lt;or=4.0; it was 87% in patients with posttreatment PSA nadirs &lt;or=0.50. Rates dropped with rises in initial and nadir PSA values. Long-term survival outcomes were comparable with those reported for other modalities intended for cure. CONCLUSIONS: Conformal proton radiation therapy at the reported dose levels yielded disease-free survival rates comparable with other forms of local therapy, and with minimal morbidity. Dose-escalation strategies are being implemented to further improve long-term results</style></abstract><notes><style face="normal" font="default">15145147g97, 7603616IM0 (Protons)EC 3-4-21-77 (Prostate-Specific Antigen)Journal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1078</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Koto,M.</style></author><author><style face="normal" font="default"> Miyamoto,T.</style></author><author><style face="normal" font="default"> Yamamoto,N.</style></author><author><style face="normal" font="default"> Nishimura,H.</style></author><author><style face="normal" font="default"> Yamada,S.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-Ku, Chiba-shi, Chiba 263-8555, Japan</style></auth-address><titles><title><style face="normal" font="default">Local control and recurrence of stage I non-small cell lung cancer after carbon ion radiotherapy.[see comment]</style></title><secondary-title><style face="normal" font="default">Radiotherapy &amp; Oncology.71(2):147.-56.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Radiotherapy &amp; Oncology.71(2):147.-56.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Dose-Response Relationship,Radiation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Neoplasm Staging</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Radiation Tolerance</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Planning,Computer-Assisted/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Conformal/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="5" Year="2004">2004/5</year></dates><pub-location><style face="normal" font="default">Ireland</style></pub-location><isbn><style face="normal" font="default">0167-8140</style></isbn><abstract><style face="normal" font="default">BACKGROUND AND PURPOSE: For a proper evaluation of the relationship between carbon ion beam dose escalation and local control in the 81 patients with 82 lesions of stage I non-small cell lung cancer, we have identified the incidence of in-field recurrence by collating the dose distribution with the CT images. PATIENTS AND METHODS: Eighteen fractions over 6 weeks for 47 patients (48 lesions) and nine fractions over 3 weeks for 34 patients were applied in the carbon dose escalation method from 59.4 to 95.4 gray equivalents (GyE) by a 10% increment and from 68.4 to 79.2GyE by a 5% increment, respectively. The radiation target consisted of primary tumor. Image analysis of the patients with local recurrence was systematically performed after the treatment by focusing attention on the enhanced thin slice CT images of the primary lesion. By superimposing the dose distribution on the planning CT image and marking the anatomically identified loci of recurrence, it was possible to establish the relationship between the dose distribution and the incipient loci of recurrence and to classify the recurrence patterns from the differences in the recurrence loci. RESULTS: Local recurrence was found in 19 (23.2%) out of a total of 82 lesions. It is possible to distinguish between three recurrence patterns: Pattern 1 representing marginal recurrence and patterns 2a and 2b, which are both instances of in-field recurrence. In pattern 1, four recurrences take place from a region on the upper tumor margin. In pattern 2a, 13 recurrences take place from the center of the tumor. In pattern 2b, two recurrences take place from the near-center of the tumor. CONCLUSIONS: For the 15 in-field recurrence lesions (patterns 2a and 2b) after excluding the four marginal recurrence lesions (patterns 1), we have established that the local control shows dose-dependence. Based on this, we have determined the optimal therapeutic dose</style></abstract><notes><style face="normal" font="default">15110447rae, 8407192IM0 (Carbon Radioisotopes)Clinical TrialClinical Trial, Phase IClinical Trial, Phase IIComparative StudyJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1102</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bechrakis,N.E.</style></author><author><style face="normal" font="default"> Hocht,S.</style></author><author><style face="normal" font="default"> Martus,P.</style></author><author><style face="normal" font="default"> Kreusel,K.M.</style></author><author><style face="normal" font="default"> Heese,J.</style></author><author><style face="normal" font="default"> Foerster,M.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Augenklinik, Charite - Universitatsmedizin Berlin, Campus Benjamin Franklin. nikolaos.bechrakis@medizin.fu-berlin.de</style></auth-address><titles><title><style face="normal" font="default">[Endoresection following proton beam irradiation of large uveal melanomas]. [German]</style></title><secondary-title><style face="normal" font="default">Ophthalmologe.101.(4):370.-6,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ophthalmologe.101.(4):370.-6,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Berlin</style></keyword><keyword><style face="normal" font="default"> Combined Modality Therapy</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Image Processing,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Imaging,Three-Dimensional</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Lenses,Intraocular</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Neoadjuvant Therapy</style></keyword><keyword><style face="normal" font="default"> Optic Nerve</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Postoperative Complications/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Planning,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Retina/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword><keyword><style face="normal" font="default"> Visual Acuity/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Vitrectomy</style></keyword></keywords><dates><year Day="0" Month="4" Year="2004">2004/4</year></dates><pub-location><style face="normal" font="default">Germany</style></pub-location><isbn><style face="normal" font="default">0941-293X</style></isbn><abstract><style face="normal" font="default">PURPOSE: Large uveal melanomas located close to the optic nerve and/ or to the fovea have an unfavourable prognosis with regard to visual preservation and eye retention, due to the high incidence of radiation and tumour necrosis induced complications. Endoresection of the tumour after proton beam irradiation, is an alternative approach, aiming to reduce the incidence of ocular morbidity caused by tumour necrosis after sole radiotherapy. PATIENTS AND METHODS: 32 patients with large uveal melanomas (mean tumour thickness: 9.1 mm, mean tumour volume: 0.77 cc), received a primary proton beam irradiation (60 CGE) and underwent subsequent endoresection via a 3-port pars plana vitrectomy. The median pretreatment visual acuity was 0.2. The mean follow-up was 13.9 months. RESULTS: The postoperative visual acuity after 12 months was 0.12 (median, mean visual acuity loss 0.08). The probability of developing radiation retinopathy or papillopathy within the first year after treatment was 35% and 28% respectively and the probability of enucleation was 9% within the first postoperative year. No tumour recurrences were observed and 2 patients developed liver metastases. CONCLUSIONS: Endoresection following irradiation of large uveal melanomas located close to the optic nerve and/ or the fovea seems to be a useful and safe alternative to the traditional irradiation or enucleation. The incidence of complications following our approach seems to be lower when compared to radiation alone, where tumour necrosis is a substantial problem</style></abstract><notes><style face="normal" font="default">15067418bgv, 9206148IM0 (Protons)English AbstractJournal ArticleGerman</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1111</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhang,H.</style></author><author><style face="normal" font="default"> Yoshikawa,K.</style></author><author><style face="normal" font="default"> Tamura,K.</style></author><author><style face="normal" font="default"> Tomemori,T.</style></author><author><style face="normal" font="default"> Sagou,K.</style></author><author><style face="normal" font="default"> Tian,M.</style></author><author><style face="normal" font="default"> Kandatsu,S.</style></author><author><style face="normal" font="default"> Kamada,T.</style></author><author><style face="normal" font="default"> Tsuji,H.</style></author><author><style face="normal" font="default"> Suhara,T.</style></author><author><style face="normal" font="default"> Suzuki,K.</style></author><author><style face="normal" font="default"> Tanada,S.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medical Imaging, National Institute of Radiological Sciences, Chiba, Japan</style></auth-address><titles><title><style face="normal" font="default">[(11)C]methionine positron emission tomography and survival in patients with bone and soft tissue sarcomas treated by carbon ion radiotherapy</style></title><secondary-title><style face="normal" font="default">Clinical Cancer Research.10(5):1764.-72.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clinical Cancer Research.10(5):1764.-72.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> Biological Transport</style></keyword><keyword><style face="normal" font="default"> Bone Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Bone Neoplasms/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> Bone Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes/pk [Pharmacokinetics]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methionine/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> Methionine/pk [Pharmacokinetics]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Sarcoma</style></keyword><keyword><style face="normal" font="default"> Sarcoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Sarcoma/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> Sarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Soft Tissue Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Soft Tissue Neoplasms/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> Soft Tissue Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Tomography,Emission-Computed</style></keyword></keywords><dates><year Day="1" Month="3" Year="2004">2004/3/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">1078-0432</style></isbn><abstract><style face="normal" font="default">PURPOSE: The development of the novel carbon ion radiotherapy (CIRT) in the treatment of refractory cancers has resulted in the need for a way to accurately evaluate patient prognosis. We evaluated whether L-[methyl-(11)C]-methionine (MET) uptake and its change after CIRT were the early survival predictors in patients with unresectable bone and soft tissue sarcomas. EXPERIMENTAL DESIGN: MET positron emission tomography was prospectively performed in 62 patients with unresectable bone and soft tissue sarcomas before and within 1 month after CIRT. Tumor MET uptake was measured with the semiquantitative tumor:nontumor ratio (T/N ratio). The MET uptake in the tumor and relevant clinical parameters were entered into univariate and multivariate survival analysis. RESULTS: The overall median survival time was 20 months. Patients with a baseline T/N ratio of &lt;or=6 had a significant better survival than patients with a baseline T/N ratio >6 (2-year survival rate: 69.4% versus 32.3%; P = 0.01). Patients with a post-CIRT ratio of &lt;or=4.4 had a better survival than that with a post-CIRT ratio >4.4 (2-year survival rate: 63.7% versus 41.3%; P = 0.01). A significant higher survival rate was observed in patients with post-therapeutic MET uptake change of >30% than patients in lower change group (2-year survival rate: 74.6% versus 41.6%; P = 0.049). The multivariate analysis showed that both baseline and post-CIRT T/N ratio were statistically significant independent predictors of patient survival. Tumors with larger T/N ratio had a significantly poorer prognosis. CONCLUSIONS: MET uptake as measured by either baseline or post-CIRT T/N ratio was an independent predictor of survival in patients with bone and soft tissue sarcomas treated by carbon ion radiotherapy, whereas post-therapeutic MET uptake change might have potential value for the same purpose</style></abstract><notes><style face="normal" font="default">15014030c2h, 9502500IM0 (Carbon Radioisotopes)63-68-3 (Methionine)Clinical TrialJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1129</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gambrelle,J.</style></author><author><style face="normal" font="default"> Kodjikian,L.</style></author><author><style face="normal" font="default"> Rouberol,F.</style></author><author><style face="normal" font="default"> Donate,D.</style></author><author><style face="normal" font="default"> Duquesne,N.</style></author><author><style face="normal" font="default"> Jean-Louis,B.</style></author><author><style face="normal" font="default"> Chauvel,P.</style></author><author><style face="normal" font="default"> Gerard,J.P.</style></author><author><style face="normal" font="default"> Romestaing,P.</style></author><author><style face="normal" font="default"> Grange,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Service d'Ophtalmologie, Hopital de la Croix-Rousse, Lyon</style></auth-address><titles><title><style face="normal" font="default">[Ciliary body melanomas. Survival and prognostic aspects after brachytherapy or proton therapy]. [French]</style></title><secondary-title><style face="normal" font="default">Journal Francais.d.Opthalmologie.27.(1):40.-7.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Journal Francais.d.Opthalmologie.27.(1):40.-7.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Brachytherapy</style></keyword><keyword><style face="normal" font="default"> Cataract/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Ciliary Body</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Melanoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Retinal Detachment</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Ruthenium Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Telangiectasis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="0" Month="1" Year="2004">2004/1</year></dates><pub-location><style face="normal" font="default">France</style></pub-location><isbn><style face="normal" font="default">0181-5512</style></isbn><abstract><style face="normal" font="default">INTRODUCTION: Our main goals were to study the survival of patients with uveal melanomas involving the ciliary body 5 and 10 years after treatment and to review prognosis. MATERIAL AND METHODS: This study investigated 106 tumors (27 ciliary body melanomas and 79 choroidal-ciliary melanomas) of patients treated between June 1983 and April 1998. Seventy-two patients were treated with 106-ruthenium applicators and 34 were treated with proton therapy. Some large tumors or recurrences required a second treatment. The mean follow-up period was 91 months. RESULTS: The mean tumor sizes before treatment were 6,6mm for melanoma thickness and 10.3mm for mean largest basal melanoma diameters (LTD). Of the patients studied, 71% were still alive at 5 years, 35% had metastasis and 27.7% developed recurrences. Multivariate analysis showed that the risk factors for melanoma-related death were LTD greater than 13mm, presence of exudative retinal detachment, macroscopic iris root involvement at the time of diagnosis, and choroidal-ciliary location. DISCUSSION AND CONCLUSION: With 71% of patients still alive at 5 years, this review shows that melanomas involving the ciliary body do not seem less severe than more posterior uveal tumors. Because of size differences between ciliary body melanomas and choroidal-ciliary melanomas, we cannot come to the conclusion that choroidal-ciliary melanomas have a poorer prognosis than ciliary body melanomas. Largest tumor diameter over 13mm, presence of exudative retinal detachment, and macroscopic iris root involvement at the time of diagnosis are important risk factors for melanoma-related death, as shown by the multivariate analysis</style></abstract><notes><style face="normal" font="default">14968076iae, 7804128IM0 (Protons)0 (Ruthenium Radioisotopes)Comparative StudyEnglish AbstractJournal ArticleFrench</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1133</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tokuuye,K.</style></author><author><style face="normal" font="default"> Akine,Y.</style></author><author><style face="normal" font="default"> Kagei,K.</style></author><author><style face="normal" font="default"> Hata,M.</style></author><author><style face="normal" font="default"> Hashimoto,T.</style></author><author><style face="normal" font="default"> Mizumoto,T.</style></author><author><style face="normal" font="default"> Ohshiro,Y.</style></author><author><style face="normal" font="default"> Sugahara,S.</style></author><author><style face="normal" font="default"> Ohara,K.</style></author><author><style face="normal" font="default"> Okumura,T.</style></author><author><style face="normal" font="default"> Kusakari,J.</style></author><author><style face="normal" font="default"> Yoshida,H.</style></author><author><style face="normal" font="default"> Otsuka,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan, ktokuue@pmrc.tsukuba.ac.jp</style></auth-address><titles><title><style face="normal" font="default">Proton therapy for head and neck malignancies at Tsukuba</style></title><secondary-title><style face="normal" font="default">Strahlentherapie und Onkologie.180.(2):96.-101.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Strahlentherapie und Onkologie.180.(2):96.-101.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Combined Modality Therapy</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Feasibility Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Neoadjuvant Therapy</style></keyword><keyword><style face="normal" font="default"> Neoplasm Staging</style></keyword><keyword><style face="normal" font="default"> Otorhinolaryngologic Neoplasms/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Otorhinolaryngologic Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Otorhinolaryngologic Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Otorhinolaryngologic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> X-Ray Therapy</style></keyword><keyword><style face="normal" font="default"> X-Rays</style></keyword></keywords><dates><year Day="0" Month="2" Year="2004">2004/2</year></dates><pub-location><style face="normal" font="default">Germany</style></pub-location><isbn><style face="normal" font="default">0179-7158</style></isbn><abstract><style face="normal" font="default">PURPOSE: To evaluate the effectiveness and feasibility of proton therapy for head and neck cancers. PATIENTS AND METHODS: From 1983 to 2000, 33 patients with head and neck malignancies but no history of surgical resection were treated with 250-MeV protons with or without X-ray irradiation. This study retrospectively evaluated local control, survival, and treatment sequelae of these patients. The median total target dose using protons with or without X-rays was 76 Gy (range: 42-99 Gy) and the median proton dose per fraction 2.8 Gy (range: 1.5-6.0 Gy). RESULTS: Overall 5-year survival and local control rates were 44% and 74%, respectively. One (3%) and six patients (18%) suffered from treatment-related acute and late toxicity > grade 3 (RTOG/EORTC acute and late radiation morbidity scoring criteria). One patient with a history of radiotherapy suffered from acute toxicity > grade 3. CONCLUSION: Proton therapy appeared to offer high local control rates with few toxicities relative to conventional radiotherapy. However, late toxicity was seen in areas where large radiation doses had been given</style></abstract><notes><style face="normal" font="default">14762662vcm, 8603469IM0 (Protons)Journal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1136</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schulz-Ertner,D.</style></author><author><style face="normal" font="default"> Nikoghosyan,A.</style></author><author><style face="normal" font="default"> Thilmann,C.</style></author><author><style face="normal" font="default"> Haberer,T.</style></author><author><style face="normal" font="default"> Jakel,O.</style></author><author><style face="normal" font="default"> Karger,C.</style></author><author><style face="normal" font="default"> Kraft,G.</style></author><author><style face="normal" font="default"> Wannenmacher,M.</style></author><author><style face="normal" font="default"> Debus,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical Radiology, University of Heidelberg, INF 400, 69120 Heidelberg, Germany. d.ertner@dkfz.de</style></auth-address><titles><title><style face="normal" font="default">Results of carbon ion radiotherapy in 152 patients</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.58.(2):631.-40.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.58.(2):631.-40.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Adenoid Cystic/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Heavy Ions/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Ions</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Sacrococcygeal Region</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Base</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="1" Month="2" Year="2004">2004/2/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: This study summarizes the experience with raster scanned carbon ion radiation therapy (RT) at the Gesellschaft fur Schwerionenforschung (GSI), Darmstadt, Germany since 1997. METHODS AND MATERIALS: Between December 1997 and December 2002, 152 patients were treated at GSI with carbon ion RT. Eighty-seven patients with chordomas and low-grade chondrosarcomas of the skull base received carbon ion RT alone (median dose 60 GyE); 21 patients with unfavorable adenoid cystic carcinomas and 17 patients with spinal (n = 9) and sacrococcygeal (n = 8) chordomas and chondrosarcomas were treated with combined photon and carbon ion RT. Twelve patients received reirradiation with carbon ions with or without photon RT for recurrent tumors. Furthermore, 15 patients with skull base tumors other than chordoma and low-grade chondrosarcoma were treated with carbon ions. RESULTS: Actuarial 3-year local control was 81% for chordomas, 100% for chondrosarcomas, and 62% for adenoid cystic carcinomas. Local control was obtained in 15/17 patients with spinal (8/9) and sacral (7/8) chordomas or chondrosarcomas and in 11/15 patients with skull base tumors other than chordomas and low-grade chondrosarcomas, respectively. Six of 12 patients who received reirradiation are still alive without signs of tumor progression. Common Toxicity Criteria Grade 4 or Grade 5 toxicity was not observed. CONCLUSION: Carbon ion therapy is safe with respect to toxicity and offers high local control rates for skull base tumors such as chordomas, low-grade chondrosarcomas, and unfavorable adenoid cystic carcinomas</style></abstract><notes><style face="normal" font="default">14751537g97, 7603616IM7440-44-0 (Carbon)Clinical TrialClinical Trial, Phase IClinical Trial, Phase IIJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1138</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Akakura,K.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author><author><style face="normal" font="default"> Morita,S.</style></author><author><style face="normal" font="default"> Tsuji,H.</style></author><author><style face="normal" font="default"> Yagishita,T.</style></author><author><style face="normal" font="default"> Isaka,S.</style></author><author><style face="normal" font="default"> Ito,H.</style></author><author><style face="normal" font="default"> Akaza,H.</style></author><author><style face="normal" font="default"> Hata,M.</style></author><author><style face="normal" font="default"> Fujime,M.</style></author><author><style face="normal" font="default"> Harada,M.</style></author><author><style face="normal" font="default"> Shimazaki,J.</style></author><author><style face="normal" font="default"> Working Group for Genitourinary Tumors,National Institute of Radiological Science</style></author></authors></contributors><auth-address><style face="normal" font="default">National Institute of Radiological Science, Chiba, Japan. akakurak@tkn-hosp.gr.jp</style></auth-address><titles><title><style face="normal" font="default">Phase I/II clinical trials of carbon ion therapy for prostate cancer.[erratum appears in Prostate. 2004 Sep 15;61(1):103]</style></title><secondary-title><style face="normal" font="default">Prostate.58.(3):252.-8.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Prostate.58.(3):252.-8.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Carbon/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Chemotherapy,Adjuvant</style></keyword><keyword><style face="normal" font="default"> Combined Modality Therapy</style></keyword><keyword><style face="normal" font="default"> Dose-Response Relationship,Radiation</style></keyword><keyword><style face="normal" font="default"> Energy Transfer</style></keyword><keyword><style face="normal" font="default"> Heavy Ions/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Heavy Ions/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Linear Energy Transfer</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Neoadjuvant Therapy</style></keyword><keyword><style face="normal" font="default"> Prostate</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Rectal Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Relative Biological Effectiveness</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Urethral Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Urinary Bladder Diseases/et [Etiology]</style></keyword></keywords><dates><year Day="15" Month="2" Year="2004">2004/2/15</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0270-4137</style></isbn><abstract><style face="normal" font="default">BACKGROUND: Heavy ion beams possess high linear energy transfer components and a prominent Bragg peak in the human body, resulting in higher relative biological effectiveness and improved dose distribution. To establish heavy ion therapy techniques for the treatment of prostate cancer, phase I/II clinical trials were initiated. METHODS: For 96 patients with T1b-T3 prostate cancer, three carbon ion beams were used to irradiate the prostate and seminal vesicles (20 times/5 weeks) with or without endocrine therapy. Radiation dose was expressed in GyE which was initially thought to be equivalent to photon dose. Total dose was gradually increased from 54 to 72 GyE. RESULTS: Carbon ion therapy was completed in 20 cases of T1b/T1c/T2aN0M0 as monotherapy, in 8 cases of T2b/T3pN0M0 with neoadjuvant endocrine therapy, and in 68 cases of T2b/T3N0/pN1M0 with neoadjuvant and adjuvant endocrine therapy. Median observation period was 47 months. Grade 3 late radiation morbidity of rectum and/or bladder/urethra developed in one and five cases who received 66 and 72 GyE of radiation, respectively. After these adverse effects were observed, total dose was decreased to 66 GyE and the radiation field was coned down during the treatment course. At 5 years, overall, cause-specific, clinical recurrence-free, and biochemical recurrence-free survival rates were 87.7, 94.9, 90.0, and 82.6%, respectively. Local control was achieved in all patients except one patient who received 54 GyE of radiation. CONCLUSIONS: The therapeutic techniques of carbon ion therapy have been established for patients with prostate cancer. Carbon ion therapy may exert excellent effect to the tissues of prostate cancer. Copyright 2003 Wiley-Liss, Inc</style></abstract><notes><style face="normal" font="default">14743464pb4, 8101368IM7440-44-0 (Carbon)Clinical TrialClinical Trial, Phase IClinical Trial, Phase IIJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1160</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Spatola,C.</style></author><author><style face="normal" font="default"> Privitera,G.</style></author><author><style face="normal" font="default"> Raffaele,L.</style></author><author><style face="normal" font="default"> Salamone,V.</style></author><author><style face="normal" font="default"> Cuttone,G.</style></author><author><style face="normal" font="default"> Cirrone,P.</style></author><author><style face="normal" font="default"> Sabini,M.G.</style></author><author><style face="normal" font="default"> Lo,Nigro S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Servizio di Radioterapia, Policlinico Universitario Catania, Catania, Italy. cor_spatola@hotmail.com</style></auth-address><titles><title><style face="normal" font="default">Clinical application of proton beams in the treatment of uveal melanoma: the first therapies carried out in Italy and preliminary results (CATANA Project)</style></title><secondary-title><style face="normal" font="default">Tumori.89.(5):502.-9,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Tumori.89.(5):502.-9,</style></abbr-1></periodical><pages end="Oct" start="">-Oct</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Ciliary Body</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Cyclotrons</style></keyword><keyword><style face="normal" font="default"> Diffusion</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eye Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glaucoma</style></keyword><keyword><style face="normal" font="default"> Great Britain</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> International Cooperation</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Relative Biological Effectiveness</style></keyword><keyword><style face="normal" font="default"> Retinal Detachment</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword></keywords><dates><year Day="0" Month="9" Year="2003">2003/9</year></dates><pub-location><style face="normal" font="default">Italy</style></pub-location><isbn><style face="normal" font="default">0300-8916</style></isbn><abstract><style face="normal" font="default">BACKGROUND: The first Italian proton therapy facility was realized in Catania, at the INFN-LNS. With its energy (62 MeV proton beam), it is ideal for the treatment of shallow tumors like those of the ocular region: uveal melanoma, first of all (the most common primary intraocular malignancy of adults) and other less frequent lesions like choroidal hemangioma, conjunctiva melanoma, and eyelid tumors. MATERIAL AND METHODS: The first patient was enrolled in February 2002, and to date 30 patients have been treated. All patients had a localized uveal melanoma, with no systemic metastases, and had specific indications for proton beam radiation therapy: lesions between 5-25 mm basal diameter, not exceeding 15 mm thickness, absence of total retinal detachment or glaucoma. According to the tumor dimensions, 2 patients had a small lesion or T1 (6%), 3 had a medium-sized lesion or T2 (10%), 14 had a large lesion or T3 (47%), and 11 had an extra-large lesion or T3 (37%); no patient had extrascleral invasion or T4 of the TNM-AJCC Staging System. In most cases, the tumor infiltrated only the choroid (14 patients, 47%) or the choroid plus the ciliary body (14 patients, 47%). We also treated a primitive iris melanoma, without diffusion to the ciliary body. The target volume was defined as the tumor plus a safety margin of 2.5 mm, laterally and antero-posteriorly; this margin was increased to 3 mm if ciliary body involvement was present. The treatment was carried out in 4 fractions on 4 consecutive days to a total dose of 54.5 Gy (single fraction 13.6 Gy), which corresponds to 60 CGE (Cobalt Gray Equivalent; single fraction 15 CGE), because the relative biological effectiveness is 1.1. RESULTS: The first follow-up is planned at 6-8 months after the end of the treatment, and our clinical end points are local control (defined as cessation of growth or tumor shrinkage), eye retention, and maintenance of a good visual function. At the time of this writing, we had preliminary results from 13 patients. Nine patients showed tumor shrinkage (69%), 3 a substantially stable dimension (23%), but almost all patients presented an increased ultrasound reflectivity (a surrogate for tumor control). DISCUSSION AND CONCLUSIONS: The literature data show that charged particle therapy has allowed an optimal local control in the treatment of uveal melanomas (about 96% in the different series, superior to that obtained with plaquetherapy [between 83% and 92%]), a metastatic rate slightly better than enucleation reports, and a survival rate of almost 90% at 5 years. Our preliminary results show a tumor response in almost all cases, with no major acute or subacute side effects. We thus plan to continue with our treatment procedures and our dose prescription</style></abstract><notes><style face="normal" font="default">14870772wjs, 0111356IM0 (Protons)Clinical TrialJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1183</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schulz-Ertner,D.</style></author><author><style face="normal" font="default"> Nikoghosyan,A.</style></author><author><style face="normal" font="default"> Thilmann,C.</style></author><author><style face="normal" font="default"> Haberer,T.</style></author><author><style face="normal" font="default"> Jakel,O.</style></author><author><style face="normal" font="default"> Karger,C.</style></author><author><style face="normal" font="default"> Scholz,M.</style></author><author><style face="normal" font="default"> Kraft,G.</style></author><author><style face="normal" font="default"> Wannenmacher,M.</style></author><author><style face="normal" font="default"> Debus,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical Radiology, University of Heidelberg, Germany. d.ertner@dkfz.de</style></auth-address><titles><title><style face="normal" font="default">Carbon ion radiotherapy for chordomas and low-grade chondrosarcomas of the skull base. Results in 67 patients</style></title><secondary-title><style face="normal" font="default">Strahlentherapie und Onkologie.179.(9):598.-605.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Strahlentherapie und Onkologie.179.(9):598.-605.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Clinical Trials,Phase I as Topic</style></keyword><keyword><style face="normal" font="default"> Clinical Trials,Phase II as Topic</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Heavy Ions/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Imaging,Three-Dimensional</style></keyword><keyword><style face="normal" font="default"> Ions</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Planning,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Base</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2003">2003/9</year></dates><pub-location><style face="normal" font="default">Germany</style></pub-location><isbn><style face="normal" font="default">0179-7158</style></isbn><abstract><style face="normal" font="default">PURPOSE: To prospectively evaluate outcome and toxicity after carbon ion radiotherapy (RT) in chordomas and low-grade chondrosarcomas. PATIENTS AND METHODS: Between September 1998 and December 2001, 74 patients were treated for chordomas and chondrosarcomas with carbon ion RT at the "Gesellschaft fur Schwerionenforschung" (GSI). Seven patients reirradiated with reduced carbon ion doses after conventional RT were excluded from the analysis, leaving 67 evaluable patients (44 chordomas and 23 chondrosarcomas) who received a full course of carbon ion therapy. Tumor-conform application of carbon ion beams was realized by intensity-controlled raster scanning with active energy variation. Three-dimensional treatment planning included intensity modulation and biological plan optimization. A median dose of 60 GyE was applied to the target volume within 20 consecutive days at a dose of 3.0 GyE per fraction. RESULTS: Median follow-up was 15 months (range 3-46 months). At 3 years, actuarial local control was 100% for chondrosarcomas and 87% for chordomas, respectively. Partial tumor remission was observed in 14/44 (31%) chordoma patients and in 4/23 (17%) chondrosarcoma patients. At 3 years, actuarial overall survival was 100% for chondrosarcomas and 89% for chordomas, respectively. No severe side effects > CTC degrees III have been observed. CONCLUSIONS: These data demonstrate the clinical efficiency and safety of scanning beam delivery of carbon ion beams in patients with skull base chordomas and chondrosarcomas. The observation of tumor regressions at a dose level of 60 GyE may indicate that the biological effectiveness of carbon ions in chordomas and chondrosarcomas is higher than initially estimated</style></abstract><notes><style face="normal" font="default">14628125vcm, 8603469IM7440-44-0 (Carbon)Clinical TrialComparative StudyEvaluation StudiesJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1280</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Char,D.H.</style></author><author><style face="normal" font="default"> Bove,R.</style></author><author><style face="normal" font="default"> Phillips,T.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Tumori Foundation CPMC , San Francisco, California, USA. devron@tumori.org</style></auth-address><titles><title><style face="normal" font="default">Laser and proton radiation to reduce uveal melanoma-associated exudative retinal detachments</style></title><secondary-title><style face="normal" font="default">American Journal of Ophthalmology.136.(1):180.-2,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">American Journal of Ophthalmology.136.(1):180.-2,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Combined Modality Therapy</style></keyword><keyword><style face="normal" font="default"> Exudates and Transudates</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperthermia,Induced/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Lasers</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Melanoma/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Retinal Detachment/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Retinal Detachment/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword></keywords><dates><year Day="0" Month="7" Year="2003">2003/7</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0002-9394</style></isbn><abstract><style face="normal" font="default">PURPOSE: To assess whether laser-induced hyperthermia with proton irradiation of choroidal melanoma may decrease exudative retinal detachments more rapidly. DESIGN: Case control study. METHODS: Patients treated with laser-induced hyperthermia and proton radiation; results were compared with similar patients treated with only protons. RESULTS: All 11 patients treated with combined laser and proton therapy had resorption of subretinal fluid with a mean duration of retinal detachment of 193 days compared with 263 days in the group treated with only proton therapy (P &lt;.04). At 1 year, visual acuity was similar. CONCLUSIONS: Combined laser radiation more rapidly dissipates exudative detachments than radiation alone</style></abstract><notes><style face="normal" font="default">128346893oq, 0370500AIM, IM0 (Protons)Comparative StudyDuplicate PublicationJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1314</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Desjardins,L.</style></author><author><style face="normal" font="default"> Lumbroso,L.</style></author><author><style face="normal" font="default"> Levy,C.</style></author><author><style face="normal" font="default"> Mazal,A.</style></author><author><style face="normal" font="default"> Delacroix,S.</style></author><author><style face="normal" font="default"> Rosenwald,J.C.</style></author><author><style face="normal" font="default"> Dendale,R.</style></author><author><style face="normal" font="default"> Plancher,C.</style></author><author><style face="normal" font="default"> Asselain,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institut Curie, 26, rue d'Ulm, 75005 Paris</style></auth-address><titles><title><style face="normal" font="default">[Treatment of uveal melanoma with iodine 125 plaques or proton beam therapy: indications and comparison of local recurrence rates]. [French]</style></title><secondary-title><style face="normal" font="default">Journal Francais.d.Opthalmologie.26.(3):269.-76.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Journal Francais.d.Opthalmologie.26.(3):269.-76.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Iodine Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Iodine Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Melanoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Neoplasm Invasiveness</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Statistics,Nonparametric</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="0" Month="3" Year="2003">2003/3</year></dates><pub-location><style face="normal" font="default">France</style></pub-location><isbn><style face="normal" font="default">0181-5512</style></isbn><abstract><style face="normal" font="default">INTRODUCTION: This retrospective study compared the rate of local recurrence after irradiation of uveal melanoma treated with iodine 125 plaques or proton beam therapy. PATIENTS AND METHODS: Iodine 125 plaques were used to treat all uveal melanomas between the end of 1989 and 1991. Since 1991, we have used iodine plaques for small anterior tumors and proton beam for other tumors. We use a plaque with a larger diameter than the tumor diameter (2-4mm) with a dose of 90Gy at the apex. Proton beam therapy is used for all tumors at the equator or posterior to the equator not thicker than 12mm. The dose given is 60Gy cobalt equivalent in four fractions. For each patient, the initial size and location of the tumor were noted as well as the follow-up each year: the outcome for the eye (local recurrence, ocular conservation, and functional results), the occurrence of metastasis, and survival. A statistical analysis was performed. RESULTS: Between December 1989 and September 1998, 1272 patients were treated: 926 (72.8%) were treated with proton beam irradiation and 346 (27.8%) with iodine 125 plaques. The median follow-up was 5 years (60 months). For the patients treated with proton beam therapy, the mean age was 58 years, the tumor location was anterior to the equator for 3.8%, at the equator for 43.6%, and posterior to the equator for 52.6%. The mean tumor diameter was 13.4mm and the mean tumor thickness was 5.69mm. For the patients treated with iodine 125 plaques, the mean age was 61.5 years. The location of the tumor was anterior to the equator for 34.4%, at the equator for 46.5%, and posterior to the equator for 19.1%. The mean tumor diameter was 11.5mm and the mean tumor thickness was 5.12mm. The recurrence rate was 4% for the proton beam treatment and 3.75% for iodine plaques. There was no statistical difference. DISCUSSION: In the literature, the rate of local recurrence is usually higher with iodine 125 plaques than proton beam therapy. We discuss the risk factors for local recurrence after iodine 125 plaques: tumor diameter, lower dose to the tumor apex and lower dose rate, and posterior location of the tumor. We found a higher mortality rate in patients who presented local recurrence. CONCLUSION: When we use iodine 125 plaques for anterior tumors with the proper dose and dose rate to the apex of the tumor, we do not find more recurrence than with proton beam therapy</style></abstract><notes><style face="normal" font="default">12746603iae, 7804128IM0 (Iodine Radioisotopes)0 (Protons)Comparative StudyEnglish AbstractJournal ArticleFrench</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1320</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schulz-Ertner,D.</style></author><author><style face="normal" font="default"> Nikoghosyan,A.</style></author><author><style face="normal" font="default"> Jakel,O.</style></author><author><style face="normal" font="default"> Haberer,T.</style></author><author><style face="normal" font="default"> Kraft,G.</style></author><author><style face="normal" font="default"> Scholz,M.</style></author><author><style face="normal" font="default"> Wannenmacher,M.</style></author><author><style face="normal" font="default"> Debus,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical Radiology, University of Heidelberg, Heidelberg, Germany. d.ertner@dkfz.de</style></auth-address><titles><title><style face="normal" font="default">Feasibility and toxicity of combined photon and carbon ion radiotherapy for locally advanced adenoid cystic carcinomas</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.56.(2):391.-8.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.56.(2):391.-8.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Adenoid Cystic/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Adenoid Cystic/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Feasibility Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Head and Neck Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Head and Neck Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Conformal</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Salivary Gland Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Salivary Gland Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="1" Month="6" Year="2003">2003/6/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To investigate clinical feasibility and toxicity of combined photon and carbon ion radiotherapy in locally advanced adenoid cystic carcinomas (ACC) within a prospective Phase I/II trial. METHODS AND MATERIALS: Between September 1998 and April 2002, 16 patients with histopathologically proven ACC and residual macroscopic tumor were treated with combined photon RT and a carbon ion boost to the macroscopic tumor. Median total tumor dose within the gross tumor volume (GTV) was 72 GyE. Photon radiation therapy (RT) consisted of fractionated stereotactic RT in 7 patients; 9 patients received stereotactic intensity-modulated RT. Carbon ion boost was delivered by intensity-controlled raster scanning at the heavy ion synchrotron (SIS) at the Heavy Ion Research Center (GSI) in Darmstadt. RESULTS: Median follow-up was 12 months. Three patients developed locoregional recurrences 9, 11, and 24 months after RT, respectively. Actuarial local control rates were 80.8% and 64.6% at 1 and 3 years, respectively. Overall survival rates were 100% and 83.3% at 1 and 3 years, respectively. Acute side effects greater than Common Toxicity Criteria (CTC) Grade 2 were observed in 2 patients; no patient developed late effects > CTC Grade 2. CONCLUSIONS: Combined photon and carbon ion RT is feasible and effective in patients with locally advanced ACC. Acute and late toxicity is moderate with respect to the delivered tumor doses and in accordance with the radiobiologic modeling. A Phase III trial is designed</style></abstract><notes><style face="normal" font="default">12738314g97, 7603616IM0 (Carbon Radioisotopes)Clinical TrialClinical Trial, Phase IClinical Trial, Phase IIJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1327</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Noel,G.</style></author><author><style face="normal" font="default"> Habrand,J.L.</style></author><author><style face="normal" font="default"> Jauffret,E.</style></author><author><style face="normal" font="default"> de,Crevoisier R.</style></author><author><style face="normal" font="default"> Dederke,S.</style></author><author><style face="normal" font="default"> Mammar,H.</style></author><author><style face="normal" font="default"> Haie-Meder,C.</style></author><author><style face="normal" font="default"> Pontvert,D.</style></author><author><style face="normal" font="default"> Hasboun,D.</style></author><author><style face="normal" font="default"> Ferrand,R.</style></author><author><style face="normal" font="default"> Boisserie,G.</style></author><author><style face="normal" font="default"> Beaudre,A.</style></author><author><style face="normal" font="default"> Gaboriaud,G.</style></author><author><style face="normal" font="default"> Guedea,F.</style></author><author><style face="normal" font="default"> Petriz,L.</style></author><author><style face="normal" font="default"> Mazeron,J.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre de Protontherapie d'Orsay, Orsay, France. noel@ipno.in2p3.fr</style></auth-address><titles><title><style face="normal" font="default">Radiation therapy for chordoma and chondrosarcoma of the skull base and the cervical spine. Prognostic factors and patterns of failure</style></title><secondary-title><style face="normal" font="default">Strahlentherapie und Onkologie.179.(4):241.-8.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Strahlentherapie und Onkologie.179.(4):241.-8.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Cervical Vertebrae</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Data Interpretation,Statistical</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons</style></keyword><keyword><style face="normal" font="default"> Photons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Rest</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Base</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword></keywords><dates><year Day="0" Month="4" Year="2003">2003/4</year></dates><pub-location><style face="normal" font="default">Germany</style></pub-location><isbn><style face="normal" font="default">0179-7158</style></isbn><abstract><style face="normal" font="default">BACKGROUND: Prospective analysis of local tumor control, survival and treatment complications in 67 consecutive patients treated with fractionated photon and proton radiation for chordoma or chondrosarcoma of the base of the skull and the cervical spine. PATIENTS AND METHODS: Between December 1995 and January 2000, 67 patients with a median age of 52 years (range: 14-85 years), were treated at the Centre de Protontherapie d'Orsay (CPO), France, using the 201-MeV proton beam, 49 for chordoma and 18 for chondrosarcoma. Irradiation combined high-energy photons and protons. Photons represented two thirds of the total dose and protons one third. The median total dose delivered within gross tumor volume (GTV) was 67 Cobalt Gray Equivalents (CGE; range: 60-70 CGE). RESULTS: Within a median follow-up of 29 months (range: 4-71 months), the 3-year local control rates were 71% and 85% for chordomas and chondrosarcomas, respectively, and the 3-year overall survival rates 88% and 75%, respectively. 14 tumors (21.5%) failed locally (eight within the GTV, four within the clinical target volume [CTV], and two without further assessment). Seven patients died from their tumor and another one from a nonrelated condition (pulmonary embolism). The maximum tumor diameter and, similarly, the GTV were larger in relapsing patients, compared with the rest of the population: 56 mm vs 44 mm (p = 0.024) and 50 ml vs 22 ml (p = 0.0083), respectively. In univariate analysis, age &lt; or = 52 years at the time of radiotherapy (p = 0.002), maximum diameter &lt; 45 mm (p = 0.02), and GTV &lt; 28 ml (p = 0.02) impacted positively on local control. On multivariate analysis, only age was an independent prognostic factor of local control. CONCLUSION: In chordomas and chondrosarcomas of the skull base and cervical spine, combined photon and proton radiation therapy offers excellent chances of cure. In two thirds of the cases, relapses are located in the GTV. Maximum diameter, GTV, and age are prognostic indicators of local control. These results should be confirmed during a longer follow-up</style></abstract><notes><style face="normal" font="default">12707713vcm, 8603469IM0 (Protons)Comparative StudyJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1338</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shioyama,Y.</style></author><author><style face="normal" font="default"> Tokuuye,K.</style></author><author><style face="normal" font="default"> Okumura,T.</style></author><author><style face="normal" font="default"> Kagei,K.</style></author><author><style face="normal" font="default"> Sugahara,S.</style></author><author><style face="normal" font="default"> Ohara,K.</style></author><author><style face="normal" font="default"> Akine,Y.</style></author><author><style face="normal" font="default"> Ishikawa,S.</style></author><author><style face="normal" font="default"> Satoh,H.</style></author><author><style face="normal" font="default"> Sekizawa,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, The University Hospital, Tsukuba, Japan</style></auth-address><titles><title><style face="normal" font="default">Clinical evaluation of proton radiotherapy for non-small-cell lung cancer</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.56.(1):7.-13,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.56.(1):7.-13,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adenocarcinoma</style></keyword><keyword><style face="normal" font="default"> Adenocarcinoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Adenocarcinoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Adenocarcinoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Large Cell/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Large Cell/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Large Cell/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Squamous Cell/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Squamous Cell/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Squamous Cell/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Japan/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Life Tables</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Staging</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Conformal</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="1" Month="5" Year="2003">2003/5/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To evaluate the clinical results of proton radiotherapy for patients with non-small-cell lung cancer (NSCLC). MATERIALS AND METHODS: Between 1983 and 2000, 51 NSCLC patients were treated with proton beams at the University of Tsukuba. There were 28 patients in Stage I, 9 in Stage II, 8 in Stage III, 1 in Stage IV, and 5 with recurrent disease. Thirty-three patients had squamous cell carcinoma, 17 had adenocarcinoma, and 1 had large-cell carcinoma. Median fraction and total doses given were 3.0 Gy (range 2.0-6.0 Gy), and 76.0 Gy (range 49.0-93.0 Gy), respectively. RESULTS: The 5-year overall survival rate was 29% for all patients, 70% for 9 Stage IA patients, and 16% for 19 Stage IB patients, respectively (IA vs. IB: p &lt; 0.05). The 5-year in-field local control rate was higher in patients with Stage IA (89%) when compared with those with Stage IB (39%). Forty-seven patients (92%) experienced acute lung toxicity of Grade 1 or less; 3 had Grade 2, 1 had Grade 3, and none experienced Grade 4 or higher. Patients in the present series showed very little late toxicity. CONCLUSIONS: Proton therapy is a very safe and effective treatment for patients with NSCLC, especially for those with early stages. The relative merit of proton therapy in comparison with stereotactic photon radiotherapy or three-dimensional conformal photon radiotherapy remains to be defined through future clinical trials</style></abstract><notes><style face="normal" font="default">12694818g97, 7603616IM0 (Protons)Evaluation StudiesJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1349</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kagei,K.</style></author><author><style face="normal" font="default"> Tokuuye,K.</style></author><author><style face="normal" font="default"> Okumura,T.</style></author><author><style face="normal" font="default"> Ohara,K.</style></author><author><style face="normal" font="default"> Shioyama,Y.</style></author><author><style face="normal" font="default"> Sugahara,S.</style></author><author><style face="normal" font="default"> Akine,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Proton Medical Research Center, University Hospital, University of Tsukuba, Ibaraki, Japan. kkagei@md.tsukaba.ac.jp</style></auth-address><titles><title><style face="normal" font="default">Long-term results of proton beam therapy for carcinoma of the uterine cervix</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.55.(5):1265.-71,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.55.(5):1265.-71,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Squamous Cell/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Squamous Cell/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Cobalt Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Cobalt Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Colitis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Cystitis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Enteritis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Life Tables</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pelvis</style></keyword><keyword><style face="normal" font="default"> Photons/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Photons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Radioisotope Teletherapy</style></keyword><keyword><style face="normal" font="default"> Radioisotope Teletherapy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Planning,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Synchrotrons</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urinary Bladder</style></keyword><keyword><style face="normal" font="default"> Uterine Cervical Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Uterine Cervical Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="1" Month="4" Year="2003">2003/4/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To determine the role of proton therapy in patients with carcinoma of the uterine cervix. METHODS AND MATERIALS: Between 1983 and 1991, 25 patients with squamous cell carcinoma of the uterine cervix (stages IIB-IVA) were treated with a curative intent by external photon irradiation to the pelvis, followed by proton irradiation to the primary tumor, delivering a median total tumor dose of 86 Gy (range 71 Gy/26 Fr-101 Gy/46 Fr), and were followed for a median period of 139 months (range 11-184 months). RESULTS: Ten-year overall survival rates for stages IIB and IIIB/IVA patients were 89% and 40%, respectively. Five-year local control rates for stages IIB and IIIB/IVA patients were 100% and 61%, respectively. Four percent of patients experienced severe (Grade 4 or more) late complications in the intestine or urinary bladder at 5 years. CONCLUSION: External photon and proton therapy is effective for those who are not eligible for intracavitary irradiation, and who otherwise have a poor prognosis. The results show that tumor control, survival, and morbidity are similar to those after conventional therapy</style></abstract><notes><style face="normal" font="default">12654436g97, 7603616IM0 (Cobalt Radioisotopes)Clinical TrialJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1351</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Noel,G.</style></author><author><style face="normal" font="default"> Habrand,J.L.</style></author><author><style face="normal" font="default"> Helfre,S.</style></author><author><style face="normal" font="default"> Mammar,H.</style></author><author><style face="normal" font="default"> Kalifa,C.</style></author><author><style face="normal" font="default"> Ferrand,R.</style></author><author><style face="normal" font="default"> Beaudre,A.</style></author><author><style face="normal" font="default"> Gaboriaud,G.</style></author><author><style face="normal" font="default"> Mazeron,J.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre de Protontherapie d'Orsay, BP 65, France. noel@ipno.in2p3.fr</style></auth-address><titles><title><style face="normal" font="default">Proton beam therapy in the management of central nervous system tumors in childhood: the preliminary experience of the Centre de Protontherapie d'Orsay</style></title><secondary-title><style face="normal" font="default">Medical &amp; Pediatric Oncology.40.(5):309.-15,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Medical &amp; Pediatric Oncology.40.(5):309.-15,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Central Nervous System Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Central Nervous System Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Central Nervous System Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Cranial Irradiation/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Cranial Irradiation/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> France/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Planning,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Conformal/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Conformal/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="0" Month="5" Year="2003">2003/5</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0098-1532</style></isbn><abstract><style face="normal" font="default">BACKGROUND: The purpose of the study was to evaluate clinical results and complications of a combination of proton and photon irradiation administered to 17 children with selected central nervous system (CNS) tumors. PROCEDURE: Between July 1994 and September 2000, 17 children, aged from 5 to 17 years (median: 12 years) with intracranial benign (6 cases) or malignant (11 cases) tumors, were treated with photons (median dose: 40 Gy; 24-54) and protons (median dose: 20 CGE; 9-31) at the Centre de Protontherapie d'Orsay (CPO). RESULTS: Mean follow-up was 27 months (3-81). Two patients recurred locally (one marginal and one in situ). Fifteen patients are alive and doing well. Overall, 12, 24, and 36-month local control rate was 92 +/- 8% and, 12, 24, and 36-month overall survival rates were 93 +/- 6%, 83 +/- 11%, and 83 +/- 11%, respectively. Clinical initial symptoms remained stable or subsided in all patients. Early toxicities were in the expected range. CONCLUSIONS: With a mean 27 months follow-up, protontherapy was well tolerated for doses upto 69 CGE and with an excellent local control rate. Copyright 2003 Wiley-Liss, Inc</style></abstract><notes><style face="normal" font="default">12652619m6p, 7506654IM0 (Protons)Clinical TrialJournal ArticleMulticenter StudyEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1352</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Miyamoto,T.</style></author><author><style face="normal" font="default"> Yamamoto,N.</style></author><author><style face="normal" font="default"> Nishimura,H.</style></author><author><style face="normal" font="default"> Koto,M.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author><author><style face="normal" font="default"> Mizoe,J.E.</style></author><author><style face="normal" font="default"> Kamada,T.</style></author><author><style face="normal" font="default"> Kato,H.</style></author><author><style face="normal" font="default"> Yamada,S.</style></author><author><style face="normal" font="default"> Morita,S.</style></author><author><style face="normal" font="default"> Yoshikawa,K.</style></author><author><style face="normal" font="default"> Kandatsu,S.</style></author><author><style face="normal" font="default"> Fujisawa,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, 9-1 Anagawa, 4-chome, Inage-Ku, Chiba-shi 263-8555, Japan</style></auth-address><titles><title><style face="normal" font="default">Carbon ion radiotherapy for stage I non-small cell lung cancer</style></title><secondary-title><style face="normal" font="default">Radiotherapy &amp; Oncology.66.(2):127.-40.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Radiotherapy &amp; Oncology.66.(2):127.-40.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Carbon/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Dose-Response Relationship,Radiation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heavy Ions/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Heavy Ions/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local</style></keyword><keyword><style face="normal" font="default"> Neoplasm Staging</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Pneumonitis</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Conformal</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="2" Year="2003">2003/2</year></dates><pub-location><style face="normal" font="default">Ireland</style></pub-location><isbn><style face="normal" font="default">0167-8140</style></isbn><abstract><style face="normal" font="default">BACKGROUND AND PURPOSE: Heavy ion radiotherapy is a promising modality because of its excellent dose localization and high biological effect on tumors. Using carbon beams, a dose escalation study was conducted for the treatment of stage I non-small cell lung cancer (NSCLC) to determine the optimal dose. MATERIALS AND METHODS: The first stage phase I/II trial using 18 fractions over 6 weeks for 47 patients and the second one using nine fractions over 3 weeks for 34 patients were conducted by the dose escalation method from 59.4 to 95.4 Gray equivalents (GyE) in incremental steps of 10% and from 68.4 to 79.2 GyE in 5% increments, respectively. The local control and survival rates were obtained using the Kaplan-Meier method. RESULTS: Radiation pneumonitis at grade III occurred in three of 81 patients, but they fully recovered. This was not a dose-limiting factor. The local control rates in the first and second trials were 64% and 84%, respectively. The total recurrence rate in both trials was 23.2%. The infield local recurrence in the first trial was significantly dependent on carbon dose. The doses greater than 86.4 GyE at 18 fractions and 72 GyE at nine fractions achieved a local control of 90% and 95%, respectively. The 5 year overall and cause-specific survivals in 81 patients were 42% and 60%, respectively. CONCLUSIONS: With our dose escalation study, the optimum safety and efficacy dose of carbon beams was determined. Carbon beam therapy attained almost the same results as surgery for stage I NSCLC although this was a I/II study</style></abstract><notes><style face="normal" font="default">12648784rae, 8407192IM7440-44-0 (Carbon)Clinical TrialClinical Trial, Phase IClinical Trial, Phase IIJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1357</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Miyamoto,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan</style></auth-address><titles><title><style face="normal" font="default">[Heavy ion therapy for non-small cell lung cancer--new, radical radiotherapy for advanced-age patients as an alternative to surgery]. [Japanese]</style></title><secondary-title><style face="normal" font="default">Gan to Kagaku Ryoho [Japanese Journal of Cancer &amp; Chemotherapy].30.(2):209.-14,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Gan to Kagaku Ryoho [Japanese Journal of Cancer &amp; Chemotherapy].30.(2):209.-14,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Carbon</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Heavy Ions/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Planning,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="0" Month="2" Year="2003">2003/2</year></dates><pub-location><style face="normal" font="default">Japan</style></pub-location><isbn><style face="normal" font="default">0385-0684</style></isbn><abstract><style face="normal" font="default">Clinical trials of carbon beam radiotherapy for stage I non-small cell lung cancer (NSCLL), and their results, are briefly described. The local control rate, cause-specific and overall survival rates of 146 patients with clinical stage I NSCLC were 82.0%, 59.0% and 59.0%, respectively. Radiation pneumonia was not serious and infrequent (2.1%). In the phase II clinical study, the local control rate of 50 patients was 100% without radiation pneumonia, resulting in a 74.0% overall survival rate. Carbon beam therapy could be an alternative to surgery, especially for lung cancer patients of advanced age and/or with complications. For locally advanced lung cancer treated with carbon beams, excellent local control as in stage I NSCLC has been demonstrated, providing hopeful prospects for the treatment of lung cancer</style></abstract><notes><style face="normal" font="default">126108687810034, 6t8IMEnglish AbstractJournal ArticleJapanese</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1359</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nishimura,H.</style></author><author><style face="normal" font="default"> Miyamoto,T.</style></author><author><style face="normal" font="default"> Yamamoto,N.</style></author><author><style face="normal" font="default"> Koto,M.</style></author><author><style face="normal" font="default"> Sugimura,K.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Center of Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan. westvill@med.kobe-u.ac.jp</style></auth-address><titles><title><style face="normal" font="default">Radiographic pulmonary and pleural changes after carbon ion irradiation</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.55.(4):861.-6,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.55.(4):861.-6,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Squamous Cell/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Squamous Cell/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Squamous Cell/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Dose-Response Relationship,Radiation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heavy Ions/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Lung/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Lung/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Staging</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pleura/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Pleura/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword></keywords><dates><year Day="15" Month="3" Year="2003">2003/3/15</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: For the treatment of Stage I non-small-cell lung cancers, a Phase I/II study of carbon ion irradiation was undertaken. In the present study, we focus on posttreatment radiographic lung damage: specifically, its timing, features, and relation to dose-volume factors. MATERIALS AND METHODS: Forty-three patients with 44 Stage I non-small-cell lung cancers were treated with carbon ion irradiation ranging from 59.4 to 95.4 photon Gy equivalent dose (GyE) in 18 fractions over 6 weeks, according to our dose escalation protocols. Primary lesions were irradiated by 2-4 portals. Follow-up evaluation with computed tomography (CT) was sequentially performed to assess changes in the lung. CT findings were classified into two categories: pulmonary reaction and pleural reaction. A dose-volume histogram for each patient was calculated, using a three-dimensional CT planning system. Statistical analysis was conducted using Spearman's rank test. RESULTS: The median appearance period of pulmonary reactions was 3 months after the start of carbon ion irradiation, whereas the maximum period was 6 months. The severity of pulmonary reactions statistically correlated with lung volumes irradiated no less than 20 GyE (vol. 20) and 40 GyE (vol. 40) (p = 0.017 and p = 0.0089). Geometrically unique findings in the irradiated fields were observed in 7 patients (16%). The median appearance period of pleural reactions was 4 months after the start of carbon ion irradiation. The occurrence of pleural reactions significantly correlated with planning target volume (p = 0.000098), vol. 20 (p = 0.00011), and vol. 40 (p = 0.00097). CONCLUSIONS: Lung damage after carbon ion irradiation was observed in the parenchyma and in the pleura. The severity of pulmonary reactions was correlated with dose-volume factors. These findings might provide useful information in the planning and management of carbon ion irradiation</style></abstract><notes><style face="normal" font="default">12605963g97, 7603616IM7440-44-0 (Carbon)Clinical TrialClinical Trial, Phase IClinical Trial, Phase IIJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1378</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Li,W.</style></author><author><style face="normal" font="default"> Gragoudas,E.S.</style></author><author><style face="normal" font="default"> Egan,K.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Retina Service, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, USA</style></auth-address><titles><title><style face="normal" font="default">Tumor basal area and metastatic death after proton beam irradiation for choroidal melanoma</style></title><secondary-title><style face="normal" font="default">Archives of Ophthalmology.121.(1):68-72.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Archives of Ophthalmology.121.(1):68-72.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Boston</style></keyword><keyword><style face="normal" font="default"> Canada/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Melanoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Models,Biological</style></keyword><keyword><style face="normal" font="default"> Neoplasm Metastasis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Survivors</style></keyword><keyword><style face="normal" font="default"> Tantalum</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Ultrasonography</style></keyword><keyword><style face="normal" font="default"> United States/ep [Epidemiology]</style></keyword></keywords><dates><year Day="0" Month="1" Year="2003">2003/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0003-9950</style></isbn><abstract><style face="normal" font="default">BACKGROUND: Tumor dimension is an established prognostic factor for metastasis-related death after radiotherapy for uveal melanoma. OBJECTIVE: To compare various methods of modeling the relationship between tumor dimension and metastatic death. PATIENTS AND METHODS: The analyses were based on a consecutive series of 1204 patients with primary choroidal melanoma treated with proton beam irradiation (70 cobalt-gray equivalent in 5 fractions) at the Harvard Cyclotron Laboratory, Boston, Mass, between January 1985 and December 1998. Largest basal diameter and largest perpendicular basal diameter were recorded at the time of surgical placement of tantalum rings used for tumor localization during proton treatment. The height of the tumor and the axial diameter of the eye were measured by ultrasonography prior to treatment. Using proportional hazards regression, we compared the prognostic influence of different indices of tumor size with estimated risk ratios and death rates according to tumor basal area and largest basal diameter. All estimates were adjusted for other established prognostic factors. RESULTS: Patients were followed up annually through June 30, 2000. Of the 1204 patients analyzed, 193 died of melanoma metastasis. The median follow-up among survivors was 7.9 years. The 5- and 10-year metastatic death rates were 12.8% and 20.7%, respectively. Among various approaches for modeling tumor dimension, the logarithm of tumor basal area had the highest log-likelihood and performed better than other approaches in 85% of the simulations. Based on this model, the covariate-adjusted rate ratio for any doubling in tumor basal area was 1.92 (95% confidence interval, 1.62-2.28). CONCLUSION: Tumor basal area is a better prognostic indicator than largest tumor diameter and tumor volume in the prediction of metastatic death after proton beam irradiation for uveal melanoma</style></abstract><notes><style face="normal" font="default">125238877706534, 830AIM, IM0 (Protons)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1400</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gragoudas,E.S.</style></author><author><style face="normal" font="default"> Lane,A.M.</style></author><author><style face="normal" font="default"> Munzenrider,J.</style></author><author><style face="normal" font="default"> Egan,K.M.</style></author><author><style face="normal" font="default"> Li,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinical Research Unit, Retina Service, Massachusetts Eye and Ear Infirmary, Boston, USA</style></auth-address><titles><title><style face="normal" font="default">Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma</style></title><secondary-title><style face="normal" font="default">Transactions of the American Ophthalmological.Society.100.:43.-8.; discussion.48.-9,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Transactions of the American Ophthalmological.Society.100.:43.-8.; discussion.48.-9,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Boston</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Ciliary Body/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Ciliary Body/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Melanoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treatment Failure</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="0" Month="0" Year="2002">2002</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0065-9533</style></isbn><abstract><style face="normal" font="default">PURPOSE: To quantitate long-term risk of local treatment failure after proton irradiation of choroidal/ciliary body melanomas and to evaluate risk of metastasis-related deaths after local failure. METHODS: We followed prospectively 1,922 patients treated at the Harvard Cyclotron between January 1975 and December 1996 for local recurrences of their tumors. Mortality surveillance was completed through June 1999. For analysis, patient follow-up continued until tumor regrowth was detected or, in patients without recurrence, until the date of the last dilated examination prior to April 1998. Actuarial methods were used to calculate rates of recurrence and metastatic deaths. Cox regression models were constructed to evaluate risk factors for these outcomes. RESULTS: Median ocular follow-up after irradiation was 5.2 years. Local recurrence was documented in 45 patients by ultrasound and/or sequential fundus photographs; in 17 more patients, the eye was enucleated due to suspected but unconfirmed tumor growth. Recurrences were documented between 2 months and 11.3 years after irradiation. The 5- and 10-year rates of regrowth, including suspected cases, were 3.2% (95% confidence interval [CI], 2.5%-4.2%), and 4.3% (95% CI, 3.3%-5.6%). Among the 45 documented recurrences, about one half (21) occurred at the margin, presumably due to treatment planning errors. The remaining cases represented extrascleral extensions (nine cases), ring melanomas (six cases), or uncontrolled tumor (nine cases). Recurrence of the tumor was independently related to risk of tumor-related death. CONCLUSION: These data, based on relatively long-term follow-up, demonstrate that excellent local control is maintained after proton therapy and that patients with recurrences experience poorer survival</style></abstract><notes><style face="normal" font="default">12545676w49, 7506106IM0 (Protons)Journal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1424</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kadono,K.</style></author><author><style face="normal" font="default"> Homma,T.</style></author><author><style face="normal" font="default"> Kamahara,K.</style></author><author><style face="normal" font="default"> Nakayama,M.</style></author><author><style face="normal" font="default"> Satoh,H.</style></author><author><style face="normal" font="default"> Sekizawa,K.</style></author><author><style face="normal" font="default"> Miyamoto,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Respiratory Disease, Institute of Clinical Medicine, University of Tsukuba, Tennodai 1-1-1, Tsukuba-city, Ibaraki 305-8575, Japan. md995447@md.tsukuba.ac.jp</style></auth-address><titles><title><style face="normal" font="default">Effect of heavy-ion radiotherapy on pulmonary function in stage I non-small cell lung cancer patients</style></title><secondary-title><style face="normal" font="default">Chest.122.(6):1925.-32.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Chest.122.(6):1925.-32.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heavy Ions</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Lung/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Staging</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Respiratory Function Tests</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="12" Year="2002">2002/12</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0012-3692</style></isbn><abstract><style face="normal" font="default">STUDY OBJECTIVES: The purpose of this study was to investigate the effect of heavy-ion radiotherapy on pulmonary function in patients with clinical stage I non-small cell lung cancer (NSCLC) patients. DESIGN: Retrospective study. SETTING: Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan. PATIENTS: From a total of 81 patients who were not candidates for surgical resection due to medical reasons or patient refusal, and who were treated with carbon beam radiotherapy from October 1994 to February 1999, the 52 patients who had completed the repeat overall pulmonary function tests at 6 and 12 months after undergoing heavy-ion radiotherapy were examined. The total heavy-ion irradiation dose ranged from 59.4 to 95.4 photon gray equivalents (GyE), with a mean dose of 76.2 GyE. INTERVENTIONS AND MEASUREMENT: Pulmonary function was evaluated prior to heavy-ion radiotherapy and at 6 and 12 months after heavy-ion radiotherapy. Comparisons of all pulmonary function indexes between, before, and at 6 and 12 months after heavy-ion radiotherapy were made using repeated-measures analysis of variance using the Dunnett test for post hoc comparison. RESULTS: A statistically significant decrease in FEV(1) and total lung capacity was detected at both 6 and 12 months after the patient had undergone heavy-ion radiotherapy. No significant decreases in other pulmonary function indexes in patients were observed at either 6 or 12 months after heavy-ion radiotherapy. The magnitude of the decrease in all pulmonary function indexes was &lt; 8% at both 6 and 12 months after heavy-ion radiotherapy. CONCLUSIONS: These findings suggest that heavy-ion radiotherapy is feasible for stage I NSCLC patients without a severe loss of pulmonary function</style></abstract><notes><style face="normal" font="default">124758280231335, d1cAIM, IM0 (Carbon Radioisotopes)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1436</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kamada,T.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author><author><style face="normal" font="default"> Tsuji,H.</style></author><author><style face="normal" font="default"> Yanagi,T.</style></author><author><style face="normal" font="default"> Mizoe,J.E.</style></author><author><style face="normal" font="default"> Miyamoto,T.</style></author><author><style face="normal" font="default"> Kato,H.</style></author><author><style face="normal" font="default"> Yamada,S.</style></author><author><style face="normal" font="default"> Morita,S.</style></author><author><style face="normal" font="default"> Yoshikawa,K.</style></author><author><style face="normal" font="default"> Kandatsu,S.</style></author><author><style face="normal" font="default"> Tateishi,A.</style></author><author><style face="normal" font="default"> Working Group for the Bone and Soft Tissue Sarcomas</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, and Chiba University Graduate School of Medicine, Chiba, Japan. t_kamada@nirs.go.jp</style></auth-address><titles><title><style face="normal" font="default">Efficacy and safety of carbon ion radiotherapy in bone and soft tissue sarcomas</style></title><secondary-title><style face="normal" font="default">Journal of Clinical Oncology.</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Journal of Clinical Oncology.</style></abbr-1></periodical><pages end="4471" start="4466">4466-4471</pages><number><style face="normal" font="default">22</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Bone Neoplasms/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Bone Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Extremities</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pelvis</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Sarcoma</style></keyword><keyword><style face="normal" font="default"> Sarcoma/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Sarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Soft Tissue Neoplasms/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Soft Tissue Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="15" Month="11" Year="1920">1920/11/15</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0732-183X</style></isbn><abstract><style face="normal" font="default">PURPOSE: To evaluate the tolerance for and effectiveness of carbon ion radiotherapy in patients with unresectable bone and soft tissue sarcomas. PATIENTS AND METHODS: We conducted a phase I/II dose escalation study of carbon ion radiotherapy. Fifty-seven patients with 64 sites of bone and soft tissue sarcomas not suited for resection received carbon ion radiotherapy. Tumors involved the spine or paraspinous soft tissues in 19 patients, pelvis in 32 patients, and extremities in six patients. The total dose ranged from 52.8 to 73.6 gray equivalent (GyE) and was administered in 16 fixed fractions over 4 weeks (3.3 to 4.6 GyE/fraction). The median tumor size was 559 cm(3) (range, 20 to 2,290 cm(3)). The minimum follow-up was 18 months. RESULTS: Seven of 17 patients treated with the highest total dose of 73.6 GyE experienced Radiation Therapy Oncology Group grade 3 acute skin reactions. Dose escalation was then halted at this level. No other severe acute reactions (grade > 3) were observed in this series. The overall local control rates were 88% and 73% at 1 year and 3 years of follow-up, respectively. The median survival time was 31 months (range, 2 to 60 months), and the 1- and 3-year overall survival rates were 82% and 46%, respectively. CONCLUSION: Carbon ion radiotherapy seems to be a safe and effective modality in the management of bone and soft tissue sarcomas not eligible for surgical resection, providing good local control and offering a survival advantage without unacceptable morbidity</style></abstract><notes><style face="normal" font="default">12431970jco, 8309333IM0 (Carbon Radioisotopes)Journal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1467</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schulz-Ertner,D.</style></author><author><style face="normal" font="default"> Haberer,T.</style></author><author><style face="normal" font="default"> Scholz,M.</style></author><author><style face="normal" font="default"> Thilmann,C.</style></author><author><style face="normal" font="default"> Wenz,F.</style></author><author><style face="normal" font="default"> Jakel,O.</style></author><author><style face="normal" font="default"> Kraft,G.</style></author><author><style face="normal" font="default"> Wannenmacher,M.</style></author><author><style face="normal" font="default"> Debus,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical Radiology, University of Heidelberg, Heidelberg, Germany</style></auth-address><titles><title><style face="normal" font="default">Acute radiation-induced toxicity of heavy ion radiotherapy delivered with intensity modulated pencil beam scanning in patients with base of skull tumors</style></title><secondary-title><style face="normal" font="default">Radiotherapy &amp; Oncology.64.(2):189.-95.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Radiotherapy &amp; Oncology.64.(2):189.-95.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Cobalt Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Erythema/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Ions</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Mastoiditis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Conformal/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Conformal/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Sinusitis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Base</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Stereotaxic Techniques</style></keyword><keyword><style face="normal" font="default"> Temporal Lobe</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="8" Year="2002">2002/8</year></dates><pub-location><style face="normal" font="default">Ireland</style></pub-location><isbn><style face="normal" font="default">0167-8140</style></isbn><abstract><style face="normal" font="default">PURPOSE: The purpose of this paper is to evaluate acute radiation-induced toxicity of carbon ion therapy. MATERIAL AND METHODS: From December 1997 to November 2000, 37 patients with chordomas and low-grade chondrosarcomas of the skull base have been treated with carbon ions at the heavy ion synchrotron (SIS) at GSI, Darmstadt. Tumor-conformal application of carbon beams was realized by intensity-controlled raster scanning in combination with pulse-to-pulse energy variation. The treatment planning procedure included a biological plan optimization. We applied a cobalt-Gray equivalent dose of 60GyE. Acute toxicity was assessed according to the common toxicity criteria (CTC). RESULTS: Acute toxicity included skin reactions ( degrees I+ degrees II) in four patients, mucositis ( degrees I- degrees III) in eight patients, otitis and middle ear effusion in four, sinusitis in four, nausea/weight loss in one and edema of the temporal lobes in one patient. In two patients, preexisting neurological symptoms worsened. We did not observe acute morbidity > degrees III of normal tissues. CONCLUSION: Scanning beam delivery of heavy charged particles is safe and reliable. No unexpected acute dose limiting toxicity was observed. With regard to toxicity, a substantial improvement compared to passive beam shaping technology is achieved</style></abstract><notes><style face="normal" font="default">12242129rae, 8407192IM0 (Carbon Radioisotopes)0 (Cobalt Radioisotopes)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1473</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Noel,G.</style></author><author><style face="normal" font="default"> Jauffret,E.</style></author><author><style face="normal" font="default"> Crevoisier,R.D.</style></author><author><style face="normal" font="default"> Habrand,J.L.</style></author><author><style face="normal" font="default"> Mammar,H.</style></author><author><style face="normal" font="default"> Haie-Meder,C.</style></author><author><style face="normal" font="default"> Hasboun,D.</style></author><author><style face="normal" font="default"> Ferrand,R.</style></author><author><style face="normal" font="default"> Boisserie,G.</style></author><author><style face="normal" font="default"> Pontvert,D.</style></author><author><style face="normal" font="default"> Beaudre,A.</style></author><author><style face="normal" font="default"> Gaboriaud,G.</style></author><author><style face="normal" font="default"> Mazal,A.</style></author><author><style face="normal" font="default"> Guedea,F.</style></author><author><style face="normal" font="default"> Petriz,L.</style></author><author><style face="normal" font="default"> Mazeron,J.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre de protontherapie, BP 65, 91402 Orsay Cedex, France. noel@ipno.in2p3.fr</style></auth-address><titles><title><style face="normal" font="default">[Radiation therapy for chordomas and chondrosarcomas of the base of the skull and cervical spine]. [French]</style></title><secondary-title><style face="normal" font="default">Bulletin du Cancer.89.(7.-8.):713.-23,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Bulletin du Cancer.89.(7.-8.):713.-23,</style></abbr-1></periodical><pages end="Aug" start="">-Aug</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Cervical Vertebrae</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons</style></keyword><keyword><style face="normal" font="default"> Photons/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Photons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword></keywords><dates><year Day="0" Month="7" Year="2002">2002/7</year></dates><pub-location><style face="normal" font="default">France</style></pub-location><isbn><style face="normal" font="default">0007-4551</style></isbn><abstract><style face="normal" font="default">PURPOSE: Prospective analysis of local tumour control, survival and treatment complications in 67 consecutive patients treated with fractionated photon and proton radiation for a chordoma or a chondrosarcoma of the base of the skull and of the cervical spine. PATIENTS AND METHODS: Between December 1995 and January 2000, 67 patients with a median age of 52.3 years (14-85), were treated using 201 MeV proton beam of the centre de protontherapie d'Orsay (CPO), 49 for a chordoma and 18 for a chondrosarcoma. Irradiation combined high-energy photons and protons. Photons represented 2/3 of the total dose and protons 1/3. The median total dose delivered within gross tumour volume was 67 Cobalt Gray Equivalent (CGE) (60-70). RESULTS: With a mean follow-up of 32 months (4-71), the 3-year local control rates were for chordomas and chondrosarcomas of 70.8% and 85.2%, respectively and 4-year overall survival rates of 87.7% and 75%, respectively. Fourteen tumours (21.5%) failed locally (eight within the gross tumor volume, four into the CTV and 2 in an unknown site). Seven patients died of tumour and one of intercurrent disease. In univariate analysis, age inferieur ou egal a 52.3 years (p = 0.002), maximum tumoral diameter &lt; 44.7 mm (p = 0.02) and GTV &lt; 28.4 mL (0.02), at time of radiotherapy, influenced positively the local control. According to multivariate analysis, only age was an independent prognostic factor of local control. Only five (7.7%) patients presented grade 3 or 4 complications. CONCLUSION: In base of skull chordomas and chondrosarcomas, the combined photon and proton therapy offers excellent chances of cure at the price of an acceptable toxicity. These results should be confirmed with a longer follow-up</style></abstract><notes><style face="normal" font="default">12206985bdz, 0072416IM0 (Protons)English AbstractJournal ArticleFrench</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1490</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fitzek,M.M.</style></author><author><style face="normal" font="default"> Thornton,A.F.</style></author><author><style face="normal" font="default"> Varvares,M.</style></author><author><style face="normal" font="default"> Ancukiewicz,M.</style></author><author><style face="normal" font="default"> Mcintyre,J.</style></author><author><style face="normal" font="default"> Adams,J.</style></author><author><style face="normal" font="default"> Rosenthal,S.</style></author><author><style face="normal" font="default"> Joseph,M.</style></author><author><style face="normal" font="default"> Amrein,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. markus.fitzek@uni-essen.de</style></auth-address><titles><title><style face="normal" font="default">Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy</style></title><secondary-title><style face="normal" font="default">Cancer.94.(10):2623.-34.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cancer.94.(10):2623.-34.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Cisplatin</style></keyword><keyword><style face="normal" font="default"> Cisplatin/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Combined Modality Therapy</style></keyword><keyword><style face="normal" font="default"> Drug Therapy,Combination</style></keyword><keyword><style face="normal" font="default"> Etoposide/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Neuroendocrine Tumors/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Nose Neoplasms/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Otorhinolaryngologic Surgical Procedures</style></keyword><keyword><style face="normal" font="default"> Paranasal Sinus Neoplasms/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Salvage Therapy</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Temporal Lobe</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword></keywords><dates><year Day="15" Month="5" Year="2002">2002/5/15</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0008-543X</style></isbn><abstract><style face="normal" font="default">BACKGROUND: The authors report the results of a prospective study of patients with malignant neuroendocrine tumors of the sinonasal tract who received multimodality treatment incorporating high-dose proton-photon radiotherapy. METHODS: Nineteen patients with olfactory neuroblastoma (ONB) or neuroendocrine carcinoma (NEC) were treated between 1992 and 1998 on a prospective study. Four patients had Kadish Stage B disease, and 15 patients had Kadish Stage C disease. The median patient age was 44 years. Patients received chemotherapy with 2 courses of cisplatin and etoposide followed by high-dose proton-photon radiotherapy to 69.2 cobalt-Gray equivalents (CGE) using 1.6-1.8 CGE per fraction twice daily in a concomitant boost schedule. Two further courses of chemotherapy were given to responders. RESULTS: Of 19 patients, 15 patients were alive at the time of this report with a median follow-up of 45 months (range, 20-92 months). Four patients died from disseminated disease 8-47 months after their original diagnosis. The 5-year survival rate was 74%. There were two local recurrences, and both patients underwent salvage surgery. The 5-year local control rate of initial treatment was 88%. Acute toxicity of chemotherapy was tolerable, with no patient sustaining more than Grade 3 hematologic toxicity. Thirteen patients showed a partial or complete response to chemotherapy. One patient developed unilateral visual loss after the first course of chemotherapy; otherwise, visual preservation was achieved in all patients. Four patients who were clinically intact developed radiation-induced damage to the frontal or temporal lobe by magnetic resonance imaging criteria. Two patients showed soft tissue and/or bone necrosis, and one of these patients required surgical repair of a cerebrospinal fluid leak. CONCLUSIONS: Neoadjuvant chemotherapy and high-dose proton-photon radiotherapy is a successful treatment approach for patients with ONB and NEC. Radical surgery is reserved for nonresponders. Due to the precision of delivery of radiation with stereotactic setup and protons, no radiation-induced visual loss was observed</style></abstract><notes><style face="normal" font="default">121733300374236, clzAIM, IM15663-27-1 (Cisplatin)33419-42-0 (Etoposide)Journal ArticleResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1540</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schulz-Ertner,D.</style></author><author><style face="normal" font="default"> Haberer,T.</style></author><author><style face="normal" font="default"> Jakel,O.</style></author><author><style face="normal" font="default"> Thilmann,C.</style></author><author><style face="normal" font="default"> Kramer,M.</style></author><author><style face="normal" font="default"> Enghardt,W.</style></author><author><style face="normal" font="default"> Kraft,G.</style></author><author><style face="normal" font="default"> Wannenmacher,M.</style></author><author><style face="normal" font="default"> Debus,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, University of Heidelberg, INF 400, Heidelberg 69120, Germany. d.ertner@dkfz-heidelberg.de</style></auth-address><titles><title><style face="normal" font="default">Radiotherapy for chordomas and low-grade chondrosarcomas of the skull base with carbon ions</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.53.(1):36.-42.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.53.(1):36.-42.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Ions</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Base</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Stereotaxic Techniques</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="1" Month="5" Year="2002">2002/5/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: Compared to photon irradiation, carbon ions provide physical and biologic advantages that may be exploited in chordomas and chondrosarcomas. METHODS AND MATERIALS: Between August 1998 and December 2000, 37 patients with chordomas (n = 24) and chondrosarcomas (n = 13) were treated with carbon ion radiotherapy within a Phase I/II trial. Tumor conformal application of carbon ion beams was realized by intensity-controlled raster scanning with pulse-to-pulse energy variation. Three-dimensional treatment planning included biologic plan optimization. The median tumor dose was 60 GyE (GyE = Gy x relative biologic effectiveness). RESULTS: The mean follow-up was 13 months. The local control rate after 1 and 2 years was 96% and 90%, respectively. We observed 2 recurrences outside the gross tumor volume in patients with chordomas. Progression-free survival was 100% for chondrosarcomas and 83% for chordomas at 2 years. Partial remission after carbon ion radiotherapy was observed in 6 patients. Treatment toxicity was mild. CONCLUSION: These are the first data demonstrating the clinical feasibility, safety, and effectiveness of scanning beam delivery of ion beams in patients with skull base tumors. The preliminary results in patients with skull base chordomas and low-grade chondrosarcomas are encouraging, although the follow-up was too short to draw definite conclusions concerning outcome. In the absence of major toxicity, dose escalation might be considered</style></abstract><notes><style face="normal" font="default">12007939g97, 7603616IM0 (Carbon Radioisotopes)Clinical TrialClinical Trial, Phase IClinical Trial, Phase IIJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1549</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hug,E.B.</style></author><author><style face="normal" font="default"> Muenter,M.W.</style></author><author><style face="normal" font="default"> Archambeau,J.O.</style></author><author><style face="normal" font="default"> DeVries,A.</style></author><author><style face="normal" font="default"> Liwnicz,B.</style></author><author><style face="normal" font="default"> Loredo,L.N.</style></author><author><style face="normal" font="default"> Grove,R.I.</style></author><author><style face="normal" font="default"> Slater,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Medicine, Loma Linda University Medical Center, Loma Linda, California, USA. Eugen.Hug@Hitchcock.org</style></auth-address><titles><title><style face="normal" font="default">Conformal proton radiation therapy for pediatric low-grade astrocytomas</style></title><secondary-title><style face="normal" font="default">Strahlentherapie und Onkologie.178.(1):10-7.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Strahlentherapie und Onkologie.178.(1):10-7.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Astrocytoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Astrocytoma/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Astrocytoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Brain Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Brain Neoplasms/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Brain Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Brain Stem</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Child,Preschool</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Diencephalon</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypothalamus</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Conformal</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vision</style></keyword></keywords><dates><year Day="0" Month="1" Year="2002">2002/1</year></dates><pub-location><style face="normal" font="default">Germany</style></pub-location><isbn><style face="normal" font="default">0179-7158</style></isbn><abstract><style face="normal" font="default">BACKGROUND: To evaluate the safety and efficacy of proton radiation therapy (PRT) for intracranial low-grade astrocytomas, the authors analyzed the first 27 pediatric patients treated at Loma Linda University Medical Center (LLUMC). PATIENTS AND METHOD: Between September 1991 and August 1997, 27 patients (13 female, 14 male) underwent fractionated proton radiation therapy for progressive or recurrent low-grade astrocytoma. Age at time of treatment ranged from 2 to 18 years (mean: 8.7 years). Tumors were located centrally (diencephalic) in 15 patients, in the cerebral and cerebellar hemispheres in seven patients, and in the brainstem in five patients. 25/27 patients (92%) were treated for progressive, unresectable, or residual disease following subtotal resection. Tissue diagnosis was available in 23/27 patients (85%). Four patients with optic pathway tumors were treated without histologic confirmation. Target doses between 50.4 and 63.0 CGE (Cobalt Gray Equivalent, mean: 55.2 CGE) were prescribed at 1.8 CGE per fraction, five treatments per week. RESULTS: At a mean follow-up period of 3.3 years (0.6-6.8 years), 6/27 patients experienced local failure (all located within the irradiated field), and 4/27 patients had died. By anatomic site these data translated into rates of local control and survival of 87% (13/15 patients) and 93% (14/15 patients) for central tumors, 71% (5/7 patients) and 86% (6/7 patients) for hemispheric tumors, and 60% (3/5 patients) and 60% (3/5 patients) for tumors located in the brainstem. Proton radiation therapy was generally well tolerated. All children with local control maintained their performance status. One child with associated neurofibromatosis, Type 1, developed Moyamoya disease. All six patients with optic pathway tumors and useful vision maintained or improved their visual status. CONCLUSIONS: This report on pediatric low-grade astrocytomas confirms proton radiation therapy as a safe and efficacious 3-D conformal treatment modality. Results are encouraging for central tumors as well as large optic pathway tumors, where dose conformity is of particular importance; yet it is difficult to achieve. Longer follow-up time is needed to fully evaluate the benefits of normal tissue sparing</style></abstract><notes><style face="normal" font="default">11977386vcm, 8603469IM0 (Protons)Comparative StudyJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1554</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hug,E.B.</style></author><author><style face="normal" font="default"> Sweeney,R.A.</style></author><author><style face="normal" font="default"> Nurre,P.M.</style></author><author><style face="normal" font="default"> Holloway,K.C.</style></author><author><style face="normal" font="default"> Slater,J.D.</style></author><author><style face="normal" font="default"> Munzenrider,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA</style></auth-address><titles><title><style face="normal" font="default">Proton radiotherapy in management of pediatric base of skull tumors</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.52(4):1017.-24.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.52(4):1017.-24.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Angiofibroma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Child,Preschool</style></keyword><keyword><style face="normal" font="default"> Chondroblastoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Giant Cell Tumors/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Planning,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Conformal/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Conformal/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Rhabdomyosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Sarcoma</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Base</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword></keywords><dates><year Day="15" Month="3" Year="2002">2002/3/15</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: Primary skull base tumors of the developing child are rare and present a formidable challenge to both surgeons and radiation oncologists. Gross total resection with negative margins is rarely achieved, and the risks of functional, structural, and cosmetic deficits limit the radiation dose using conventional radiation techniques. Twenty-nine children and adolescents treated with conformal proton radiotherapy (proton RT) were analyzed to assess treatment efficacy and safety. MATERIALS AND METHODS: Between July 1992 and April 1999, 29 patients with mesenchymal tumors underwent fractionated proton (13 patients) or fractionated combined proton and photon (16 patients) irradiation. The age at treatment ranged from 1 to 19 years (median 12); 14 patients were male and 15 female. Tumors were grouped as malignant or benign. Twenty patients had malignant histologic findings, including chordoma (n = 10), chondrosarcoma (n = 3), rhabdomyosarcoma (n = 4), and other sarcomas (n = 3). Target doses ranged between 50.4 and 78.6 Gy/cobalt Gray equivalent (CGE), delivered at doses of 1.8-2.0 Gy/CGE per fraction. The benign histologic findings included giant cell tumors (n = 6), angiofibromas (n = 2), and chondroblastoma (n = 1). RT doses for this group ranged from 45.0 to 71.8 Gy/CGE. Despite maximal surgical resection, 28 (97%) of 29 patients had gross disease at the time of proton RT. Follow-up after proton RT ranged from 13 to 92 months (mean 40). RESULTS: Of the 20 patients with malignant tumors, 5 (25%) had local failure; 1 patient had failure in the surgical access route and 3 patients developed distant metastases. Seven patients had died of progressive disease at the time of analysis. Local tumor control was maintained in 6 (60%) of 10 patients with chordoma, 3 (100%) of 3 with chondrosarcoma, 4 (100%) of 4 with rhabdomyosarcoma, and 2 (66%) of 3 with other sarcomas. The actuarial 5-year local control and overall survival rate was 72% and 56%, respectively, and the overall survival of the males was significantly superior to that of the female patients (p = 0.002). Of the patients with benign tumors, 1 patient (giant cell tumor) had local failure at 10 months. The other 8 patients continued to have local tumor control; all 9 patients were alive at last follow-up (actuarial 5-year local control and overall survival rate of 89% and 100%, respectively). Severe late effects (motor weakness and sensory deficits) were observed in 2 (7%) of 29 patients. CONCLUSION: Proton RT for children with aggressively recurring tumors after major skull base surgery can offer a considerable prospect of tumor control and survival. Longer follow-up is necessary to assess the real value of protons, in particular with regard to bone growth and cosmetic outcome</style></abstract><notes><style face="normal" font="default">11958897g97, 7603616IM0 (Protons)Journal ArticleMulticenter StudyEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1557</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lumbroso,L.</style></author><author><style face="normal" font="default"> Levy,C.</style></author><author><style face="normal" font="default"> Plancher,C.</style></author><author><style face="normal" font="default"> Frau,E.</style></author><author><style face="normal" font="default"> D'Hermies,F.</style></author><author><style face="normal" font="default"> Schlienger,P.</style></author><author><style face="normal" font="default"> Dendale,R.</style></author><author><style face="normal" font="default"> Mammar,H.</style></author><author><style face="normal" font="default"> Delacroix,S.</style></author><author><style face="normal" font="default"> Nauraye,C.</style></author><author><style face="normal" font="default"> Noel,G.</style></author><author><style face="normal" font="default"> Ferrand,R.</style></author><author><style face="normal" font="default"> Desblancs,C.</style></author><author><style face="normal" font="default"> Mazal,A.</style></author><author><style face="normal" font="default"> Validire,P.</style></author><author><style face="normal" font="default"> Asselain,B.</style></author><author><style face="normal" font="default"> Desjardins,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Service d'Ophtalmologie, Institut Curie, 26 rue d'Ulm, 75231, Paris Cedex 05</style></auth-address><titles><title><style face="normal" font="default">[Results of proton beam irradiation for treatment of choroidal melanoma]. [French]</style></title><secondary-title><style face="normal" font="default">Journal Francais.d.Opthalmologie.25.(3):290.-7.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Journal Francais.d.Opthalmologie.25.(3):290.-7.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eye Enucleation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fluorescein Angiography</style></keyword><keyword><style face="normal" font="default"> Glaucoma</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Neoplasm Metastasis</style></keyword><keyword><style face="normal" font="default"> Optic Nerve</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Retina/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="3" Year="2002">2002/3</year></dates><pub-location><style face="normal" font="default">France</style></pub-location><isbn><style face="normal" font="default">0181-5512</style></isbn><abstract><style face="normal" font="default">PURPOSE: To evaluate the results of proton beam irradiation of choroidal melanomas on a large series of patients. PATIENTS AND METHODS: Retrospective analysis of a series of patients treated with proton beam irradiation between 1991 and December 1998. The data were analyzed to evaluate the local tumor control as well as the general progression and metastatic rate of the patients. Statistical analysis served to isolate risk factors for relapse or metastasis. RESULTS: We treated 1062 patients during the study period, with a median follow-up of 38 months. Local control was obtained for 97.1% of the patients. Tumors anterior to the equator were at risk for relapse. The survival rate was 92% at 2 years and 78% at 5 years. 73.1% of the 1062 patients died from metastasis, 6.1% of living patients presented with metastatic disease. The risk factors for death were the initial diameter, the age of the patient, and large tumor volume at diagnosis. Metastasis were essentially hepatic (94.6%). Risk factors for metastasis were: a large tumor volume, a lesion anterior or straddling the equator and the age of the patient. Ocular complications may induce a visual loss of 0.1 and less in 47% of the patients, due to optic nerve head and macular ischemia. 6% of the patients required secondary enucleation due to local complications (neovascular glaucoma). CONCLUSION: Proton beam irradiation of choroidal melanoma allows good tumor control and eye retention. The survival prognosis is associated with the initial volume of the tumor. The functional results may be improved and new therapeutics are needed to treat metastatic disease</style></abstract><notes><style face="normal" font="default">11941255iae, 7804128IM0 (Protons)Comparative StudyEnglish AbstractJournal ArticleFrench</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1568</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Miyamoto,T.</style></author><author><style face="normal" font="default"> Yamamoto,N.</style></author><author><style face="normal" font="default"> Koto,M.</style></author><author><style face="normal" font="default"> Nishimura,H.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author><author><style face="normal" font="default"> Fujisawa,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Center of Charged Particles, National Institute of Radiological Sciences, Chiba, Japan</style></auth-address><titles><title><style face="normal" font="default">[Heavy-ion therapy for non-small cell lung cancer]. [Review] [5 refs] [Japanese]</style></title><secondary-title><style face="normal" font="default">Nippon Geka Gakkai Zasshi.Journal of Japan.Surgical Society.103.(2):250.-5,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Nippon Geka Gakkai Zasshi.Journal of Japan.Surgical Society.103.(2):250.-5,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon Isotopes</style></keyword><keyword><style face="normal" font="default"> Carbon Isotopes/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Carbon Isotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Heavy Ions/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Heavy Ions/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Isotopes</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="2" Year="2002">2002/2</year></dates><pub-location><style face="normal" font="default">Japan</style></pub-location><isbn><style face="normal" font="default">0301-4894</style></isbn><abstract><style face="normal" font="default">Since carbon beam therapy for non-small cell lung cancer (NSCLC) was initiated in October 1996, seven trials have been conducted; three have already closed and the remaining four are ongoing. The local control rate, cause-specific survival rate, and overall survival rate of 141 patients with clinical stage I NSCLC were 82%, 58%, and 42%, respectively. Radiation pneumonia was rare (2.1%) and not serious. In the phase II clinical study, the local control rate achieved in 50 patients was 100%, with no radiation pneumonia, resulting in a 60% overall survival rate. Carbon beam therapy could be an alternative to surgery, especially for lung cancer patients of advanced age and/or with complications. For locally advanced lung cancer treated with carbon beam therapy, excellent local control comparable to that in stage INSCLC has been demonstrated and offers hopeful prospects for the treatment of lung cancer. [References: 5]</style></abstract><notes><style face="normal" font="default">11904989ngg, 0405405IM0 (Carbon Isotopes)English AbstractJournal ArticleReviewJapanese</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1583</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gardner,B.G.</style></author><author><style face="normal" font="default"> Zietman,A.L.</style></author><author><style face="normal" font="default"> Shipley,W.U.</style></author><author><style face="normal" font="default"> Skowronski,U.E.</style></author><author><style face="normal" font="default"> McManus,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Cambridge, MA, USA</style></auth-address><titles><title><style face="normal" font="default">Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer</style></title><secondary-title><style face="normal" font="default">Journal of Urology.167.(1):123.-6,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Journal of Urology.167.(1):123.-6,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Hematuria/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons</style></keyword><keyword><style face="normal" font="default"> Prostate</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Conformal/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword></keywords><dates><year Day="0" Month="1" Year="2002">2002/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0022-5347</style></isbn><abstract><style face="normal" font="default">PURPOSE: We determined the long-term normal tissue effects of 77.4 Gy. delivered to the prostate in patients with locally advanced prostate cancer. METHODS AND MATERIALS: Between 1976 and 1992, 167 men with stages T3 to 4 prostate cancer were treated on protocol with 50.4 Gy. photons at 1.8 Gy. per fraction using a 4-field box arrangement, followed by a conformal perineal proton boost of 27 Gy. (cobalt Gy. equivalent) in 11 fractions. The chart was reviewed and 39 of the 42 surviving patients were interviewed. Median followup was 13.1 years (range 7 to 23). Normal tissue morbidity was recorded using Radiation Therapy Oncology Group criteria and the late effects normal tissue scale. RESULTS: The actuarial incidence of grade 2 or greater genitourinary morbidity was 59% at 15 years. However, these grade 2 or greater problems persisted to the time of the interview in only 7 of 39 cases. The actuarial incidence of grade 2 or greater hematuria was 21% at 5 years and 47% at 15. For grade 3 or greater hematuria the risk was 3% and 8% at 5 and 15 years, respectively. No patient required cystectomy but 1 required diversion for morbidity. Urethral stricture and urinary incontinence with pads needed developed in 4 and 3 men, respectively. This particular morbidity was strongly associated with previous or subsequent prostate surgery. The actuarial incidence of grade 2 or greater gastrointestinal morbidity was 13% at 5 and 15 years, while grade 1 rectal bleeding occurred in another 41%. CONCLUSIONS: High dose conformal radiation to the prostate is followed by a high rate of low grade rectal bleeding but a low rate of grade 2 or higher gastrointestinal morbidity. This rate is stable and does not increase beyond 5 years. Genitourinary morbidity continues to develop well into the second decade after treatment, although high grade morbidity is uncommon. These findings do not suggest that the modern trend toward high dose prostate treatment with conformal techniques will result in a high incidence of serious and permanent late sequelae but it appears that hematuria will be common</style></abstract><notes><style face="normal" font="default">11743288kc7, 0376374AIM, IMClinical TrialJournal ArticleRandomized Controlled TrialEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1625</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Colli,B.</style></author><author><style face="normal" font="default"> Al-Mefty,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Neurosurgery, Department of Surgery, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil. bocolli@fmrp.usp.br</style></auth-address><titles><title><style face="normal" font="default">Chordomas of the craniocervical junction: follow-up review and prognostic factors</style></title><secondary-title><style face="normal" font="default">Journal of Neurosurgery.95.(6):933.-43.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Journal of Neurosurgery.95.(6):933.-43.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Cranial Fossa,Posterior</style></keyword><keyword><style face="normal" font="default"> Diploidy</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Postoperative Complications</style></keyword><keyword><style face="normal" font="default"> Postoperative Complications/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Proliferating Cell Nuclear Antigen/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Receptors,Estrogen/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Receptors,Progesterone/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Recovery of Function</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="12" Year="2001">2001/12</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0022-3085</style></isbn><abstract><style face="normal" font="default">OBJECT: Chordomas are rare tumors that arise from the remnants of the notochord. Because of their deep location, local infiltrative nature, and involvement of surrounding bone, treatment of chordomas is a challenge. In this study the authors analyze the data and prognostic factors obtained during the follow-up period (range 1-150 months, median 38 months) in 53 patients with craniocervical junction chordomas and 10 patients with chondrosarcomas. METHODS: Several surgical approaches were used, and some tumor excisions required staged procedures. Survival was calculated according the Kaplan-Meier method. Statistical analysis was performed using Fisher exact, log rank and Kruskal-Wallis tests. Radical/subtotal resection was achieved in 77.8% of the patients. The mortality rate during the follow-up period was 14.3%. In patients harboring chondrosarcoma better 5-year recurrence-free survival (RFS) rates were demonstrated than in those with chordoma (100% and 50.7%. respectively). Histological patterns (typical or chondroid chordomas) and patient age at onset of symptoms had no effect on the RFS rates. Radical/subtotal resections were associated with better RFS rates than partial resection. Adjuvant proton-beam therapy was shown to increase the RFS rates compared with conventional radiotherapy (90.9% and 19.4%, respectively, at 4 years posttreatment). Karyotypically abnormal tumors were associated with the worst RFS rates compared with karyotypically normal lesions (44.5% and 90.3%, respectively, at 3 years). Cases of cranial nerve palsy followed by those with cerebrospinal fluid leakages were the most frequent postoperative complications. Permanent postoperative neurological deficit was observed in 28.6% of the patients. CONCLUSIONS: A better prognosis was observed in patients with chondrosarcoma compared with those harboring chordoma. Histological pattern and patient age at symptom onset were not factors that influenced prognosis in cases of chordoma. Extensive resection and possibly adjuvant proton-beam therapy provided better prognoses for these patients</style></abstract><notes><style face="normal" font="default">11765837jd3, 0253357AIM, IM0 (Proliferating Cell Nuclear Antigen)0 (Receptors, Estrogen)0 (Receptors, Progesterone)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1627</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bonnet,R.B.</style></author><author><style face="normal" font="default"> Bush,D.</style></author><author><style face="normal" font="default"> Cheek,G.A.</style></author><author><style face="normal" font="default"> Slater,J.D.</style></author><author><style face="normal" font="default"> Panossian,D.</style></author><author><style face="normal" font="default"> Franke,C.</style></author><author><style face="normal" font="default"> Slater,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pulmonary Medicine, Zentralklinik Bad Berka GmbH, Bad Berka, Germany. r.bonnet.pn@zentralklinik-bad.berka.de</style></auth-address><titles><title><style face="normal" font="default">Effects of proton and combined proton/photon beam radiation on pulmonary function in patients with resectable but medically inoperable non-small cell lung cancer</style></title><secondary-title><style face="normal" font="default">Chest.120.(6):1803.-10,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Chest.120.(6):1803.-10,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Combined Modality Therapy</style></keyword><keyword><style face="normal" font="default"> Diffusion</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Mediastinum</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoadjuvant Therapy</style></keyword><keyword><style face="normal" font="default"> Neoplasm Staging</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Respiratory Function Tests</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="12" Year="2001">2001/12</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0012-3692</style></isbn><abstract><style face="normal" font="default">STUDY OBJECTIVES: We evaluated the effects on pulmonary function of irradiating lung cancer with protons alone or protons combined with photons. DESIGN: Prospective phase I/II study. SETTING: University medical center. PATIENTS AND INTERVENTIONS: Ten patients with stage I-II non-small cell lung cancer (NSCLC) and FEV(1) &lt; or = 1.0 L were irradiated with protons to areas of gross disease only, using 51 cobalt gray equivalents (CGE) in 10 fractions (protocol 1). Fifteen patients with stage I-IIIA NSCLC and FEV(1) > 1.0 L received 45-Gy photon irradiation to the primary lung tumor and the mediastinum, plus a 28.8-CGE proton boost to the gross tumor volume (protocol 2). MEASUREMENTS: Pulmonary function was evaluated prior to treatment and 1 month, 3 months, and 6 to 12 months following irradiation. RESULTS: In patients receiving protocol 1, no significant changes in pulmonary function occurred. In patients receiving protocol 2, at 6 to 12 months, the diffusion capacity of the lung for carbon monoxide had declined from 61% of predicted to 45% of predicted (p &lt; 0.05), total lung capacity had declined from 114% of predicted to 95% of predicted (p &lt; 0.05), and residual volume had declined from 160% of predicted to 132% of predicted (p &lt; 0.05). Airway resistance increased from 3.8 to 5.2 cm H(2)O/L/s (p &lt; 0.05). No statistically significant changes occurred in vital capacity, FEV(1), or PaO(2). CONCLUSIONS: Our observations indicate that it is feasible to apply higher-than-conventional doses of radiation at a higher-than-conventional dose per fraction without excess pulmonary toxicity when conformal radiation techniques with protons are used</style></abstract><notes><style face="normal" font="default">117429050231335, d1cAIM, IM0 (Protons)Clinical TrialClinical Trial, Phase IClinical Trial, Phase IIComparative StudyJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1652</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lumbroso,L.</style></author><author><style face="normal" font="default"> Desjardins,L.</style></author><author><style face="normal" font="default"> Levy,C.</style></author><author><style face="normal" font="default"> Plancher,C.</style></author><author><style face="normal" font="default"> Frau,E.</style></author><author><style face="normal" font="default"> D'Hermies,F.</style></author><author><style face="normal" font="default"> Schlienger,P.</style></author><author><style face="normal" font="default"> Mammar,H.</style></author><author><style face="normal" font="default"> Delacroix,S.</style></author><author><style face="normal" font="default"> Nauraye,C.</style></author><author><style face="normal" font="default"> Ferrand,R.</style></author><author><style face="normal" font="default"> Desblancs,C.</style></author><author><style face="normal" font="default"> Mazal,A.</style></author><author><style face="normal" font="default"> Asselain,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophthalmology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France</style></auth-address><titles><title><style face="normal" font="default">Intraocular inflammation after proton beam irradiation for uveal melanoma</style></title><secondary-title><style face="normal" font="default">British Journal of Ophthalmology.85.(11):1305.-8.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">British Journal of Ophthalmology.85.(11):1305.-8.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> Anti-Inflammatory Agents/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Melanoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Mydriatics/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Uveitis,Anterior/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Uveitis,Anterior/et [Etiology]</style></keyword></keywords><dates><year Day="0" Month="11" Year="2001">2001/11</year></dates><pub-location><style face="normal" font="default">England</style></pub-location><isbn><style face="normal" font="default">0007-1161</style></isbn><abstract><style face="normal" font="default">AIM: To describe the inflammatory reaction that can occur following proton beam irradiation of uveal melanomas based on a large series of patients and to try to determine the risk factors for this reaction. METHODS: Data from a cohort of patients with uveal melanoma treated by proton beam irradiation between 1991 and 1994 were analysed. The presence of inflammation was recorded and evaluated. Kaplan-Meier estimates and statistical analysis of general and tumour related risk factors were performed. RESULTS: 28% of patients treated during this period presented with ocular inflammation (median follow up 62 months). Risks factors were essentially tumour related and were correlated with larger lesions (height > 5 mm, diameter > 12 mm, volume > 0.4 cm(3)). Multivariate analysis identified initial tumour height and irradiation of a large volume of the eye as the two most important risk factors. Ocular inflammation usually consisted of mild anterior uveitis, resolving rapidly after topical steroids and cycloplegics. The incidence of inflammation after proton beam irradiation of melanomas seems higher than previously reported and is related to larger lesions. Evidence of inflammation associated with uveal melanoma has been described and seems to be associated with tumour necrosis (spontaneous or after irradiation). The appearance of transient inflammation during the follow up of these patients may be related to the release of inflammatory cytokines during tumour necrosis. CONCLUSION: Inflammation following proton beam irradiation is not unusual. It is correlated with larger initial tumours and may be related to tumour necrosis</style></abstract><notes><style face="normal" font="default">11673294azk, 0421041IM0 (Anti-Inflammatory Agents)0 (Mydriatics)0 (Steroids)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1677</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Noel,G.</style></author><author><style face="normal" font="default"> Habrand,J.L.</style></author><author><style face="normal" font="default"> Mammar,H.</style></author><author><style face="normal" font="default"> Pontvert,D.</style></author><author><style face="normal" font="default"> Haie-Meder,C.</style></author><author><style face="normal" font="default"> Hasboun,D.</style></author><author><style face="normal" font="default"> Moisson,P.</style></author><author><style face="normal" font="default"> Ferrand,R.</style></author><author><style face="normal" font="default"> Beaudre,A.</style></author><author><style face="normal" font="default"> Boisserie,G.</style></author><author><style face="normal" font="default"> Gaboriaud,G.</style></author><author><style face="normal" font="default"> Mazal,A.</style></author><author><style face="normal" font="default"> Kerody,K.</style></author><author><style face="normal" font="default"> Schlienger,M.</style></author><author><style face="normal" font="default"> Mazeron,J.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre de Protontherapie d'Orsay, Orsay, France. noel@ipno.in2p3.fr</style></auth-address><titles><title><style face="normal" font="default">Combination of photon and proton radiation therapy for chordomas and chondrosarcomas of the skull base: the Centre de Protontherapie D'Orsay experience</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.51.(2):392.-8.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.51.(2):392.-8.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Bone Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Bone Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons</style></keyword><keyword><style face="normal" font="default"> Photons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Base</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Treatment Failure</style></keyword></keywords><dates><year Day="1" Month="10" Year="2001">2001/10/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: Prospective analysis of local tumor control, survival, and treatment complications in 44 consecutive patients treated with fractionated photon and proton radiation for a chordoma or chondrosarcoma of the skull base. METHODS AND MATERIALS : Between December 1995 and December 1998, 45 patients with a median age of 55 years (14-85) were treated using a 201-MeV proton beam at the Centre de Protontherapie d'Orsay, 34 for a chordoma and 11 for a chondrosarcoma. Irradiation combined high-energy photons and protons. Photons represented two-thirds of the total dose and protons one-third. The median total dose delivered within the gross tumor volume was 67 cobalt Gray equivalent (CGE) (range: 60-70). RESULTS: With a mean follow-up of 30.5 months (range: 2-56), the 3-year local control rates for chordomas and chondrosarcomas were 83.1% and 90%, respectively, and 3-year overall survival rates were 91% and 90%, respectively. Eight patients (18%) failed locally (7 within the clinical tumor volume and 1 unknown). Four patients died of tumor and 2 others of intercurrent disease. In univariate analysis, young age at time of radiotherapy influenced local control positively (p &lt; 0.03), but not in multivariate analysis. Only 2 patients presented Grade 3 or 4 complications. CONCLUSION: In skull-base chordomas and chondrosarcomas, the combination of photons with a proton boost of one-third the total dose offers an excellent chance of cure at the price of an acceptable toxicity. These results should be confirmed with a longer follow-up</style></abstract><notes><style face="normal" font="default">11567813g97, 7603616IM0 (Protons)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1687</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fitzek,M.M.</style></author><author><style face="normal" font="default"> Thornton,A.F.</style></author><author><style face="normal" font="default"> Harsh,G.</style></author><author><style face="normal" font="default"> Rabinov,J.D.</style></author><author><style face="normal" font="default"> Munzenrider,J.E.</style></author><author><style face="normal" font="default"> Lev,M.</style></author><author><style face="normal" font="default"> Ancukiewicz,M.</style></author><author><style face="normal" font="default"> Bussiere,M.</style></author><author><style face="normal" font="default"> Hedley-Whyte,E.T.</style></author><author><style face="normal" font="default"> Hochberg,F.H.</style></author><author><style face="normal" font="default"> Pardo,F.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA</style></auth-address><titles><title><style face="normal" font="default">Dose-escalation with proton/photon irradiation for Daumas-Duport lower-grade glioma: results of an institutional phase I/II trial</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.51.(1):131.-7.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.51.(1):131.-7.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Brain Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Brain Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Brain Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glioma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Glioma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Glioma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Supratentorial Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Supratentorial Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Supratentorial Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Survivors</style></keyword></keywords><dates><year Day="1" Month="9" Year="2001">2001/9/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: The role of dose escalation with proton/photon radiotherapy in lower-grade gliomas was assessed in a prospective Phase I/II trial. We report the results in terms of local control, toxicity, and survival. MATERIALS AND METHODS: Twenty patients with Grade 2/4 (n = 7) and Grade 3/4 (n = 13) gliomas according to the Daumas-Duport classification were treated on a prospective institutional protocol at Massachusetts General Hospital/Harvard Cyclotron Laboratory between 1993 and 1996. Doses prescribed to the target volumes were 68.2 cobalt Gray equivalent (CGE, 1 proton Gray = 1.1 CGE) to gross tumor in Grade 2 lesions and 79.7 CGE in Grade 3 lesions. Fractionation was conventional, with 1.8 to 1.92 CGE once per day. Eligibility criteria included age between 18 and 70 years, biopsy-proven Daumas-Duport Grade 2/4 or 3/4 malignant glioma, Karnofsky performance score of 70 or greater, and supratentorial tumor. Median age of the patient population at diagnosis was 35.9 years (range 19-49). Ten tumors were mixed gliomas, one an oligodendroglioma. RESULTS: Five patients underwent biopsy, 12 a subtotal resection, and 3 a gross total resection. Median interval from surgery to first radiation treatment was 2.9 months. Actuarial 5-year survival rate for Grade 2 lesions was 71% as calculated from diagnosis (median survival not yet reached); actuarial 5-year survival for Grade 3 lesions was 23% (median 29 months). Median follow-up is 61 months and 55 months for 4 patients alive with Grade 2 and 3 patients alive with Grade 3 lesions, respectively. Three patients with Grade 2 lesions died from tumor recurrence, whereas 2 of the 4 survivors have evidence of radiation necrosis. Eight of 10 patients who have died with Grade 3 lesions died from tumor recurrence, 1 from pulmonary embolus, and 1 most likely from radiation necrosis. One of 3 survivors in this group has evidence of radiation necrosis. CONCLUSION: Tumor recurrence was neither prevented nor noticeably delayed in our patients relative to published series on photon irradiation. Dose escalation using this fractionation scheme and total dose delivered failed to improve outcome for patients with Grade 2 and 3 gliomas</style></abstract><notes><style face="normal" font="default">11516862g97, 7603616IM0 (Protons)Clinical TrialClinical Trial, Phase IClinical Trial, Phase IIJournal ArticleResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1753</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Galbraith,M.E.</style></author><author><style face="normal" font="default"> Ramirez,J.M.</style></author><author><style face="normal" font="default"> Pedro,L.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Nursing, Loma Linda University, Loma Linda, CA, USA. mgalbraith@sn.llu.edu</style></auth-address><titles><title><style face="normal" font="default">Quality of life, health outcomes, and identity for patients with prostate cancer in five different treatment groups</style></title><secondary-title><style face="normal" font="default">Oncology Nursing Forum.28.(3):551.-60,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Oncology Nursing Forum.28.(3):551.-60,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Gender Identity</style></keyword><keyword><style face="normal" font="default"> Health Status</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Oncologic Nursing</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prostate</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/nu [Nursing]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/px [Psychology]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="4" Year="2001">2001/4</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0190-535X</style></isbn><abstract><style face="normal" font="default">PURPOSE/OBJECTIVES: To describe how different treatments for prostate cancer affect health-related quality of life (QOL), health status, and masculinity. DESIGN: Longitudinal survey design with descriptive, correlational, and comparative elements. SETTING: A tertiary medical center and associated clinics in a suburban community in the Southwestern United States. SAMPLE: 185 men with localized prostate cancer were enrolled from five treatment groups: watchful waiting (n = 30), surgery (n = 59), conventional radiation (n = 25), proton-beam radiation (n = 24), and a combination of conventional radiation and proton-beam radiation or mixed-beam radiation (n = 47). At six months, 163 remained on the study; at 12 months, 154 remained: and at 18 months, 153 remained. The average age was 68 years, and 82% of the men were white. METHODS: Men were enrolled at treatment and given a questionnaire with a self-addressed, stamped envelope for return. Questionnaires were mailed again at 6, 12, and 18 months. MAIN RESEARCH VARIABLES: Health-related QOL health status, prostate treatment-specific symptoms, and sex-role identity. FINDINGS: No overall difference in health-related QOL or health status was found, but post-hoc analysis revealed specific differences. The differences existed in sexual functioning and gastrointestinal treatment-specific symptoms. No relationship existed between masculinity and health-related QOL. CONCLUSIONS: Health-related QOL and health status are similar regardless of type of treatment. Radiation tends to produce more gastrointestinal symptoms, and surgery tends to produce more sexual functioning symptoms. Watchful waiting is associated with poorer general health. IMPLICATIONS FOR NURSING PRACTICE: Nurses can provide specific treatment-related information to men who are faced with making treatment decisions for prostate cancer and, in consultation with the healthcare team, can select a treatment best sulted to them</style></abstract><notes><style face="normal" font="default">113387627809033, padIM, NJournal ArticleResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1806</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ahmadi,T.</style></author><author><style face="normal" font="default"> Itai,Y.</style></author><author><style face="normal" font="default"> Onaya,H.</style></author><author><style face="normal" font="default"> Yoshioka,H.</style></author><author><style face="normal" font="default"> Okumura,T.</style></author><author><style face="normal" font="default"> Akine,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiology, Institute of Clinical Medicine, University of Tsukuba, Japan</style></auth-address><titles><title><style face="normal" font="default">CT evaluation of hepatic injury following proton beam irradiation: appearance, enhancement, and 3D size reduction pattern</style></title><secondary-title><style face="normal" font="default">Journal of Computer Assisted.Tomography.23(5):655.-63,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Journal of Computer Assisted.Tomography.23(5):655.-63,</style></abbr-1></periodical><pages end="Oct" start="">-Oct</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chi-Square Distribution</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Liver/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Liver/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Remission,Spontaneous</style></keyword><keyword><style face="normal" font="default"> Sex Characteristics</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed/sn [Statistics &amp; Numerical Data]</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="1999">1999/9</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0363-8715</style></isbn><abstract><style face="normal" font="default">PURPOSE: The purpose of this study was to investigate the long-term imaging appearances of hepatic injury following proton beam irradiation. The time-attenuation curves, time of appearance and recovery, and 3D size reduction pattern are described in patients of different ages and genders with different irradiation doses, irradiated portals, and Child groups. METHOD: Forty-six patients with hepatocellular carcinoma underwent 50 to 84 Gy proton beam irradiation in periods of 14-52 days. CT including noncontrast and dynamic study was performed every 3 months starting 3 weeks after the end of irradiation. The 3D volume measurement of areas of radiation-induced hepatic injury was performed through incremental dynamic CT images in every follow-up study. CT follow-up study of the patients was done for 12-76 months. RESULTS: Radiation-induced hepatic injury was observed as low attenuation areas on noncontrast CT and enhanced areas on dynamic study in the regions corresponding to the irradiation portals. Of our cases, 67.5% showed the appearance of radiation hepatitis in 3-4 weeks and 95.3% in 3-4 months after the end of irradiation. In both periods, there was a significant delay in the female patients. The time-attenuation curve showed an early and prolonged enhancement of the irradiated regions. The volume reduction pattern of the injured areas was found to be longstanding, exponential, and directed from periphery to the center. CONCLUSION: Early appearance of radiation-induced hepatic injury was found only to be gender dependent, with a tendency to occur with higher irradiated doses; no other parameters affected this phenomenon in our cases. Disappearance of the injured areas, if present, takes a long time (at least 42 months)</style></abstract><notes><style face="normal" font="default">10524841hvt, 7703942IM0 (Protons)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1842</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bush,D.A.</style></author><author><style face="normal" font="default"> Dunbar,R.D.</style></author><author><style face="normal" font="default"> Bonnet,R.</style></author><author><style face="normal" font="default"> Slater,J.D.</style></author><author><style face="normal" font="default"> Cheek,G.A.</style></author><author><style face="normal" font="default"> Slater,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Medicine, Loma Linda University Medical Center, CA 92354, USA</style></auth-address><titles><title><style face="normal" font="default">Pulmonary injury from proton and conventional radiotherapy as revealed by CT</style></title><secondary-title><style face="normal" font="default">AJR.American Journal of Roentgenology.172.(3):735.-9,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">AJR.American Journal of Roentgenology.172.(3):735.-9,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Pneumonitis/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="1999">1999/3</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0361-803X</style></isbn><abstract><style face="normal" font="default">OBJECTIVE: Although radiation therapy is used in early-stage inoperable lung cancer, it often results in injury to functional lung tissue. A study was undertaken to determine the frequency and severity of pulmonary injury revealed by CT in patients who had undergone conformal proton (to a limited volume) radiation therapy. We compared these findings with those from a group of patients who had undergone a combination of photon and conformal proton (to a larger volume) radiation therapy. CONCLUSION: Proton radiation therapy was associated with a lower frequency of pulmonary injury than the combined regimen. Injury correlated well with the volume of normal lung that was irradiated. Conformal proton radiation therapy appears to be able to reduce the incidence and severity of pulmonary injury revealed by CT</style></abstract><notes><style face="normal" font="default">100638713ae, 7708173AIM, IM0 (Protons)Clinical TrialJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1843</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bush,D.A.</style></author><author><style face="normal" font="default"> Slater,J.D.</style></author><author><style face="normal" font="default"> Bonnet,R.</style></author><author><style face="normal" font="default"> Cheek,G.A.</style></author><author><style face="normal" font="default"> Dunbar,R.D.</style></author><author><style face="normal" font="default"> Moyers,M.</style></author><author><style face="normal" font="default"> Slater,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Medicine, Loma Linda University Medical Center, Loma Linda, CA 92354, USA. dbush@dominion.llumc.edu</style></auth-address><titles><title><style face="normal" font="default">Proton-beam radiotherapy for early-stage lung cancer</style></title><secondary-title><style face="normal" font="default">Chest.116.(5):1313.-9,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Chest.116.(5):1313.-9,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Arm</style></keyword><keyword><style face="normal" font="default"> Biopsy,Needle</style></keyword><keyword><style face="normal" font="default"> Bronchoscopy</style></keyword><keyword><style face="normal" font="default"> California/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Mediastinum</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Staging</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> X-Rays</style></keyword></keywords><dates><year Day="0" Month="11" Year="1999">1999/11</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0012-3692</style></isbn><abstract><style face="normal" font="default">STUDY OBJECTIVE: A prospective study was undertaken to assess the efficacy and toxicity of conformal proton-beam radiotherapy for early-stage, medically inoperable non-small cell lung cancer. DESIGN: Eligible patients had clinical stage I to IIIa non-small cell lung cancer and were not candidates for surgical resection for medical reasons or because of patient refusal. Patients with adequate cardiopulmonary function received 45 Gy to the mediastinum and gross tumor volume with photons with a concurrent proton boost to the gross tumor volume of an additional 28.8 cobalt gray equivalents (CGE). Total tumor dose was 73.8 CGE given over 5 weeks. Patients with poor cardiopulmonary function received proton-beam radiotherapy to the gross tumor volume only, with 51 CGE given in 10 fractions over a 2-week period. RESULTS: Thirty-seven patients were treated in the study from July 1994 to March 1998. Clinical staging of patients was as follows: stage I, 27 patients; stage II, 2 patients; and stage IIIa, 8 patients. Eighteen patients received a combination of protons and x rays, while 19 patients received proton-beam radiation only. Follow-up of evaluable patients ranged from 3 to 45 months, with a median of 14 months. Two patients in the proton and photon arm developed pneumonitis that resolved with oral steroids; otherwise, no significant toxicities were encountered. The actuarial disease-free survival at 2 years for the entire group was 63%; for stage I patients, disease-free survival at 2 years was 86%. Local disease control was 87%. CONCLUSION: Preliminary results from this study indicate that proton-beam radiotherapy can be used safely in this group of patients. Disease-free survival and local control appear to be good and compare favorably with published reports utilizing conventional photon irradiation</style></abstract><notes><style face="normal" font="default">105590930231335, d1cAIM, IM0 (Protons)Clinical TrialComparative StudyJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1864</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Courdi,A.</style></author><author><style face="normal" font="default"> Caujolle,J.P.</style></author><author><style face="normal" font="default"> Grange,J.D.</style></author><author><style face="normal" font="default"> allo-Rosier,L.</style></author><author><style face="normal" font="default"> Sahel,J.</style></author><author><style face="normal" font="default"> Bacin,F.</style></author><author><style face="normal" font="default"> Zur,C.</style></author><author><style face="normal" font="default"> Gastaud,P.</style></author><author><style face="normal" font="default"> Iborra-Brassart,N.</style></author><author><style face="normal" font="default"> Herault,J.</style></author><author><style face="normal" font="default"> Chauvel,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre A. Lacassagne, Nice, France</style></auth-address><titles><title><style face="normal" font="default">Results of proton therapy of uveal melanomas treated in Nice</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.45.(1):5-11,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.45.(1):5-11,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Ciliary Body</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Tantalum</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Ultrasonography</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Vision</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword></keywords><dates><year Day="1" Month="8" Year="1999">1999/8/1</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To present the first results of uveal melanomas treated with the Medicyc Cyclotron 65 MeV proton beam facility in Nice, analyzing the factors that affect the cause-specific survival (CSS), metastatic rate, and reporting the visual outcome. METHODS AND MATERIALS: This study concerns 538 patients referred by French institutions between June 1991 and December 1996. The eye and tumor parameters were measured using ultrasonography and angiography. Since 1994, CT scans were performed in most patients to help determine the axial length and the shape of the ocular globe. Tantalum clips were inserted around the tumor by the referring ophthalmologist. There were 349 posterior pole tumors (64.9%), 130 equatorial tumors (24.1%), and 59 ciliary body tumors (11%). Two hundred four patients (37.9%) had T1 or T2 tumors, and 334 patients (62.1%) had T3 or T4 tumors. The median tumor diameter was 14.6 mm, and the median tumor height was 5.1 mm. All patients received 52 Gy (57.20 Gy Co-equivalent dose) on 4 consecutive days. The data were analyzed by December 1997. RESULTS: The CSS was 77.4% at 78 months, the overall survival was 73.8% and the local control was 89.0%. The CSS was not influenced by the patient age or the site of the tumor. It was 81.5% for T1 and T2 tumors, versus 75% for T3 and T4 tumors (P = 0.035). It was found that the tumor diameter, rather than the height, was the most important parameter affecting outcome. The metastatic rate was 8%. It depended on the T stage, tumor diameter and thickness, but not the tumor site. Thirty-eight enucleations were performed, most of them due to tumor progression and/or glaucoma. One-third of the patients in whom visual acuity was adequately scored before and after treatment had a stable, if not improved vision, and half the patients retained useful vision after treatment. CONCLUSION: The outcome of patients suffering from uveal melanoma and treated with high-energy protons compares favorably with other techniques of treatment. The tumor dimensions affected CSS and metastatic rate. Even though two-thirds of patients had posterior pole tumors, half of them retained useful vision</style></abstract><notes><style face="normal" font="default">10477000g97, 7603616IM0 (Protons)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1872</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Debus,J.</style></author><author><style face="normal" font="default"> Haberer,T.</style></author><author><style face="normal" font="default"> Schulz-Ertner,D.</style></author><author><style face="normal" font="default"> Jakel,O.</style></author><author><style face="normal" font="default"> Wenz,F.</style></author><author><style face="normal" font="default"> Enghardt,W.</style></author><author><style face="normal" font="default"> Schlegel,W.</style></author><author><style face="normal" font="default"> Kraft,G.</style></author><author><style face="normal" font="default"> Wannenmacher,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Radiologische Universitatsklinik, Heidelberg. j.debus@dkfz-heidelberg.de</style></auth-address><titles><title><style face="normal" font="default">[Carbon ion irradiation of skull base tumors at GSI. First clinical results and future perspectives]. [German]</style></title><secondary-title><style face="normal" font="default">Strahlentherapie und Onkologie.176.(5):211.-6,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Strahlentherapie und Onkologie.176.(5):211.-6,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Chordoma/ri [Radionuclide Imaging]</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Heavy Ions/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Positron-Emission Tomography</style></keyword><keyword><style face="normal" font="default"> Quality Assurance,Health Care</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Planning,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/st [Standards]</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Base</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Tomography,Emission-Computed</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="5" Year="2000">2000/5</year></dates><pub-location><style face="normal" font="default">GERMANY</style></pub-location><isbn><style face="normal" font="default">0179-7158</style></isbn><abstract><style face="normal" font="default">BACKGROUND: Radiobiological and physical examinations suggest clinical advantages of heavy ion irradiation. We report the results of 23 women and 22 men (median age 48 years) with skull base tumors irradiated with carbon ion beams at the Gesellschaft fur Schwerionenforschung (GSI), Darmstadt, from December 1997 until September 1999. PATIENTS AND METHODS: The study included patients with chordomas (17), chondrosarcomas (10) and other skull base tumors (Table 1). It is the first time that the intensity-controlled rasterscan-technique and the application of positron-emission tomography (PET) for quality assurance was used. All patients had computed tomography for three-dimensional-treatment planning (Figure 1). Patients with chordomas and chondrosarcomas underwent fractionated carbon ion irradiation in 20 consecutive days (median total dose 60 GyE). Other histologies were treated with a carbon ion boost of 15 to 18 GyE delivered to the macroscopic tumor after fractionated stereotactic radiotherapy (median total dose 63 GyE). RESULTS: Mean follow-up was 9 months. Irradiation was well tolerated by all patients. Partial tumor remission was seen in 7 patients (15.5%) (Figure 2). One-year local control rate was 94%. One patient (2.2%) deceased. No severe toxicity and no local recurrence within the treated volume were observed. CONCLUSION: Clinical effectiveness and technical feasibility of this therapy modality could clearly be demonstrated in our study. To evaluate the clinical relevance of the different beam modalities studies with larger patient numbers are necessary. To continue our project a new heavy ion accelerator exclusively for clinical use is planned to be constructed in Heidelberg</style></abstract><notes><style face="normal" font="default">10847117vcm, 8603469IM, S7440-44-0 (Carbon)Clinical TrialEnglish AbstractJournal ArticleGerman</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1885</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Egan,K.M.</style></author><author><style face="normal" font="default"> Quinn,J.L.</style></author><author><style face="normal" font="default"> Gragoudas,E.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Massachusetts Eye and Ear Infirmary, Department of Epidemiology, Harvard School of Public Health, Boston 02114-3096, USA. Kathleen.Egan@channing.harvard.edu</style></auth-address><titles><title><style face="normal" font="default">Childbearing history associated with improved survival in choroidal melanoma</style></title><secondary-title><style face="normal" font="default">Archives of Ophthalmology.117.(7.):939.-42.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Archives of Ophthalmology.117.(7.):939.-42.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Massachusetts/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Reproductive History</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="7" Year="1999">1999/7</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0003-9950</style></isbn><abstract><style face="normal" font="default">BACKGROUND: Research in cutaneous melanoma suggests that women may experience better tumor-dependent survival than men, and some studies have shown that the advantage is specific to childbearing. OBJECTIVE: To examine whether childbearing may be a favorable prognostic factor in melanoma of the uveal tract. DESIGN: Prospective follow-up study. SETTING: Hospital. MAIN OUTCOME MEASURE: Death from metastatic choroidal melanoma. METHODS: We evaluated a consecutive series of 1818 patients with choroidal melanoma, 748 parous and 165 nulliparous women and 905 men, after treatment with proton irradiation. Three hundred fifty-two deaths from metastasis were documented in follow-up. RESULTS: Overall multivariate-adjusted death rates from metastasis were approximately 25% higher in nulliparous women (relative risk [RR], 1.23; 95% confidence interval [CI], 0.83-1.82) and men (RR, 1.25; 95% CI, 1.00-1.56) than in women who had given birth. The protective influence of parity was strongest in the early period following diagnosis and treatment (RR, 1.58; 95% CI, 0.88-2.86, and RR, 1.51; 95% CI, 1.04-2.19, in nulliparous women and men, respectively, during the first 36 months of follow-up). The level of protection increased with the number of live births (P for trend, .04). CONCLUSION: These data provide support for the hypothesis that a history of childbearing confers protection from death in choroidal melanoma</style></abstract><notes><style face="normal" font="default">104084607706534, 830AIM, IMJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1896</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fitzek,M.M.</style></author><author><style face="normal" font="default"> Thornton,A.F.</style></author><author><style face="normal" font="default"> Rabinov,J.D.</style></author><author><style face="normal" font="default"> Lev,M.H.</style></author><author><style face="normal" font="default"> Pardo,F.S.</style></author><author><style face="normal" font="default"> Munzenrider,J.E.</style></author><author><style face="normal" font="default"> Okunieff,P.</style></author><author><style face="normal" font="default"> Bussiere,M.</style></author><author><style face="normal" font="default"> Braun,I.</style></author><author><style face="normal" font="default"> Hochberg,F.H.</style></author><author><style face="normal" font="default"> Hedley-Whyte,E.T.</style></author><author><style face="normal" font="default"> Liebsch,N.J.</style></author><author><style face="normal" font="default"> Harsh,G.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA. markus.fitzek@charite.de</style></auth-address><titles><title><style face="normal" font="default">Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial</style></title><secondary-title><style face="normal" font="default">Journal of Neurosurgery.91.(2):251.-60,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Journal of Neurosurgery.91.(2):251.-60,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Actuarial Analysis</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Brain Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Brain Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Cobalt Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Cobalt Radioisotopes/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Cobalt Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Contrast Media</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Gadolinium/du [Diagnostic Use]</style></keyword><keyword><style face="normal" font="default"> Glioblastoma</style></keyword><keyword><style face="normal" font="default"> Glioblastoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Glioblastoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Karnofsky Performance Status</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiopharmaceuticals</style></keyword><keyword><style face="normal" font="default"> Radiopharmaceuticals/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Radiopharmaceuticals/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Supratentorial Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword></keywords><dates><year Day="0" Month="8" Year="1999">1999/8</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0022-3085</style></isbn><abstract><style face="normal" font="default">OBJECT: After conventional doses of 55 to 65 Gy of fractionated irradiation, glioblastoma multiforme (GBM) usually recurs at its original location. This institutional phase II study was designed to assess whether dose escalation to 90 cobalt gray equivalent (CGE) with conformal protons and photons in accelerated fractionation would improve local tumor control and patient survival. METHODS: Twenty-three patients were enrolled in this study. Eligibility criteria included age between 18 and 70 years, Karnofsky Performance Scale score of greater than or equal to 70, residual tumor volume of less than 60 ml, and a supratentorial, unilateral tumor. Actuarial survival rates at 2 and 3 years were 34% and 18%, respectively. The median survival time was 20 months, with four patients alive 22 to 60 months postdiagnosis. Analysis by Radiation Therapy Oncology Group prognostic criteria or Medical Research Council indices showed a 5- to 11-month increase in median survival time over those of comparable conventionally treated patients. All patients developed new areas of gadolinium enhancement during the follow-up period. Histological examination of tissues obtained at biopsy, resection, or autopsy was conducted in 15 of 23 patients. Radiation necrosis only was demonstrated in seven patients, and their survival was significantly longer than that of patients with recurrent tumor (p = 0.01). Tumor regrowth occurred most commonly in areas that received doses of 60 to 70 CGE or less; recurrent tumor was found in only one case in the 90-CGE volume. CONCLUSIONS: A dose of 90 CGE in accelerated fractionation prevented central recurrence in almost all cases. The median survival time was extended to 20 months, likely as a result of central control. Tumors will usually recur in areas immediately peripheral to this 90-CGE volume, but attempts to extend local control by enlarging the central volume are likely to be limited by difficulties with radiation necrosis</style></abstract><notes><style face="normal" font="default">10433313jd3, 0253357AIM, IM0 (Cobalt Radioisotopes)0 (Contrast Media)0 (Radiopharmaceuticals)7440-54-2 (Gadolinium)Clinical TrialClinical Trial, Phase IIComparative StudyJournal ArticleResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1900</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fuss,M.</style></author><author><style face="normal" font="default"> Hug,E.B.</style></author><author><style face="normal" font="default"> Schaefer,R.A.</style></author><author><style face="normal" font="default"> Nevinny-Stickel,M.</style></author><author><style face="normal" font="default"> Miller,D.W.</style></author><author><style face="normal" font="default"> Slater,J.M.</style></author><author><style face="normal" font="default"> Slater,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Medicine, Loma Linda University Medical Center, CA, USA</style></auth-address><titles><title><style face="normal" font="default">Proton radiation therapy (PRT) for pediatric optic pathway gliomas: comparison with 3D planned conventional photons and a standard photon technique</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.45.(5):1117.-26.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.45.(5):1117.-26.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Child</style></keyword><keyword><style face="normal" font="default"> Child,Preschool</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Glioma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Glioma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Optic Chiasm</style></keyword><keyword><style face="normal" font="default"> Optic Nerve</style></keyword><keyword><style face="normal" font="default"> Optic Nerve Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Optic Nerve Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons</style></keyword><keyword><style face="normal" font="default"> Photons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Conformal/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Software</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Temporal Lobe</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="1" Month="12" Year="1999">1999/12/1</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: Following adequate therapy, excellent long-term survival rates can be achieved for patients with optic pathway gliomas. Therefore, avoidance of treatment-related functional long-term sequelae is of utmost importance. Optimized sparing of normal tissue is of primary concern in the development of new treatment modalities. The present study compares proton radiation therapy (PRT) with a three-dimensional (3D)-planned multiport photon and a lateral beam photon technique for localized and extensive optic pathway tumors. METHODS AND MATERIALS: Between February 1992 and November 1997, seven children with optic pathway gliomas underwent PRT. For this study, we computed proton, 3D photon, and lateral photon plans based on the same CT data sets, and using the same treatment planning software for all plans. Radiation exposure for normal tissue and discrete organs at risk was quantified based on dose-volume histograms. RESULTS: Gross tumor volume (GTV) ranged from 3.9 cm3 to 127.2 cm3. Conformity index (relation of encompassing isodose to GTV volume) was 2.3 for protons, 2.9 for 3D photons, and 7.3 for lateral photons. The relative increase of normal tissue (NT) encompassed at several isodose levels in relation to NT encompassed by the 95% proton isodose volume was computed. Relative NT volume of proton plan isodoses at the 95%, 90%, 80%, 50%, and 25% isodose level increased from 1 to 1.6, 2.8, 6.4, to a maximum of 13.3. Relative volumes for 3D photons were 1.6, 2.4, 3.8, 11.5, and 34.8. Lateral plan relative values were 6, 8.3, 11.5, 19.2, and 26.8. Analysis for small (&lt;20 cm3) and larger (> 80 cm3) tumors showed that protons encompassed the smallest volumes of NT at all isodose levels. Comparable conformity and high-dose gradient were achieved for proton and 3D photon plans in small tumors. However, with increasing tumor volume and complexity, differences became larger. At the 50% isodose level, 3D photons were superior to lateral photons for small tumors; this advantage was equalized for larger tumors. At the lowest isodose level, 3D photons encompassed the highest amount of NT. Analysis of organs at risk showed that PRT reduced doses to the contralateral optic nerve by 47% and 77% compared to 3D photons and lateral photons, respectively. Reductions were also seen for the chiasm (11% and 16%) and pituitary gland (13% and 16%), with differences at clinically relevant tolerance levels. Furthermore, reduced dose exposure of both temporal lobes (sparing 39% and 54%) and frontal lobes was achieved with PRT. CONCLUSION: PRT offered a high degree of conformity to target volumes and steep dose gradients, thus leading to substantial normal tissue sparing in high- and low-dose areas. It is expected that this will result in decreased long-term toxicity in the maturing child. Advantages of proton versus 3D photon plans became increasingly apparent with increasing target size and tumor complexity. Even in small tumors, conformity of 3D photon irradiation came at the expense of a larger amount of NT receiving moderate to low radiation doses. Lateral photons resulted in inferior dose distribution with high radiation exposure of clinically relevant normal tissues</style></abstract><notes><style face="normal" font="default">10613303g97, 7603616IM0 (Protons)Comparative StudyJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1912</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gragoudas,E.S.</style></author><author><style face="normal" font="default"> Li,W.</style></author><author><style face="normal" font="default"> Lane,A.M.</style></author><author><style face="normal" font="default"> Munzenrider,J.</style></author><author><style face="normal" font="default"> Egan,K.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Retina Service, Massachusetts Eye and Ear Infirmary, Boston 02114, USA</style></auth-address><titles><title><style face="normal" font="default">Risk factors for radiation maculopathy and papillopathy after intraocular irradiation</style></title><secondary-title><style face="normal" font="default">Ophthalmology.106.(8.):1571.-7.; discussion.1577.-8.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ophthalmology.106.(8.):1571.-7.; discussion.1577.-8.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Macula Lutea/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Optic Disk/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Optic Nerve</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Retinal Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Vision</style></keyword><keyword><style face="normal" font="default"> Vision Disorders/et [Etiology]</style></keyword></keywords><dates><year Day="0" Month="8" Year="1999">1999/8</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0161-6420</style></isbn><abstract><style face="normal" font="default">PURPOSE: To evaluate rates of occurrence and risk factors for radiation maculopathy and radiation papillopathy in patients with choroidal melanoma at high risk for these complications. DESIGN: Cohort study. PARTICIPANTS: A total of 558 patients treated with proton irradiation for choroidal melanoma between 1986 and 1996 with small to moderate sized tumors (less than 5 mm in height and 15 mm in diameter) located within 4 disc diameters of the macula or optic nerve and with a median ocular follow-up of 4 years. METHODS: Annual and cumulative rates of each endpoint were estimated using life table approaches. Prognostic factors were evaluated using the Cox proportional hazards regression. MAIN OUTCOME MEASURES: Radiation maculopathy, radiation papillopathy, and vision loss to worse than 20/100. RESULTS: Cumulative 5-year rates for radiation maculopathy, radiation papillopathy, and vision loss were 64%, 35%, and 68%, respectively. Complication rates rose as a function of radiation exposure to the macula (P for trend = 0.04) or optic disc (P for trend &lt; 0.001), although dose-response patterns were nonlinear. History of diabetes was a significant risk factor for maculopathy (P &lt; 0.001) and optic neuropathy (P = 0.009). CONCLUSIONS: The onset of radiation vasculopathy is determined primarily by the degree of irradiation exposure to the macula and optic disc. Risk may be enhanced among those with underlying vascular disorders</style></abstract><notes><style face="normal" font="default">10442906oi5, 7802443IM0 (Protons)Journal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1913</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gragoudas,E.S.</style></author><author><style face="normal" font="default"> Lane,A.M.</style></author><author><style face="normal" font="default"> Regan,S.</style></author><author><style face="normal" font="default"> Li,W.</style></author><author><style face="normal" font="default"> Judge,H.E.</style></author><author><style face="normal" font="default"> Munzenrider,J.E.</style></author><author><style face="normal" font="default"> Seddon,J.M.</style></author><author><style face="normal" font="default"> Egan,K.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Retina Service, Massachusetts Eye and Ear Infirmary, 243 Charles St, Boston, MA 02114, USA</style></auth-address><titles><title><style face="normal" font="default">A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma</style></title><secondary-title><style face="normal" font="default">Archives of Ophthalmology.118.(6):773.-8.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Archives of Ophthalmology.118.(6):773.-8.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Cobalt Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Cobalt Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Dose-Response Relationship,Radiation</style></keyword><keyword><style face="normal" font="default"> Double-Blind Method</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Dosage</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword><keyword><style face="normal" font="default"> Visual Acuity/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Visual Fields/re [Radiation Effects]</style></keyword></keywords><dates><year Day="0" Month="6" Year="2000">2000/6</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0003-9950</style></isbn><abstract><style face="normal" font="default">OBJECTIVE: To determine if a reduction in proton radiation dose from the standard dose of 70 cobalt gray equivalents (CGE) to 50 CGE would decrease radiation-induced complications, thereby improving visual prognosis, without compromising local tumor control for patients with uveal melanoma at high risk of these complications. DESIGN: Randomized, double-masked clinical trial. PARTICIPANTS: A total of 188 patients with small or medium-sized choroidal melanomas (&lt;15 mm in diameter and &lt;5 mm in height) near the optic disc or macula (within 4 disc diameters of either structure). METHODS: Patients were treated with proton beam therapy at doses of either 50 CGE or 70 CGE between October 1989 and July 1994, and followed up biannually through April 1998. Outcomes included visual acuity, radiation complications, melanoma recurrence, and metastasis. RESULTS: Proportions of patients retaining visual acuity of at least 20/200 were similar in the 2 dose groups at 5 years after radiation (approximately 55%). Similar numbers of patients in each group experienced tumor regrowth (2 patients at 50 CGE vs 3 patients at 70 CGE; P>.99) and metastasis (7 patients at 50 CGE vs 8 patients at 70 CGE;P=.79). Five-year rates of radiation maculopathy also were similar (for both groups, approximately 75% for tumors within 1 disc diameter and 40% for tumors >1 disc diameter from the macula). Rates of radiation papillopathy were nonsignificantly decreased in the 50-CGE treatment group when tumors were located 1 disc diameter or less from the optic disc (P=.20). Patients treated with the lower dose also experienced significantly less visual field loss. CONCLUSIONS: This level of dose reduction did not result in a lesser degree of visual acuity loss. The lower-dose group did experience significantly less visual field loss. Local tumor recurrence and metastatic death rates were similar in both dose groups. Arch Ophthalmol. 2000;118:773-778</style></abstract><notes><style face="normal" font="default">108653137706534, 830AIM, IM0 (Cobalt Radioisotopes)Clinical TrialComparative StudyJournal ArticleRandomized Controlled TrialResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1933</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Homma,T.</style></author><author><style face="normal" font="default"> Ohtsu,I.</style></author><author><style face="normal" font="default"> Tomioka,S.</style></author><author><style face="normal" font="default"> Inoue,M.</style></author><author><style face="normal" font="default"> Hasegawa,S.</style></author><author><style face="normal" font="default"> Miyamoto,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Respiratory Disease, University of Tsukuba, Ibaraki, Japan</style></auth-address><titles><title><style face="normal" font="default">[Quantitative analysis of pulmonary functional damage due to heavy ion particle irradiation therapy for lung cancer]. [Japanese]</style></title><secondary-title><style face="normal" font="default">Nihon Kokyuki.Gakkai Zasshi.37.(2):97.-101.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Nihon Kokyuki.Gakkai Zasshi.37.(2):97.-101.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Blood Gas Analysis</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> Heavy Ions</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Lung/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="2" Year="1999">1999/2</year></dates><pub-location><style face="normal" font="default">JAPAN</style></pub-location><isbn><style face="normal" font="default">1343-3490</style></isbn><abstract><style face="normal" font="default">Seventeen patients with clinical stage I lung cancer were given irradiation therapy with heavy ion radioactive rays at 73.1 +/- 11.2 GyE. Lung injury due to irradiation was evaluated by measuring routing parameters of pulmonary function. No statistically significant changes in these parameters were observed after irradiation, even in patients followed up for a period of 1 year. Chest X-ray examinations, including CT scan images, disclosed the development of nonsegmental consolidations in the irradiated areas, changing into minor fibrosis 1 year later. We concluded that heavy ion particle irradiation has minimal impact on pulmonary function, and is of therapeutic valve to elderly patients and patients with complications</style></abstract><notes><style face="normal" font="default">102140369808802, c33, 9808802IMEnglish AbstractJournal ArticleJapanese</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1935</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hug,E.B.</style></author><author><style face="normal" font="default"> Loredo,L.N.</style></author><author><style face="normal" font="default"> Slater,J.D.</style></author><author><style face="normal" font="default"> DeVries,A.</style></author><author><style face="normal" font="default"> Grove,R.I.</style></author><author><style face="normal" font="default"> Schaefer,R.A.</style></author><author><style face="normal" font="default"> Rosenberg,A.E.</style></author><author><style face="normal" font="default"> Slater,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Medicine, Loma Linda University Medical Center, California 92354, USA. ehug@dominion.llumc.edu</style></auth-address><titles><title><style face="normal" font="default">Proton radiation therapy for chordomas and chondrosarcomas of the skull base.[see comment]</style></title><secondary-title><style face="normal" font="default">Journal of Neurosurgery.91.(3):432.-9,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Journal of Neurosurgery.91.(3):432.-9,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Actuarial Analysis</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Brain Stem/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Brain Stem/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Cause of Death</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Invasiveness</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Neoplasm,Residual/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Neoplasm,Residual/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Base</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treatment Failure</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="1999">1999/9</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0022-3085</style></isbn><abstract><style face="normal" font="default">OBJECT: Local tumor control, patient survival, and treatment failure outcomes were analyzed to assess treatment efficacy in 58 patients in whom fractionated proton radiation therapy (RT) was administered for skull base chordomas and chondrosarcomas. METHODS: Between March 1992 and January 1998, a total of 58 patients who could be evaluated were treated for skull base tumors, 33 for chordoma and 25 for chondrosarcoma. Following various surgical procedures, residual tumor was detected in 91% of patients; 59% demonstrated brainstem involvement. Target dosages ranged from 64.8 and 79.2 (mean 70.7) Co Gy equivalent. The range of follow up was 7 to 75 months (mean 33 months). In 10 patients (17%) the treatment failed locally, resulting in local control rates of 92% (23 of 25 patients) for chondrosarcomas and 76% (25 of 33 patients) for chordomas. Tumor volume and brainstem involvement influenced control rates. All tumors with volumes of 25 ml or less remained locally controlled, compared with 56% of tumors larger than 25 ml (p = 0.02); 94% of patients without brainstem involvement did not experience recurrence; in patients with brainstem involvement (and dose reduction because of brainstem tolerance constraints) the authors achieved a tumor control rate of 53% (p = 0.04). Three patients died of their disease, and one died of intercurrent disease. Actuarial 5-year survival rates were 100% for patients with chondrosarcoma and 79% for patients with chordoma. Grade 3 and 4 late toxicities were observed in four patients (7%) and were symptomatic in three (5%). CONCLUSIONS: High-dose proton RT offers excellent chances of lasting tumor control and survival, with acceptable risks. In this series all small- and medium-sized tumors with no demonstrable brainstem involvement have been controlled; all such patients are alive. Surgical debulking enhanced delivery of full tumoricidal doses, but even patients with large tumors and disease abutting crucial normal structures benefited</style></abstract><notes><style face="normal" font="default">10470818jd3, 0253357AIM, IM0 (Protons)Comparative StudyJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1938</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hug,E.B.</style></author><author><style face="normal" font="default"> DeVries,A.</style></author><author><style face="normal" font="default"> Thornton,A.F.</style></author><author><style face="normal" font="default"> Munzenride,J.E.</style></author><author><style face="normal" font="default"> Pardo,F.S.</style></author><author><style face="normal" font="default"> Hedley-Whyte,E.T.</style></author><author><style face="normal" font="default"> Bussiere,M.R.</style></author><author><style face="normal" font="default"> Ojemann,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Eugen.Hug@Hitchcock.org</style></auth-address><titles><title><style face="normal" font="default">Management of atypical and malignant meningiomas: role of high-dose, 3D-conformal radiation therapy</style></title><secondary-title><style face="normal" font="default">Journal of Neuro-Oncology.48.(2):151.-60,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Journal of Neuro-Oncology.48.(2):151.-60,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Combined Modality Therapy</style></keyword><keyword><style face="normal" font="default"> Cranial Irradiation/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Cranial Irradiation/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Life Tables</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Meningeal Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Meningeal Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Meningeal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Meningeal Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Meningioma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Meningioma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Meningioma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Meningioma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Metastasis</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons</style></keyword><keyword><style face="normal" font="default"> Photons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Salvage Therapy</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="0" Month="6" Year="2000">2000/6</year></dates><pub-location><style face="normal" font="default">NETHERLANDS</style></pub-location><isbn><style face="normal" font="default">0167-594X</style></isbn><abstract><style face="normal" font="default">OBJECTIVE: Atypical and malignant meningiomas are at high risk for local failure. The role of radiation therapy (RT) and dose levels required to improve tumor control are poorly defined. This study reviews our experience with RT. MATERIAL AND METHODS: Thirty-one patients underwent fractionated RT for atypical (AM, 15 patients) or malignant meningioma (MM, 16 patients) of the cranium. Sixteen patients presented with primary and 15 with recurrent disease. Eight patients received RT following total resection, 21 patients after subtotal resection and 2 patient following biopsy only. RT was given using megavoltage photons in 15 patients and combined photons and 160 MeV protons in 16 patients. Total target doses ranged from 50 to 68 (AM, mean 62) and from 40 to 72 (MM, mean 58) Gy or CGE (= cobalt-gray-equivalent). RESULTS: With mean observation time of 59 months (range: 7-155 months) actuarial local control rates at 5- and 8-years were similar for both histologies (38% and 19% for AM and 52 and 17% for MM). However, significantly improved local control was observed for proton versus photon RT (80% versus 17% at 5 years, p = 0.003) and target doses > or = 60 Gy for both, atypical (p = 0.025) and malignant meningioma (p = 0.0006). At time of analysis, 14/15 patients (93%) with AM and 6/16 (38%) with MM were alive. Three patients (19%) with MM developed distant metastasis. Actuarial 5- and 8-year survival rates for MM were significantly improved by use of proton over photon RT and radiation doses > 60 CGE. Three patients developed symptomatic radiation damage after 59.3, 68.4 and 72 Gy/CGE. CONCLUSION: Conformal, high dose RT resulted in significant improvement of local control for atypical and malignant meningiomas. Increased local control resulted also in improved rates of survival for patients with malignant meningioma</style></abstract><notes><style face="normal" font="default">11083080jcp, 8309335IM0 (Protons)Comparative StudyJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>1993</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Li,W.</style></author><author><style face="normal" font="default"> Gragoudas,E.S.</style></author><author><style face="normal" font="default"> Egan,K.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Retina Service, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA</style></auth-address><titles><title><style face="normal" font="default">Metastatic melanoma death rates by anatomic site after proton beam irradiation for uveal melanoma</style></title><secondary-title><style face="normal" font="default">Archives of Ophthalmology.118.(8.):1066.-70.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Archives of Ophthalmology.118.(8.):1066.-70.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Boston</style></keyword><keyword><style face="normal" font="default"> Boston/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Ciliary Body</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Metastasis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Survivors</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="0" Month="8" Year="2000">2000/8</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0003-9950</style></isbn><abstract><style face="normal" font="default">BACKGROUND: Ciliary body location is an established prognostic factor for metastasis-related death from uveal melanoma. We evaluated alternative approaches for classifying this covariate when constructing predictive models of patient survival. METHODS AND DESIGN: The analyses were based on a consecutive series of 1848 primary choroidal and/or ciliary body melanoma patients treated with proton beam irradiation (70 cobalt gray equivalent in 5 fractions) at the Harvard Cyclotron Laboratory, Boston, Mass, between July 1975 and December 1995. For each patient, the anatomic site of the tumor was classified according to an estimate of the proportion of the tumor base lying anterior to the ora serrata. Using proportional hazards regression, we estimated relative risk ratios and death rates from melanoma metastasis according to the extent of ciliary body involvement. All estimates were adjusted for other established prognostic factors. RESULTS: Patients were followed up through April 30, 1998; none were lost to follow-up. Of 1848 patients analyzed, 378 died of melanoma metastasis. The median follow-up period among survivors was 9.5 years. Ciliary body origin (>50% of tumor base anterior to the ora serrata) was positively associated with tumor pigmentation (P&lt;.001), tumor height (P&lt;.001), and extrascleral extension of the tumor (P&lt;.001). Compared with tumors involving only the choroid, melanoma-associated death rates increased with the proportion of the tumor base lying within the ciliary body (P =. 006); the multivariate-adjusted relative risk ratio for greater than 75% involvement was 2.30 (95% confidence interval [CI], 1.26-4.23). The covariate-adjusted 5-year death rates for ciliary body origin and choroidal origin were 15.9% (95% CI, 11.3%-21.2%) and 9.8% (95% CI, 8.3%-11.7%), respectively. CONCLUSION: Patients with melanomas of presumed ciliary body origin seem to be subject to a higher risk of death resulting from melanoma metastasis. Arch Ophthalmol. 2000;118:1066-1070</style></abstract><notes><style face="normal" font="default">109221997706534, 830AIM, IM0 (Protons)Journal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2024</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Meyer,A.</style></author><author><style face="normal" font="default"> Levy,C.</style></author><author><style face="normal" font="default"> Blondel,J.</style></author><author><style face="normal" font="default"> D'Hermies,F.</style></author><author><style face="normal" font="default"> Frau,E.</style></author><author><style face="normal" font="default"> Schlienger,P.</style></author><author><style face="normal" font="default"> Mammar,H.</style></author><author><style face="normal" font="default"> Delacroix,S.</style></author><author><style face="normal" font="default"> Nauraye,C.</style></author><author><style face="normal" font="default"> Desblancs,C.</style></author><author><style face="normal" font="default"> Ferrand,R.</style></author><author><style face="normal" font="default"> Mazal,A.</style></author><author><style face="normal" font="default"> Asselain,B.</style></author><author><style face="normal" font="default"> Plancher,C.</style></author><author><style face="normal" font="default"> Habrand,J.</style></author><author><style face="normal" font="default"> Desjardins,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Service d'Ophtalmologie, Institut Curie, 26, rue d'Ulm, 75005 Paris</style></auth-address><titles><title><style face="normal" font="default">[Optic neuropathy after proton-beam therapy for malignant choroidal melanoma]. [French]</style></title><secondary-title><style face="normal" font="default">Journal Francais.d.Opthalmologie.23(6):543.-53.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Journal Francais.d.Opthalmologie.23(6):543.-53.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Choroid Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Optic Nerve</style></keyword><keyword><style face="normal" font="default"> Optic Nerve Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Optic Nerve Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="0" Month="6" Year="2000">2000/6</year></dates><pub-location><style face="normal" font="default">FRANCE</style></pub-location><isbn><style face="normal" font="default">0181-5512</style></isbn><abstract><style face="normal" font="default">Proton-beam irradiation is a conservative therapy commonly used for the treatment of uveal malignant melanomas. Some adverse effects such as optic neuropathy can compromise the visual outcome. We were interested in determining the risk factors for radiation papillopathy. Since there is currently no effective therapy, this is an interesting way to improve prevention of optic neuropathy. Six hundred sixty-two eyes had more than 24 month follow-up after proton-beam irradiation for uveal melanoma. In five hundred twenty-two cases, the clinical examination of the optic nerve head by ophthalmoscopy was possible. One-hundred eleven optic discs were pathologic, whereas 411 remained disease-free. Retrospective study of these two groups allowed to quantify the risk factors for optic neuropathy. The irradiation of more than 2mm of optic nerve at 30 Grays-equivalents appeared to be the major risk factor for optic neuropathy. For a given irradiation dose, the observed pattern of clinical responses was heterogeneous. These results are discussed and compared to the previous published reports. Visual results and life prognosis are also discussed, considering the optic nerve head status. Proton-beam therapy can preserve the optic nerve when the tumor location allows to keep it away from the irradiation-field. Patients must be informed about the risk of optic neuropathy after proton-beam irradiation</style></abstract><notes><style face="normal" font="default">10880919iae, 7804128IM0 (Protons)English AbstractJournal ArticleFrench</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2044</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nakano,T.</style></author><author><style face="normal" font="default"> Suzuki,M.</style></author><author><style face="normal" font="default"> Abe,A.</style></author><author><style face="normal" font="default"> Suzuki,Y.</style></author><author><style face="normal" font="default"> Morita,S.</style></author><author><style face="normal" font="default"> Mizoe,J.</style></author><author><style face="normal" font="default"> Sato,S.</style></author><author><style face="normal" font="default"> Miyamoto,T.</style></author><author><style face="normal" font="default"> Kamada,T.</style></author><author><style face="normal" font="default"> Kato,H.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Radiation Medicine, Center of Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan</style></auth-address><titles><title><style face="normal" font="default">The phase I/II clinical study of carbon ion therapy for cancer of the uterine cervix</style></title><secondary-title><style face="normal" font="default">Cancer Journal From.Scientific American.5(6):362.-9,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cancer Journal From.Scientific American.5(6):362.-9,</style></abbr-1></periodical><pages end="Dec" start="">-Dec</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adenocarcinoma</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heavy Ions/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Heavy Ions/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Linear Energy Transfer</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Staging</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pelvis</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Uterine Cervical Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Uterine Cervical Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Uterine Cervical Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="0" Month="11" Year="1999">1999/11</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">1081-4442</style></isbn><abstract><style face="normal" font="default">PURPOSE: The phase I/II clinical study of carbon beam therapy was undertaken for 31 cases of advanced cervical cancer of stages IIIB and IVA from June 1995 to November 1997. The main purpose was to determine clinically useful fraction doses without severe acute reaction of normal tissues and to assess tumor control dose levels achievable without significant normal tissue toxicity. PATIENTS AND METHODS: The treatment was given with four fixed fractions per week (24 fractions over 6 weeks) and was initiated with a fraction dose of 2.2 Gray equivalent (GyE), and the dose was increased as 2.4 GyE, 2.6 GyE, 2.8 GyE, and 3.0 GyE. Consequently, the total dose initiated was 52.8 GyE, to increase up to 72.0 GyE in 4.8-GyE increments in the dose-escalation fashion. Thirty patients with eligible advanced cervical cancers consisting of 27 squamous cell carcinomas and three adenocarcinomas were analyzed. RESULTS: Acute response of normal tissues was less than with photon treatment until fraction doses of 2.8 GyE were administered, and patients finished treatment with comfortable conditions. Severe late complications occurred in the two patients who received more than 67.2 GyE. The 2-year cumulative survival rate and the local control rate of 27 patients with squamous cell carcinoma were 61.5% and 59.3%, respectively. According to stages, the 2-year survival rates of stage IIIB and IVA patients were 54.4% and 75.0%, respectively. The 2-year local control rates of stage IIIB and IVA patients were 52.6% and 75.0%, respectively. DISCUSSION: These results indicated that the disease control seems to be relatively better for very advanced disease and with dose escalation treatment. Local control was not significantly correlated with total dose and tumor volume. The results of the present study, despite small numbers and short observation, suggest that an adequate fraction dose for pelvis fields is 2.8 to 3.0 GyE and that the carbon beam therapy might be advantageous for advanced cervical cancer</style></abstract><notes><style face="normal" font="default">10606478cr8, 9513568, 9513568IM, S7440-44-0 (Carbon)Clinical TrialClinical Trial, Phase IClinical Trial, Phase IIJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2087</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Regan,S.</style></author><author><style face="normal" font="default"> Judge,H.E.</style></author><author><style face="normal" font="default"> Gragoudas,E.S.</style></author><author><style face="normal" font="default"> Egan,K.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Retina Service, Massachusetts Eye and Ear Infirmary, Boston 02114, USA</style></auth-address><titles><title><style face="normal" font="default">Iris color as a prognostic factor in ocular melanoma</style></title><secondary-title><style face="normal" font="default">Archives of Ophthalmology.117.(6):811.-4,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Archives of Ophthalmology.117.(6):811.-4,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Boston</style></keyword><keyword><style face="normal" font="default"> Boston/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Color</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eye Color</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Melanoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Metastasis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword></keywords><dates><year Day="0" Month="6" Year="1999">1999/6</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0003-9950</style></isbn><abstract><style face="normal" font="default">BACKGROUND: Ocular melanoma may be more prevalent among patients with light irises than those with dark irises. OBJECTIVE: To examine a large clinical series of patients with intraocular melanoma to determine if light irises are associated with increased risk of death from these tumors. METHODS: A total of 1162 patients treated with proton irradiation between 1984 and 1996 were observed through 1997. RESULTS: Iris color in the patients was blue or gray in 48%, green or hazel in 30%, and brown in 23%. Tumors in patients with blue or gray irises were less heavily pigmented (P&lt;.001) and closer to the optic disc and macula (P&lt;.001). Five- and 10-year metastasis-related death rates were 0.14 and 0.21, respectively, for those with blue or gray irises and 0.10 and 0.15, respectively, for those with darker irises (P = .02). In a Cox proportional hazards regression controlling for tumor characteristics, patients with blue or gray irises died of metastatic disease at a rate 1.90 times (95% confidence interval, 1.26-2.85) that of patients with brown irises. The rate of metastatic death was not significantly elevated for those with green or hazel irises (relative risk, 1.43; 95% confidence interval, 0.91-2.23). CONCLUSION: Patients with blue or gray irises appear to be at increased risk of metastatic death from choroidal melanoma, independent of other risk factors</style></abstract><notes><style face="normal" font="default">103695957706534, 830AIM, IMJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2093</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rosenberg,A.E.</style></author><author><style face="normal" font="default"> Nielsen,G.P.</style></author><author><style face="normal" font="default"> Keel,S.B.</style></author><author><style face="normal" font="default"> Renard,L.G.</style></author><author><style face="normal" font="default"> Fitzek,M.M.</style></author><author><style face="normal" font="default"> Munzenrider,J.E.</style></author><author><style face="normal" font="default"> Liebsch,N.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">James Homer Wright Pathology Laboratories, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA</style></auth-address><titles><title><style face="normal" font="default">Chondrosarcoma of the base of the skull: a clinicopathologic study of 200 cases with emphasis on its distinction from chordoma</style></title><secondary-title><style face="normal" font="default">American Journal of Surgical Pathology.23(11):1370.-8.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">American Journal of Surgical Pathology.23(11):1370.-8.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Diagnosis,Differential</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasms</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Base</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="0" Month="11" Year="1999">1999/11</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0147-5185</style></isbn><abstract><style face="normal" font="default">Conventional chondrosarcoma (CSA) of the skull base is an uncommon neoplasm that can resemble chordoma, and indeed it is misdiagnosed frequently as such. This has important clinical implications, because when treated with similar aggressive treatment strategies, CSA has a much better prognosis than chordoma. In an effort to identify those morphologic and immunohistochemical features that help to identify conventional skull base CSA correctly and to understand its prognosis better, particularly compared with chordoma, when treated with surgery and proton beam irradiation, the authors performed a clinicopathologic analysis of 200 CSAs. The patients ranged in age from 10 to 79 years (mean, 39 years), 87 patients were male and 113 patients were female, and most presented with symptoms related to the central nervous system. Approximately 6% of the tumors arose in the sphenoethmoid complex, 28% originated in the clivus, and 66% developed in the temperooccipital junction. Histologically, 15 tumors (7.5%) were classified as hyaline CSA, 59 (29.5%) as myxoid CSA, and 126 (63%) as mixed hyaline and myxoid CSA. A total of 101 (50.5%) tumors were grade 1, 57 (28.5%) had areas of grades 1 and 2, and 42 (21%) were pure grade 2 neoplasms. The vast majority of patients originated from referring hospitals, and the diagnosis was changed prospectively at our institution to CSA from chordoma in 74 patients (37%). Of the tumors studied immunohistochemically, 96 of 97 (98.9%) stained for S-100 protein, 0 of 97 (0%) stained for keratin, and faint staining for epithelial membrane antigen was seen in 7 of 88 tumors (7.95%). All patients underwent high-dose postoperative fractionated precision conformal radiation therapy with a dose that ranged from 64.2 to 79.6 Cobalt-Gray-equivalents (median, 72.1 Cobalt-Gray-equivalents, given in 38 fractions. The 200 patients had a median follow-up of 63 months (range, 2.1 mos - 18.5 yrs). Tumor control was defined as lack of progression by clinical and radiographic assessment. Based on this definition, there were three local recurrences, and two of these patients died of tumor-related complications. The 5- and 10-year local control rates were 99% and 98% respectively, and the 5- and 10-year disease-specific survival rates were both 99%. In contrast to CSA, the 5- and 10-year survival rates of chordoma have been reported to be approximately 51 % and 35% respectively, and in our institution intensive treatment has resulted in 5- and 10-year progression-free survival rates of 70% and 45% respectively. CSA of the skull base can be distinguished reliably from chordoma, and this distinction is important because skull base CSA has an excellent prognosis when treated with surgery and proton beam irradiation, whereas chordomas have a substantially poorer clinical course despite similar aggressive management</style></abstract><notes><style face="normal" font="default">105550053yv, 7707904IMJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2112</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schulte,R.W.</style></author><author><style face="normal" font="default"> Slater,J.D.</style></author><author><style face="normal" font="default"> Rossi,C.J.,Jr.</style></author><author><style face="normal" font="default"> Slater,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Medicine, Loma Linda University Medical Center (LLUMC), USA. rschulte@prolit.llu.edu</style></auth-address><titles><title><style face="normal" font="default">Value and perspectives of proton radiation therapy for limited stage prostate cancer</style></title><secondary-title><style face="normal" font="default">Strahlentherapie und Onkologie.176.(1):3-8.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Strahlentherapie und Onkologie.176.(1):3-8.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Neoplasm Staging</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prostate</style></keyword><keyword><style face="normal" font="default"> Prostate-Specific Antigen</style></keyword><keyword><style face="normal" font="default"> Prostate-Specific Antigen/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="1" Year="2000">2000/1</year></dates><pub-location><style face="normal" font="default">GERMANY</style></pub-location><isbn><style face="normal" font="default">0179-7158</style></isbn><abstract><style face="normal" font="default">BACKGROUND: This review article will focus on clinical results and limitations of proton beam irradiation. Possible technological, biological and medical perspectives will be addressed. PATIENTS AND METHODS: A total of 911 patients with limited stage prostate cancer were treated with proton beam irradiation at Loma Linda University between 1991 and 1996. Endpoints of this evaluation were biochemically no evidence of disease survival (bNED) as well as acute and late treatment-related toxicity. RESULTS: The bNED survival rate was 82% at 5 years. Among 870 patients evaluable for late toxicity the following late effects were observed: Grade 3/4: 0%, Grade 2 rectal: 3.5% and bladder: 5.4%. CONCLUSIONS: Despite relatively short follow-up times it seems justified to conclude that proton beam irradiation of prostate cancer can improve bNED rates by 10% and decrease Grade 2 late effects by more than 10%. There were no Grade 3 and 4 late effects</style></abstract><notes><style face="normal" font="default">10650829vcm, 8603469IM0 (Protons)EC 3-4-21-77 (Prostate-Specific Antigen)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2130</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Slater,J.D.</style></author><author><style face="normal" font="default"> Rossi,C.J.,Jr.</style></author><author><style face="normal" font="default"> Yonemoto,L.T.</style></author><author><style face="normal" font="default"> Reyes-Molyneux,N.J.</style></author><author><style face="normal" font="default"> Bush,D.A.</style></author><author><style face="normal" font="default"> Antoine,J.E.</style></author><author><style face="normal" font="default"> Miller,D.W.</style></author><author><style face="normal" font="default"> Teichman,S.L.</style></author><author><style face="normal" font="default"> Slater,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Medicine, Loma Linda University Medical Center, California 92354, USA</style></auth-address><titles><title><style face="normal" font="default">Conformal proton therapy for early-stage prostate cancer</style></title><secondary-title><style face="normal" font="default">Urology.53.(5):978.-84.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Urology.53.(5):978.-84.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons</style></keyword><keyword><style face="normal" font="default"> Prostate</style></keyword><keyword><style face="normal" font="default"> Prostate-Specific Antigen</style></keyword><keyword><style face="normal" font="default"> Prostate-Specific Antigen/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Prostatectomy</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/bl [Blood]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="1999">1999/5</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0090-4295</style></isbn><abstract><style face="normal" font="default">OBJECTIVES: To assess the effect of proton radiation on clinical and biochemical outcomes for early prostate cancer. METHODS: Three hundred nineteen patients with T1-T2b prostate cancer and initial prostate-specific antigen (PSA) levels 15.0 ng/mL or less received conformal radiation doses of 74 to 75 cobalt gray equivalent with protons alone or combined with photons. No patient had pre- or post-treatment hormonal therapy until disease progression was documented. Patients were evaluated for biochemical disease-free survival, PSA nadir, and toxicity; the mean and median follow-up period was 43 months. RESULTS: Overall 5-year clinical and biochemical disease-free survival rates were 97% and 88%, respectively. Initial PSA level, stage, and post-treatment PSA nadir were independent prognostic variables for biochemical disease-free survival: a PSA nadir 0.5 ng/mL or less was associated with a 5-year biochemical disease-free survival rate of 98%, versus 88% and 42% for nadirs 0.51 to 1.0 and greater than 1.0 ng/mL, respectively. No severe treatment-related morbidity was seen. CONCLUSIONS: It appears that patients treated with conformal protons have 5-year biochemical disease-free survival rates comparable to those who undergo radical prostatectomy, and display no significant toxicity. A Phase III randomized dose-escalation trial is underway to define the optimum radiation dose for early-stage prostate cancer</style></abstract><notes><style face="normal" font="default">10223493wsy, 0366151IMEC 3-4-21-77 (Prostate-Specific Antigen)Clinical TrialJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2152</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Terahara,A.</style></author><author><style face="normal" font="default"> Niemierko,A.</style></author><author><style face="normal" font="default"> Goitein,M.</style></author><author><style face="normal" font="default"> Finkelstein,D.</style></author><author><style face="normal" font="default"> Hug,E.</style></author><author><style face="normal" font="default"> Liebsch,N.</style></author><author><style face="normal" font="default"> O'Farrell,D.</style></author><author><style face="normal" font="default"> Lyons,S.</style></author><author><style face="normal" font="default"> Munzenrider,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA</style></auth-address><titles><title><style face="normal" font="default">Analysis of the relationship between tumor dose inhomogeneity and local control in patients with skull base chordoma</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.45.(2):351.-8.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.45.(2):351.-8.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Brain</style></keyword><keyword><style face="normal" font="default"> Brain Stem</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Dose-Response Relationship,Radiation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Base</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword></keywords><dates><year Day="1" Month="9" Year="1999">1999/9/1</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: When irradiating a tumor that abuts or displaces any normal structures, the dose constraints to those structures (if lower than the prescribed dose) may cause dose inhomogeneity in the tumor volume at the tumor-critical structure interface. The low-dose region in the tumor volume may be one of the reasons for local failure. The aim of this study is to quantitate the effect of tumor dose inhomogeneity on local control and recurrence-free survival in patients with skull base chordoma. METHODS AND MATERIALS: 132 patients with skull base chordoma were treated with combined photon and proton irradiation between 1978 and 1993. This study reviews 115 patients whose dose-volume data and follow-up data are available. The prescribed doses ranged from 66.6 Cobalt-Gray-Equivalent (CGE) to 79.2 CGE (median of 68.9 CGE). The dose to the optic structures (optic nerves and chiasm), the brain stem surface, and the brain stem center was limited to 60, 64, and 53 CGE, respectively. We used the dose-volume histogram data derived with the three-dimensional treatment planning system to evaluate several dose-volume parameters including the Equivalent Uniform Dose (EUD). We also analyzed several other patient and treatment factors in relation to local control and recurrence-free survival. RESULTS: Local failure developed in 42 of 115 patients, with the actuarial local control rates at 5 and 10 years being 59% and 44%. Gender was a significant predictor for local control with the prognosis in males being significantly better than that in females (P = 0.004, hazard ratio = 2.3). In a Cox univariate analysis, with stratification by gender, the significant predictors for local control (at the probability level of 0.05) were EUD, the target volume, the minimum dose, and the D5cc dose. The prescribed dose, histology, age, the maximum dose, the mean dose, the median dose, the D90% dose, and the overall treatment time were not significant factors. In a Cox multivariate analysis, the models including gender and EUD, or gender and the target volume, or gender and the minimum target dose were significant. The more biologically meaningful of these models is that of gender and EUD. CONCLUSION: This study suggests that the probability of recurrence of skull base chordomas depends on gender, target volume, and the level of target dose inhomogeneity. EUD was shown to be a useful parameter to evaluate dose distribution for the target volume</style></abstract><notes><style face="normal" font="default">10487555g97, 7603616IM0 (Protons)Journal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2185</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wilson,M.W.</style></author><author><style face="normal" font="default"> Hungerford,J.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">St. Bartholomew's Hospital, London, England</style></auth-address><titles><title><style face="normal" font="default">Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma</style></title><secondary-title><style face="normal" font="default">Ophthalmology.106.(8.):1579.-87.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ophthalmology.106.(8.):1579.-87.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Brachytherapy</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> England</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Iodine Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Iodine Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Ruthenium Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Sclera/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword></keywords><dates><year Day="0" Month="8" Year="1999">1999/8</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0161-6420</style></isbn><abstract><style face="normal" font="default">PURPOSE: To compare the efficacy of iodine-125 (125I) and ruthenium-106 (106Ru) episcleral plaque radiation therapy and proton beam radiation therapy (PBRT) in the treatment of choroidal melanoma. DESIGN: A retrospective, nonrandomized comparative study. METHODS: Charts of patients treated with 125I, 106Ru, and PBRT for choroidal melanoma between January 1988 and June 1996 at St. Bartholomew's Hospital and Moorfields Eye Hospitals were reviewed. MAIN OUTCOME MEASURE: Local control of choroidal melanomas after 125I, 106Ru, or PBRT. RESULTS: A total of 597 patients were identified (125I = 190, 106Ru = 140, PBRT = 267). Patients treated with 106Ru had a significantly greater risk of local tumor recurrence than did patients treated with either 125I (P = 0.0133; confidence interval [CI], 1.26-7.02; risk ratio, 2.97) or PBRT (P = 0.0097; CI, 1.30-6.66; risk ratio, 2.94). A stepwise Cox proportional hazard model found maximal basal diameter to be a significant covariate (P = 0.0033). CONCLUSION: Patients treated with 106Ru had a significantly greater risk of local tumor recurrence than did those patients treated with either 125I or PBRT</style></abstract><notes><style face="normal" font="default">10442907oi5, 7802443IM0 (Iodine Radioisotopes)0 (Protons)0 (Ruthenium Radioisotopes)Comparative StudyJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2241</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Al-Mefty,O.</style></author><author><style face="normal" font="default"> Borba,L.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Neurosurgery, University of Arkansas for Medical Sciences, Little Rock, USA</style></auth-address><titles><title><style face="normal" font="default">Skull base chordomas: a management challenge</style></title><secondary-title><style face="normal" font="default">Journal of Neurosurgery.86.(2):182.-9.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Journal of Neurosurgery.86.(2):182.-9.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adenocarcinoma</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Brain Stem/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Chordoma/cl [Classification]</style></keyword><keyword><style face="normal" font="default"> Chordoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Postoperative Complications</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Adjuvant/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Skull Base</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/cl [Classification]</style></keyword><keyword><style face="normal" font="default"> Skull Base Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Temporal Lobe/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Tomography,Emission-Computed,Single-Photon</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="2" Year="1997">1997/2</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0022-3085</style></isbn><abstract><style face="normal" font="default">Because of their critical location, invasive nature, and aggressive recurrence, skull base chordomas are challenging and, at times, frustrating tumors to treat. Both radical surgical removal and high-dose radiation therapy, particularly proton beam therapy, reportedly are effective in tumor control and improve survival rates. The authors posit that these tumors are best treated with radical surgery and proton-photon beam therapy. During the last 5 years, they treated 25 patients (15 females and 10 males) who harbored pathologically diagnosed skull base chordomas. The mean age of the patients was 38.4 years (range 8-61 years). Previous surgery or radiation therapy was performed at other institutions in seven and two patients, respectively. The authors performed 33 surgical procedures on 23 patients. Radical removal (defined as absence of residual tumor on operative inspection and postoperative imaging) was achieved in 10 patients; subtotal resection (defined as resection of > 90% of the tumor) was achieved in 11 patients; and partial resection (defined as resection of &lt; 90% of the tumor) was achieved in two patients. Radical surgical removal included not only the excision of soft-tumor tissue, but also extensive drilling of the adjacent bone. Adjuvant therapy consisted of postoperative combined proton-photon beam therapy (given to 17 patients and planned for one patient) and conventional radiation therapy (two patients); three patients received no adjunct therapy. To date, four patients have died. One patient who had undergone previous surgery and sacrifice of the internal carotid artery died postoperatively from a massive stroke; one patient died from adenocarcinoma of the pancreas without evidence of recurrence; and two patients died at 25 and 39 months of recurrent tumor. Permanent neurological complications included third cranial nerve palsy (one patient) and hemianopsia (one patient); radiation necrosis occurred in three patients. Of the 21 patients followed for more than 3 months after surgery, 16 have had no evidence of recurrence and five (including the two mortalities noted above) have had recurrent tumors (four diagnosed clinically and one radiologically). The mean disease-free interval was 14.4 months. A longer follow-up period will, hopefully, support the early indication that radical surgical removal and postoperative proton-photon beam therapy is an efficacious treatment. The use of skull base approaches based on the tumor classification introduced in this paper is associated with low mortality and morbidity rates</style></abstract><notes><style face="normal" font="default">9010416jd3, 0253357AIM, IMJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2284</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Arimoto,T.</style></author><author><style face="normal" font="default"> Maruhashi,N.</style></author><author><style face="normal" font="default"> Takada,Y.</style></author><author><style face="normal" font="default"> Hayakawa,Y.</style></author><author><style face="normal" font="default"> Inada,T.</style></author><author><style face="normal" font="default"> Kitagawa,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Particle Radiation Medical Science Center, University of Tsukuba, Ibaraki, Japan</style></auth-address><titles><title><style face="normal" font="default">Acute skin reactions observed in fractionated proton irradiation</style></title><secondary-title><style face="normal" font="default">Radiation Medicine.7.(1):23-7.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Radiation Medicine.7.(1):23-7.,</style></abbr-1></periodical><pages end="Feb" start="">-Feb</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Dose-Response Relationship,Radiation</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiodermatitis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Relative Biological Effectiveness</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> X-Rays</style></keyword></keywords><dates><year Day="0" Month="1" Year="1989">1989/1</year></dates><pub-location><style face="normal" font="default">JAPAN</style></pub-location><isbn><style face="normal" font="default">0288-2043</style></isbn><abstract><style face="normal" font="default">Between May 1985 and July 1987, 49 skin reactions of 43 patients treated by proton irradiation were observed at the Particle Radiation Medical Science Center (PARMS), The University of Tsukuba. Taking the peak skin score as an endpoint, the radiobiological effects [relative biological effectiveness (RBE) and time-dose relationships] of the proton beam in multi-fractionated treatments were estimated. Factors influencing the skin dose, such as the prescribed tumor dose, tumor site, and number of applied fields, were also analyzed. The following conclusions regarding acute skin reactions to the clinical use of proton irradiation were obtained: 1) the physical skin-sparing effect of proton irradiation in single-field irradiation, especially in superficial regions, is not large compared with that of high-energy photon irradiation; 2) multidirectional proton irradiation significantly reduced the skin dose and severity of acute reactions; 3) the radiobiological effects of the proton beam, RBE and the time factor, estimated in human skin in multi-fractional treatment were slightly smaller than those of X-rays, i.e., 0.92 and -0.25 +/- 0.09, respectively</style></abstract><notes><style face="normal" font="default">2548232rad, 8412264IM0 (Protons)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2285</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Arimoto,T.</style></author><author><style face="normal" font="default"> Kitagawa,T.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author><author><style face="normal" font="default"> Ohhara,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiology, Hokkaido University, School of Medicine, Sapporo, Japan</style></auth-address><titles><title><style face="normal" font="default">High-energy proton beam radiation therapy for gynecologic malignancies. Potential of proton beam as an alternative to brachytherapy</style></title><secondary-title><style face="normal" font="default">Cancer.68.(1):79.-83.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cancer.68.(1):79.-83.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Brachytherapy</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lymphatic Irradiation</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Uterine Cervical Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Uterine Cervical Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Uterine Cervicitis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Vaginal Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Vaginal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Vaginitis/et [Etiology]</style></keyword></keywords><dates><year Day="1" Month="7" Year="1991">1991/7/1</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0008-543X</style></isbn><abstract><style face="normal" font="default">Fifteen patients with advanced gynecologic malignancies were treated with high-energy proton beam radiation therapy (RT) at the Particle Radiation Medical Science Center (PARMS), Tsukuba University, Japan, from 1983 to 1987. The potential of proton beam RT as an alternative to conventional brachytherapy was evaluated. Except for one local recurrence, 14 of 15 patients were locoregionally controlled for 15 to 57 months. Two-year local control rate and 2-year survival rate were 92.3% and 93.3%, respectively. Two cases of transient, radiation-induced proctitis (neither of which required surgical treatment) were the only complications despite a target dose that exceeded 8000 cGy in most cases. The results suggest that sharply localized, high-dose proton beam RT can produce an antitumor effect equivalent to that of conventional brachytherapy</style></abstract><notes><style face="normal" font="default">19047940374236, clzAIM, IMJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2360</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Benk,V.</style></author><author><style face="normal" font="default"> Liebsch,N.J.</style></author><author><style face="normal" font="default"> Munzenrider,J.E.</style></author><author><style face="normal" font="default"> Efird,J.</style></author><author><style face="normal" font="default"> McManus,P.</style></author><author><style face="normal" font="default"> Suit,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, Massachusetts General Hospital, Boston 02114</style></auth-address><titles><title><style face="normal" font="default">Base of skull and cervical spine chordomas in children treated by high-dose irradiation</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.31.(3):577.-81.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.31.(3):577.-81.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Cervical Vertebrae</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Child,Preschool</style></keyword><keyword><style face="normal" font="default"> Chordoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Skull Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Temporal Lobe</style></keyword></keywords><dates><year Day="1" Month="2" Year="1995">1995/2/1</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To evaluate the outcome of children with base of skull or cervical spine chordomas treated by high dose irradiation. METHODS AND MATERIALS: Eighteen children, 4 to 18 years of age, with base of skull or cervical spine chordomas, received fractionated high-dose postoperative radiation using mixed photon and 160 MeV proton beams. The median tumor dose was 69 Cobalt Gray-equivalent (CGE) with a 1.8 CGE daily fraction. RESULTS: The median follow-up was 72 months. The 5-year actuarial survival was 68% and the 5-year disease-free survival (DFS) was 63%. The only significant prognostic factor was the location: patients with cervical spine chordomas had a worse survival than those with base of skull lesions (p = 0.008). The incidence of treatment-related morbidity was acceptable: two patients developed a growth hormone deficit corrected by hormone replacement, one temporal lobe necrosis, and one fibrosis of the temporalis muscle, improved by surgery. CONCLUSION: Chordomas in children behave similarly to those in adults: children can receive the same high-dose irradiation as adults with acceptable morbidity</style></abstract><notes><style face="normal" font="default">7852123g97, 7603616IMJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2361</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Benk,V.A.</style></author><author><style face="normal" font="default"> Adams,J.A.</style></author><author><style face="normal" font="default"> Shipley,W.U.</style></author><author><style face="normal" font="default"> Urie,M.M.</style></author><author><style face="normal" font="default"> McManus,P.L.</style></author><author><style face="normal" font="default"> Efird,J.T.</style></author><author><style face="normal" font="default"> Willett,C.G.</style></author><author><style face="normal" font="default"> Goitein,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, Harvard Medical School, Boston, MA</style></auth-address><titles><title><style face="normal" font="default">Late rectal bleeding following combined X-ray and proton high dose irradiation for patients with stages T3-T4 prostate carcinoma</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.26.(3):551.-7.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.26.(3):551.-7.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Arm</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Gastrointestinal Hemorrhage/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Gastrointestinal Hemorrhage/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Prostate</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Rectal Diseases/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Rectal Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Rectum</style></keyword><keyword><style face="normal" font="default"> Rectum/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword></keywords><dates><year Day="15" Month="6" Year="1993">1993/6/15</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: Dose escalation for prostate cancer by external beam irradiation is feasible by a 160 MeV perineal proton beam that reduces the volume of rectum irradiated. We correlated the total doses received to portions of the anterior rectum to study the possible relationship of the volume irradiated to the incidence of late rectal toxicity. METHODS: We have randomized 191 patients with stages T3 and T4 prostatic carcinoma to one of two treatment dose arms. These were: 1) 75.6 Cobalt-Gy-equivalent (CGE), 50.4 Gy delivered by 107-25 MV photons followed by 25.2 CGE delivered perineally by protons (Arm 1) or 2) 67.2 CGE delivered by 10-25 MV photons (Arm 2). RESULTS: With a median follow-up of 3.7 years, post-irradiation rectal bleeding (grades 1 and 2 only, none requiring surgery or hospitalization) from telangiectatic rectal mucosal vessels has occurred in 34% of 99 Arm-1 patients and 16% of 92 Arm-2 patients (p = 0.013). Dose-volume histograms (DVHs) for the anterior rectal wall, the posterior rectal wall and the total rectum in 41 patients treated on Arm 1 were calculated from the three dimensional dose distributions. Rectal bleeding has occurred in 14 or 34% of the 41 DVH-analyzed subset of Arm-1 patients. Both the fractional volume of the anterior rectum and the total dose received by fractional volumes of the anterior rectum significantly correlate with the actuarial probability of bleeding. CONCLUSIONS: Clinicians planning dose escalation to men with localized prostate cancer should approve with caution treatment plans raising more than 40% of the anterior rectum to more than 75 CGE without additional effort to protect the rectal mucosa because this late sequela data indicate that more than half of these men will otherwise have rectal bleeding</style></abstract><notes><style face="normal" font="default">8514551g97, 7603616IMClinical TrialJournal ArticleRandomized Controlled TrialResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2364</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bercher,L.</style></author><author><style face="normal" font="default"> Zografos,L.</style></author><author><style face="normal" font="default"> Egger,E.</style></author><author><style face="normal" font="default"> Chamot,L.</style></author><author><style face="normal" font="default"> Uffer,S.</style></author><author><style face="normal" font="default"> Gailloud,C.</style></author><author><style face="normal" font="default"> Ducrey,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinique ophtalmologique universitaire de Lausanne, Hopital Jules Gonin</style></auth-address><titles><title><style face="normal" font="default">[Treatment of exterior extension of choroid melanomas by accelerated proton beams]. [French]</style></title><secondary-title><style face="normal" font="default">Klinische Monatsblatter.fur Augenheilkunde.</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Klinische Monatsblatter.fur Augenheilkunde.</style></abbr-1></periodical><pages end="443" start="440">440-443</pages><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Neoplasm Staging</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Ultrasonography</style></keyword></keywords><dates><year Day="0" Month="5" Year="1992">1992/5</year></dates><pub-location><style face="normal" font="default">GERMANY</style></pub-location><isbn><style face="normal" font="default">0023-2165</style></isbn><abstract><style face="normal" font="default">Among the 934 patients with a choroidal melanoma treated in first intention with an accelerated proton beam since 1984, 41 (4.4%) presented an extrascleral extension, of which 11 were located anteriorly and 30 posteriorly. For these 30 cases, the diagnosis was made by B ultrasonography only when the volume of the extension was important, between 20 and 2280 mm3. The Cox model multi-variant analysis was used to study the statistically significant parameters in the development of an extrascleral extension. It appears that the maximal diameter of the intraocular tumor (p = 0.0012), the localisation of the anterior margin (p = 0.0304) and the age of the patients (p = 0.0097) are statistically meaningful. The 4 years' survival, studied with the Kaplan-Meier curves, is estimated at 60% for the patients with extrascleral extension and at 85% for the patients without. These results are similar to those of literature, whatever treatment is chosen (enucleation and radiotherapy, exenteration)</style></abstract><notes><style face="normal" font="default">1319525kwa, 0014133IM0 (Protons)English AbstractJournal ArticleFrench</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2365</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Berson,A.M.</style></author><author><style face="normal" font="default"> Castro,J.R.</style></author><author><style face="normal" font="default"> Petti,P.</style></author><author><style face="normal" font="default"> Phillips,T.L.</style></author><author><style face="normal" font="default"> Gauger,G.E.</style></author><author><style face="normal" font="default"> Gutin,P.</style></author><author><style face="normal" font="default"> Collier,J.M.</style></author><author><style face="normal" font="default"> Henderson,S.D.</style></author><author><style face="normal" font="default"> Baken,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Medicine/Radiation Biophysics Division, University of California Lawrence Berkeley Laboratory 94720</style></auth-address><titles><title><style face="normal" font="default">Charged particle irradiation of chordoma and chondrosarcoma of the base of skull and cervical spine: the Lawrence Berkeley Laboratory experience</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.15.(3):559.-65.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.15.(3):559.-65.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Actuarial Analysis</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Biophysics</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Cervical Vertebrae</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Skull Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="1988">1988/9</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">Forty-five consecutive patients with chordoma or chondrosarcoma at the base of skull or cervical spine were treated at the University of California Lawrence Berkeley Laboratory (UCLBL) and University of California School of Medicine, San Francisco (UCSF) between November 1977 and October 1986. All patients had undergone a subtotal surgical resection. Twenty-three patients were treated definitively with charged particles, 13 patients were treated with photons and particles, and 9 patients were treated for recurrent disease. Total doses ranged from 36 to 80 Gray equivalent (GyE). Thirty-three patients are alive with a minimum followup of 1 year. The actuarial survival and local control for all patients at 5 years is 62% and 59%, respectively. Patients treated for primary disease had a 78% actuarial local control rate at 2 years, whereas the rate for patients with recurrent disease was 33%. Patients with smaller visible tumor volumes (less than 20 cc) had a significantly better local control rate than patients with larger tumor volumes (80% vs 33% actuarial rate at 5 years). Patients with chondrosarcoma had the highest local control rate, as did patients treated with particles alone. Complications included 3 patients with unilateral visual loss, two patients who became blind, and 4 patients with radiation injury to the brainstem</style></abstract><notes><style face="normal" font="default">3138208g97, 7603616IMJournal ArticleResearch Support, U.S. Gov't, Non-P.H.SResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2467</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Brovkina,A.F.</style></author><author><style face="normal" font="default"> Zarubei,G.D.</style></author></authors></contributors><titles><title><style face="normal" font="default">Ciliochoroidal melanomas treated with a narrow medical proton beam</style></title><secondary-title><style face="normal" font="default">Archives of Ophthalmology.104.(3):402.-4,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Archives of Ophthalmology.104.(3):402.-4,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Cataract/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Ciliary Body</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Glaucoma/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Metastasis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Retinal Detachment/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Retinal Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="0" Month="3" Year="1986">1986/3</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0003-9950</style></isbn><abstract><style face="normal" font="default">We treated 63 patients with intraocular melanomas by means of a narrow medical proton beam. Tumors were irradiated with 2,500 rad at each of four to five sessions, with an interval of one to two days between sessions. The melanomas ranged in diameter from 8 to 20 mm and were from 3.0 to 13.7 mm in thickness. Patients were followed up for three months to seven years. In 11 cases, the tumor was fully resorbed. Complications included radiation cataract, postradiation glaucoma, radiation retinopathy, and exudative retinal detachment. In 12 cases, enucleation was performed because tumor growth persisted. Four patients died during follow-up period because of metastasis. The eye was preserved in 47 cases</style></abstract><notes><style face="normal" font="default">30066487706534, 830AIM, IM0 (Protons)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2504</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Castro,J.R.</style></author><author><style face="normal" font="default"> Saunders,W.M.</style></author><author><style face="normal" font="default"> Quivey,J.M.</style></author><author><style face="normal" font="default"> Chen,G.T.</style></author><author><style face="normal" font="default"> Collier,J.M.</style></author><author><style face="normal" font="default"> Woodruff,K.H.</style></author><author><style face="normal" font="default"> Lyman,J.T.</style></author><author><style face="normal" font="default"> Twomey,P.</style></author><author><style face="normal" font="default"> Frey,C.</style></author><author><style face="normal" font="default"> Phillips,T.L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Clinical problems in radiotherapy of carcinoma of the pancreas</style></title><secondary-title><style face="normal" font="default">American Journal of Clinical Oncology.5(6.):579.-87.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">American Journal of Clinical Oncology.5(6.):579.-87.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adenocarcinoma/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Adenocarcinoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Alpha Particles</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default"> Fluorouracil/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Helium/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Nuclear Medicine</style></keyword><keyword><style face="normal" font="default"> Pancreatic Neoplasms/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Pancreatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Random Allocation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="12" Year="1982">1982/12</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0277-3732</style></isbn><abstract><style face="normal" font="default">Since 1975, 94 patients with localized unresectable carcinoma of the pancreas have been irradiated using helium and heavier particles at the University of California Lawrence Berkeley Laboratory. Despite surgical exploration and an extensive diagnostic workup including radiological, nuclear medicine, and computer-assisted tomographic studies, many patients proved to have occult liver metastases manifested within 9 months post treatment. In addition, local and regional control of the primary neoplasm (approximately 20%) has been difficult to obtain even with doses of 6000 equivalent rad in 7 1/2 weeks. Gastric and biliary obstruction have required surgical bypass procedures since irradiation has not been successful in relieving obstructive symptoms. Evidence of gastrointestinal injury has been present in postradiation therapy in approximately 10% of patients, a figure which might be higher if more patients had a longer survival (average 10 months). Some patients require pancreatic enzyme supplementation because of pancreatic deficiency either secondary to tumor or treatment. Further improvement in local control and survival requires better diagnostic methods for evaluation of local and metastatic spread, improved therapy for local and regional disease, as well as therapy directed at occult liver metastases that are frequently present</style></abstract><notes><style face="normal" font="default">67620863ez, 8207754IM51-21-8 (Fluorouracil)7440-59-7 (Helium)Clinical TrialJournal ArticleResearch Support, U.S. Gov't, Non-P.H.SResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2505</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Castro,J.R.</style></author><author><style face="normal" font="default"> Saunders,W.M.</style></author><author><style face="normal" font="default"> Tobias,C.A.</style></author><author><style face="normal" font="default"> Chen,G.T.</style></author><author><style face="normal" font="default"> Curtis,S.</style></author><author><style face="normal" font="default"> Lyman,J.T.</style></author><author><style face="normal" font="default"> Collier,J.M.</style></author><author><style face="normal" font="default"> Pitluck,S.</style></author><author><style face="normal" font="default"> Woodruff,K.A.</style></author><author><style face="normal" font="default"> Blakely,E.A.</style></author><author><style face="normal" font="default"> Tenforde,T.</style></author><author><style face="normal" font="default"> Char,D.</style></author><author><style face="normal" font="default"> Phillips,T.L.</style></author><author><style face="normal" font="default"> Alpen,E.L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Treatment of cancer with heavy charged particles</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.8.(12.):2191.-8.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.8.(12.):2191.-8.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Argon</style></keyword><keyword><style face="normal" font="default"> Brain</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Squamous Cell/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default"> Elementary Particles</style></keyword><keyword><style face="normal" font="default"> Esophageal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Esophagus</style></keyword><keyword><style face="normal" font="default"> Eye Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Ions</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Neon</style></keyword><keyword><style face="normal" font="default"> Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Pancreatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Silicon</style></keyword><keyword><style face="normal" font="default"> Skull Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Stomach</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="12" Year="1982">1982/12</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">A clinical radiotherapeutic trial using heavy charged particles in the treatment of human cancers has accrued over 400 patients since 1975, 378 of whom were treated with particles and 28 with low LET photons as control patients. Heavy charged particle radiotherapy offers the potential advantages of improved dose localization and/or enhanced biologic effect, depending on particle selected for treatment. Target sites have included selected head and neck tumors, ocular melanomata, malignant gliomata of the brain, carcinoma of the esophagus, carcinoma of the stomach, carcinoma of the pancreas, selected juxtaspinal tumors and other locally advanced, unresectable tumors. A Phase III prospective clinical trial has been started in carcinoma of the pancreas using helium ions. Phase I-II studies are underway with heavier particles such as carbon, neon and argon ions in order to prepare for prospective Phase III trials. Silicon ions are also under consideration for clinical trial. These studies are supported by the United States Department of Energy and National Institutes of Health</style></abstract><notes><style face="normal" font="default">6819279g97, 7603616IM, S0 (Ions)7440-59-7 (Helium)Clinical TrialJournal ArticleResearch Support, U.S. Gov't, Non-P.H.SResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2507</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Castro,J.R.</style></author><author><style face="normal" font="default"> Chen,G.T.</style></author><author><style face="normal" font="default"> Pitluck,S.</style></author><author><style face="normal" font="default"> Cartigny,A.</style></author><author><style face="normal" font="default"> Phillips,T.L.</style></author><author><style face="normal" font="default"> Saunders,W.M.</style></author><author><style face="normal" font="default"> Collier,J.M.</style></author><author><style face="normal" font="default"> Woodruff,K.H.</style></author><author><style face="normal" font="default"> Friedman,M.</style></author><author><style face="normal" font="default"> ustin-Seymour,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Helium charged-particle radiotherapy of locally advanced carcinoma of the esophagus, stomach, and biliary tract</style></title><secondary-title><style face="normal" font="default">American Journal of Clinical Oncology.6.(6.):629.-37.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">American Journal of Clinical Oncology.6.(6.):629.-37.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adenocarcinoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Biliary Tract Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Squamous Cell/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Esophageal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Esophagus</style></keyword><keyword><style face="normal" font="default"> Evaluation Studies as Topic</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Helium/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Neon</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation Tolerance</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Silicon</style></keyword><keyword><style face="normal" font="default"> Stomach</style></keyword><keyword><style face="normal" font="default"> Stomach Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="0" Month="12" Year="1983">1983/12</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0277-3732</style></isbn><abstract><style face="normal" font="default">Sixty-five patients with squamous carcinoma of the esophagus (32 patients), carcinoma of the stomach (18 patients) and carcinoma of the biliary tract (15 patients) received from 6000 to 7000 equivalent rad (60-70 Gray-equivalents) of helium radiotherapy at 2.0 GyE per fraction, four fractions per day, using multiportal, spread-out Bragg peak therapy. All patients had locally advanced disease without evidence of distant metastases. Partial compensation for tissue inhomogeneities was accomplished. Although palliation of symptoms and regression of tumor was commonly seen, local failure occurred in most patients (77%). The median survival was 8 months. It does not appear that an increase in tumor dose relative to normal tissues can be achieved that would be high enough to increase locoregional control rates over historical control rates with low-LET irradiation. Further studies will be carried out with heavier particles such as neon or silicon in hopes of achieving greater biological effect on these difficult-to-control tumors</style></abstract><notes><style face="normal" font="default">66378753ez, 8207754IM7440-59-7 (Helium)Journal ArticleResearch Support, U.S. Gov't, Non-P.H.SResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2511</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Castro,J.R.</style></author><author><style face="normal" font="default"> Reimers,M.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, University of California, San Francisco School of Medicine</style></auth-address><titles><title><style face="normal" font="default">Charged particle radiotherapy of selected tumors in the head and neck</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.14(4):711.-20.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.14(4):711.-20.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> Head and Neck Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Head and Neck Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Ions</style></keyword><keyword><style face="normal" font="default"> Kinetics</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Neon</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Silicon</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Skull Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="4" Year="1988">1988/4</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">For selected tumors in some sites in the head and neck region, charged particles such as protons or helium, carbon, neon and silicon ions provide improved dose distributions, higher tumor doses, and an increased chance of local control and prolonged survival. In tumors with "radioresistant" histologies, slow growth kinetics and/or hypoxic cells, the high-LET component of neon or silicon ions may also offer and added potential for increased effect on tumors. Sixty-seven (67) evaluable patients with tumors in the head and neck region having a histology other than squamous carcinoma received partial or full treatment with charged particles at the University of California Lawrence Berkeley Laboratory. The tumor sites included base of skull or cervical spine, salivary glands, paranasal sinuses, nasopharynx, and miscellaneous sites such as lacrimal gland, soft tissues of the neck, or thyroid. Follow-up ranges from 1-9 years with a mean of 36 months and a median survival (Kaplan-Meier technique) of 50 months. The actuarial local control rate is 60% at 24 months post-treatment. Thirty-one (31) patients with squamous carcinoma of various sites in the head and neck have also been treated using charged particle irradiation; local control was lower (11 of 31 pts) and survival shorter (mean: 9 months) in this group of patients with advanced squamous carcinoma</style></abstract><notes><style face="normal" font="default">3350726g97, 7603616IMCase ReportsJournal ArticleResearch Support, U.S. Gov't, Non-P.H.SResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2512</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Castro,J.R.</style></author><author><style face="normal" font="default"> Collier,J.M.</style></author><author><style face="normal" font="default"> Petti,P.L.</style></author><author><style face="normal" font="default"> Nowakowski,V.</style></author><author><style face="normal" font="default"> Chen,G.T.</style></author><author><style face="normal" font="default"> Lyman,J.T.</style></author><author><style face="normal" font="default"> Linstadt,D.</style></author><author><style face="normal" font="default"> Gauger,G.</style></author><author><style face="normal" font="default"> Gutin,P.</style></author><author><style face="normal" font="default"> Decker,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, University of California, San Francisco School of Medicine</style></auth-address><titles><title><style face="normal" font="default">Charged particle radiotherapy for lesions encircling the brain stem or spinal cord</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.17(3):477.-84.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.17(3):477.-84.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Brain</style></keyword><keyword><style face="normal" font="default"> Brain Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Brain Stem</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Immobilization</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Ions</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Particle Accelerators</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Spinal Cord Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Uncertainty</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="1989">1989/9</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">Since 1981, a specialized technique has been under development at the University of California Lawrence Berkeley Laboratory for charged particle irradiation of tumors partially or completely encircling the brain stem or spinal cord. By dividing the target volume into two or more portions and using a combination of beams, a reasonably homogeneous irradiation of the target volume can be obtained which protects critical CNS structures from over-irradiation. This technique requires knowledge of the physical and biological effects of charged particles, precise, reproducible patient immobilization, careful treatment planning based upon Metrizamide contrast CT and/or MRI scanning, compensation for tissue inhomogeneities, and accurate, verifiable radiation delivery. Uncertainties in the dose distribution must be taken into account when prescribing treatment. We have used this technique in 47 patients with a variety of tumors abutting the brain stem and spinal cord, including chordoma, chondrosarcoma, meningioma, osteosarcoma and metastatic tumors. The results have shown a significant local control rate (62%) and the incidence of serious complications has been acceptable (13%). The median follow-up is 20 months with a range of 6-90 months. We conclude that charged particles can be safely and effectively used to irradiate lesions encircling the brain stem or spinal cord to doses higher than can be achieved with low-LET irradiation</style></abstract><notes><style face="normal" font="default">2506156g97, 7603616IM, S0 (Ions)Journal ArticleResearch Support, U.S. Gov't, Non-P.H.SResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2514</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Castro,J.R.</style></author><author><style face="normal" font="default"> Linstadt,D.E.</style></author><author><style face="normal" font="default"> Bahary,J.P.</style></author><author><style face="normal" font="default"> Petti,P.L.</style></author><author><style face="normal" font="default"> Daftari,I.</style></author><author><style face="normal" font="default"> Collier,J.M.</style></author><author><style face="normal" font="default"> Gutin,P.H.</style></author><author><style face="normal" font="default"> Gauger,G.</style></author><author><style face="normal" font="default"> Phillips,T.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of California Lawrence Berkeley Laboratory, Berkeley 94720</style></auth-address><titles><title><style face="normal" font="default">Experience in charged particle irradiation of tumors of the skull base: 1977-1992.[see comment]. [Review] [35 refs]</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.29.(4):647.-55.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.29.(4):647.-55.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adenocarcinoma</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Head and Neck Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Ions</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Neon</style></keyword><keyword><style face="normal" font="default"> Neoplasms</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Sarcoma</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Base</style></keyword><keyword><style face="normal" font="default"> Skull Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="1" Month="7" Year="1994">1994/7/1</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To review the experience at University of California Lawrence Berkeley Laboratory in using charged particles to irradiate primary neoplasms of the skull base and those extending to the skull base from the nasopharynx and paranasal sinuses. METHODS AND MATERIALS: During the period from 1977 to 1992, 223 patients were irradiated with charged particles at the Lawrence Berkeley Laboratory for tumors either arising in or extending to the skull base, of whom 48 (22%) had recurrent lesions, either post previous surgery or radiotherapy. One hundred twenty-six patients had lesions arising in the cranial base, mostly chordoma (53), chondrosarcoma (27), paraclival meningioma (27) with 19 patients having other histologies such as osteosarcoma or neurofibrosarcoma. There were also 31 patients with primary or recurrent squamous carcinoma of the nasopharynx extending to the skull base, 44 patients with major or minor salivary gland tumors, mostly adenocarcinoma, and 22 patients with squamous carcinoma of the paranasal sinuses, all with cranial base extension. RESULTS: Local control and survival appeared improved in tumors arising in the skull base, following the ability with charged particles to deliver high doses (mean of 65 Gy-equivalent) with relative sparing of the adjacent normal tissues. The Kaplan-Meier 5-year local control was 85% for meningioma, 78% for chondrosarcoma, 63% for chordoma and 58% for other sarcoma. Follow-up ranged from 4-191 months with a median of 51 months. CONCLUSION: Charged particle radiotherapy is highly effective in controlling cranial base lesions which have have been partially resected. Better tumor localization with CT and MRI, improved 3-D treatment planning and beam delivery techniques have continued to reduce the level of serious complications and increase local control and survival. [References: 35]</style></abstract><notes><style face="normal" font="default">8040010g97, 7603616IM0 (Ions)7440-01-9 (Neon)7440-59-7 (Helium)Journal ArticleResearch Support, U.S. Gov't, Non-P.H.SResearch Support, U.S. Gov't, P.H.SReviewEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2516</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Castro,J.R.</style></author><author><style face="normal" font="default"> Char,D.H.</style></author><author><style face="normal" font="default"> Petti,P.L.</style></author><author><style face="normal" font="default"> Daftari,I.K.</style></author><author><style face="normal" font="default"> Quivey,J.M.</style></author><author><style face="normal" font="default"> Singh,R.P.</style></author><author><style face="normal" font="default"> Blakely,E.A.</style></author><author><style face="normal" font="default"> Phillips,T.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">The University of California, San Francisco, Medical Center, USA</style></auth-address><titles><title><style face="normal" font="default">15 years experience with helium ion radiotherapy for uveal melanoma</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.39.(5):989.-96.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.39.(5):989.-96.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Ciliary Body</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eye Enucleation</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Helium/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Optic Nerve</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Vision</style></keyword><keyword><style face="normal" font="default"> Vision Disorders/et [Etiology]</style></keyword></keywords><dates><year Day="1" Month="12" Year="1997">1997/12/1</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To review the long-term experience of helium ion therapy as a therapeutic alternative to enucleation for uveal melanoma, particularly with respect to survival, local control, and morbidity. METHODS AND MATERIALS: 347 patients with uveal melanoma were treated with helium ion RT from 1978-1992. A nonrandomized dose-searching study was undertaken, with doses progressively reduced from 80 GyE in five fractions to 48 GyE in four fractions, given in 3-15 days, mean of 7 days. RESULTS: Local control was achieved in 96% of patients, with no difference in the rate of local control being seen at 80, 70, 60, or 50 GyE in five fractions. At the lowest dose level of 48 GyE in four fractions, the local control rate fell to 87%. Fifteen of 347 patients (4%) had local regrowth in the eye requiring enucleation (12 patients), laser (1 patient) or reirradiation (2 patients). The time of appearance of local regrowth ranged from 4 months to 5 years posttreatment, with 85% occurring within 3 years. Of the 347 patients, 208 are alive as of May 1, 1997. The median follow up of all patients is 8.5 years, range 1-17 years. Kaplan-Maier (K-M) survival is 80% at 5 years, 76% at 10 years, and 72% at 15 years posttreatment. Patients with tumors not involving the ciliary body have a 15-year K-M survival of 80%. The results for patients whose tumors involved the ciliary body are poor, with a 15-year K-M survival of 43%. Seventy-five percent of patients with tumors at least 3.0 mm from the fovea and optic nerve, and initial ultrasound height less than 6.0 mm, retained vision of 20/200 or better posttreatment. Patients with tumors larger than 6 mm in thickness, or with tumors lying close to the optic nerve or fovea, have a reduced chance of retaining useful vision. The enucleation rate is 19%, 3% for local failure and 16% because of complications of the helium RT, particularly neovascular glaucoma, which occurred in 35% of patients. CONCLUSIONS: Local control and retention of the eye are excellent. Complications of therapy reduce vision and eye preservation. Twenty-four percent of patients manifested distant metastases 6 to 146 months posttreatment, mean of 43 months, median of 36 months. Late-appearing distant metastases do not appear to be caused by persistent tumor in the eye. The risk of metastases is high for patients with tumors greater than 7 mm in initial ultrasound height (37%), anterior tumors involving the ciliary body (47%), and in those with local failure (53%). Patients with tumors not involving the ciliary body and initial dimensions less than 10 mm had only an 8% chance of death from melanoma. A search for effective adjuvant therapy is needed for patients at high risk of metastases (large tumors, ciliary body involved, local regrowth in eye)</style></abstract><notes><style face="normal" font="default">9392536g97, 7603616IM, S7440-59-7 (Helium)Journal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, Non-P.H.SResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2517</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Castro,J.R.</style></author><author><style face="normal" font="default"> Phillips,T.L.</style></author><author><style face="normal" font="default"> Prados,M.</style></author><author><style face="normal" font="default"> Gutin,P.</style></author><author><style face="normal" font="default"> Larson,D.A.</style></author><author><style face="normal" font="default"> Petti,P.L.</style></author><author><style face="normal" font="default"> Daftari,I.K.</style></author><author><style face="normal" font="default"> Collier,J.M.</style></author><author><style face="normal" font="default"> Lillis-Hearne,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, University of California, Medical Center, San Francisco, USA</style></auth-address><titles><title><style face="normal" font="default">Neon heavy charged particle radiotherapy of glioblastoma of the brain</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.38.(2):257.-61.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.38.(2):257.-61.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Arm</style></keyword><keyword><style face="normal" font="default"> Brain</style></keyword><keyword><style face="normal" font="default"> Brain Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Brain Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Cause of Death</style></keyword><keyword><style face="normal" font="default"> Energy Transfer</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glioblastoma</style></keyword><keyword><style face="normal" font="default"> Glioblastoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Glioblastoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Linear Energy Transfer</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neon</style></keyword><keyword><style face="normal" font="default"> Neon/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Neutron Capture Therapy</style></keyword><keyword><style face="normal" font="default"> Neutrons</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="1" Month="5" Year="1997">1997/5/1</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: High-linear energy transfer (LET) radiation beams have potential applications in the treatment of glioblastoma, but have not yet demonstrated significant improvement in results. However, some patients have had local control of glioblastoma with high-LET irradiations such as neutrons and heavy charged particles. METHODS AND MATERIALS: In this collaborative study, 15 patients were entered into a randomized protocol comparing two dose levels of 20 and 25 Gy in 4 weeks of neon ion irradiation. This trial was intended to determine the optimal neon dose in terms of survival and effects of radiation. RESULTS: Fourteen patients were evaluable with no significant differences in median survival (13 and 14 months; p = NS) or median time to failure (7 and 9 months; p = NS) between the two dose arms. Three patients died of nontumor-related causes, of whom one (who died 19 months posttreatment) had autopsy confirmation of no tumor on pathological exam. The other two patients had stable magnetic resonance imaging scans at 6 and 22 months posttreatment. CONCLUSION: Although the results did not demonstrate the optimal high-LET dose level, there is an intriguing effect in that two patients had control of glioblastoma until death at 19 and 22 months. This suggests that better conformation of the high-LET dose to the tumor with neutron capture therapy or dynamic conformal heavy charged particle therapy might control glioblastoma while minimizing brain damage from radiation</style></abstract><notes><style face="normal" font="default">9226311g97, 7603616IM, S7440-01-9 (Neon)Clinical TrialJournal ArticleRandomized Controlled TrialResearch Support, U.S. Gov't, Non-P.H.SResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2529</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Char,D.H.</style></author><author><style face="normal" font="default"> Castro,J.R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Helium ion therapy for choroidal melanoma</style></title><secondary-title><style face="normal" font="default">Archives of Ophthalmology.100.(6.):935.-8.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Archives of Ophthalmology.100.(6.):935.-8.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Helium/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Ions</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Ultrasonography</style></keyword></keywords><dates><year Day="0" Month="6" Year="1982">1982/6</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0003-9950</style></isbn><abstract><style face="normal" font="default">Forty patients with choroidal melanomas received radiation therapy with helium ion-charged particles. Thirty-six of 30 patients either remained stable or demonstrated tumor shrinkage. Seventeen of 18 patients followed up for at least one year after therapy demonstrated tumor regression, with a mean tumor shrinkage of approximately 40%. The most effective method of choroidal melanoma management is unclear. Charged-particle external-beam irradiation may be more applicable and have less ocular morbidity than either radioactive plaques or photocoagulation</style></abstract><notes><style face="normal" font="default">70926317706534, 830AIM, IM0 (Ions)7440-59-7 (Helium)Journal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2530</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Char,D.H.</style></author><author><style face="normal" font="default"> Saunders,W.</style></author><author><style face="normal" font="default"> Castro,J.R.</style></author><author><style face="normal" font="default"> Quivey,J.M.</style></author><author><style face="normal" font="default"> Irvine,A.R.</style></author><author><style face="normal" font="default"> Stone,R.D.</style></author><author><style face="normal" font="default"> Crawford,J.B.</style></author><author><style face="normal" font="default"> Barricks,M.</style></author><author><style face="normal" font="default"> Lonn,L.I.</style></author><author><style face="normal" font="default"> Hilton,G.F.</style></author></authors></contributors><titles><title><style face="normal" font="default">Helium ion therapy for choroidal melanoma</style></title><secondary-title><style face="normal" font="default">Ophthalmology.90.(10):1219.-25.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ophthalmology.90.(10):1219.-25.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Eye/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Helium/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation,Ionizing/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword></keywords><dates><year Day="0" Month="10" Year="1983">1983/10</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0161-6420</style></isbn><abstract><style face="normal" font="default">Eighty-two patients with choroidal melanomas were treated with helium ion charged particle irradiation. Seventy-eight of 82 patients have either remained stable or demonstrated tumor shrinkage. Forty-five of 46 patients followed for at least 1 year after therapy have demonstrated tumor regression with a mean tumor shrinkage of approximately 31%. No tumor-related mortality has been observed. The most effective method of choroidal melanoma management is unclear. Charged particle external beam irradiation may be more applicable and have less ocular morbidity than either radioactive plaques or photocoagulation</style></abstract><notes><style face="normal" font="default">6657197oi5, 7802443IM7440-59-7 (Helium)Journal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, Non-P.H.SResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2532</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Char,D.H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Radiation therapy for uveal melanomas involving the ciliary body</style></title><secondary-title><style face="normal" font="default">Transactions of the Ophthalmological Societies of the United Kingdom.105.( Pt.2):252.-6.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Transactions of the Ophthalmological Societies of the United Kingdom.105.( Pt.2):252.-6.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Brachytherapy</style></keyword><keyword><style face="normal" font="default"> Ciliary Body</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Neoplasm Metastasis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword></keywords><dates><year Day="0" Month="0" Year="1986">1986</year></dates><pub-location><style face="normal" font="default">ENGLAND</style></pub-location><isbn><style face="normal" font="default">0078-5334</style></isbn><abstract><style face="normal" font="default">Thirty-four patients with medium (2) or large (32) uveal melanomas which involved the ciliary body (ciliary-choroidal, ciliary, and iris-ciliary) were treated with helium ion (29) or I-125 brachytherapy (5). Thirty-one of 34 eyes were retained after treatment. Most melanomas were too large for surgical removal with retention of the eye. Eyes containing very large tumours often had poor visual acuity after treatment</style></abstract><notes><style face="normal" font="default">3467500wa1, 0200570IMJournal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2534</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Char,D.H.</style></author><author><style face="normal" font="default"> Castro,J.R.</style></author><author><style face="normal" font="default"> Quivey,J.M.</style></author><author><style face="normal" font="default"> Phillips,T.L.</style></author><author><style face="normal" font="default"> Irvine,A.R.</style></author><author><style face="normal" font="default"> Stone,R.D.</style></author><author><style face="normal" font="default"> Kroll,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophthalmology, University of California, San Francisco 94143</style></auth-address><titles><title><style face="normal" font="default">Uveal melanoma radiation. 125I brachytherapy versus helium ion irradiation</style></title><secondary-title><style face="normal" font="default">Ophthalmology.96.(12.):1708.-15.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ophthalmology.96.(12.):1708.-15.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Brachytherapy</style></keyword><keyword><style face="normal" font="default"> Brachytherapy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Helium/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Helium/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Iodine Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Iodine Radioisotopes/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Iodine Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Ions</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="0" Month="12" Year="1989">1989/12</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0161-6420</style></isbn><abstract><style face="normal" font="default">The optimum radiation therapy for uveal melanoma is uncertain. Both helium ion irradiation and 125I brachytherapy have been used to treat this neoplasm. This investigation analyzed the control and complication rates of uveal melanomas treated with helium ions of 125I plaques. In both a retrospective and a prospective dynamically balanced study, the control rates appeared to be similar. There were more posterior segment complications after 125I plaques and more anterior segment complications, including neovascular glaucoma, after helium ion irradiation. The follow-up period is too short to draw definitive conclusions on the radiation complications. Overall, approximately 89% of eyes were retained and less than 4% of treated eyes were removed because of failure to control the tumor</style></abstract><notes><style face="normal" font="default">2695875oi5, 7802443IM0 (Iodine Radioisotopes)7440-59-7 (Helium)Clinical TrialComparative StudyJournal ArticleRandomized Controlled TrialResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2536</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Char,D.H.</style></author><author><style face="normal" font="default"> Castro,J.R.</style></author><author><style face="normal" font="default"> Kroll,S.M.</style></author><author><style face="normal" font="default"> Irvine,A.R.</style></author><author><style face="normal" font="default"> Quivey,J.M.</style></author><author><style face="normal" font="default"> Stone,R.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophthalmology, University of California, San Francisco 94143</style></auth-address><titles><title><style face="normal" font="default">Five-year follow-up of helium ion therapy for uveal melanoma</style></title><secondary-title><style face="normal" font="default">Archives of Ophthalmology.108.(2):209.-14,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Archives of Ophthalmology.108.(2):209.-14,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Cataract/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Evaluation Studies as Topic</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eye Enucleation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Glaucoma,Neovascular/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Helium/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Melanoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Optic Nerve</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword></keywords><dates><year Day="0" Month="2" Year="1990">1990/2</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0003-9950</style></isbn><abstract><style face="normal" font="default">One hundred sixty-four patients with uveal melanoma were treated with helium ion irradiation prior to May 1984, and the data were analyzed in June 1989. Most uveal melanomas were large, with a mean tumor thickness of 6.5 mm; approximately 60% of the patients had tumors that extended anterior to the equator. A complete follow-up was obtained for all patients. One hundred twelve patients were alive at the time of this report; 18% of the patients developed clinical and laboratory evidence of metastases and eventually died of widespread tumor. Eighty-four percent of eyes were retained. Data were analyzed with a number of parametric and nonparametric techniques. Larger tumors and those located in close proximity to the optic nerve and fovea had a higher incidence of most complications, especially visual loss</style></abstract><notes><style face="normal" font="default">23021037706534, 830AIM, IM0 (Radioisotopes)7440-59-7 (Helium)Journal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2537</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Char,D.H.</style></author><author><style face="normal" font="default"> Quivey,J.M.</style></author><author><style face="normal" font="default"> Castro,J.R.</style></author><author><style face="normal" font="default"> Kroll,S.</style></author><author><style face="normal" font="default"> Phillips,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophthalmology, University of California, San Francisco 94143</style></auth-address><titles><title><style face="normal" font="default">Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. A prospective, randomized, dynamically balanced trial</style></title><secondary-title><style face="normal" font="default">Ophthalmology.100.(10):1547.-54.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ophthalmology.100.(10):1547.-54.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Brachytherapy</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eye Enucleation</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Helium/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Helium/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Iodine Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Iodine Radioisotopes/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Iodine Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Ions</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasms,Second Primary/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Postoperative Complications</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="0" Month="10" Year="1993">1993/10</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0161-6420</style></isbn><abstract><style face="normal" font="default">PURPOSE: Optimal radiation therapy for uveal melanoma is uncertain, and the relative efficacies of radioactive plaques and charged particles are unclear. METHODS: The authors prospectively studied helium-ion irradiation and iodine 125 (125I) brachytherapy in a randomized, dynamically balanced trial. Of the 184 patients who met the eligibility criteria, 86 were treated with helium ions and 98 with 125I brachytherapy. RESULTS: No patients with uveal melanoma had a history of systemic malignancy. Tumors were less than 15 mm in maximum diameter and less than 10 mm in thickness. A minimum tumor dose of 70 GyE was delivered to the tumor apex. There was a significantly higher local recurrence rate after 125I brachytherapy than after helium-ion irradiation. Enucleations occurred more frequently after brachytherapy (relative risk = 1.99; 95% confidence interval, 0.78-5.78). More anterior segment complications occurred after helium-ion irradiation. To date, there has been no measurable impact on survival. CONCLUSIONS: Most uveal melanomas can be managed with radiation with retention of the eye. There was better tumor control with helium-ion irradiation; however, there were more anterior segment complications</style></abstract><notes><style face="normal" font="default">8414414oi5, 7802443IM0 (Iodine Radioisotopes)7440-59-7 (Helium)Clinical TrialComparative StudyJournal ArticleRandomized Controlled TrialResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, Non-P.H.SResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2538</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Char,D.H.</style></author><author><style face="normal" font="default"> Kroll,S.</style></author><author><style face="normal" font="default"> Quivey,J.M.</style></author><author><style face="normal" font="default"> Castro,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophthalmology, University of California, San Francisco, CA 94143, USA</style></auth-address><titles><title><style face="normal" font="default">Long term visual outcome of radiated uveal melanomas in eyes eligible for randomisation to enucleation versus brachytherapy</style></title><secondary-title><style face="normal" font="default">British Journal of Ophthalmology.80.(2):117.-24.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">British Journal of Ophthalmology.80.(2):117.-24.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Brachytherapy</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Ciliary Body</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eye Enucleation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Helium/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Iodine Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Iodine Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Ions</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Optic Nerve</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation,Ionizing</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Vision</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword><keyword><style face="normal" font="default"> Visual Acuity/re [Radiation Effects]</style></keyword></keywords><dates><year Day="0" Month="2" Year="1996">1996/2</year></dates><pub-location><style face="normal" font="default">ENGLAND</style></pub-location><isbn><style face="normal" font="default">0007-1161</style></isbn><abstract><style face="normal" font="default">AIMS: To determine the long term visual outcome of patients who were eligible for randomisation to enucleation versus brachytherapy in a US collaborative ocular melanoma study (COMS) but were treated with either helium ion or 125I radioactive plaque therapy. METHOD: A retrospective analysis was performed of 426 ciliochoroidal melanomas that met COMS inclusion criteria for randomisation to enucleation versus radioactive plaque but were treated with either helium ions or 125I brachytherapy. RESULTS: At 3 years 36.0% of eyes had 6/12 or better visual acuity. The length of visual retention was most dependent on tumour thickness, tumour location with respect to the optic nerve, fovea, or ciliary body, and patient age. In addition to these factors, the retention of 6/12 visual acuity and the time to 6/120 visual acuity were dependent on the preoperative visual acuity. The risk of visual loss was greatest immediately after treatment and decreased with time. The 5 year actuarial metastatic rate was approximately 13%. Patients at the greatest risk of post-radiation visual loss had significantly greater risk of tumour related mortality. CONCLUSIONS: Some patients who would have been eligible for randomisation to either enucleation or radioactive plaque therapy can be irradiated with retention of excellent vision</style></abstract><notes><style face="normal" font="default">8814740azk, 0421041IM0 (Iodine Radioisotopes)7440-59-7 (Helium)Clinical TrialComparative StudyJournal ArticleRandomized Controlled TrialResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2539</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Char,D.H.</style></author><author><style face="normal" font="default"> Kroll,S.M.</style></author><author><style face="normal" font="default"> Castro,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophthalmology, University of California, San Francisco, School of Medicine, USA</style></auth-address><titles><title><style face="normal" font="default">Long-term follow-up after uveal melanoma charged particle therapy</style></title><secondary-title><style face="normal" font="default">Transactions of the American Ophthalmological Society.95.:171.-87.; discussion.187.-91.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Transactions of the American Ophthalmological Society.95.:171.-87.; discussion.187.-91.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eye Enucleation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Melanoma/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Metastasis</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local</style></keyword><keyword><style face="normal" font="default"> Optic Nerve</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Vision</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword><keyword><style face="normal" font="default"> Visual Acuity/ph [Physiology]</style></keyword></keywords><dates><year Day="0" Month="0" Year="1997">1997</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0065-9533</style></isbn><abstract><style face="normal" font="default">PURPOSE: To examine the results of helium ion irradiation in 218 uveal melanoma patients treated more than 10 years ago. METHODS: Retrospective review of 218 eyes treated with helium ion radiation for uveal melanoma between 1978 and 1984. Several parametric and non-parametric statistical analysis techniques were used. RESULTS: In 218 eyes treated with helium ion radiation for uveal melanoma, the mean dimension for largest basal diameter was 11.9 mm (range 5 mm to 24 mm). The mean tumor thickness was 6.7 mm (range 1.3 mm to 14.2 mm). Following helium ion radiation 208 (95.4%) of 218 eyes had local tumor control. At 10 years after radiation 46 (22.4%) of 218 eyes were enucleated; the majority (37 of 46) of enucleations were due to anterior ocular segment complications. At 10 years after radiation 102 (46.8%) of the 218 patients were dead; half had non-tumor related deaths and 51 died from metastatic melanoma. Best corrected visual acuity after radiation was > or = 20/40 in 21 of 93 eyes of patients that were alive and retained their eyes 10 or more years after treatment. In patients with tumors that were less than 6 mm in height and more than 3 mm away from the nerve or the fovea, 13 of 18 (72%) retained > or = 20/40. In contrast, only 11% of the patients with either thicker tumors or those close to the nerve or fovea retained that level of acuity. The actuarial enucleation rate at 5 years was 17.2% (2.7% S.E.) and at 10 years this was 22.4% (3.1% S.E). The recurrence tumor control rate at both 5 and 10 years was 5.3% (S.E 1.7%). CONCLUSIONS: Helium ion radiation of uveal melanoma is associated with good local tumor control and reasonable retention of the treated eye 10 years after treatment. In tumors that are less than 6 mm in thickness and greater than 3 mm from the optic nerve and fovea, many retain excellent vision. Approximately one-half of the deaths 10 years after treatment were due to non-tumor-related causes</style></abstract><notes><style face="normal" font="default">9440169w49, 7506106IM7440-59-7 (Helium)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2630</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Crawford,J.F.</style></author><author><style face="normal" font="default"> Konijnenberg,M.W.</style></author><author><style face="normal" font="default"> Perks,C.A.</style></author><author><style face="normal" font="default"> Stecher-Rasmussen,F.</style></author><author><style face="normal" font="default"> Watkins,P.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Paul Scherrer Institute, Villingen, Switzerland</style></auth-address><titles><title><style face="normal" font="default">A scintillation spectrometer for direct comparison of neutron energy spectra at high and low rates</style></title><secondary-title><style face="normal" font="default">Strahlentherapie und Onkologie.169.(1):21-4,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Strahlentherapie und Onkologie.169.(1):21-4,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Electronics</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hydrogen</style></keyword><keyword><style face="normal" font="default"> Neutron Capture Therapy/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> Neutron Capture Therapy/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Scintillation Counting/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword></keywords><dates><year Day="0" Month="1" Year="1993">1993/1</year></dates><pub-location><style face="normal" font="default">GERMANY</style></pub-location><isbn><style face="normal" font="default">0179-7158</style></isbn><abstract><style face="normal" font="default">The energy spectrum of the HB11 beam at HFR, Petten, has previously been measured by proton and alpha recoil in hydrogen and helium gas proportional counters at power levels of a few kW. There is some doubt whether the spectrum remains the same at the much higher power of 45 MW required for therapeutic fluxes. In order to test this point, a scintillation detector has been developed at the Paul Scherrer Institute, Villingen, Switzerland. While the device is again based on the proton recoil reaction, a combination of mm-sized plastic scintillators and fast electronics will allow it to operate at both a few kW and 45 MW, permitting direct comparison of energy spectra at these very different power levels. Results of preliminary tests at LFR, Petten, are presented</style></abstract><notes><style face="normal" font="default">8434335vcm, 8603469IMComparative StudyJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2643</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Daftari,I.K.</style></author><author><style face="normal" font="default"> Char,D.H.</style></author><author><style face="normal" font="default"> Verhey,L.J.</style></author><author><style face="normal" font="default"> Castro,J.R.</style></author><author><style face="normal" font="default"> Petti,P.L.</style></author><author><style face="normal" font="default"> Meecham,W.J.</style></author><author><style face="normal" font="default"> Kroll,S.</style></author><author><style face="normal" font="default"> Blakely,E.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, University of California San Francisco, 94143, USA</style></auth-address><titles><title><style face="normal" font="default">Anterior segment sparing to reduce charged particle radiotherapy complications in uveal melanoma</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.39.(5):997.-1010.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.39.(5):997.-1010.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> Anterior Eye Segment</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eye Enucleation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glaucoma,Neovascular/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Helium/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Helium/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="1" Month="12" Year="1997">1997/12/1</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: The purpose of this investigation is to delineate the risk factors in the development of neovascular glaucoma (NVG) after helium-ion irradiation of uveal melanoma patients and to propose treatment technique that may reduce this risk. METHODS AND MATERIALS: 347 uveal melanoma patients were treated with helium-ions using a single-port treatment technique. Using univariate and multivariate statistics, the NVG complication rate was analyzed according to the percent of anterior chamber in the radiation field, tumor size, tumor location, sex, age, dose, and other risk factors. Several University of California San Francisco-Lawrence Berkeley National Laboratory (LBNL) patients in each size category (medium, large, and extralarge) were retrospectively replanned using two ports instead of a single port. By using appropriate polar and azimuthal gaze angles or by treating patients with two ports, the maximum dose to the anterior segment of the eye can often be reduced. Although a larger volume of anterior chamber may receive a lower dose by using two ports than a single port treatment. We hypothesize that this could reduce the level of complications that result from the irradiation of the anterior chamber of the eye. Dose-volume histograms were calculated for the lens, and compared for the single and two-port techniques. RESULTS: NVG developed in 121 (35%) patients. The risk of NVG peaked between 1 and 2.5 years posttreatment. By univariate and multivariate analysis, the percent of lens in the field was strongly correlated with the development of NVG. Other contributing factors were tumor height, history of diabetes, and vitreous hemorrhage. Dose-volume histogram analysis of single-port vs. two-port techniques demonstrate that for some patients in the medium and large category tumor groups, a significant decrease in dose to the structures in the anterior segment of the eye could have been achieved with the use of two ports. CONCLUSION: The development of NVG after helium-ion irradiation is correlated to the amount of lens, anterior chamber in the treatment field, tumor height, proximity to the fovea, history of diabetes, and the development of vitreous hemorrhage. Although the influence of the higher LET deposition of helium-ions is unclear, this study suggests that by reducing the dose to the anterior segment of the eye may reduce the NVG complications. Based on this retrospective analysis of LBNL patients, we have implemented techniques to reduce the amount of the anterior segment receiving a high dose in our new series of patients treated with protons using the cyclotron at the UC Davis Crocker Nuclear Laboratory (CNL)</style></abstract><notes><style face="normal" font="default">9392537g97, 7603616IM, S7440-59-7 (Helium)Journal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, Non-P.H.SResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2697</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Desjardins,L.</style></author><author><style face="normal" font="default"> Levy,C.</style></author><author><style face="normal" font="default"> D'Hermies,F.</style></author><author><style face="normal" font="default"> Frau,E.</style></author><author><style face="normal" font="default"> Schlienger,P.</style></author><author><style face="normal" font="default"> Habrand,J.L.</style></author><author><style face="normal" font="default"> Mammar,H.</style></author><author><style face="normal" font="default"> Schwartz,L.</style></author><author><style face="normal" font="default"> Mazal,A.</style></author><author><style face="normal" font="default"> Delacroix,S.</style></author><author><style face="normal" font="default"> Nauraye,C.</style></author><author><style face="normal" font="default"> Ferrand,R.</style></author><author><style face="normal" font="default"> Asselain,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre de protontherapie d'Orsay, BP 65, France</style></auth-address><titles><title><style face="normal" font="default">[Initial results of proton therapy in choroidal melanoma at the d'Orsey Center for Proton Therapy; the first 464 cases]. [French]</style></title><secondary-title><style face="normal" font="default">Cancer Radiotherapie.1(3):222.-6.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cancer Radiotherapie.1(3):222.-6.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Choroid Neoplasms/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eye Enucleation</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> France/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Glaucoma/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Melanoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Neoplasm Metastasis</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local</style></keyword><keyword><style face="normal" font="default"> Optic Nerve</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Visual Acuity/re [Radiation Effects]</style></keyword></keywords><dates><year Day="0" Month="0" Year="1997">1997</year></dates><pub-location><style face="normal" font="default">FRANCE</style></pub-location><isbn><style face="normal" font="default">1278-3218</style></isbn><abstract><style face="normal" font="default">PURPOSE: Retrospective analysis of the treatment of choroidal melanoma with protontherapy at the Centre de protontherapie d'Orsay, France. PATIENTS AND METHODS: Between September 1991 and September 1995, 612 patients presenting with choroidal melanoma were treated by protontherapy in Orsay. Following initial management of the first 464 patients, results were analyzed, as were results after a 1-year follow-up for 305 patients, a 2-year follow-up for 169 patients, and a 3-year follow-up for 59 patients. RESULTS: Univariate analysis showed that the actuarial local recurrence rate was 5%, the 3-year survival rate 88%, and the overall metastasic rate 5%. The initial tumor volume was the most significant predictive factor for visual results and metastases. Multivariate analysis revealed that visual results were significantly related to the initial tumor volume, initial retinal detachment, and total dose delivered to the optic nerve and macula. CONCLUSION: Protontherapy of choroidal melanoma allows in most cases conservation of the eye without modification of survival. Visual results mainly depend on the site and size of the tumor</style></abstract><notes><style face="normal" font="default">9295876cqv, 9711272IM0 (Protons)English AbstractJournal ArticleFrench</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2736</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Duttenhaver,J.R.</style></author><author><style face="normal" font="default"> Shipley,W.U.</style></author><author><style face="normal" font="default"> Perrone,T.</style></author><author><style face="normal" font="default"> Verhey,L.J.</style></author><author><style face="normal" font="default"> Goitein,M.</style></author><author><style face="normal" font="default"> Munzenrider,J.E.</style></author><author><style face="normal" font="default"> Prout,G.R.</style></author><author><style face="normal" font="default"> Parkhurst,E.C.</style></author><author><style face="normal" font="default"> Suit,H.D.</style></author></authors></contributors><titles><title><style face="normal" font="default">Protons or megavoltage X-rays as boost therapy for patients irradiated for localized prostatic carcinoma. An early phase I/II comparison</style></title><secondary-title><style face="normal" font="default">Cancer.51.(9.):1599.-604.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cancer.51.(9.):1599.-604.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Carcinoma</style></keyword><keyword><style face="normal" font="default"> Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Palpation</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pelvis</style></keyword><keyword><style face="normal" font="default"> Prostate</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Random Allocation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> X-Ray Therapy</style></keyword><keyword><style face="normal" font="default"> X-Rays</style></keyword></keywords><dates><year Day="1" Month="5" Year="1983">1983/5/1</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0008-543X</style></isbn><abstract><style face="normal" font="default">A total of 180 patients with carcinoma of the prostate limited to the pelvis were treated with one of two external beam irradiation techniques between 1972 and 1979. One hundred and sixteen patients were treated with conventional pelvic megavoltage x-ray therapy. Sixty-four patients were treated with combined pelvic x-ray therapy plus a perineal proton beam boost to a carefully defined prostatic tumor volume. A 160 MeV proton beam has been modified to irradiate patients with localized tumors by using conventional treatment schedules. This proton beam has the physical advantage over megavoltage x-rays of reducing the dose to normal tissues adjacent to the tumor volume. By using the proton beam boost we have delivered an increased prostatic tumor dose of 500 to 700 cGy without increasing treatment morbidity at all. The two groups are actuarially analyzed for patient survival, disease-free survival and local recurrence-free survival, and thus far, no significant differences have been noted. Because of the minimal complications observed in the proton group despite a 10% increase in dose, a randomized clinical trial comparing these two treatment techniques is studied</style></abstract><notes><style face="normal" font="default">62995030374236, clzAIM, IM0 (Protons)Clinical TrialComparative StudyJournal ArticleResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2750</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Egan,K.M.</style></author><author><style face="normal" font="default"> Gragoudas,E.S.</style></author><author><style face="normal" font="default"> Seddon,J.M.</style></author><author><style face="normal" font="default"> Glynn,R.J.</style></author><author><style face="normal" font="default"> Munzenreider,J.E.</style></author><author><style face="normal" font="default"> Goitein,M.</style></author><author><style face="normal" font="default"> Verhey,L.</style></author><author><style face="normal" font="default"> Urie,M.</style></author><author><style face="normal" font="default"> Koehler,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophthalmology, Harvard Medical School, Boston, MA</style></auth-address><titles><title><style face="normal" font="default">The risk of enucleation after proton beam irradiation of uveal melanoma</style></title><secondary-title><style face="normal" font="default">Ophthalmology.96.(9.):1377.-82.; discussion.1382.-3,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ophthalmology.96.(9.):1377.-82.; discussion.1382.-3,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Boston</style></keyword><keyword><style face="normal" font="default"> Ciliary Body</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eye Enucleation</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Glaucoma</style></keyword><keyword><style face="normal" font="default"> Glaucoma,Neovascular/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Retinal Detachment/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Vision</style></keyword></keywords><dates><year Day="0" Month="9" Year="1989">1989/9</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0161-6420</style></isbn><abstract><style face="normal" font="default">Enucleation after proton beam irradiation of uveal melanomas occurred in 64 (6.4%) of 994 eyes with a median follow-up time of 2.7 years. The median time between irradiation and enucleation in the 64 enucleated eyes was 13 months. The probability of retaining the eye was 95 and 90%, 2 and 5 years postirradiation, respectively. Three percent of eyes were enucleated during posttreatment year 1, and the yearly rate was 1% by the fourth year. No patient had enucleation later than 5 1/2 years posttreatment. The complication most likely to result in enucleation was neovascular glaucoma although this was frequently managed without enucleation. Other common reasons for enucleation were documented or suspected tumor growth and complete retinal detachment with associated loss of vision. The leading risk factors for enucleation were anterior tumor margin involving the ciliary body, tumor height greater than 8 mm, and proximity of the tumor to the fovea. Based on the presence or absence of these factors, 5-year eye retention rates were 99, 92, and 76% for low-, moderate-, and high-risk groups, respectively. Thus, the probability of eye retention after proton beam irradiation is high even among those at greatest risk of enucleation</style></abstract><notes><style face="normal" font="default">2550868oi5, 7802443IM0 (Protons)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2751</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Egan,K.M.</style></author><author><style face="normal" font="default"> Gragoudas,E.S.</style></author><author><style face="normal" font="default"> Seddon,J.M.</style></author><author><style face="normal" font="default"> Walsh,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston 02114</style></auth-address><titles><title><style face="normal" font="default">Smoking and the risk of early metastases from uveal melanoma</style></title><secondary-title><style face="normal" font="default">Ophthalmology.99.(4):537.-41.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ophthalmology.99.(4):537.-41.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Ciliary Body</style></keyword><keyword><style face="normal" font="default"> Ciliary Body/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Melanoma/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Smoking/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Smoking/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/pa [Pathology]</style></keyword></keywords><dates><year Day="0" Month="4" Year="1992">1992/4</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0161-6420</style></isbn><abstract><style face="normal" font="default">Smoking is suspected of altering host immunity and may therefore hasten the development of metastases among cancer patients. The authors followed 946 patients with melanomas of the choroid and/or ciliary body who had been treated with proton beam irradiation and who had provided a smoking history during their evaluation before treatment. After a mean follow-up of 33 months, 98 patients were diagnosed with metastatic disease. Metastasis-free survival rates 3 years after irradiation were similar in association with never, past, and current cigarette smoking (86%, 89%, and 90%, respectively; P = 0.90). Rates also were similar with increasing pack-years of exposure and when the product smoked was cigarettes versus pipes or cigars only. Estimates for smoking effects were unchanged after adjusting for established prognostic factors for metastases. Results suggest that smoking does not alter the risk of metastases during the first few years after irradiation of choroidal melanomas</style></abstract><notes><style face="normal" font="default">1584571oi5, 7802443IMComparative StudyJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2752</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Egan,K.M.</style></author><author><style face="normal" font="default"> Walsh,S.M.</style></author><author><style face="normal" font="default"> Seddon,J.M.</style></author><author><style face="normal" font="default"> Gragoudas,E.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Retina Service, Massachusetts Eye and Ear Infirmary, Boston 02114</style></auth-address><titles><title><style face="normal" font="default">An evaluation of the influence of reproductive factors on the risk of metastases from uveal melanoma</style></title><secondary-title><style face="normal" font="default">Ophthalmology.100.(8.):1160.-5; discussion.1166.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ophthalmology.100.(8.):1160.-5; discussion.1166.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Contraceptives,Oral</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Pregnancy Complications,Neoplastic/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Pregnancy Complications,Neoplastic/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Pregnancy Complications,Neoplastic/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Reproductive History</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="8" Year="1993">1993/8</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0161-6420</style></isbn><abstract><style face="normal" font="default">BACKGROUND: There is a paucity of data concerning the possible role played by hormonal factors in the risk of metastases from intraocular melanomas. METHODS: The authors studied the influence of post-diagnosis pregnancy and oral contraceptive use in a group of women of reproductive age (45 or younger) who were treated for uveal melanoma by proton beam irradiation. A baseline reproductive history had been collected before irradiation for all women, and interim reproductive data were collected by mailed questionnaire. RESULTS: In this age group, the overall rate of metastasis among women was similar to that of men treated during the same interval (adjusted rate ratio: 1.28; 95% confidence interval: 0.62-2.67). A total of 24 full-term pregnancies were reported among the 139 women still menstruating at diagnosis. Twenty-three women reported regular oral contraceptive use. Metastases developed in 15 of the 139 women. Compared with other women in the series, rates of metastases were not higher among the women who reported pregnancies (P = 0.932) or oral contraceptive use (P = 0.424) after diagnosis. CONCLUSION: Although based on limited numbers, results suggest that the hormonal environment has no appreciable influence on risk of metastases in younger women with uveal melanoma</style></abstract><notes><style face="normal" font="default">8341495oi5, 7802443IM, J0 (Contraceptives, Oral)Comparative StudyJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2784</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fagundes,M.A.</style></author><author><style face="normal" font="default"> Hug,E.B.</style></author><author><style face="normal" font="default"> Liebsch,N.J.</style></author><author><style face="normal" font="default"> Daly,W.</style></author><author><style face="normal" font="default"> Efird,J.</style></author><author><style face="normal" font="default"> Munzenrider,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA</style></auth-address><titles><title><style face="normal" font="default">Radiation therapy for chordomas of the base of skull and cervical spine: patterns of failure and outcome after relapse</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.33.(3):579.-84.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.33.(3):579.-84.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Bone Neoplasms/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Cervical Vertebrae</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Chordoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Nasal Cavity</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Salvage Therapy</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Skull Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Treatment Failure</style></keyword></keywords><dates><year Day="15" Month="10" Year="1995">1995/10/15</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To determine the patterns of failure and outcome following relapse of chordomas of the base of skull and cervical spine. METHODS AND MATERIALS: Between November 1975 and October 1993, 204 patients were treated for chordoma of the base of skull or cervical spine, of which 63 have developed relapse. These 63 patients constitute the main focus of this study. Forty-five patients presented with base of skull and 18 with cervical spine tumors. All patients received combined proton and photon beam radiation. The median prescribed dose was 70.1 cobalt-Gray equivalent (CGE) (range 66.6-77.4). There were 25 males and 38 females, with a median age of 41 years (range 7-66). Median follow-up was 54 months (range 8-158). RESULTS: Sixty-three of the 204 patients treated (31%) had treatment failure. Among the 63 patients who relapsed, 60 (95%) experienced local recurrence, and in 49 patients (78%), this was the only site of failure. Two of 63 patients (3%) developed regional lymph node relapse and 3 of 63 (5%) developed surgical pathway recurrence (1 left neck, 1 palate and 1 nasal cavity). Thirteen of 204 patients relapsed in distant sites, accounting for 20% (13 of 63) of all patients with recurrence in this series. The most common metastatic sites were lungs and bones presenting in 7 of 13 and 6 of 13 patients, respectively. Only 2 of 13 patients failed with isolated distant metastasis. The actuarial 3- and 5-year survival rates after local relapse (60 patients) were 44 and 5%, respectively. Following distant failure (13 patients), the 3- and 5-year survival rates were 25 and 12%, respectively. After any relapse (63 patients) the corresponding survival rates were 43 and 7%. Following local relapse, 49 of 60 patients underwent salvage therapy consisting of subtotal resection in most patients (46 of 49). The remaining 11 of 60 patients received supportive care only. Salvage therapy resulted in stable or improved status without subsequent disease progression in 26 of 49 (53%), and progressive disease in 16 of 49 patients (33%). The actuarial 2- and 5-year overall survival rates following relapse for the 49 patients who underwent salvage treatment were 63 and 6%, which favorably compared to the 2-year survival rate of 21% for those who received supportive care only (p = 0.001). CONCLUSION: Local relapse is the predominant type of treatment failure for chordomas of the base of skull and cervical spine. Salvage treatment may relieve symptoms; however, most patients will ultimately succumb to their disease. Poor long-term survival rates following relapse emphasize the importance of a combined treatment approach with experienced surgeons and radiation oncologists at the time of primary treatment. For most patients, only permanent local tumor control will offer a chance of cure</style></abstract><notes><style face="normal" font="default">7558946g97, 7603616IMJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2819</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Foss,A.J.</style></author><author><style face="normal" font="default"> Whelehan,I.</style></author><author><style face="normal" font="default"> Hungerford,J.L.</style></author><author><style face="normal" font="default"> Anderson,D.F.</style></author><author><style face="normal" font="default"> Errington,R.D.</style></author><author><style face="normal" font="default"> Kacperek,A.</style></author><author><style face="normal" font="default"> Restori,M.</style></author><author><style face="normal" font="default"> Kongerud,J.</style></author><author><style face="normal" font="default"> Sheen,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Oncology Clinic, Moorfields Eye Hospital, London</style></auth-address><titles><title><style face="normal" font="default">Predictive factors for the development of rubeosis following proton beam radiotherapy for uveal melanoma</style></title><secondary-title><style face="normal" font="default">British Journal of Ophthalmology.81.(9.):748.-54.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">British Journal of Ophthalmology.81.(9.):748.-54.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eye Enucleation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Iris/bs [Blood Supply]</style></keyword><keyword><style face="normal" font="default"> Iris/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neovascularization,Pathologic/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Retinal Detachment</style></keyword><keyword><style face="normal" font="default"> Retinal Detachment/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/su [Surgery]</style></keyword></keywords><dates><year Day="0" Month="9" Year="1997">1997/9</year></dates><pub-location><style face="normal" font="default">ENGLAND</style></pub-location><isbn><style face="normal" font="default">0007-1161</style></isbn><abstract><style face="normal" font="default">AIMS/BACKGROUND: Proton beam radiotherapy can effectively treat primary uveal melanomas of any size. Some patients, however, develop adverse late effects following treatment and the purpose of this study was to determine which factors give rise to a poor local outcome. METHODS: The hospital records from a first cohort of 127 patients treated by protons from 1989 to 1992 were reviewed retrospectively. The presence of rubeosis was selected as a measure of significant ocular damage. Split file analysis was performed with 73 cases forming a test group with the remaining 54 cases acting as a validation group. RESULTS: Large tumour size and the presence of retinal detachment were significant, independent risk factors for developing rubeosis for both the test and validation groups. These factors also predicted subsequent enucleation for uncontrolled ocular pain. Patients with tumours too large to plaque and with an associated retinal detachment had a 90% chance of developing rubeosis within 4 years of proton beam radiotherapy. CONCLUSIONS: Patients with a uveal melanoma too large for plaque therapy and an associated retinal detachment run a very high risk of developing rubeosis after proton beam radiotherapy and one third of individuals developing rubeosis required enucleation for pain even if local tumour control was satisfactory</style></abstract><notes><style face="normal" font="default">9422926azk, 0421041IMClinical TrialClinical Trial, Phase IIControlled Clinical TrialJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2875</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Glynn,R.J.</style></author><author><style face="normal" font="default"> Seddon,J.M.</style></author><author><style face="normal" font="default"> Gragoudas,E.S.</style></author><author><style face="normal" font="default"> Egan,K.M.</style></author><author><style face="normal" font="default"> Hart,L.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston 02114</style></auth-address><titles><title><style face="normal" font="default">Evaluation of tumor regression and other prognostic factors for early and late metastasis after proton irradiation of uveal melanoma</style></title><secondary-title><style face="normal" font="default">Ophthalmology.96.(10):1566.-73.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ophthalmology.96.(10):1566.-73.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Boston</style></keyword><keyword><style face="normal" font="default"> Ciliary Body</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Remission Induction</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Ultrasonography</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="0" Month="10" Year="1989">1989/10</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0161-6420</style></isbn><abstract><style face="normal" font="default">The authors examined the relationship of change in tumor height after proton beam irradiation with the risk of metastasis in 700 patients treated for uveal melanoma before July 1, 1986. Rates of change in tumor height were computed for each patient using follow-up ultrasonographic measures during the first 2 years after treatment. Risk of metastasis was evaluated separately in the first 2 years after treatment when tumor decline was assessed (concurrent metastasis), and 2 years or later after treatment (subsequent metastasis). Using Cox proportional hazards models to adjust for other known risk factors, tumors regressing rapidly were significantly more likely to metastasize concurrently with their regression (P less than 0.05). The opposite was found for subsequent metastasis: tumors with a slow annual decline were more likely to metastasize after 2 years after treatment (P less than 0.05). Substantial changes also were noted in the ability of previously described prognostic factors (largest tumor diameter, tumor height, ciliary body involvement, and patient's age) to predict early and late metastasis. Characteristics placing individuals at high risk of metastasis may change markedly with time after treatment</style></abstract><notes><style face="normal" font="default">2685710oi5, 7802443IMJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2910</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gragoudas,E.S.</style></author><author><style face="normal" font="default"> Goitein,M.</style></author><author><style face="normal" font="default"> Verhey,L.</style></author><author><style face="normal" font="default"> Munzenreider,J.</style></author><author><style face="normal" font="default"> Urie,M.</style></author><author><style face="normal" font="default"> Suit,H.</style></author><author><style face="normal" font="default"> Koehler,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Proton beam irradiation of uveal melanomas. Results of 5 1/2-year study</style></title><secondary-title><style face="normal" font="default">Archives of Ophthalmology.100.(6.):928.-34.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Archives of Ophthalmology.100.(6.):928.-34.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Computers</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Neoplasm Metastasis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/su [Surgery]</style></keyword></keywords><dates><year Day="0" Month="6" Year="1982">1982/6</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0003-9950</style></isbn><abstract><style face="normal" font="default">Proton beam irradiation was used in the treatment of 76 uveal melanomas from July 1975 to December 1980. Five (7%) were small, 32 (42%) were medium, and 39 (51%) were large melanomas. The follow-up period ranged from two months to 5 1/2 years; 19 patients were followed up for more than two years and 39 were observed for more than a year. Tumor regression has been achieved in all eyes with more than 12 months of follow-up except one, which was enucleated because of secondary complications. Three patients in whom metastatic disease developed died. Our data indicate that proton irradiation can be used for the treatment of relatively large lesions that previously were considered untreatable and reduces the high ocular morbidity experienced with other methods in the treatment of medium and small melanomas</style></abstract><notes><style face="normal" font="default">62840977706534, 830AIM, IM0 (Protons)Journal ArticleResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2911</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gragoudas,E.S.</style></author><author><style face="normal" font="default"> Goitein,M.</style></author><author><style face="normal" font="default"> Seddon,J.</style></author><author><style face="normal" font="default"> Verhey,L.</style></author><author><style face="normal" font="default"> Munzenrider,J.</style></author><author><style face="normal" font="default"> Urie,M.</style></author><author><style face="normal" font="default"> Suit,H.D.</style></author><author><style face="normal" font="default"> Blitzer,P.</style></author><author><style face="normal" font="default"> Johnson,K.N.</style></author><author><style face="normal" font="default"> Koehler,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Preliminary results of proton beam irradiation of macular and paramacular melanomas</style></title><secondary-title><style face="normal" font="default">British Journal of Ophthalmology.68.(7.):479.-85.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">British Journal of Ophthalmology.68.(7.):479.-85.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fluorescein Angiography</style></keyword><keyword><style face="normal" font="default"> Fovea Centralis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Macula Lutea/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword></keywords><dates><year Day="0" Month="7" Year="1984">1984/7</year></dates><pub-location><style face="normal" font="default">ENGLAND</style></pub-location><isbn><style face="normal" font="default">0007-1161</style></isbn><abstract><style face="normal" font="default">Proton beam irradiation has been used for the treatment of 60 eyes with choroidal melanomas located 3 mm or less from the fovea. The average follow-up period was 18 months. 86% of the treated lesions showed regression at the time of this analysis, and the 14% that did not were followed up for less than a year. Visual acuity remained the same in 47% of the treated eyes, improved in 20%, and deteriorated in 33%. 58% of the treated eyes had visual acuity of 20/100 or better at the last follow-up examination. Radiation vasculopathy with macular oedema was the most common complication, and it was observed in 22% of the treated eyes. These preliminary observations suggest that proton beam irradiation may be a reasonable alternative to enucleation even for this group of choroidal melanomas, which is considered unfavourable in respect of the preservation of visual function</style></abstract><notes><style face="normal" font="default">6329261azk, 0421041IM0 (Protons)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2912</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gragoudas,E.S.</style></author><author><style face="normal" font="default"> Seddon,J.</style></author><author><style face="normal" font="default"> Goitein,M.</style></author><author><style face="normal" font="default"> Verhey,L.</style></author><author><style face="normal" font="default"> Munzenrider,J.</style></author><author><style face="normal" font="default"> Urie,M.</style></author><author><style face="normal" font="default"> Suit,H.D.</style></author><author><style face="normal" font="default"> Blitzer,P.</style></author><author><style face="normal" font="default"> Koehler,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Current results of proton beam irradiation of uveal melanomas</style></title><secondary-title><style face="normal" font="default">Ophthalmology.92.(2):284.-91.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ophthalmology.92.(2):284.-91.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword></keywords><dates><year Day="0" Month="2" Year="1985">1985/2</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0161-6420</style></isbn><abstract><style face="normal" font="default">Proton beam irradiation has been used for the treatment of 241 uveal melanomas over the past 7 1/2 years. Twelve melanomas (5%) were small, 99 (41%) medium, 103 (43%) large and 27 (1%) extra-large melanomas. The mean length of follow-up was 21 months and the median 15 months. Ninety-four percent of the treated lesions with a follow-up more than two years and 65% of tumors with shorter follow-up showed regression. The most recent visual acuity was 20/40 or better in 47% and 20/100 or better in 66%. Ten eyes were enucleated because of complications (9) or continued tumor growth (1). Thirteen patients developed metastases from 4 to 50 months of treatment. Our data indicate that proton irradiation can be used to treat melanomas of various sizes and in a variety of locations, and preliminary results suggest that proton therapy has no deleterious effect on the likelihood of the development of metastases</style></abstract><notes><style face="normal" font="default">2984625oi5, 7802443IM0 (Protons)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2913</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gragoudas,E.S.</style></author><author><style face="normal" font="default"> Seddon,J.M.</style></author><author><style face="normal" font="default"> Egan,K.M.</style></author><author><style face="normal" font="default"> Polivogianis,L.</style></author><author><style face="normal" font="default"> Hsieh,C.C.</style></author><author><style face="normal" font="default"> Goitein,M.</style></author><author><style face="normal" font="default"> Verhey,L.</style></author><author><style face="normal" font="default"> Munzenrider,J.</style></author><author><style face="normal" font="default"> ustin-Seymour,M.</style></author><author><style face="normal" font="default"> Urie,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Prognostic factors for metastasis following proton beam irradiation of uveal melanomas</style></title><secondary-title><style face="normal" font="default">Ophthalmology.93.(5):675.-80.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ophthalmology.93.(5):675.-80.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Ciliary Body</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Metastasis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Skin Neoplasms/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="0" Month="5" Year="1986">1986/5</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0161-6420</style></isbn><abstract><style face="normal" font="default">Prognostic indicators for the development of metastasis following proton beam irradiation of uveal melanomas were evaluated for 510 patients treated from 1975 to 1984. Thirty-three patients developed metastasis (6.5%) from 3 to 51 months following treatment. The primary site of metastasis was the liver in 28 cases (85%). Both demographic and clinical factors were considered. The three leading predictors of survival without metastasis after proton beam irradiation in order of importance were: (1) largest diameter of the tumor; (2) location of the anterior margin of the tumor; and (3) age at treatment. Worse prognosis was associated with largest tumor diameter greater than 15.0 mm, tumor involvement of the ciliary body and age at treatment older than 59 years</style></abstract><notes><style face="normal" font="default">3014416oi5, 7802443IM0 (Protons)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2916</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gragoudas,E.S.</style></author><author><style face="normal" font="default"> Seddon,J.M.</style></author><author><style face="normal" font="default"> Egan,K.</style></author><author><style face="normal" font="default"> Glynn,R.</style></author><author><style face="normal" font="default"> Munzenrider,J.</style></author><author><style face="normal" font="default"> ustin-Seymour,M.</style></author><author><style face="normal" font="default"> Goitein,M.</style></author><author><style face="normal" font="default"> Verhey,L.</style></author><author><style face="normal" font="default"> Urie,M.</style></author><author><style face="normal" font="default"> Koehler,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Long-term results of proton beam irradiated uveal melanomas</style></title><secondary-title><style face="normal" font="default">Ophthalmology.94.(4):349.-53.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ophthalmology.94.(4):349.-53.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">complications</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eye Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Glaucoma/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Iris Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Macula Lutea/bs [Blood Supply]</style></keyword><keyword><style face="normal" font="default"> Macula Lutea/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Melanoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Vision</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword><keyword><style face="normal" font="default"> Visual Acuity/re [Radiation Effects]</style></keyword></keywords><dates><year Day="0" Month="4" Year="1987">1987/4</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0161-6420</style></isbn><abstract><style face="normal" font="default">The first 128 consecutive patients with uveal melanomas treated with proton beam irradiation were studied in order to evaluate survival and visual acuity status of patients with relatively long-term follow-up. The median follow-up was 5.4 years, and no patient was lost to follow-up. All tumors showed regression. The most recent visual acuity was 20/40 or better in 35% and 20/100 or better in 58%. Eight eyes were enucleated because of complications. Metastasis developed in 26 patients (20.5%) from 3 months to 7 years after treatment. Results indicate that proton irradiation is quite successful for achieving local control of uveal melanomas. A large proportion of the treated eyes maintained useful vision. Five-year follow-up data indicate that proton irradiation has no deleterious effect on the likelihood of the development of metastasis</style></abstract><notes><style face="normal" font="default">3035451oi5, 7802443IM0 (Protons)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2917</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gragoudas,E.S.</style></author><author><style face="normal" font="default"> Seddon,J.M.</style></author><author><style face="normal" font="default"> Egan,K.M.</style></author><author><style face="normal" font="default"> Glynn,R.J.</style></author><author><style face="normal" font="default"> Goitein,M.</style></author><author><style face="normal" font="default"> Munzenrider,J.</style></author><author><style face="normal" font="default"> Verhey,L.</style></author><author><style face="normal" font="default"> Urie,M.</style></author><author><style face="normal" font="default"> Koehler,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Retina Service, Massachusetts Eye and Ear Infirmary, Boston 02114</style></auth-address><titles><title><style face="normal" font="default">Metastasis from uveal melanoma after proton beam irradiation</style></title><secondary-title><style face="normal" font="default">Ophthalmology.95.(7.):992.-9.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ophthalmology.95.(7.):992.-9.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Ciliary Body</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="0" Month="7" Year="1988">1988/7</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0161-6420</style></isbn><abstract><style face="normal" font="default">The incidence of metastasis and prognostic factors for metastasis in 780 consecutive patients with uveal melanomas treated with proton beam irradiation were evaluated. Metastasis developed in 64 patients (8%). The median time from treatment to the diagnosis of metastasis was 2.1 years (range, 3 months to 7.3 years). The liver was primarily involved in 58 (90%) patients. The 5-year cumulative probability of metastasis developing was 20%. Prognostic factors for metastasis developing were quite comparable to those found for patients treated by enucleation and included largest tumor diameter, involvement of the ciliary body, older age, and extrascleral extension. Surgical localization, tumor height, and elevated liver enzymes before treatment were not important factors in the development of metastasis</style></abstract><notes><style face="normal" font="default">2845324oi5, 7802443IM0 (Protons)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2920</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gragoudas,E.S.</style></author><author><style face="normal" font="default"> Egan,K.M.</style></author><author><style face="normal" font="default"> Seddon,J.M.</style></author><author><style face="normal" font="default"> Walsh,S.M.</style></author><author><style face="normal" font="default"> Munzenrider,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Retina Service, Massachusetts Eye and Ear Infirmary, Boston 02114</style></auth-address><titles><title><style face="normal" font="default">Intraocular recurrence of uveal melanoma after proton beam irradiation</style></title><secondary-title><style face="normal" font="default">Ophthalmology.99.(5):760.-6.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ophthalmology.99.(5):760.-6.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eye Enucleation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treatment Failure</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/su [Surgery]</style></keyword></keywords><dates><year Day="0" Month="5" Year="1992">1992/5</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0161-6420</style></isbn><abstract><style face="normal" font="default">The authors evaluated tumor recurrence as an end point in 1077 uveal melanoma patients treated by proton beam irradiation between 1975 and 1987, with a mean follow-up of 4.0 years. Twenty tumors (1.9%) exhibited definitive growth between 4 months and 66 months after irradiation (median, 19 months): 10 were marginal recurrences, 5 were ring melanomas, 3 were uncontrolled tumors, and 2 were extrascleral extensions. Ten of these eyes were enucleated without further intervention, 2 patients died of metastases soon after the growth was detected, and 8 patients had further conservative therapy. In 5 other patients, tumor growth was suspected but unconfirmed and the eye was enucleated elsewhere; the 5-year probability of local tumor control based on 25 recurrences was 97% +/- 1%. There was a nonsignificant increase in the rate of metastases among patients with documented tumor recurrence (adjusted relative risk, 1.5; 95% confidence interval, 0.66 to 3.4). Results suggest that recurrence of uveal melanomas treated by proton beam therapy is uncommon, but that treatment failure may increase risk of death from metastasis</style></abstract><notes><style face="normal" font="default">1594223oi5, 7802443IMJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2921</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gragoudas,E.S.</style></author><author><style face="normal" font="default"> Egan,K.M.</style></author><author><style face="normal" font="default"> Arrigg,P.G.</style></author><author><style face="normal" font="default"> Seddon,J.M.</style></author><author><style face="normal" font="default"> Glynn,R.J.</style></author><author><style face="normal" font="default"> Munzenrider,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophthalmology, Harvard Medical School, Boston, MA</style></auth-address><titles><title><style face="normal" font="default">Cataract extraction after proton beam irradiation for malignant melanoma of the eye.[see comment]</style></title><secondary-title><style face="normal" font="default">Archives of Ophthalmology.110.(4):475.-9.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Archives of Ophthalmology.110.(4):475.-9.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Cataract</style></keyword><keyword><style face="normal" font="default"> Cataract Extraction</style></keyword><keyword><style face="normal" font="default"> Cataract/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eye Enucleation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Postoperative Complications</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Vision</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword></keywords><dates><year Day="0" Month="4" Year="1992">1992/4</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0003-9950</style></isbn><abstract><style face="normal" font="default">We evaluated visual outcome and risk of metastases in patients who underwent cataract extraction after protonbeam irradiation of a uveal melanoma. A total of 84 patients underwent cataract extraction between 2 months and 11 years after irradiation. One year after cataract extraction, approximately half of the patients had visual acuity of 20/100 or better, and approximately one third had an acuity of 20/40 or better. Larger tumor size was highly correlated with poor visual outcome 1 year after extraction. Six patients underwent enucleation after cataract removal, five due to blind, painful eyes and one due to continued growth of a previously undiagnosed ring melanoma. The rate of metastases was not higher among patients who underwent cataract extraction (adjusted rate ratio, 0.83). Results suggest that cataract extraction offers improvement of vision in selected eyes previously irradiated for a uveal melanoma, without adding to the risk of metastases among patients undergoing the procedure</style></abstract><notes><style face="normal" font="default">15622517706534, 830AIM, IMJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2922</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gragoudas,E.S.</style></author><author><style face="normal" font="default"> Egan,K.M.</style></author><author><style face="normal" font="default"> Saornil,M.A.</style></author><author><style face="normal" font="default"> Walsh,S.M.</style></author><author><style face="normal" font="default"> Albert,D.M.</style></author><author><style face="normal" font="default"> Seddon,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Retina Service, Massachusetts Eye and Ear Infirmary, Boston 02114</style></auth-address><titles><title><style face="normal" font="default">The time course of irradiation changes in proton beam-treated uveal melanomas</style></title><secondary-title><style face="normal" font="default">Ophthalmology.100.(10):1555.-9.; discussion.1560.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ophthalmology.100.(10):1555.-9.; discussion.1560.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Autopsy</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Cyclotrons</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eye Enucleation</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Uveitis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Uveitis/pa [Pathology]</style></keyword></keywords><dates><year Day="0" Month="10" Year="1993">1993/10</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0161-6420</style></isbn><abstract><style face="normal" font="default">BACKGROUND: Although histopathologic changes in uveal melanomas treated by irradiation have been well characterized, the timing of these effects after irradiation has not been previously evaluated. METHODS: The series consisted of a total of 92 eyes with uveal melanoma, enucleated at various intervals after proton irradiation (range, 1 month to 8 years) due to complications (n = 66) or tumor growth (n = 22), or at autopsy (n = 4). Study slides were read, using a standard protocol, by two pathologists masked to the timing of the enucleation after irradiation and the reason for the surgery. RESULTS: The prevalence of inflammation decreased whereas fibrosis increased with time from 15% of cases enucleated within 12 months (early cases) to 61% of those enucleated more than 30 months (late cases) after irradiation (P for trend = 0.0005). Tumor necrosis and blood vessel damage occurred early, and the prevalence of these changes was constant over time. Excluding tumors with evidence of growth after irradiation, mitotic figures became progressively less common as the interval between irradiation and enucleation increased (P for trend = 0.015); no mitotic figures were present in 40 high-power fields more than 30 months after irradiation. CONCLUSION: Histopathologic changes in irradiated melanomas vary according to the time elapsed since irradiation. Inflammation decreases with time whereas fibrosis becomes more prevalent with time after irradiation. Among controlled tumors, mitotic figures appear only in recently irradiated tumors</style></abstract><notes><style face="normal" font="default">8414415oi5, 7802443IM0 (Protons)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2923</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gragoudas,E.S.</style></author><author><style face="normal" font="default"> Egan,K.M.</style></author><author><style face="normal" font="default"> Walsh,S.M.</style></author><author><style face="normal" font="default"> Regan,S.</style></author><author><style face="normal" font="default"> Munzenrider,J.E.</style></author><author><style face="normal" font="default"> Taratuta,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston 02114</style></auth-address><titles><title><style face="normal" font="default">Lens changes after proton beam irradiation for uveal melanoma</style></title><secondary-title><style face="normal" font="default">American Journal of Ophthalmology.119.(2):157.-64.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">American Journal of Ophthalmology.119.(2):157.-64.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Cataract/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Lens,Crystalline/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="0" Month="2" Year="1995">1995/2</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0002-9394</style></isbn><abstract><style face="normal" font="default">PURPOSE: Because limited data exist on the incidence of lens changes after therapeutic intraocular irradiation, we studied a group of patients who underwent proton irradiation for uveal melanoma, in order to estimate cumulative rates of radiation-induced posterior subcapsular opacities and age-related lens changes at specific time points. after irradiation. METHODS: Cumulative rates for each type of opacity were estimated from among the 383 patients, treated between 1987 and 1989, who had clear lenses or minimal lens changes before irradiation. Cox's proportional hazards model was used to evaluate the independent effects of tumor and treatment-related characteristics on the development of posterior subcapsular opacities in these patients. Risk factors for posterior subcapsular opacities were evaluated. RESULTS: By three years after irradiation, posterior subcapsular opacities had developed in 42% of the patients, and rates increased significantly with lens dose and with tumor height. The risk of posterior subcapsular opacities was over three times higher when the lens received a substantial dose of irradiation (adjusted relative risk, 3.25; 95% confidence interval, 1.60-6.59), as compared with minimal dose, and was three times higher when the tumor was highly elevated (adjusted relative risk, 3.05; 95% confidence interval, 1.45-6.40) as compared with minimally elevated lesions. Opacities in the other segments of the lens were age related. CONCLUSIONS: These data show that patients receiving therapeutic intraocular irradiation have a high risk of developing posterior subcapsular opacities. As expected, the leading risk determinant of posterior subcapsular change is the amount of irradiation received by the lens</style></abstract><notes><style face="normal" font="default">78322213oq, 0370500AIM, IM0 (Protons)Journal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>2972</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Guyer,D.R.</style></author><author><style face="normal" font="default"> Mukai,S.</style></author><author><style face="normal" font="default"> Egan,K.M.</style></author><author><style face="normal" font="default"> Seddon,J.M.</style></author><author><style face="normal" font="default"> Walsh,S.M.</style></author><author><style face="normal" font="default"> Gragoudas,E.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Retina Service, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA 02114</style></auth-address><titles><title><style face="normal" font="default">Radiation maculopathy after proton beam irradiation for choroidal melanoma</style></title><secondary-title><style face="normal" font="default">Ophthalmology.99.(8.):1278.-85.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ophthalmology.99.(8.):1278.-85.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Color</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fluorescein Angiography</style></keyword><keyword><style face="normal" font="default"> Fundus Oculi</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Macula Lutea/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photography</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Retinal Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Retinal Vessels/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Vision</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword><keyword><style face="normal" font="default"> Visual Acuity/re [Radiation Effects]</style></keyword></keywords><dates><year Day="0" Month="8" Year="1992">1992/8</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0161-6420</style></isbn><abstract><style face="normal" font="default">PURPOSE: Radiation maculopathy is a microangiopathy of the retina, which is often observed after irradiation of the eye. To quantitatively determine the frequency of anatomic and functional features of this condition, the authors reviewed a large series of patients with choroidal melanomas who were treated by proton beam irradiation. METHODS: Color photographs and/or fluorescein angiograms of 218 patients with paramacular choroidal melanomas were graded by two independent masked readers to determine the frequency of the various lesions of radiation maculopathy. RESULTS: Overall, 194 (89%) of the 218 patients in this study developed some degree of radiation maculopathy. The earliest and most common finding was macular edema, which was observed in 87% of patients, overall, by the end of year 3. Microvascular changes (microaneurysms and/or telangiectasia), intraretinal hemorrhages, and capillary nonperfusion were noted in 76%, 70%, and 64% of eyes, respectively, by the end of postirradiation year 3. Visual acuity was retained at 20/200 or better in 90% of eyes 1 year after irradiation and in 67% of eyes 3 years after treatment. CONCLUSION: Radiation maculopathy is common after proton beam irradiation of paramacular choroidal melanomas. However, ambulatory vision is preserved in many eyes</style></abstract><notes><style face="normal" font="default">1325044oi5, 7802443IM0 (Protons)Journal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>3002</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Harbour,J.W.</style></author><author><style face="normal" font="default"> Char,D.H.</style></author><author><style face="normal" font="default"> Kroll,S.</style></author><author><style face="normal" font="default"> Quivey,J.M.</style></author><author><style face="normal" font="default"> Castro,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophthalmology, University of California, San Francisco, USA</style></auth-address><titles><title><style face="normal" font="default">Metastatic risk for distinct patterns of postirradiation local recurrence of posterior uveal melanoma</style></title><secondary-title><style face="normal" font="default">Ophthalmology.104.(11):1785.-92.; discussion.1792.-3,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ophthalmology.104.(11):1785.-92.; discussion.1792.-3,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Brachytherapy</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Helium/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Iodine Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Iodine Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radioisotope Teletherapy</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="0" Month="11" Year="1997">1997/11</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0161-6420</style></isbn><abstract><style face="normal" font="default">OBJECTIVE: The purpose of the study is to compare the prognostic significance of horizontal/marginal versus vertical/diffuse patterns of postirradiation local recurrence of posterior uveal melanoma. DESIGN: The study design was a nonrandomized, retrospective clinical study. Semiparametric and nonparametric statistical techniques were used. PARTICIPANTS: Seven hundred sixty-six posterior uveal melanoma patients were studied. INTERVENTION: Either iodine-125 plaque or helium ion radiation therapy was performed. MAIN OUTCOME MEASURES: Local tumor recurrence and systemic metastasis were measured. RESULTS: Local tumor recurrence was detected in 66 (8.6%) of 766 irradiated tumors. The 5-year actuarial rate of local recurrence was 10%. The recurrence pattem was horizontal/marginal in 27 patients (41%) and vertical/diffuse in 39 patients (59%). Systemic metastasis was detected in 5 patients (19%) with horizontal/marginal recurrence and in 19 patients (49%) with vertical/diffuse recurrence. After known metastatic risk factors were controlled, the relative risk for metastasis was 2.2 for horizontal/marginal recurrence and 5.1 for vertical/diffuse recurrence (P = 0.05). The actuarial rate of systemic metastasis was 2.9% per year for all patients, 6.3% per year for patients with horizontal/marginal recurrence, and 15.5% per year for patients with vertical/diffuse recurrence. CONCLUSIONS: Postirradiation local recurrence of posterior uveal melanoma is a risk factor for systemic metastasis. Vertical/diffuse recurrences may be associated more strongly with metastatic disease than horizontal/marginal recurrences</style></abstract><notes><style face="normal" font="default">9373108oi5, 7802443IM0 (Iodine Radioisotopes)7440-59-7 (Helium)Comparative StudyJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>3077</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hug,E.B.</style></author><author><style face="normal" font="default"> Fitzek,M.M.</style></author><author><style face="normal" font="default"> Liebsch,N.J.</style></author><author><style face="normal" font="default"> Munzenrider,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston 02114</style></auth-address><titles><title><style face="normal" font="default">Locally challenging osteo- and chondrogenic tumors of the axial skeleton: results of combined proton and photon radiation therapy using three-dimensional treatment planning</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.31.(3):467.-76.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.31.(3):467.-76.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Bone Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Chondroblastoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Giant Cell Tumors/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Osteosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons</style></keyword><keyword><style face="normal" font="default"> Photons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Planning,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Sarcoma</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="1" Month="2" Year="1995">1995/2/1</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: Tumors of the axial skeleton are at high risk for local failure. Total surgical resection is rarely possible. Critical normal tissues limit the efficacy of conventional photon therapy. This study reviews our experience of using combined high dose proton and photon radiation therapy following three-dimensional (3D) treatment planning. METHODS AND MATERIALS: Between December 1980 and September 1992, 47 patients were treated at the Massachusetts General Hospital and Harvard Cyclotron Laboratory for primary or recurrent chordomas and chondrosarcomas (group 1, 20 patients), osteogenic sarcomas (group 2, 15 patients) and giant cell tumors, osteo-or chondroblastomas (group 3, 12 patients). Radiation treatment was given postoperatively in 23 patients, pre- and postoperatively in 17 patients, and 7 patients received radiation therapy as definitive treatment modality following biopsy only. The proton radiation component was delivered using a 160 MeV proton beam and the photon component using megavoltage photons up to 23 MV energy with 1.8-2.0 Cobalt Gray Equivalent (CGE) per fraction, once a day. Total external beam target dose ranged from 55.3 CGE to 82.0 CGE with mean target doses of 73.9 CGE (group 1), 69.8 CGE (group 2), and 61.8 CGE (group 3). RESULTS: Group 1 (chordoma and chondrosarcoma): Five of 14 patients (36%) with chordoma recurred locally, and 2 out of 5 patients developed distant metastasis, resulting in 1 death from disease. A trend for improved local control was noted for primary vs. recurrent tumors, target doses > 77 CGE and gross total resection. All patients with chondrosarcoma achieved and maintained local control and disease-free status. Five-year actuarial local control and overall survival rates were 53% and 50% for chordomas and 100% and 100% for chondrosarcomas, respectively. Group 2 (osteogenic sarcoma): Three of 15 patients (20%) never achieved local control and died within 6 months of completion of radiation treatment. Only 1 out of 12 patients who were controlled for more than 6 months failed locally, yielding a 5-year local control rate of 59% for 15 patients. Overall, 4 patients (27%) developed distant metastasis (two in patients with uncontrolled primary); 4 patients succumbed to their disease, 3 patients died of intercurrent disease, resulting in overall survival of 44% at 5 years. Group 3 (giant cell tumors, osteo- and chondroblastoma): One of 8 patients with giant cell tumor failed locally, 1 patient distantly, and all patients are alive. Three of 4 patients with osteo- or chondroblastoma are alive and well. One patient suffered local recurrence and died of disease. Local control rate and overall survival for this group of 12 patients was 76% and 87% and local control for patients with giant cell tumors 83% at 5 years. In the majority of cases radiotherapy was well tolerated. However, one patient with a large base of skull tumor developed retinopathy, one patient required enucleation of a previously blind eye, and another patient with sacral tumor developed chronic diarrhea. CONCLUSION: Combined proton and photon radiation therapy optimized by 3D treatment planning, allows the delivery of higher radiation doses to tumors of the axial skeleton, while respecting normal tissue constraints. High radiation doses can result in improved long-term local control</style></abstract><notes><style face="normal" font="default">7852108g97, 7603616IM0 (Protons)Journal ArticleResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>3086</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hungerford,J.L.</style></author><author><style face="normal" font="default"> Foss,A.J.</style></author><author><style face="normal" font="default"> Whelahan,I.</style></author><author><style face="normal" font="default"> Errington,R.D.</style></author><author><style face="normal" font="default"> Kacperek,A.</style></author><author><style face="normal" font="default"> Kongerud,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Moorfields Eye Hospital, Saint Bartholomew's Hospital, London, UK</style></auth-address><titles><title><style face="normal" font="default">Side effects of photon and proton radiotherapy for ocular melanoma</style></title><secondary-title><style face="normal" font="default">Frontiers of Radiation Therapy &amp; Oncology.30.:287.-93.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Frontiers of Radiation Therapy &amp; Oncology.30.:287.-93.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Brachytherapy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eye Enucleation</style></keyword><keyword><style face="normal" font="default"> Eye Neoplasms/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Eye Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Glaucoma,Neovascular/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Glaucoma,Neovascular/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Glaucoma,Neovascular/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Photons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Retinal Detachment/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Retinal Detachment/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Retinal Detachment/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword></keywords><dates><year Day="0" Month="0" Year="1997">1997</year></dates><pub-location><style face="normal" font="default">SWITZERLAND</style></pub-location><isbn><style face="normal" font="default">0071-9676</style></isbn><notes><style face="normal" font="default">92059120125544IM0 (Protons)Comparative StudyJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>3224</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,M.K.</style></author><author><style face="normal" font="default"> Char,D.H.</style></author><author><style face="normal" font="default"> Castro,J.L.</style></author><author><style face="normal" font="default"> Saunders,W.M.</style></author><author><style face="normal" font="default"> Chen,G.T.</style></author><author><style face="normal" font="default"> Stone,R.D.</style></author></authors></contributors><titles><title><style face="normal" font="default">Neovascular glaucoma after helium ion irradiation for uveal melanoma</style></title><secondary-title><style face="normal" font="default">Ophthalmology.93.(2):189.-93.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ophthalmology.93.(2):189.-93.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anterior Eye Segment/bs [Blood Supply]</style></keyword><keyword><style face="normal" font="default"> Dose-Response Relationship,Radiation</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Glaucoma</style></keyword><keyword><style face="normal" font="default"> Glaucoma/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Glaucoma/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Helium/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Intraocular Pressure</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Neovascularization,Pathologic/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Neovascularization,Pathologic/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pressure</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Dosage</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="0" Month="2" Year="1986">1986/2</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0161-6420</style></isbn><abstract><style face="normal" font="default">Neovascular glaucoma developed in 22 of 169 uveal melanoma patients treated with helium ion irradiation. Most patients had large melanomas; no eyes containing small melanomas developed anterior segment neovascularization. The mean onset of glaucoma was 14.1 months (range, 7-31 months). The incidence of anterior segment neovascularization increased with radiation dosage; there was an approximately three-fold increase at 80 GyE versus 60 GyE of helium ion radiation (23% vs. 8.5%) (P less than 0.05). Neovascular glaucoma occurred more commonly in larger tumors; the incidence was not affected by tumor location, presence of subretinal fluid, nor rate of tumor regression. Fifty-three percent of patients had some response with intraocular pressures of 21 mmHg or less to a combination of antiglaucoma treatments</style></abstract><notes><style face="normal" font="default">2419816oi5, 7802443IM7440-59-7 (Helium)Journal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>3242</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kitagawa,T.</style></author><author><style face="normal" font="default"> Inada,T.</style></author><author><style face="normal" font="default"> Arimoto,T.</style></author><author><style face="normal" font="default"> Maruhashi,A.</style></author><author><style face="normal" font="default"> Takada,Y.</style></author><author><style face="normal" font="default"> Hayakawa,Y.</style></author><author><style face="normal" font="default"> Kobayashi,K.</style></author><author><style face="normal" font="default"> Sato,M.</style></author><author><style face="normal" font="default"> Suwa,S.</style></author><author><style face="normal" font="default"> Iwasaki,Y.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Clinical investigation of indications in proton therapy]. [Japanese]</style></title><secondary-title><style face="normal" font="default">Gan No Rinsho - Japanese Journal of Cancer Clinics.32.(7.):729.-39.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Gan No Rinsho - Japanese Journal of Cancer Clinics.32.(7.):729.-39.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Skin Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Tongue Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Uterine Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="0" Month="6" Year="1986">1986/6</year></dates><pub-location><style face="normal" font="default">JAPAN</style></pub-location><isbn><style face="normal" font="default">0021-4949</style></isbn><abstract><style face="normal" font="default">The indications for curative treatment with proton therapy were investigated by the clinical results of 31 cancer patients treated with proton beams between 1983 and 1985 at the Particle Radiation Medical Science Center of Tsukuba University. Many locally extended, radioresistant lesions, lesions with large volume and small radiocurable lesions in this series revealed sufficient improvement without definite late damage in the surrounding normal tissues. This clinical result suggests that proton beam treatment could be applied to lesions in a much wider range for curative purposes as compared with conventional radiotherapy. This study is to be continued further</style></abstract><notes><style face="normal" font="default">3016360kif, 1257753IM0 (Protons)English AbstractJournal ArticleJapanese</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>3244</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kitagawa,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Particle Research Center for Medicine, Tsukuba Univ</style></auth-address><titles><title><style face="normal" font="default">[Proton beam therapy of cancer in deep-seated organs]. [Japanese]</style></title><secondary-title><style face="normal" font="default">Gan No Rinsho - Japanese Journal of Cancer Clinics.34.(13):1839.-44.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Gan No Rinsho - Japanese Journal of Cancer Clinics.34.(13):1839.-44.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Stomach Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Uterine Cervical Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="0" Month="10" Year="1988">1988/10</year></dates><pub-location><style face="normal" font="default">JAPAN</style></pub-location><isbn><style face="normal" font="default">0021-4949</style></isbn><abstract><style face="normal" font="default">Radiation therapy has shown definite technical improvement due to application of proton beam irradiation. Clinical results of proton beam therapy also suggested enlargement of indication ranges in radial treatment and decrease of post radiation damages of the treatment of cancers in deep-seated organs. Improvement of result in cancer therapy could be expected by this treatment technique in the future</style></abstract><notes><style face="normal" font="default">2848958kif, 1257753IM0 (Protons)English AbstractJournal ArticleJapanese</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>3295</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Koyama,S.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author><author><style face="normal" font="default"> Yokota,H.</style></author><author><style face="normal" font="default"> Hotta,S.</style></author><author><style face="normal" font="default"> Miyo,Y.</style></author><author><style face="normal" font="default"> Fukutomi,H.</style></author><author><style face="normal" font="default"> Osuga,T.</style></author><author><style face="normal" font="default"> Tsuji,H.</style></author><author><style face="normal" font="default"> Okumura,T.</style></author><author><style face="normal" font="default"> Ohara,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, University of Tsukuba, Ibaraki</style></auth-address><titles><title><style face="normal" font="default">Proton beam therapy for patients with esophageal carcinoma</style></title><secondary-title><style face="normal" font="default">Japanese Journal of Clinical Oncology.24.(3):144.-53.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Japanese Journal of Clinical Oncology.24.(3):144.-53.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Autopsy</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Squamous Cell/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Squamous Cell/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Esophageal Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Esophageal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Esophagoscopy</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Invasiveness</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="6" Year="1994">1994/6</year></dates><pub-location><style face="normal" font="default">JAPAN</style></pub-location><isbn><style face="normal" font="default">0368-2811</style></isbn><abstract><style face="normal" font="default">Fifteen patients with esophageal carcinoma (superficial, six cases; advanced, nine cases) were treated with 250 MeV proton beam irradiation with or without external x-ray irradiation (12 MV linear accelerator) from October, 1985, to May, 1991. Eleven patients were initially treated with x-ray at doses of 16.2-50.4 (mean 42.5) Gy, followed by proton beam at doses of 30.0-52.9 (mean 37.6) Gy. The other four patients were treated with proton beams alone at total doses of 75.0-88.5 (mean 81.4) Gy. The mean total dose for the 15 patients was 80.4 Gy. As a result, the primary tumor lesions of all 15 patients disappeared and complete responses were obtained. Approximately four to five months later, nine of the 15 patients developed esophageal ulcer formations at the circumferences of their primary lesions. The ulcerations were healed, however, by conservative management. There was no evidence of local recurrence throughout the observations on six cases of superficial carcinoma. Among nine advanced carcinoma patients, three relapsed into esophageal carcinoma. Recurrences were observed eight, 16 and 44 months, respectively, after the treatment. Ten of the 15 patients died, but eight died of other diseases. Three of four cases at autopsy did not show any cancer cells in irradiated primary lesions. Four of the 15 patients lived for over five years. The results suggest that a high dose of irradiation delivered by a well-defined proton field could result in improved local control and long-term survival in esophageal carcinoma without undue risk of injury to primary and adjacent organs</style></abstract><notes><style face="normal" font="default">8007424kin, 0313225IM0 (Protons)Journal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>3410</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Linstadt,D.</style></author><author><style face="normal" font="default"> Castro,J.</style></author><author><style face="normal" font="default"> Char,D.</style></author><author><style face="normal" font="default"> Decker,M.</style></author><author><style face="normal" font="default"> Ahn,D.</style></author><author><style face="normal" font="default"> Petti,P.</style></author><author><style face="normal" font="default"> Nowakowski,V.</style></author><author><style face="normal" font="default"> Quivey,J.</style></author><author><style face="normal" font="default"> Phillips,T.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, UCSF 94143-0226</style></auth-address><titles><title><style face="normal" font="default">Long-term results of helium ion irradiation of uveal melanoma</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.</style></abbr-1></periodical><pages end="618" start="613">613-618</pages><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eye Enucleation</style></keyword><keyword><style face="normal" font="default"> Glaucoma</style></keyword><keyword><style face="normal" font="default"> Glaucoma,Neovascular/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Ions</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Vision</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword></keywords><dates><year Day="0" Month="9" Year="1919">1919/9</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">Between 1978 and 1988, 307 patients with uveal melanoma were irradiated using helium ions at Lawrence Berkeley Laboratory. The length of follow-up ranged from 1-115 months (median 42 months). The 5-year actuarial treatment results were: local control rate, 96.8%, determinate survival rate, 81%, freedom from distant metastases, 76%, eye retention rate, 83%, and risk of developing neovascular glaucoma, 36%. Long-term vision outcome was analyzed in 81 patients with a minimum follow-up of 5 years. Forty-seven percent of patients retained vision of 20/200 or better. The median change in vision was a loss of four lines on the standard eye chart. Thirty-eight percent of patients had visual acuity either improve or remain within two lines of their pretreatment vision. A multivariate analysis identified tumor size as the only independently significant risk factor affecting survival, development of neovascular glaucoma, or the risk of enucleation; no risk factor correlated with local recurrence. Tumor size, tumor-fovea distance, and pretreatment visual acuity were independently significant risk factors influencing vision outcome. These results confirm that helium ion irradiation is an effective treatment for uveal melanoma which combines high rates of local control, survival, and eye retention with a substantial likelihood of long-term vision preservation</style></abstract><notes><style face="normal" font="default">2120158g97, 7603616IM0 (Ions)7440-59-7 (Helium)Journal ArticleResearch Support, U.S. Gov't, Non-P.H.SResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>3412</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Linstadt,D.</style></author><author><style face="normal" font="default"> Char,D.H.</style></author><author><style face="normal" font="default"> Castro,J.R.</style></author><author><style face="normal" font="default"> Phillips,T.L.</style></author><author><style face="normal" font="default"> Quivey,J.M.</style></author><author><style face="normal" font="default"> Reimers,M.</style></author><author><style face="normal" font="default"> Hannigan,J.</style></author><author><style face="normal" font="default"> Collier,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Biology and Medicine Division, Lawrence Berkeley Laboratory, Berkeley, CA</style></auth-address><titles><title><style face="normal" font="default">Vision following helium ion radiotherapy of uveal melanoma: a Northern California Oncology Group study.[see comment]</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.15.(2):347.-52.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.15.(2):347.-52.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Ciliary Body</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Ions</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Vision</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword><keyword><style face="normal" font="default"> Visual Acuity/re [Radiation Effects]</style></keyword></keywords><dates><year Day="0" Month="8" Year="1988">1988/8</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">One hundred eighty-six uveal melanoma patients were treated with helium ion radiotherapy at Lawrence Berkeley Laboratory and followed for at least 6 months. (Follow-up times ranged from 6 to 90 months; median 26.4 months.) At last examination, 92 of 186 patients (49%) had visual acuity of 20/200 or better in the treated eye. Univariate statistical analysis revealed that post-treatment vision correlated with tumor size, distance between tumor and optic disc, distance between tumor and fovea, pretreatment visual acuity, dose delivered to the optic disc, and dose delivered to the fovea (p less than .05). Neither the maximum tumor dose nor site of tumor origin (ciliary body vs. choroid) correlated with post-treatment vision on a univariate basis. However, multivariate statistical analysis revealed that the strongest independent risk factors influencing vision outcome (p less than .05) were tumor size, pretreatment visual acuity, tumor-fovea distance, and maximum tumor dose. Neither the fovea dose nor the dose to optic disc appeared to significantly affect vision outcome when other variables were taken into account. These results suggest that post-treatment visual acuity of 20/200 or better can be achieved in one-half of uveal melanoma patients treated using helium ion irradiation. Several independent risk factors affecting vision outcome have been identified</style></abstract><notes><style face="normal" font="default">3403315g97, 7603616IM0 (Ions)7440-59-7 (Helium)Journal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, Non-P.H.SResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>3413</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Linstadt,D.</style></author><author><style face="normal" font="default"> Quivey,J.M.</style></author><author><style face="normal" font="default"> Castro,J.R.</style></author><author><style face="normal" font="default"> Andejeski,Y.</style></author><author><style face="normal" font="default"> Phillips,T.L.</style></author><author><style face="normal" font="default"> Hannigan,J.</style></author><author><style face="normal" font="default"> Gribble,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, University of California, San Francisco</style></auth-address><titles><title><style face="normal" font="default">Comparison of helium-ion radiation therapy and split-course megavoltage irradiation for unresectable adenocarcinoma of the pancreas. Final report of a Northern California Oncology Group randomized prospective clinical trial</style></title><secondary-title><style face="normal" font="default">Radiology.168.(1):261.-4,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Radiology.168.(1):261.-4,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adenocarcinoma</style></keyword><keyword><style face="normal" font="default"> Adenocarcinoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Arm</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Helium/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Ions</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Pancreatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Particle Accelerators</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Random Allocation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="1988">1988/7</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0033-8419</style></isbn><abstract><style face="normal" font="default">Forty-nine patients with locally advanced carcinoma of the pancreas were treated in a randomized, prospective study comparing definitive helium ion radiation therapy with conventional split-course megavoltage photon irradiation. Patients in each treatment arm underwent exploratory staging laparotomy followed by concurrent radiation therapy and 5-fluorouracil chemotherapy. Patients treated with photons received 6,000 cGy over a period of 10 weeks; patients treated with helium irradiation received a 6,000-7,000-cGy-equivalent dose over a period of 8-9 weeks. There was no significant difference in overall survival between patients in the two treatment arms (P = .29). Patients treated with helium ions had a slightly longer median survival (7.8 months) than the photon-treated patients (6.5 months). Local control rates were slightly higher in the helium-treated patients (10% vs 5%). Complications included one chemotherapy-related death. Four of the five helium-treated patients who survived longer than 18 months died of local failure without distant metastases. These results suggest that more aggressive local therapy could result in improved survival in helium-treated patients</style></abstract><notes><style face="normal" font="default">3132732qsh, 0401260AIM, IM7440-59-7 (Helium)Clinical TrialComparative StudyJournal ArticleRandomized Controlled TrialResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, Non-P.H.SResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>3414</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Linstadt,D.E.</style></author><author><style face="normal" font="default"> Castro,J.R.</style></author><author><style face="normal" font="default"> Phillips,T.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, University of California, San Francisco</style></auth-address><titles><title><style face="normal" font="default">Neon ion radiotherapy: results of the phase I/II clinical trial</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.</style></abbr-1></periodical><pages end="769" start="761">761-769</pages><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Cell Cycle</style></keyword><keyword><style face="normal" font="default"> Drug Evaluation</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Ions</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Neon</style></keyword><keyword><style face="normal" font="default"> Neon/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Oxygen</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prostate</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Relative Biological Effectiveness</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Sarcoma</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survivors</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> X-Ray Therapy</style></keyword><keyword><style face="normal" font="default"> X-Rays</style></keyword></keywords><dates><year Day="0" Month="4" Year="1920">1920/4</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">Neon ion radiotherapy possesses biologic and physical advantages over megavoltage X rays. Biologically, the neon beam reduces the oxygen enhancement ratio and increases relative biological effectiveness. Cells irradiated by neon ions show less variation in cell-cycle related radiosensitivity and decreased repair of radiation injury. The physical behavior of heavy charged particles allows precise delivery of high radiation doses to tumors while minimizing irradiation of normal tissues. In 1979 a Phase I-II clinical trial was started at Lawrence Berkeley Laboratory using neon ions to irradiate patients for whom conventional treatment modalities were ineffective. By the end of 1988 a total of 239 patients had received a minimum neon physical dose of 1000 cGy (median follow-up for survivors 32 months). Compared with historical results, the 5-year actuarial disease-specific survival (DSS5) and local control (LC5) rates suggest that neon treatment improves outcome for several types of tumors: a) advanced or recurrent macroscopic salivary gland carcinomas (DSS5 59%; LC5 61%); b) paranasal sinus tumors (DSS5 69%; LC5 69% for macroscopic disease); c) advanced soft tissue sarcomas (DSS5 56%, LC5 56% for macroscopic disease); d) macroscopic sarcomas of bone (DSS5 45%; LC5 59%); e) locally advanced prostate carcinomas (DSS5 90%; LC5 75%); and f) biliary tract carcinomas (DSS5 28%; LC5 44%). Treatment of malignant gliomas, pancreatic, gastric, esophageal, lung, and advanced or recurrent head and neck cancer has been less successful; results for these tumors appear no better than those achieved with conventional x-ray therapy. These findings suggest that Phase III trials using the neon beam should be implemented for selected malignancies</style></abstract><notes><style face="normal" font="default">2004953g97, 7603616IM, S0 (Radioisotopes)7440-01-9 (Neon)Clinical TrialJournal ArticleResearch Support, U.S. Gov't, Non-P.H.SResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>3447</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lovato,A.A.</style></author><author><style face="normal" font="default"> Char,D.H.</style></author><author><style face="normal" font="default"> Castro,J.R.</style></author><author><style face="normal" font="default"> Kroll,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophthalmology, University of California, San Francisco</style></auth-address><titles><title><style face="normal" font="default">The effect of silicone nasolacrimal intubation on epiphora after helium ion irradiation of uveal melanomas</style></title><secondary-title><style face="normal" font="default">American Journal of Ophthalmology.108.(4):431.-4,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">American Journal of Ophthalmology.108.(4):431.-4,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Drainage</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Helium/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Intubation</style></keyword><keyword><style face="normal" font="default"> Intubation/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Lacrimal Apparatus</style></keyword><keyword><style face="normal" font="default"> Lacrimal Apparatus Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Lacrimal Apparatus Diseases/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Nasolacrimal Duct</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Silicones</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="15" Month="10" Year="1989">1989/10/15</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0002-9394</style></isbn><abstract><style face="normal" font="default">We evaluated prophylactic silicone tube intubation of the nasolacrimal drainage system prior to helium ion irradiation of uveal melanomas located on the nasal side of the globe. Twelve patients received silicone tubes and were compared to a control group of 12 patients with irradiated nasal tumors without silicone tubes. Symptoms of nasolacrimal duct obstruction and epiphora were evaluated by means of a questionnaire. All patients had nasolacrimal duct irrigation. Patients intubated before irradiation maintained patency (11 of 12), whereas those in the control group did not (zero of 12) (P less than .0014); ten of 12 control patients had closure of both superior and inferior puncta. No significant difference in symptoms of epiphora was observed between the two groups</style></abstract><notes><style face="normal" font="default">28018623oq, 0370500AIM, IM0 (Radioisotopes)0 (Silicones)7440-59-7 (Helium)Journal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, Non-P.H.SResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>3534</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Matsuzaki,Y.</style></author><author><style face="normal" font="default"> Osuga,T.</style></author><author><style face="normal" font="default"> Saito,Y.</style></author><author><style face="normal" font="default"> Chuganji,Y.</style></author><author><style face="normal" font="default"> Tanaka,N.</style></author><author><style face="normal" font="default"> Shoda,J.</style></author><author><style face="normal" font="default"> Tsuji,H.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, University of Tsukuba, Ibaraki, Japan</style></auth-address><titles><title><style face="normal" font="default">A new, effective, and safe therapeutic option using proton irradiation for hepatocellular carcinoma</style></title><secondary-title><style face="normal" font="default">Gastroenterology.106.(4):1032.-41.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Gastroenterology.106.(4):1032.-41.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> alpha-Fetoproteins/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="4" Year="1994">1994/4</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0016-5085</style></isbn><abstract><style face="normal" font="default">BACKGROUND/AIMS: Conventional radiation is almost useless for hepatocellular carcinoma (HCC) because of the severe adverse effects of the irradiation to the accompanying liver cirrhosis. In contrast, the proton beam has Bragg peak, which limits distribution of the beam. The aim of this study was to prove the usefulness of proton irradiation for HCC. METHODS: The proton irradiation was performed in 32 nodular lesions in 24 patients with HCC who had unresectable tumors or serious complications; the proton irradiation was performed either as monotherapy (15 lesions) or as combination therapy to insufficient Lipiodol-targeted chemotherapy (Kodama Co. Ltd., Tokyo, Japan) (17 lesions). The energy was 250 MeV, and 50-87 Gy (76.5 +/- 9.5, mean +/- SD) in total was irradiated for a time period of 17-69 days. RESULTS: After 1 year, size reduction was seen in 12 out of 13 lesions (92%) in the monotherapy group and 9 out of 9 lesions (100%) in the combination therapy group; after 2 years, size reduction was seen 4 out of 5 lesions (80%) in the monotherapy group and 5 out of 5 lesions (100%) in the combination therapy group. Local tumor control has being assured for 2 years of the observation, which is continuing for another 2 years. None of the patients have experienced any serious adverse effects. CONCLUSIONS: These results show that proton irradiation is a new, safe, and effective therapeutic option in cases of HCC, even in patients with unresectable tumors or those with serious complications</style></abstract><notes><style face="normal" font="default">7511552fh3, 0374630AIM, IM0 (Protons)0 (alpha-Fetoproteins)Case ReportsClinical TrialControlled Clinical TrialJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>3550</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">McAllister,B.</style></author><author><style face="normal" font="default"> Archambeau,J.O.</style></author><author><style face="normal" font="default"> Nguyen,M.C.</style></author><author><style face="normal" font="default"> Slater,J.D.</style></author><author><style face="normal" font="default"> Loredo,L.</style></author><author><style face="normal" font="default"> Schulte,R.</style></author><author><style face="normal" font="default"> Alvarez,O.</style></author><author><style face="normal" font="default"> Bedros,A.A.</style></author><author><style face="normal" font="default"> Kaleita,T.</style></author><author><style face="normal" font="default"> Moyers,M.</style></author><author><style face="normal" font="default"> Miller,D.</style></author><author><style face="normal" font="default"> Slater,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Medicine, Loma Linda University Medical Center, CA 92354, USA</style></auth-address><titles><title><style face="normal" font="default">Proton therapy for pediatric cranial tumors: preliminary report on treatment and disease-related morbidities</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.39.(2):455.-60.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.39.(2):455.-60.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Brain</style></keyword><keyword><style face="normal" font="default"> Brain Neoplasms/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Brain Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Child,Preschool</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> Medical Records</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Physical Examination</style></keyword><keyword><style face="normal" font="default"> Pituitary Neoplasms/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Pituitary Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Seizures/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="1" Month="9" Year="1997">1997/9/1</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: Accelerated protons were used in an attempt to limit treatment-related morbidity in children with tumors in or near the developing brain, by reducing the integral dose to adjacent normal tissues. METHODS AND MATERIALS: Children treated with protons at Loma Linda University Medical Center between August 1991 and December 1994 were analyzed retrospectively. Twenty-eight children, aged 1 to 18 years, were identified as at risk for brain injury from treatment. Medical records, physical examinations, and correspondence with patients, their parents, and referring physicians were analyzed. The investigators tabulated post-treatment changes in pre-treatment signs and symptoms and made judgments as to whether improvement, no change, or worsening related to disease or treatment had supervened. Magnetic resonance images were correlated with clinical findings and radiographic impressions were tabulated. RESULTS: Follow-up ranged from 7 to 49 months (median 25 months). Four instances of treatment-related morbidity were identified. Forty-one instances of site-specific, disease-related morbidity were identified: 15 improved or resolved and 26 remained unchanged after treatment. Four patients had radiographic evidence of local failure. Three of these patients, including two with high-grade glioma, have died. CONCLUSION: Early treatment-related morbidity associated with proton therapy is low. Tumor progression remains a problem when treating certain histologies such as high-grade glioma. Escalating the dose delivered to target volumes may benefit children with tumors associated with poor rates of local control. Long-term follow-up, including neurocognitive testing, is in progress to assess integral-dose effects on cognitive, behavioral and developmental outcomes in children with cranial tumors</style></abstract><notes><style face="normal" font="default">9308950g97, 7603616IM0 (Protons)Journal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>3568</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Meecham,W.J.</style></author><author><style face="normal" font="default"> Char,D.H.</style></author><author><style face="normal" font="default"> Chen,G.T.</style></author><author><style face="normal" font="default"> Juster,R.</style></author><author><style face="normal" font="default"> Castro,J.R.</style></author><author><style face="normal" font="default"> Stone,R.D.</style></author><author><style face="normal" font="default"> Saunders,W.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Correlation of visual field, treatment fields, and dose in helium ion irradiation of uveal melanoma</style></title><secondary-title><style face="normal" font="default">American Journal of Ophthalmology.100.(5):658.-65.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">American Journal of Ophthalmology.100.(5):658.-65.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Helium</style></keyword><keyword><style face="normal" font="default"> Helium/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photography</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Dosage</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Scotoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Visual Fields</style></keyword></keywords><dates><year Day="15" Month="11" Year="1985">1985/11/15</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0002-9394</style></isbn><abstract><style face="normal" font="default">We correlated predicted radiation distributions in 29 patients with uveal melanoma (treated with 5,000 to 8,000 rads of helium ion therapy) with fundus photography and visual field deficits. The tumor was entirely within the treatment region in all patients. The fraction of the predicted high-dose and low-dose regions corresponding with an absolute scotoma was fitted by a linear regression model (r2 = .721) with three independent variables: dose region, initial condition, and time since therapy. The defect in the maximum-dose region increased at an average rate of 0.270/year. This differed (P = .002) from the rate in the penumbra region: (0.104/year). The rate in the penumbra differed (P = .01) from that in the predicted low-dose region, where scotoma did not increase with time. The pattern and time course of visual field loss in the different radiation dose regions tended to support the conclusion that isodose calculations are accurate. The data were consistent with the hypothesis that visual loss secondary to irradiation results primarily from radiation vasculopathy and not from direct damage to photoreceptors or ganglion cells. Development of an absolute scotoma may require a dose in excess of 5,000 rads</style></abstract><notes><style face="normal" font="default">40615453oq, 0370500AIM, IM7440-59-7 (Helium)Journal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, Non-P.H.SResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>3569</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Meecham,W.J.</style></author><author><style face="normal" font="default"> Char,D.H.</style></author><author><style face="normal" font="default"> Kroll,S.</style></author><author><style face="normal" font="default"> Castro,J.R.</style></author><author><style face="normal" font="default"> Blakely,E.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophthalmology, University of California, San Francisco</style></auth-address><titles><title><style face="normal" font="default">Anterior segment complications after helium ion radiation therapy for uveal melanoma. Radiation cataract</style></title><secondary-title><style face="normal" font="default">Archives of Ophthalmology.112.(2):197.-203.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Archives of Ophthalmology.112.(2):197.-203.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Cataract</style></keyword><keyword><style face="normal" font="default"> Cataract/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Cataract/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Ciliary Body</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glaucoma</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Lens,Crystalline/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Lens,Crystalline/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Life Tables</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="0" Month="2" Year="1994">1994/2</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0003-9950</style></isbn><abstract><style face="normal" font="default">OBJECTIVE: To delineate the factors in the development of visually significant cataract after helium ion irradiation of eyes with uveal melanomas. DESIGN: Retrospective analysis with multivariate analysis using life tables and Cox proportional hazard models in addition to other nonparametric techniques. PATIENTS: All patients with a noncataractous other eye and adequate dosimetry data who were treated with helium ion irradiation. RESULTS: Significant cataracts (grade 3+ or 4+ on a 0 to 4+ scale) developed in 129 patients (44%). The risk of cataract development peaked at 3 years (25% per person-year) and then declined to a sustained level of 7% to 9% per year after 7 years. In multivariate analysis, the percentage of lens included in the treatment port was the predominant predictive correlate with time to significant cataract (relative risk of 2.97 for a 25% increase in the percentage of lens in the treatment port). Patient age, preexisting cortical opacity, and ultrasound tumor height were also significant; ciliary body involvement and tumor dose had smaller effects. Kaplan-Meier analysis demonstrated an increased rate of cataractogenesis with each increment of the percentage of lens in the treatment port; when more than half of the lens was in the beam, the risk of cataract exceeded 90% within 7 years. CONCLUSIONS: Cataract development after helium ion irradiation is a function of the amount of the lens in the beam. Unlike neovascular glaucoma that develops mainly in the first few years after treatment, cataract continues to develop during the entire length of follow-up</style></abstract><notes><style face="normal" font="default">83117727706534, 830AIM, IM, S7440-59-7 (Helium)Journal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, Non-P.H.SResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>3611</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Miyanaga,N.</style></author><author><style face="normal" font="default"> Ami,Y.</style></author><author><style face="normal" font="default"> Ohtani,M.</style></author><author><style face="normal" font="default"> Koiso,K.</style></author><author><style face="normal" font="default"> Tsuji,H.</style></author><author><style face="normal" font="default"> Arimoto,T.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author><author><style face="normal" font="default"> Inada,T.</style></author><author><style face="normal" font="default"> Kitagawa,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Urology, University of Tsukuba</style></auth-address><titles><title><style face="normal" font="default">[Clinical study of proton radiotherapy in urological cancers]. [Japanese]</style></title><secondary-title><style face="normal" font="default">Nippon Hinyokika Gakkai Zasshi - Japanese Journal of Urology.81.(2):251.-7.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Nippon Hinyokika Gakkai Zasshi - Japanese Journal of Urology.81.(2):251.-7.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Kidney Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urinary Bladder Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Urologic Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="0" Month="2" Year="1990">1990/2</year></dates><pub-location><style face="normal" font="default">JAPAN</style></pub-location><isbn><style face="normal" font="default">0021-5287</style></isbn><abstract><style face="normal" font="default">Therapy with proton beam is superior to that with photon beam in concentrating the dose within a lesion. Fifteen patients with urinary malignant tumors were treated by proton irradiation during the period from June, 1985 to March, 1989 at Particle Radiation Medical Center, University of Tsukuba. Four patients were with renal cell carcinoma, five with prostatic cancer and six with bladder cancer. Treatment results were assessed by change in tumor size either three or six months after the irradiation. In all the four cases with renal cell carcinoma, the tumor sizes were found to be unchanged without any enlargement. Of the five cases with prostatic cancer, two showed that the treatment was effective and the tumor sizes in the other three cases were found to be unchanged. In three of the six cases with bladder cancer the tumors disappeared while the treatment was found effective in two other and it did not cause any enlargement of the tumor in the remaining one. Although local control of the tumor was successful in all the cases, one patient with prostatic cancer and three with bladder cancer died of cancer. Various side effects, such as radiation cystitis, were observed. This prospective therapy is expected to replace the conventional photon therapy. However, some improvement is needed to make full use of the advantageous properties in dose distribution. Combination therapy with other general therapy is required for some cases</style></abstract><notes><style face="normal" font="default">2157915krb, 2984841rIM0 (Protons)English AbstractJournal ArticleJapanese</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>3648</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Munzenrider,J.E.</style></author><author><style face="normal" font="default"> ustin-Seymour,M.</style></author><author><style face="normal" font="default"> Blitzer,P.J.</style></author><author><style face="normal" font="default"> Gentry,R.</style></author><author><style face="normal" font="default"> Goitein,M.</style></author><author><style face="normal" font="default"> Gragoudas,E.S.</style></author><author><style face="normal" font="default"> Johnson,K.</style></author><author><style face="normal" font="default"> Koehler,A.M.</style></author><author><style face="normal" font="default"> McNulty,P.</style></author><author><style face="normal" font="default"> Moulton,G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Proton therapy at Harvard</style></title><secondary-title><style face="normal" font="default">Strahlentherapie.161.(12.):756.-63.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Strahlentherapie.161.(12.):756.-63.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Animals</style></keyword><keyword><style face="normal" font="default"> Arteriovenous Malformations/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Haplorhini</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> Head and Neck Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Neoplasm Metastasis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Rectal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Retroperitoneal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Base</style></keyword><keyword><style face="normal" font="default"> Technology,Radiologic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Vision/re [Radiation Effects]</style></keyword></keywords><dates><year Day="0" Month="12" Year="1985">1985/12</year></dates><pub-location><style face="normal" font="default">GERMANY, WEST</style></pub-location><isbn><style face="normal" font="default">0039-2073</style></isbn><abstract><style face="normal" font="default">Fractionated precision high-dose proton radiotherapy has been carried out at the Harvard Cyclotron Laboratory (HCL) since 1973, in a collaborative effort with the Radiation Medicine Department of Massachusetts General Hospital (MGH) and the Retina Service of the Massachusetts Eye and Ear Infirmary (MEEI). This paper will discuss proton treatment in general, treatment planning procedures, and results to date in major patient categories. 846 patients have been treated with fractionated proton therapy at the Harvard Cyclotron, with normal tissue and tumor responses consistent with an RBE of 1.1 for the proton beam. Proton beam therapy is the treatment of choice for patients with uveal melanomas, and chordomas and chondrosarcomas involving the skull base and cervical spine. Improved dose distribution possible with protons have allowed greater doses than are given conventionally to be delivered to patients with prostatic carcinoma, head and neck malignancies, ano-rectal cancers, and retroperitoneal tumors. Doses employed have been usually 10 to 20% greater than normally would be delivered in our department to such tumors. Generally, local control rates have been good</style></abstract><notes><style face="normal" font="default">3001976v1z, 1260024IM0 (Protons)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>3649</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Munzenrider,J.E.</style></author><author><style face="normal" font="default"> Gragoudas,E.S.</style></author><author><style face="normal" font="default"> Seddon,J.M.</style></author><author><style face="normal" font="default"> Sisterson,J.</style></author><author><style face="normal" font="default"> McNulty,P.</style></author><author><style face="normal" font="default"> Birnbaum,S.</style></author><author><style face="normal" font="default"> Johnson,K.</style></author><author><style face="normal" font="default"> ustin-Seymour,M.</style></author><author><style face="normal" font="default"> Slater,J.</style></author><author><style face="normal" font="default"> Goitein,M.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Radiation Medicine Service, Massachusetts General Hospital, Boston 02114</style></auth-address><titles><title><style face="normal" font="default">Conservative treatment of uveal melanoma: probability of eye retention after proton treatment</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.15.(3):553.-8.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.15.(3):553.-8.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Actuarial Analysis</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Ciliary Body</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Immunotherapy</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Ophthalmologic Surgical Procedures</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/su [Surgery]</style></keyword></keywords><dates><year Day="0" Month="9" Year="1988">1988/9</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">Enucleation was performed after proton treatment in 57 of 1006 (5.7%) uveal melanoma patients treated with proton beam therapy at the Harvard Cyclotron Laboratory between July 1975 and December 31, 1986. Only 2% of 99 patients with small tumors and 4% of 566 patients with intermediate size tumors underwent enucleation after treatment; 10% of 341 patients with large tumors lost the treated eye. No eyes were removed after 52 months, with 89% of enucleations performed during the first 36 months after treatment. Eye retention rates at 60 months were 89.1 +/- 3.0% for the entire group, and 97 +/- 3.7%, 92.7 +/- 3.1%, and 78.3 +/- 7.0% in patients with small, intermediate, and large tumors, respectively. Significantly greater enucleation rates were observed in patients with large tumors than in those with intermediate tumors (p = less than .0001), in patients with tumor height greater than 8 mm relative to those with tumors less than or equal to 8 mm, p = (less than .0001), with tumor diameter greater than 16 mm compared to less than or equal to 16 mm, (p = less than .0001), and with tumor involvement of the ciliary body compared to involvement of the choroid only (p = less than .0001). Possible strategies to decrease the likelihood of enucleation in patients at apparently increased risk of losing the eye after conservative therapy, that is, those with large tumors involving the ciliary body, might include a lower total dose, a more protracted treatment course, or a lower radiation dose and adjuvant treatment with chemotherapy and/or immunotherapy, with hyperthermia, or with other radiation sensitizers</style></abstract><notes><style face="normal" font="default">2843486g97, 7603616IM0 (Protons)Journal ArticleResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>3650</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Munzenrider,J.E.</style></author><author><style face="normal" font="default"> Verhey,L.J.</style></author><author><style face="normal" font="default"> Gragoudas,E.S.</style></author><author><style face="normal" font="default"> Seddon,J.M.</style></author><author><style face="normal" font="default"> Urie,M.</style></author><author><style face="normal" font="default"> Gentry,R.</style></author><author><style face="normal" font="default"> Birnbaum,S.</style></author><author><style face="normal" font="default"> Ruotolo,D.M.</style></author><author><style face="normal" font="default"> Crowell,C.</style></author><author><style face="normal" font="default"> McManus,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Radiation Medicine Service, Massachusetts General Hospital, Boston 02114</style></auth-address><titles><title><style face="normal" font="default">Conservative treatment of uveal melanoma: local recurrence after proton beam therapy</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.17(3):493.-8.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.17(3):493.-8.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Light Coagulation</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Particle Accelerators</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="0" Month="9" Year="1989">1989/9</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">Twenty-three of 1006 (2.3%) uveal melanoma patients treated with proton beam therapy at the Harvard Cyclotron Laboratory between July 1975 and December 31, 1986 received additional treatment for documented (15 patients) or suspected (eight patients) tumor growth in the irradiated eye. Growth within the initially irradiated volume was documented at Massachusetts Eye and Ear Infirmary in 12 patients. Documented growth occurred in nine of 665 (1.4%) patients with small and intermediate size tumors, at times after treatment ranging from 6 to 48 months (median 16 months), and in three of 341 (.9%) patients with large tumors at 7, 11, and 12 months after treatment. Melanoma growing totally outside the treated volume was also documented in three additional patients at 7, 9, and 45 months; two of these were thought to be "ring melanomas". Eight patients had the treated eye removed elsewhere for suspected tumor growth. The additional treatment in these 23 patients was conservative in nine patients (repeat proton irradiation in five and laser photocoagulation in four). Thirteen underwent immediate enucleation and one had orbital exenteration. Ultimately, 17 of the 23 eyes (74%) were removed. Estimated probability of local control of the melanoma within the irradiated eye at 60 months was 96.3 +/- 1.5%. Dose distributions to the 12 patients with documented local failure within the irradiated volume were analyzed. Ten tumors recurred marginally in an area receiving less than the prescribed dose of 70 CGE (CGE = Cobalt Gray Equivalents = proton Gy X RBE 1.1), whereas only two recurred in the volume receiving full dose. Based on these data, it appears that a dose of 70 CGE in five fractions is associated with very high rates of local control in human uveal melanoma. It is reasonable to consider initiating studies using a lower total dose or a more protracted course, to determine if some of the observed complications are dose-related</style></abstract><notes><style face="normal" font="default">2550395g97, 7603616IM0 (Protons)Journal ArticleResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>3712</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nowakowski,V.A.</style></author><author><style face="normal" font="default"> Ivery,G.</style></author><author><style face="normal" font="default"> Castro,J.R.</style></author><author><style face="normal" font="default"> Char,D.H.</style></author><author><style face="normal" font="default"> Linstadt,D.E.</style></author><author><style face="normal" font="default"> Ahn,D.</style></author><author><style face="normal" font="default"> Phillips,T.L.</style></author><author><style face="normal" font="default"> Quivey,J.M.</style></author><author><style face="normal" font="default"> Decker,M.</style></author><author><style face="normal" font="default"> Petti,P.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, University of California, San Francisco 94143</style></auth-address><titles><title><style face="normal" font="default">Uveal melanoma: development of metastases after helium ion irradiation</style></title><secondary-title><style face="normal" font="default">Radiology.178.(1):277.-80.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Radiology.178.(1):277.-80.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Actuarial Analysis</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Helium/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Ions</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="0" Month="1" Year="1991">1991/1</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0033-8419</style></isbn><abstract><style face="normal" font="default">Forty-two (16%) of 261 patients with ocular melanoma who were treated with helium ions between January 1978 and November 1986 have developed metastatic disease. The time between start of helium ion treatment and recognition of metastatic disease ranged from 3 to 67 months (median, 27 months). The mean pretreatment tumor height in the patients with metastases was 7.7 mm. All 42 patients who developed metastatic disease have died. The median survival after diagnosis of metastatic disease was 5 months; the longest survival was 49 months. The most common site of metastasis was the liver (n = 34). Four (10%) of the 42 patients with metastases also had local recurrence of the tumor. Multivariate analysis identified three variables that predicted independently the development of metastases and lack of survival. These variables are anterior location of tumor (P = .027), tumor height greater than 5 mm (P = .02), and tumor diameter greater than 10 mm (P = .0075)</style></abstract><notes><style face="normal" font="default">1898536qsh, 0401260AIM, IM7440-59-7 (Helium)Comparative StudyJournal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, Non-P.H.SResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>3713</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nowakowski,V.A.</style></author><author><style face="normal" font="default"> Castro,J.R.</style></author><author><style face="normal" font="default"> Petti,P.L.</style></author><author><style face="normal" font="default"> Collier,J.M.</style></author><author><style face="normal" font="default"> Daftari,I.</style></author><author><style face="normal" font="default"> Ahn,D.</style></author><author><style face="normal" font="default"> Gauger,G.</style></author><author><style face="normal" font="default"> Gutin,P.</style></author><author><style face="normal" font="default"> Linstadt,D.E.</style></author><author><style face="normal" font="default"> Phillips,T.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of California Lawrence Berkeley Laboratory</style></auth-address><titles><title><style face="normal" font="default">Charged particle radiotherapy of paraspinal tumors</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.22.(2):295.-303.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.22.(2):295.-303.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Brachial Plexus</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Chordoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Sarcoma</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Spinal Cord</style></keyword><keyword><style face="normal" font="default"> Spinal Cord Neoplasms/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Spinal Cord Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Spinal Cord Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> United States/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="1992">1992</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">Between 1976 and 1987, 52 patients with tumors adjacent to and/or involving the cervical, thoracic, or lumbar spinal cord were treated with charged particles at the University of California Lawrence Berkeley Laboratory. The histologies included chordoma and chondrosarcoma (24 pts), other bone and soft tissue sarcoma (14 pts), and metastatic or unusual histology tumors (14 pts). Radiation doses ranged from 29 to 80 Gray-equivalent (GyE), with a median dose of 70 GyE. Twenty-one patients received a portion of their treatment with photons. Median followup was 28 months. For 36 previously untreated patients, local control was achieved in 21/36 patients and the 3-year actuarial survival was 61%. Of 16 patients treated for recurrent disease, 7/16 were locally controlled and the 3-year actuarial survival was 51%. For patients treated for chordoma and chondrosarcoma, probability of local control was influenced by tumor volume (less than 100 cc or greater than 150 cc) and whether disease was recurrent or previously untreated. Complications occurred in 6/52 patients, including one spinal cord injury, one cauda equina and one brachial plexus injury, and three instances of skin or subcutaneous fibrosis. Charged particle radiotherapy can safely deliver high tumor doses to paraspinal tumors with good local control</style></abstract><notes><style face="normal" font="default">1740393g97, 7603616IMCase ReportsJournal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, Non-P.H.SResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>3722</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">O'Connell,J.X.</style></author><author><style face="normal" font="default"> Renard,L.G.</style></author><author><style face="normal" font="default"> Liebsch,N.J.</style></author><author><style face="normal" font="default"> Efird,J.T.</style></author><author><style face="normal" font="default"> Munzenrider,J.E.</style></author><author><style face="normal" font="default"> Rosenberg,A.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pathology, Massachusetts General Hospital, Boston</style></auth-address><titles><title><style face="normal" font="default">Base of skull chordoma. A correlative study of histologic and clinical features of 62 cases</style></title><secondary-title><style face="normal" font="default">Cancer.74.(8.):2261.-7.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cancer.74.(8.):2261.-7.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Chordoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Chordoma/ul [Ultrastructure]</style></keyword><keyword><style face="normal" font="default"> Combined Modality Therapy</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Mitotic Index</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Sacrum</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Base</style></keyword><keyword><style face="normal" font="default"> Skull Neoplasms</style></keyword><keyword><style face="normal" font="default"> Skull Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Skull Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Skull Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Skull Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Skull Neoplasms/ul [Ultrastructure]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="15" Month="10" Year="1994">1994/10/15</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0008-543X</style></isbn><abstract><style face="normal" font="default">BACKGROUND. Chordomas are uncommon primary malignant tumors of bone that typically occur in the axial skeleton including the sacrum, vertebrae, and skull base. The base of skull tumors usually are not amenable to complete surgical resection, and most require postoperative radiotherapy. The natural history of skull base chordoma is typified by slow locally invasive tumor progression and eventual death, although few parameters are known that allow stratification of patients into prognostic groups. METHODS. Sixty-two patients with skull base chordomas treated at the Massachusetts General Hospital by proton beam irradiation therapy with at least 2 years of follow-up information were reviewed in an attempt to identify clinical and pathologic parameters that predicted outcome. RESULTS. Female sex, tumor necrosis in preradiation treatment biopsy, and tumor volume in excess of 70 ml were each independent predictors of shortened overall survival after radiation therapy for skull base chordoma. CONCLUSIONS. Stratification of patients with skull base chordoma into poor and good outcome groups can be performed using the three parameters identified in our study. In addition, the striking difference in survival between the sexes suggests that further investigations of these tumors should include determination of their hormonal receptors status and consideration of hormonal manipulation in their management</style></abstract><notes><style face="normal" font="default">79229770374236, clzAIM, IMJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>3764</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Park,S.S.</style></author><author><style face="normal" font="default"> Walsh,S.M.</style></author><author><style face="normal" font="default"> Gragoudas,E.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, USA</style></auth-address><titles><title><style face="normal" font="default">Visual-field deficits associated with proton beam irradiation for parapapillary choroidal melanoma.[erratum appears in Ophthalmology 1996 May;103(5):699]</style></title><secondary-title><style face="normal" font="default">Ophthalmology.103.(1):110.-6.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ophthalmology.103.(1):110.-6.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Color</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Optic Disk/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Scotoma/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Texas</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Visual Acuity/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Visual Fields</style></keyword><keyword><style face="normal" font="default"> Visual Fields/re [Radiation Effects]</style></keyword></keywords><dates><year Day="0" Month="1" Year="1996">1996/1</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0161-6420</style></isbn><abstract><style face="normal" font="default">PURPOSE: A large series of patients treated with proton irradiation for parapapillary choroidal melanoma were reviewed retrospectively to determine the frequency of radiation papillopathy and visual-field loss after treatment. METHODS: Among 249 patients with proton irradiation for parapapillary choroidal melanoma, the authors identified 59 patients who had visual-field testing performed before treatment and at least 18 months after treatment. The visual fields, color fundus photographs, and charts were reviewed to determine the prevalence of radiation papillopathy and visual-field loss after treatment. RESULTS: Nineteen of the 59 patients reviewed (31%) received a clinical diagnosis of radiation papillopathy. Progressive visual-field loss, defined as enlargement of absolute scotoma of greater than [corrected] or equal to 30 degrees as compared with the pretreatment visual field, was noted in 67% of patients with radiation papillopathy and 73% of patients without papillopathy. In both groups, visual-field loss correlated with the area of the retina predicted to be exposed to irradiation in the majority of patients. CONCLUSIONS: Progressive visual-field loss is common after proton irradiation for parapapillary choroidal melanoma. However, the scotoma usually correlates with the area of the retina exposed to irradiation. The development of radiation papillopathy does not appear to be associated with additional visual-field defects in most cases</style></abstract><notes><style face="normal" font="default">8628541oi5, 7802443IM0 (Protons)Journal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>3895</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Reimers,M.</style></author><author><style face="normal" font="default"> Castro,J.R.</style></author><author><style face="normal" font="default"> Linstadt,D.</style></author><author><style face="normal" font="default"> Collier,J.M.</style></author><author><style face="normal" font="default"> Henderson,S.</style></author><author><style face="normal" font="default"> Hannigan,J.</style></author><author><style face="normal" font="default"> Phillips,T.L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Heavy charged particle therapy of bone and soft tissue sarcoma. A phase I-II trial of the University of California Lawrence Berkeley Laboratory and the Northern California Oncology Group</style></title><secondary-title><style face="normal" font="default">American Journal of Clinical Oncology.9.(6.):488.-93.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">American Journal of Clinical Oncology.9.(6.):488.-93.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Actuarial Analysis</style></keyword><keyword><style face="normal" font="default"> Bone Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Bone Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Bone Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Energy Transfer</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Ions</style></keyword><keyword><style face="normal" font="default"> Neon</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Palliative Care</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Relative Biological Effectiveness</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Sarcoma</style></keyword><keyword><style face="normal" font="default"> Sarcoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Sarcoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Sarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="12" Year="1986">1986/12</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0277-3732</style></isbn><abstract><style face="normal" font="default">At the University of California Lawrence Berkeley Laboratory and the Northern California Oncology Group, a preliminary study of heavy charged particle radiotherapy in soft tissue and bone sarcoma has been carried out. Fifty-two patients with bone or soft tissue tumors were treated wholly or in part with heavy charged particles from 1978 to 1985. Eleven patients, considered inevaluable for purposes of this analysis, received less than 50 Gray-equivalents (GyE) because of the following: progressive disease (three patients); palliative treatment due to recurrent disease after previous radiation therapy (three patients); or since they were part of preliminary studies of relative biological effectiveness (RBE) (five patients). Forty-one patients received from 50 to 78.5 GyE, with a mean of 65 GyE. They had an average of 23 months follow-up, ranging from 4 to 78 months. In patients with paraspinal chondrosarcoma 9 of 11 had local control, with a mean follow-up time of 32 months. In the remaining patients with other histologies, 19 of 30 were controlled within the irradiated area, with a mean follow-up time of 20 months. Serious complications were encountered in the CNS (four patients), in the bowel (one patient), and in bone (one patient). Heavy charged particle radiotherapy appears to be of value in treating bone or soft tissue sarcoma; further trials are planned</style></abstract><notes><style face="normal" font="default">24316143ez, 8207754IM0 (Ions)7440-01-9 (Neon)7440-59-7 (Helium)Clinical TrialJournal ArticleResearch Support, U.S. Gov't, Non-P.H.SResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>3983</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Saunders,W.</style></author><author><style face="normal" font="default"> Castro,J.R.</style></author><author><style face="normal" font="default"> Chen,G.T.</style></author><author><style face="normal" font="default"> Collier,J.M.</style></author><author><style face="normal" font="default"> Zink,S.R.</style></author><author><style face="normal" font="default"> Pitluck,S.</style></author><author><style face="normal" font="default"> Phillips,T.L.</style></author><author><style face="normal" font="default"> Char,D.</style></author><author><style face="normal" font="default"> Gutin,P.</style></author><author><style face="normal" font="default"> Gauger,G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Helium-ion radiation therapy at the Lawrence Berkeley Laboratory: recent results of a Northern California Oncology Group Clinical Trial</style></title><secondary-title><style face="normal" font="default">Radiation Research - Supplement.8.:S227.-34.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Radiation Research - Supplement.8.:S227.-34.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adenocarcinoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Brain Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Squamous Cell/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default"> Esophageal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Esophagus</style></keyword><keyword><style face="normal" font="default"> Glaucoma/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Pancreatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Random Allocation</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="0" Month="0" Year="1985">1985</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0485-8611</style></isbn><abstract><style face="normal" font="default">We report on the first decade of the helium-ion radiotherapy clinical trial being carried out at the Lawrence Berkeley Laboratory. Over 500 patients have now been treated. We have had very good results to date in treating patients with small tumors critically located near a radiation-sensitive organ which would preclude delivering a curative dose with conventional radiotherapy. On the other hand, patients with larger tumors where the tumor dose cannot be increased more than 10% over conventional radiotherapy have not responded well to helium ion radiotherapy. This is illustrated by discussing selected patient groups in detail, namely those with uveal melanoma, small, low-grade tumors near the central nervous system, carcinoma of the pancreas, and carcinoma of the esophagus</style></abstract><notes><style face="normal" font="default">3937171qmq, 0401246IM7440-59-7 (Helium)Clinical TrialJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>3984</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Saunders,W.M.</style></author><author><style face="normal" font="default"> Chen,G.T.</style></author><author><style face="normal" font="default"> ustin-Seymour,M.</style></author><author><style face="normal" font="default"> Castro,J.R.</style></author><author><style face="normal" font="default"> Collier,J.M.</style></author><author><style face="normal" font="default"> Gauger,G.</style></author><author><style face="normal" font="default"> Gutin,P.</style></author><author><style face="normal" font="default"> Phillips,T.L.</style></author><author><style face="normal" font="default"> Pitluck,S.</style></author><author><style face="normal" font="default"> Walton,R.E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Precision, high dose radiotherapy. II. Helium ion treatment of tumors adjacent to critical central nervous system structures</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.11(7.):1339.-47.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.11(7.):1339.-47.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Brain</style></keyword><keyword><style face="normal" font="default"> Brain Stem</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Immobilization</style></keyword><keyword><style face="normal" font="default"> Ions</style></keyword><keyword><style face="normal" font="default"> Meningeal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Meningioma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Particle Accelerators</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Spinal Cord</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="0" Month="7" Year="1985">1985/7</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">In this paper we present a technique for treating relatively small, low grade tumors located very close to critical, radiation sensitive central nervous system structures such as the spinal cord and the brain stem. A beam of helium ions is used to irradiate the tumor. The nearby normal tissues are protected by exploiting the superb dose localization properties of this beam, particularly its well defined and controllable range in tissue, the increased dose deposited near the end of this range (i.e., the Bragg peak), the sharp decrease in dose beyond the Bragg peak, and the sharp penumbra of the beam. To execute this type of treatment, extreme care must be taken in localization of the tumor and normal tissues, as well as in treatment planning and dosimetry, patient immobilization, and verification of treatment delivery. To illustrate the technique, we present a group of 19 patients treated for chordomas, meningiomas and low grade chondrosarcomas in the base of the skull or spinal column. We have been able to deliver high, uniform doses to the target volumes (doses equivalent to 60 to 80 Gy of cobalt-60) while keeping the doses to the nearby critical tissues below the threshold for radiation damage. Follow-up on this group of patients is short, averaging 22 months (2 to 75 months). Currently, 15 patients have local control of their tumor. Two major complications, a spinal cord transection and optic tract damage, are discussed in detail. Our treatment policies have been modified to minimize the risk of these complications in the future, and we are continuing to use this method to treat such patients. We are enthusiastic about this technique, since we believe there is no other potentially curative treatment for these patients</style></abstract><notes><style face="normal" font="default">4008290g97, 7603616IM, S0 (Ions)7440-59-7 (Helium)Journal ArticleResearch Support, U.S. Gov't, Non-P.H.SResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>3985</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Saunders,W.M.</style></author><author><style face="normal" font="default"> Char,D.H.</style></author><author><style face="normal" font="default"> Quivey,J.M.</style></author><author><style face="normal" font="default"> Castro,J.R.</style></author><author><style face="normal" font="default"> Chen,G.T.</style></author><author><style face="normal" font="default"> Collier,J.M.</style></author><author><style face="normal" font="default"> Cartigny,A.</style></author><author><style face="normal" font="default"> Blakely,E.A.</style></author><author><style face="normal" font="default"> Lyman,J.T.</style></author><author><style face="normal" font="default"> Zink,S.R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Precision, high dose radiotherapy: helium ion treatment of uveal melanoma</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.11(2):227.-33.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.11(2):227.-33.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Eye/bs [Blood Supply]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glaucoma</style></keyword><keyword><style face="normal" font="default"> Glaucoma/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Immobilization</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Ions</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local</style></keyword><keyword><style face="normal" font="default"> Neovascularization,Pathologic</style></keyword><keyword><style face="normal" font="default"> Particle Accelerators</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword></keywords><dates><year Day="0" Month="2" Year="1985">1985/2</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">We report on 75 patients with uveal melanoma who were treated by placing the Bragg peak of a helium ion beam over the tumor volume. The technique localizes the high dose region very tightly around the tumor volume. This allows critical structures, such as the optic disc and the macula, to be excluded from the high dose region as long as they are 3 to 4 mm away from the edge of the tumor. Careful attention to tumor localization, treatment planning, patient immobilization and treatment verification is required. With a mean follow-up of 22 months (3 to 60 months) we have had only five patients with a local recurrence, all of whom were salvaged with another treatment. Pretreatment visual acuity has generally been preserved as long as the tumor edge is at least 4 mm away from the macula and optic disc. The only serious complication to date has been an 18% incidence of neovascular glaucoma in the patients treated at our highest dose level. Clinical results and details of the technique are presented to illustrate potential clinical precision in administering high dose radiotherapy with charged particles such as helium ions or protons</style></abstract><notes><style face="normal" font="default">2579050g97, 7603616IM, S0 (Ions)7440-59-7 (Helium)Journal ArticleResearch Support, U.S. Gov't, Non-P.H.SResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4009</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schlienger,P.</style></author><author><style face="normal" font="default"> Habrand,J.L.</style></author><author><style face="normal" font="default"> Schwartz,L.</style></author><author><style face="normal" font="default"> Desjardins,L.</style></author><author><style face="normal" font="default"> D'Hermies,F.</style></author><author><style face="normal" font="default"> Frau,E.</style></author><author><style face="normal" font="default"> Mazal,A.</style></author><author><style face="normal" font="default"> Delacroix,S.</style></author><author><style face="normal" font="default"> Nauraye,C.</style></author><author><style face="normal" font="default"> Ferrand,R.</style></author><author><style face="normal" font="default"> Louis,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institut Curie, Paris, France</style></auth-address><titles><title><style face="normal" font="default">Initial results with one-year minimum follow-up of the first 146 patients with a uveal melanoma treated with protons at CPO (Orsay)</style></title><secondary-title><style face="normal" font="default">Bulletin du Cancer.Radiotherapie.83.Suppl:212s.-4s.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Bulletin du Cancer.Radiotherapie.83.Suppl:212s.-4s.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Clinical Protocols</style></keyword><keyword><style face="normal" font="default"> Eye/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/th [Therapy]</style></keyword><keyword><style face="normal" font="default"> Visual Acuity/re [Radiation Effects]</style></keyword></keywords><dates><year Day="0" Month="0" Year="1996">1996</year></dates><pub-location><style face="normal" font="default">FRANCE</style></pub-location><isbn><style face="normal" font="default">0924-4212</style></isbn><abstract><style face="normal" font="default">Proton therapy began at the 'Centre de Protontherapie d'Orsay' (CPO) in September 1991. Our treatment protocol and the preliminary results have been presented on the first 146 irradiated patients with one-year minimal follow-up. The subsequent developments have also been mentioned</style></abstract><notes><style face="normal" font="default">8949782arq, 9005324IM0 (Protons)Comparative StudyJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4026</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schoenthaler,R.</style></author><author><style face="normal" font="default"> Castro,J.R.</style></author><author><style face="normal" font="default"> Halberg,F.E.</style></author><author><style face="normal" font="default"> Phillips,T.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, University of California, San Francisco 94143-0226</style></auth-address><titles><title><style face="normal" font="default">Definitive postoperative irradiation of bile duct carcinoma with charged particles and/or photons</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.27.(1):75.-82.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.27.(1):75.-82.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adenocarcinoma</style></keyword><keyword><style face="normal" font="default"> Adenocarcinoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Adenocarcinoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Adenocarcinoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Adenocarcinoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Bile Duct Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Bile Duct Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Bile Duct Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Bile Duct Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Neon</style></keyword><keyword><style face="normal" font="default"> Neoplasm Staging</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="1" Month="9" Year="1993">1993/9/1</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To determine the rates of survival and local control in patients with bile duct adenocarcinomas treated with post-operative photons and/or charged particles. METHODS AND MATERIALS: A retrospective study was performed analyzing all patients with bile duct adenocarcinomas who received radiotherapy through the University of California San Francisco and at Lawrence Berkeley Laboratory between 1977 and 1987, a total of 62 patients. University of California San Francisco patients received photon therapy (median dose 5400 cGy), and Lawrence Berkeley Laboratory patients were treated with the charged particles helium and/or neon (median dose 6000 cGyE). Forty-eight patients were treated post-operatively with curative intent, 30 with photons and 18 with particles. Thirty-six patients in the study had gross residual disease; none had microscopically negative margins. RESULTS: The overall two-year actuarial survival was 28%: 44% for particle-treated patients and 18% for patients treated with photons (p = .048). Median actuarial survival was 23 months in particle patients and 12 months in photon patients. Local control was also improved, though less significantly, in patients treated with particles (median disease-free survival 20 months vs. 4.5 months, p = .054). A univariate and multivariate analysis was performed and revealed that only extent of residual disease predicted local failure and overall survival; no other prognostic factors were identified. CONCLUSION: Compared to conventional photon radiotherapy, treatment with post-operative charged particle irradiation at Lawrence Berkeley Laboratory appeared to offer a survival advantage in this non-randomized series. Additional investigation into protection of surrounding normal tissue with better dose localization through the use of charged particles is planned</style></abstract><notes><style face="normal" font="default">8365945g97, 7603616IM7440-01-9 (Neon)7440-59-7 (Helium)Journal ArticleResearch Support, U.S. Gov't, Non-P.H.SResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4027</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schoenthaler,R.</style></author><author><style face="normal" font="default"> Castro,J.R.</style></author><author><style face="normal" font="default"> Petti,P.L.</style></author><author><style face="normal" font="default"> Baken-Brown,K.</style></author><author><style face="normal" font="default"> Phillips,T.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of California Lawrence Berkeley Laboratory, Department of Radiation Oncology, Berkeley 94720</style></auth-address><titles><title><style face="normal" font="default">Charged particle irradiation of sacral chordomas</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.26.(2):291.-8.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.26.(2):291.-8.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neon</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Sacrum</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Wound Healing</style></keyword></keywords><dates><year Day="0" Month="5" Year="1993">1993/5</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: The purpose of this report is determine the impact of charged particle irradiation at Lawrence Berkeley Laboratory (LBL) in treating patients with sacral chordomas. Overall survival, local control, complications, and predictive parameters are analyzed. METHODS AND MATERIALS: Fourteen patients with sacral chordomas were treated with the charged particles helium and neon between 1977 and 1989. The median dose was 7565 cGyE and the median follow up is 5 years. All patients were treated post-operatively; ten had gross residual disease. RESULTS: Kaplan-Meier survival at 5 years is 85%. Overall 5-year local control is 55%. A trend to improved local control at 5 years was seen in patients treated with neon when compared to patients treated with helium (62% vs 34%), in patients following complete resection versus patients with gross residual tumor (75% vs 40%), and in patients who had treatment courses under 73 days (61% vs 21%). Distant metastases were seen in two patients (14%). No patient developed neurologic sequelae or pain syndromes. One previously irradiated patient required colostomy, one patient had delayed wound healing following a negative post-radiation biopsy, and one patient developed a second malignancy. There were no genitourinary complications. CONCLUSION: Our experience indicates that post-operative charged particle irradiation of sacral chordomas appears to result in reasonable local control and survival with acceptable risk, and that additional evaluation on the use of heavy charged particles is warranted</style></abstract><notes><style face="normal" font="default">8491686g97, 7603616IM7440-01-9 (Neon)7440-59-7 (Helium)Comparative StudyJournal ArticleResearch Support, U.S. Gov't, Non-P.H.SResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4028</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schoenthaler,R.</style></author><author><style face="normal" font="default"> Phillips,T.L.</style></author><author><style face="normal" font="default"> Castro,J.</style></author><author><style face="normal" font="default"> Efird,J.T.</style></author><author><style face="normal" font="default"> Better,A.</style></author><author><style face="normal" font="default"> Way,L.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, University of California at San Francisco</style></auth-address><titles><title><style face="normal" font="default">Carcinoma of the extrahepatic bile ducts. The University of California at San Francisco experience</style></title><secondary-title><style face="normal" font="default">Annals of Surgery.219.(3):267.-74.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Annals of Surgery.219.(3):267.-74.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adenocarcinoma</style></keyword><keyword><style face="normal" font="default"> Adenocarcinoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Adenocarcinoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Adenocarcinoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Adenocarcinoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Bile Duct Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Bile Duct Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Bile Duct Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Bile Duct Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Bile Ducts,Extrahepatic</style></keyword><keyword><style face="normal" font="default"> Bile Ducts,Extrahepatic/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Californium</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Combined Modality Therapy</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Helium</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neon</style></keyword><keyword><style face="normal" font="default"> Neoplasm Staging</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="1994">1994/3</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0003-4932</style></isbn><abstract><style face="normal" font="default">OBJECTIVE: The authors investigated the combined experience of a single institution in treating bile duct carcinoma during the modern era. SUMMARY BACKGROUND DATA: Bile duct carcinomas are notoriously difficult to cure, with locoregional recurrence the rule, even after radical resection. Adjuvant efforts have included various radiation modalities, with limited success. Recently, charged-particle radiotherapy has also been used in these patients. METHODS: The authors performed a retrospective chart analysis of 129 patients with bile duct adenocarcinomas treated between 1977 and 1987 through the University of California at San Francisco, including 22 patients treated at Lawrence Berkeley Laboratory with the charged particles helium and neon. The minimum follow-up was 5 years. Survival, outcome, and complication results were analyzed. RESULTS: Sixty-two patients were treated with surgery alone (S), 45 patients received conventional adjuvant x-ray radiotherapy (S + X), and 22 were treated with charged particles (S + CP). The median survival times were 6.5, 11, and 14 months, respectively, for the entire group, and 16, 16, and 23 months in patients treated with curative intent. There was a survival difference in patients undergoing total resection compared with debulking (p = 0.05) and minor resections (p = 0.0001). Patients with microscopic residual disease had increased median survival times when they were treated with adjuvant irradiation, most markedly after CP (p = 0.0005) but also with conventional X (p = 0.0109). Patients with gross residual disease had a less marked but still statistically significant extended survival (p = 0.05 for S + X and p = 0.0423 for S + CP) after irradiatio CONCLUSIONS: The mainstay of bile duct carcinoma management was maximal surgical resection in these patients. Postoperative radiotherapy gave patients with positive microscopic margins a significant survival advantage and may be of value in selected patients with gross disease</style></abstract><notes><style face="normal" font="default">814760767s, 0372354AIM, IMJournal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, Non-P.H.SResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4043</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Seddon,J.M.</style></author><author><style face="normal" font="default"> Gragoudas,E.S.</style></author><author><style face="normal" font="default"> Albert,D.M.</style></author><author><style face="normal" font="default"> Hsieh,C.C.</style></author><author><style face="normal" font="default"> Polivogianis,L.</style></author><author><style face="normal" font="default"> Friedenberg,G.R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Comparison of survival rates for patients with uveal melanoma after treatment with proton beam irradiation or enucleation</style></title><secondary-title><style face="normal" font="default">American Journal of Ophthalmology.99.(3):282.-90.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">American Journal of Ophthalmology.99.(3):282.-90.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/sc [Secondary]</style></keyword><keyword><style face="normal" font="default"> Melanoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Ophthalmologic Surgical Procedures</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/su [Surgery]</style></keyword></keywords><dates><year Day="15" Month="3" Year="1985">1985/3/15</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0002-9394</style></isbn><abstract><style face="normal" font="default">We compared survival experiences for three groups with uveal melanoma: (1) 120 patients treated by proton beam irradiation from 1975 to 1981; (2) 235 patients treated by enucleation from 1953 to 1973 (enucleation group 1); and (3) 161 patients treated by enucleation from 1975 to 1981 (enucleation group 2). The following variables were predictive of melanoma-related deaths. Treatment: rate ratio (ratio of the rate of death for one category of the variable relative to the rate of death for another category) of 6.32 (95% confidence interval 1.70 to 23.51) for enucleation group 1 vs proton beam, 3.06 (0.81 to 11.54) for enucleation group 2 vs proton beam, and 2.07 (1.05 to 4.07) for enucleation group 1 vs enucleation group 2. Size: rate ratio of 3.61 (1.51 to 8.64) for large (16+ mm) vs small (less than 11 mm) tumors. Location: rate ratio of 3.19 (1.56 to 6.53) for tumors anterior vs posterior to the equator. When death from all causes was evaluated as the outcome, the estimated rate ratios were similar. When melanoma metastasis was evaluated as the outcome, the estimated rate ratios were reduced in magnitude</style></abstract><notes><style face="normal" font="default">29835583oq, 0370500AIM, IM0 (Protons)Comparative StudyJournal ArticleResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4044</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Seddon,J.M.</style></author><author><style face="normal" font="default"> Gragoudas,E.S.</style></author><author><style face="normal" font="default"> Polivogianis,L.</style></author><author><style face="normal" font="default"> Hsieh,C.C.</style></author><author><style face="normal" font="default"> Egan,K.M.</style></author><author><style face="normal" font="default"> Goitein,M.</style></author><author><style face="normal" font="default"> Verhey,L.</style></author><author><style face="normal" font="default"> Munzenrider,J.</style></author><author><style face="normal" font="default"> ustin-Seymour,M.</style></author><author><style face="normal" font="default"> Urie,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Visual outcome after proton beam irradiation of uveal melanoma</style></title><secondary-title><style face="normal" font="default">Ophthalmology.93.(5):666.-74.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ophthalmology.93.(5):666.-74.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Vision</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword><keyword><style face="normal" font="default"> Visual Acuity/re [Radiation Effects]</style></keyword></keywords><dates><year Day="0" Month="5" Year="1986">1986/5</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0161-6420</style></isbn><abstract><style face="normal" font="default">Prognostic factors for visual loss following proton irradiation of uveal melanoma were evaluated for 440 eyes treated from 1975 to 1984, with visual acuity 20/200 or better before treatment. Analysis involved Kaplan-Meier survival curves and Cox proportional hazards analysis with visual outcome defined as worse than 20/200. Prognostic factors were tumor height: rate ratio (ratio of rate of visual loss for one category of the variable relative to the rate of visual loss for a reference category of that variable) of 5.26 (95% confidence interval, 2.66-10.39) for tumors greater than 5 mm compared to tumors 3.0 mm or less in height; distance of tumor from the optic disc and fovea: rate ratio 2.59 (1.63-4.11) for tumors 2DD or less from both the optic disc and fovea compared to those greater than 2 DD from these structures. Also predictive of visual loss were tumor location close to disc only, or close to fovea only, macular detachment, worse pretreatment vision, and higher radiation doses delivered to both the disc and fovea, and lens. Regression analysis using a visual acuity scale gave similar results</style></abstract><notes><style face="normal" font="default">3014415oi5, 7802443IM0 (Protons)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4045</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Seddon,J.M.</style></author><author><style face="normal" font="default"> Gragoudas,E.S.</style></author><author><style face="normal" font="default"> Egan,K.M.</style></author><author><style face="normal" font="default"> Glynn,R.J.</style></author><author><style face="normal" font="default"> Munzenrider,J.E.</style></author><author><style face="normal" font="default"> ustin-Seymour,M.</style></author><author><style face="normal" font="default"> Goitein,M.</style></author><author><style face="normal" font="default"> Verhey,L.</style></author><author><style face="normal" font="default"> Urie,M.</style></author><author><style face="normal" font="default"> Koehler,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Uveal melanomas near the optic disc or fovea. Visual results after proton beam irradiation</style></title><secondary-title><style face="normal" font="default">Ophthalmology.94.(4):354.-61.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ophthalmology.94.(4):354.-61.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Cataract</style></keyword><keyword><style face="normal" font="default"> Cataract/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Fovea Centralis</style></keyword><keyword><style face="normal" font="default"> Fovea Centralis/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Macula Lutea</style></keyword><keyword><style face="normal" font="default"> Macula Lutea/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Optic Disk</style></keyword><keyword><style face="normal" font="default"> Optic Disk/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Retinal Detachment</style></keyword><keyword><style face="normal" font="default"> Retinal Detachment/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Retinal Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Vision</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword><keyword><style face="normal" font="default"> Visual Acuity/re [Radiation Effects]</style></keyword></keywords><dates><year Day="0" Month="4" Year="1987">1987/4</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0161-6420</style></isbn><abstract><style face="normal" font="default">Proximity to the disc and fovea is a risk factor for visual loss after proton beam irradiation of uveal melanomas. Of 562 eyes treated over a 10-year period with pretreatment visual acuity of 20/200 or better, 363 (64.6%) contained tumors within 2 disc diameters (DD) of the disc or fovea. Rates of visual loss after treatment to worse than 20/200 and causes of visual decline were evaluated using Kaplan-Meier analysis. Cumulative rates of visual loss among subjects with tumors near the disc or fovea were 33 and 47% 1 and 2 years after treatment compared to 17 and 28%, respectively, for subjects with tumors located farther from both structures. The leading cause of visual loss in the first year among eyes with tumors near the disc or fovea was retinal detachment. Controlling for other predictors of visual loss to worse than 20/200, location near the disc or fovea was independently related to visual loss primarily due to retinal detachment, cataract, and radiation retinopathy. Despite the unfavorable location of these tumors, over half of patients with 20/200 or better pretreatment visual acuity had useful vision 2 years after treatment</style></abstract><notes><style face="normal" font="default">3587916oi5, 7802443IMJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4046</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Seddon,J.M.</style></author><author><style face="normal" font="default"> Gragoudas,E.S.</style></author><author><style face="normal" font="default"> Egan,K.M.</style></author><author><style face="normal" font="default"> Glynn,R.J.</style></author><author><style face="normal" font="default"> Howard,S.</style></author><author><style face="normal" font="default"> Fante,R.G.</style></author><author><style face="normal" font="default"> Albert,D.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston 02114</style></auth-address><titles><title><style face="normal" font="default">Relative survival rates after alternative therapies for uveal melanoma</style></title><secondary-title><style face="normal" font="default">Ophthalmology.97.(6.):769.-77.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ophthalmology.97.(6.):769.-77.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Cause of Death</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Ciliary Body/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eye Enucleation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/su [Surgery]</style></keyword></keywords><dates><year Day="0" Month="6" Year="1990">1990/6</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0161-6420</style></isbn><abstract><style face="normal" font="default">Survival in a group of 556 patients with uveal melanoma treated by proton beam irradiation with a median follow-up of 5.3 years was compared with that of 238 patients enucleated during the same 10-year period as irradiated patients (July 1975 to December 1984) with a median follow-up of 8.8 years, and 257 patients enucleated during the preceding 10 years (January 1965 to June 1975) with a median follow-up of 17.0 years. Adjustments were made for known prognostic factors including age, tumor location, tumor height, and clinical estimate of tumor diameter (for enucleated patients this was estimated in a regression equation relating histologic to clinical measurement). The overall rate ratio for all cause mortality was 1.2 (95% confidence interval, 0.9-1.6) for the concurrent enucleation series versus proton beam, and 1.6 (95% confidence interval, 1.2-2.1) for the earlier enucleation series versus proton beam. Relative rates of metastatic death, cancer death, and all cause mortality comparing alternative treatments were found to vary with time after treatment. Interval-specific rate ratios were evaluated using proportional hazards models fitted to separate time intervals after treatment. For all three outcomes, rate ratios were over two and statistically significant for the first 2 years after treatment and closer to one and nonsignificant after year 6 comparing the two enucleation groups with proton beam. Results suggest that treatment choice has little overall influence on survival in patients with uveal melanoma</style></abstract><notes><style face="normal" font="default">2374681oi5, 7802443IMComparative StudyJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4083</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shipley,W.U.</style></author><author><style face="normal" font="default"> Tepper,J.E.</style></author><author><style face="normal" font="default"> Prout,G.R.,Jr.</style></author><author><style face="normal" font="default"> Verhey,L.J.</style></author><author><style face="normal" font="default"> Mendiondo,O.A.</style></author><author><style face="normal" font="default"> Goitein,M.</style></author><author><style face="normal" font="default"> Koehler,A.M.</style></author><author><style face="normal" font="default"> Suit,H.D.</style></author></authors></contributors><titles><title><style face="normal" font="default">Proton radiation as boost therapy for localized prostatic carcinoma</style></title><secondary-title><style face="normal" font="default">JAMA.241.(18.):1912.-5,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">JAMA.241.(18.):1912.-5,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adenocarcinoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Rectum</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> X-Rays</style></keyword></keywords><dates><year Day="4" Month="5" Year="1979">1979/5/4</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0098-7484</style></isbn><abstract><style face="normal" font="default">A 160-MeV proton beam has been modified to irradiate patients with localized tumors by using convention treatment schedules. This proton beam has the physical advantage of megavoltage x-rays of reducing the radiation dose to normal tissues adjacent to the tumor volume. A perineal proton technique used as boost therapy (2,000 to 2,500 rads) was evaluated in the definitive irradiation of 17 patients with localized prostatic carcinoma. This technique allows repeated daily treatment of the carefully defined target volume with a precision of +/- 2 mm. Total dose to the prostatic tumor, but not to the posterior rectum, has been increased by 500 to 700 rads. After 12 to 27 months of observation, no noteworthy rectal reaction has developed in a patient, easily managed urethral strictures have developed in two patients, and all but one are locally controlled</style></abstract><notes><style face="normal" font="default">1073387501160AIM, IM0 (Protons)Journal ArticleResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4084</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shipley,W.U.</style></author><author><style face="normal" font="default"> Verhey,L.J.</style></author><author><style face="normal" font="default"> Munzenrider,J.E.</style></author><author><style face="normal" font="default"> Suit,H.D.</style></author><author><style face="normal" font="default"> Urie,M.M.</style></author><author><style face="normal" font="default"> McManus,P.L.</style></author><author><style face="normal" font="default"> Young,R.H.</style></author><author><style face="normal" font="default"> Shipley,J.W.</style></author><author><style face="normal" font="default"> Zietman,A.L.</style></author><author><style face="normal" font="default"> Biggs,P.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, Harvard Medical School, Boston, MA 02114, USA</style></auth-address><titles><title><style face="normal" font="default">Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone.[see comment]</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.32.(1):3-12.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.32.(1):3-12.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Arm</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Clinical Protocols</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Data Interpretation,Statistical</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Hemorrhage/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/pc [Prevention &amp; Control]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons</style></keyword><keyword><style face="normal" font="default"> Photons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Prostate</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Rectum</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Urethral Stricture/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Urethral Stricture/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Urinary Bladder Diseases/et [Etiology]</style></keyword></keywords><dates><year Day="30" Month="4" Year="1995">1995/4/30</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: Following a thorough Phase I/II study, we evaluated by a Phase III trial high versus conventional dose external beam irradiation as mono-therapy for patients with Stage T3-T4 prostate cancer. Patient outcome following standard dose radiotherapy or following a 12.5% increase in total dose to 75.6 Cobalt Gray Equivalent (CGE) using a conformal perineal proton boost was compared for local tumor control, disease-free survival, and overall survival. METHODS AND MATERIALS: Stage T3-T4, Nx, N0-2, M0 patients received 50.4 Gy by four-field photons and were randomized to receive either an additional 25.2 CGE by conformal protons (arm 1--the high dose arm, 103 patients, total dose 75.6 CGE) or an additional 16.8 Gy by photons (arm 2--the conventional dose arm, 99 patients, total dose 67.2 Gy). Actuarial overall survival (OS), disease-specific survival (DSS), total recurrence-free survival (TRFS), (clinically free, prostate specific antigen (PSA) less than 4ng/ml and a negative prostate rebiopsy, done in 38 patients without evidence of disease) and local control (digital rectal exam and rebiopsy negative) were evaluated. RESULTS: The protocol completion rate was 90% for arm 1 and 97% for arm 2. With a median follow-up of 61 months (range 3 to 139 months) 135 patients are alive and 67 have died, 20 from causes other than prostate cancer. We found no significant differences in OS, DSS, TRFS or local control between the two arms. Among those completing randomized treatment (93 in arm 1 and 96 in arm 2), the local control at 5 and 8 years for arm 1 is 92% and 77%, respectively and is 80% and 60%, respectively for arm 2 (p = .089) and there are no significant differences in OS, DSS, and TRFS. The local control for the 57 patients with poorly differentiated (Gleason 4 or 5 of 5) tumors at 5 and 8 years for arm 1 is 94% and 84% and is 64% and 19% on arm 2 (p = 0.0014). In patients whose digital rectal exam had normalized following treatment and underwent prostate rebiopsy there was a lower positive rebiopsy rate for arm 1 versus arm 2 patients (28 vs. 45%) and also for those with well and moderately differentiated tumors versus poorly differentiated tumors (32 and 50%). These differences were not statistically significant. Grade 1 and 2 rectal bleeding is higher (32 vs. 12%, p = 0.002) as may be urethral stricture (19 vs. 8%, p = 0.07) in the arm 1 versus arm 2. CONCLUSIONS: An increase in prostate tumor dose by external beam of 12.5% to 75.6 CGE by a conformal proton boost compared to a conventional dose of 67.2 Gy by a photon boost significantly improved local control only in patients with poorly differentiated tumors. It has increased late radiation sequelae, and as yet, has not increased overall survival, disease-specific survival, or total recurrence-free survival in any subgroup. These results have led us to test by a subsequent Phase III trial the potential beneficial effect on local control and disease-specific survival of a 12.5% increase in total dose relative to conventional dose in patients with T1, T2a, and T2b tumors</style></abstract><notes><style face="normal" font="default">7721636g97, 7603616IM0 (Protons)Clinical TrialClinical Trial, Phase IIIJournal ArticleRandomized Controlled TrialResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4106</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Slater,J.D.</style></author><author><style face="normal" font="default"> ustin-Seymour,M.</style></author><author><style face="normal" font="default"> Munzenrider,J.</style></author><author><style face="normal" font="default"> Birnbaum,S.</style></author><author><style face="normal" font="default"> Carroll,R.</style></author><author><style face="normal" font="default"> Klibanski,A.</style></author><author><style face="normal" font="default"> Riskind,P.</style></author><author><style face="normal" font="default"> Urie,M.</style></author><author><style face="normal" font="default"> Verhey,L.</style></author><author><style face="normal" font="default"> Goitein,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dept. of Radiation Medicine, Massachusetts General Hospital-Harvard Medical School, Boston 02114</style></auth-address><titles><title><style face="normal" font="default">Endocrine function following high dose proton therapy for tumors of the upper clivus</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.15.(3):607.-11,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.15.(3):607.-11,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Endocrine System Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pituitary Gland/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Skull Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword></keywords><dates><year Day="0" Month="9" Year="1988">1988/9</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">The endocrine status of patients receiving proton radiation for tumors of the upper clivus was reviewed to evaluate the effect of high dose treatment on the pituitary gland. The fourteen patients had chordomas or low grade chondrosarcomas and were all treated by the same techniques. The median tumor dose was 69.7 Cobalt Gray Equivalent (CGE) with a range from 66.6 to 74.4 CGE. (CGE is used because modulated protons have an RBE of 1.1 compared to 60Co). The daily fraction size was 1.8-2.1 CGE. The median follow-up time is 48 months, ranging from 30 to 68 months. All treatments were planned using a computerized multi-dimensional system with the position of the pituitary outlined on the planning CT scan. Review of the dose distribution indicated that the dose to the pituitary ranged from 60.5 to 72.3 CGE, with a median of 67.6 CGE. One female patient had decreased thyroid and gonadotropin function at the time of diagnosis and has been on hormone replacement since that time. The other three females were all pre-menopausal at the time of radiotherapy. At this time four patients (3 males and 1 female) have developed endocrine abnormalities 14 to 45 months after irradiation. All four had evidence of hypothyroidism and two have also developed corticotropin deficiency. The three males had decreased testosterone levels; the female patient developed amenorrhea and hyperprolactinemia. All four are asymptomatic with ongoing hormone replacement</style></abstract><notes><style face="normal" font="default">3138212g97, 7603616IMJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4167</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sugahara,S.</style></author><author><style face="normal" font="default"> Tujii,H.</style></author><author><style face="normal" font="default"> Tuji,H.</style></author><author><style face="normal" font="default"> Tatuzaki,H.</style></author><author><style face="normal" font="default"> Ohara,K.</style></author><author><style face="normal" font="default"> Itai,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiology, University Hospital, University of Tsukuba</style></auth-address><titles><title><style face="normal" font="default">[The value of frequent positioning of treatment field in radiotherapy of esophageal cancer]. [Japanese]</style></title><secondary-title><style face="normal" font="default">Nippon Igaku Hoshasen Gakkai Zasshi - Nippon Acta Radiologica.52.(9.):1308.-14,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Nippon Igaku Hoshasen Gakkai Zasshi - Nippon Acta Radiologica.52.(9.):1308.-14,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Esophageal Neoplasms/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Esophageal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Esophagus</style></keyword><keyword><style face="normal" font="default"> Esophagus/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> X-Ray Film</style></keyword></keywords><dates><year Day="25" Month="9" Year="1992">1992/9/25</year></dates><pub-location><style face="normal" font="default">JAPAN</style></pub-location><isbn><style face="normal" font="default">0048-0428</style></isbn><abstract><style face="normal" font="default">Since 1983 a clinical trial of proton beam radiotherapy has been conducted at the Proton Medical Research Center (PMRC) of the University of Tsukuba. We have made it a rule to do field localization by X-ray pictures before each treatment. For this purpose we have developed a localize-verify system consisting of a fluoroscopic unit and a real time digital image processing device. By using this system as well as X-ray films, field placement errors or corrected distance at field localization were measured in 11 patients with esophageal cancers. Measurements of corrected distances on a total of 177 localization attempts disclosed that correction by > 5 mm was necessary in 30.6% and by > 10 mm in 10.2% of all localization attempts. Corrected distances appeared to increase with age, possibly because the skin becomes looser and ambulatory status tends to be more limited in older patients. Field placement corrections of more than 5 mm were required in 66.7% of 60 localizations in patients > 80 years old. Two patients in whom the anatomical positions of the esophagus were easily movable are presented. The following common characteristics of these patients were considered high risk factors: they were more than 80 years old; lesions were located in the lower esophagus; and they had T1 tumors. These findings suggested that frequent positioning and verification of treatment fields are necessary in the accurate treatment of esophageal cancers, especially those in high-risk patients</style></abstract><notes><style face="normal" font="default">1437536o3g, 0413544IMEnglish AbstractJournal ArticleJapanese</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4170</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Suit,H.</style></author><author><style face="normal" font="default"> Goitein,M.</style></author><author><style face="normal" font="default"> Munzenrider,J.</style></author><author><style face="normal" font="default"> Verhey,L.</style></author><author><style face="normal" font="default"> Blitzer,P.</style></author><author><style face="normal" font="default"> Gragoudas,E.</style></author><author><style face="normal" font="default"> Koehler,A.M.</style></author><author><style face="normal" font="default"> Urie,M.</style></author><author><style face="normal" font="default"> Gentry,R.</style></author><author><style face="normal" font="default"> Shipley,W.</style></author><author><style face="normal" font="default"> Urano,M.</style></author><author><style face="normal" font="default"> Duttenhaver,J.</style></author><author><style face="normal" font="default"> Wagner,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Evaluation of the clinical applicability of proton beams in definitive fractionated radiation therapy</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.8.(12.):2199.-205.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.8.(12.):2199.-205.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Bone Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Mouth Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prostate</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Rectal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Rectum</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Sarcoma</style></keyword><keyword><style face="normal" font="default"> Sarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Soft Tissue Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Uterine Cervical Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="0" Month="12" Year="1982">1982/12</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">We report on the treatment of 317 patients treated either wholly or in part with proton beams at the Harvard Cyclotron Laboratory. These include: 130 patients treated for definitive radiation therapy of choroidal melanoma; 17 patients treated for tumors of the base of skull, cervical spine and cranium, which abut structures of the central nervous system (CNS); 23 patients treated for sarcomas of soft tissue and bone; 65 patients treated for carcinoma of the prostate; 14 patients treated for carcinoma of the rectum and anus; and 23 patients treated for squamous carcinoma of the oral cavity and oro-pharynx. Data on causes of failure and morbidity of treatment are presented. Overall the results are judged to be extremely encouraging. In particular, the treatment of the choroidal melanomas and sarcomas abutting CNS structures have clear clinical value, and the treatment of prostatic tumors and tumors of the head and neck are thought to be promising</style></abstract><notes><style face="normal" font="default">6298160g97, 7603616IM0 (Protons)Journal ArticleResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4177</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Suit,H.D.</style></author><author><style face="normal" font="default"> Goitein,M.</style></author><author><style face="normal" font="default"> Munzenrider,J.</style></author><author><style face="normal" font="default"> Verhey,L.</style></author><author><style face="normal" font="default"> Davis,K.R.</style></author><author><style face="normal" font="default"> Koehler,A.</style></author><author><style face="normal" font="default"> Linggood,R.</style></author><author><style face="normal" font="default"> Ojemann,R.G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Definitive radiation therapy for chordoma and chondrosarcoma of base of skull and cervical spine</style></title><secondary-title><style face="normal" font="default">Journal of Neurosurgery.56.(3):377.-85.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Journal of Neurosurgery.56.(3):377.-85.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Bone Neoplasms/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Cervical Vertebrae</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Sarcoma</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Spinal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="0" Month="3" Year="1982">1982/3</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0022-3085</style></isbn><abstract><style face="normal" font="default">Proton-beam radiation therapy has been developed for the treatment of chordomas or sarcomas of bone or soft tissue that abut the central nervous system. The authors report the results of treatment of 10 patients, six with chordoma, three with chondrosarcoma, and one with a neurofibrosarcoma. Local control has been achieved for all patients (with, however, one marginal failure) with a follow-up period ranging from 2 months to 6 years. High doses of radiation, up to 76 Cobalt Gray Equivalents (CGE), have been delivered without significant morbidity. In particular, no neurological sequelae have been observed</style></abstract><notes><style face="normal" font="default">7057235jd3, 0253357AIM, IMJournal ArticleResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4276</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tsuji,H.</style></author><author><style face="normal" font="default"> Okumura,T.</style></author><author><style face="normal" font="default"> Maruhashi,A.</style></author><author><style face="normal" font="default"> Hayakawa,Y.</style></author><author><style face="normal" font="default"> Matsuzaki,Y.</style></author><author><style face="normal" font="default"> Tanaka,N.</style></author><author><style face="normal" font="default"> Osuga,T.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Clinical Medical Sciences, University of Tsukuba</style></auth-address><titles><title><style face="normal" font="default">[Dose-volume histogram analysis of patients with hepatocellular carcinoma regarding changes in liver function after proton therapy]. [Japanese]</style></title><secondary-title><style face="normal" font="default">Nippon Igaku Hoshasen Gakkai Zasshi - Nippon Acta Radiologica.55.(5):322.-8.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Nippon Igaku Hoshasen Gakkai Zasshi - Nippon Acta Radiologica.55.(5):322.-8.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Liver/pp [Physiopathology]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="4" Year="1995">1995/4</year></dates><pub-location><style face="normal" font="default">JAPAN</style></pub-location><isbn><style face="normal" font="default">0048-0428</style></isbn><abstract><style face="normal" font="default">Seventy-five patients with hepatocellular carcinoma were treated with proton beams from 1983-1993 at the Proton Medical Research Center, University of Tsukuba. For the purpose of confirming the feasibility of proton therapy for hepatocellular carcinoma, we investigated the influence of proton therapy on liver function and also tried to evaluate the possibility of optimization using dose-volume histogram (DVH) analysis. The results indicated that proton therapy did not cause clinically symptomatic damage in liver function and the only notable change after proton therapy was the transient increase of transminase. DVH analysis showed that this transient increase of transaminase was well correlated to the normal tissue complication probability (NTCP). These results indicate that localized high dose radiation using proton beams is feasible for the treatment of liver cancers and optimization of this treatment may be possible using DVH analysis</style></abstract><notes><style face="normal" font="default">7784153o3g, 0413544IM0 (Protons)Clinical TrialEnglish AbstractJournal ArticleJapanese</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4279</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tsujii,H.</style></author><author><style face="normal" font="default"> Tsuji,H.</style></author><author><style face="normal" font="default"> Inada,T.</style></author><author><style face="normal" font="default"> Maruhashi,A.</style></author><author><style face="normal" font="default"> Hayakawa,Y.</style></author><author><style face="normal" font="default"> Takada,Y.</style></author><author><style face="normal" font="default"> Tada,J.</style></author><author><style face="normal" font="default"> Fukumoto,S.</style></author><author><style face="normal" font="default"> Tatuzaki,H.</style></author><author><style face="normal" font="default"> Ohara,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Proton Medical Research Center, University of Tsukuba, Japan</style></auth-address><titles><title><style face="normal" font="default">Clinical results of fractionated proton therapy</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.25.(1):49.-60.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.25.(1):49.-60.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Child,Preschool</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Japan/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Neoplasms/ep [Epidemiology]</style></keyword><keyword><style face="normal" font="default"> Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Physics</style></keyword><keyword><style face="normal" font="default"> Prostate</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urinary Bladder</style></keyword></keywords><dates><year Day="0" Month="1" Year="1993">1993/1</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: Preliminary results of a multi-site Phase I-II clinical trial investigating the efficacy of high-energy proton beams in a wide variety of human malignancies are reported. METHODS AND MATERIALS: Since 1983 proton radiotherapy using 250 MeV proton beams produced by a booster synchrotron of the National Laboratory for High Energy Physics has been carried out at Proton Medical Research Center, University of Tsukuba. As of September 1990, a total of 147 patients received a partial or full treatment with proton beams with curative intent; 92 patients (63%) were treated with proton beams alone and 55 patients (37%) with combined photon and proton beams. There were 91 males and the mean age was 61.8 years old. The follow-up observation period ranged from 10 to 97 months. With regard to a total tumor dose, nearly 80% of patients received 70 Gy or more and 53% received 80 Gy or more. While dose-fractionations used depended upon tumor sites, the large majority of patients received substantially high radiation doses in terms of larger total doses (> 70 Gy) and larger fraction sizes (> 2.5 Gy) than those traditionally used. This fractionation regimen has been used because of limited availability of the accelerator or a shortage of machine time (27-30 weeks/year, 3-3.5 hr/day), and also by the expectation that the superior dose distribution possible with protons will permit administration of high radiation doses without increasing morbidities. In connection with this, we have determined the target volume by setting margins around the tumor boundary as practically small as possible, ranging from 5 to 10 mm. RESULTS AND CONCLUSIONS: The current trial has been based on a site and dose searching program, hence a wide variety of tumor sites including the aerodigestive organs has been treated. So far, our judgment is that proton therapy has proven of potential advantage in treatment of the lung, esophageal, liver, uterine cervix, prostate, and head and neck malignancies; and of possible value in treatment of high-grade gliomas, and gastric, urinary bladder, and pediatric tumors</style></abstract><notes><style face="normal" font="default">8380147g97, 7603616IM0 (Protons)Clinical TrialClinical Trial, Phase IClinical Trial, Phase IIJournal ArticleMulticenter StudyResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4281</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tsujii,H.</style></author><author><style face="normal" font="default"> Akaza,H.</style></author><author><style face="normal" font="default"> Ohtani,M.</style></author><author><style face="normal" font="default"> Miyanaga,N.</style></author><author><style face="normal" font="default"> Shimazoi,T.</style></author><author><style face="normal" font="default"> Uchida,K.</style></author><author><style face="normal" font="default"> Koiso,K.</style></author><author><style face="normal" font="default"> Tsuji,H.</style></author><author><style face="normal" font="default"> Okumura,T.</style></author><author><style face="normal" font="default"> Ohara,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiology, University of Tsukuba, Japan</style></auth-address><titles><title><style face="normal" font="default">Preliminary results of bladder-preserving therapy with definitive radiotherapy and intraarterial infusion of chemotherapy</style></title><secondary-title><style face="normal" font="default">Strahlentherapie und Onkologie.170.(9.):531.-7.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Strahlentherapie und Onkologie.170.(9.):531.-7.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Antineoplastic Combined Chemotherapy Protocols/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Cisplatin</style></keyword><keyword><style face="normal" font="default"> Cisplatin/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Combined Modality Therapy</style></keyword><keyword><style face="normal" font="default"> Cystectomy</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Infusions,Intra-Arterial</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Methotrexate/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pelvis</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Remission Induction</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urinary Bladder Neoplasms/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Urinary Bladder Neoplasms/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Urinary Bladder Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Urinary Bladder Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> X-Rays</style></keyword></keywords><dates><year Day="0" Month="9" Year="1994">1994/9</year></dates><pub-location><style face="normal" font="default">GERMANY</style></pub-location><isbn><style face="normal" font="default">0179-7158</style></isbn><abstract><style face="normal" font="default">PURPOSE: For management of muscle-invading bladder cancer (clinical stages T2 to T4), combined treatment of definitive radiotherapy (RT) and intraarterial (IA) administration of chemotherapy was carried out for local cure and bladder preservation. METHODS AND MATERIALS: Between 1987 and 1990, a pilot study (Protocol-1) was initially conducted in 16 patients to investigate the efficacy of chemoradiotherapy where RT was combined with TURB and continuous IA infusion of cisplatin. We then performed a regimen of possible bladder-preservation treatment (Protocol-2) in which 19 patients were treated with combination of TURB, full-dose RT and one-shot IA infusion of cisplatin and methotrexate. In RT small pelvis irradiation was performed with x-rays followed by proton beam boost irradiation to the original tumor site. RESULTS: Among patients treated on Protocol-1, a tumor-free bladder was observed in 50% (2/4) after 50-76 Gy but only 8% (1/14) after 30-40 Gy. In this regimen, planned cystectomy was performed in 10 patients and 13 patients (81%) are alive. Among 19 patients treated on Protocol-2, 17 patients (89%) are alive and 13 patients (68%) retained intact bladders without any recurrence. There were 3 cystectomies performed because of persistent tumors. Using a conformal mode of proton beam irradiation, a total dose of 60-80 Gy was safely administered with acceptable morbidities. CONCLUSION: In the light of good complete response and survival rates achieved in the patients treated on Protocol-2, the combined treatment of definitive RT and IA administration of chemotherapy is considered as an effective bladder-preserving strategy</style></abstract><notes><style face="normal" font="default">7940124vcm, 8603469IM15663-27-1 (Cisplatin)59-05-2 (Methotrexate)Comparative StudyJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4308</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Umebayashi,Y.</style></author><author><style face="normal" font="default"> Uyeno,K.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author><author><style face="normal" font="default"> Otsuka,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, School of Medicine, University of Tsukuba, Japan</style></auth-address><titles><title><style face="normal" font="default">Proton radiotherapy of skin carcinomas</style></title><secondary-title><style face="normal" font="default">British Journal of Dermatology.130.(1):88.-91.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">British Journal of Dermatology.130.(1):88.-91.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Bowen's Disease/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Squamous Cell/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Squamous Cell/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Verrucous/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pilot Projects</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Skin Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Skin/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="1" Year="1994">1994/1</year></dates><pub-location><style face="normal" font="default">ENGLAND</style></pub-location><isbn><style face="normal" font="default">0007-0963</style></isbn><abstract><style face="normal" font="default">At the Proton Medical Research Center, University of Tsukuba, we performed a pilot study of proton-beam radiotherapy in 12 patients with the following types of carcinoma: Bowen's disease (4), oral verrucous carcinoma (5), and squamous cell carcinoma (3). They received total doses of 51-99.2 Gy in fractions of 2-12.5 Gy. All of the tumours responded well to the treatment. All four lesions of Bowen's disease, three of the five oral verrucous carcinomas, and the three squamous cell carcinomas completely regressed following irradiation. Two squamous cell carcinomas recurred during the follow-up period. One recurrent squamous cell carcinoma was successfully treated by a salvage surgical operation, and in the other case the patient refused further therapy. In two verrucous carcinomas there was 90% regression of tumour volume. No severe radiation-related complication occurred. As proton radiotherapy produces good local tumour control without significant morbidity to the surrounding normal tissues, it may prove to be a useful therapeutic modality for the treatment of skin carcinomas</style></abstract><notes><style face="normal" font="default">8305324aw0, 0004041IM0 (Protons)Journal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4318</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Austin-Seymour,M.</style></author><author><style face="normal" font="default"> Munzenrider,J.E.</style></author><author><style face="normal" font="default"> Goitein,M.</style></author><author><style face="normal" font="default"> Gentry,R.</style></author><author><style face="normal" font="default"> Gragoudas,E.</style></author><author><style face="normal" font="default"> Koehler,A.M.</style></author><author><style face="normal" font="default"> McNulty,P.</style></author><author><style face="normal" font="default"> Osborne,E.</style></author><author><style face="normal" font="default"> Ryugo,D.K.</style></author><author><style face="normal" font="default"> Seddon,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Progress in low-LET heavy particle therapy: intracranial and paracranial tumors and uveal melanomas</style></title><secondary-title><style face="normal" font="default">Radiation Research - Supplement.8.:S219.-26.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Radiation Research - Supplement.8.:S219.-26.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Actuarial Analysis</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Brain Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Brain Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Energy Transfer</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glioma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Glioma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Skull Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Spinal Cord Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Vision</style></keyword></keywords><dates><year Day="0" Month="0" Year="1985">1985</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0485-8611</style></isbn><abstract><style face="normal" font="default">The Harvard Cyclotron Laboratory in collaboration with the Department of Radiation Medicine of the Massachusetts General Hospital and the Retina Service of the Massachusetts Eye and Ear Infirmary provides low-LET heavy particle therapy with 160 MeV protons. The improved dose distribution of protons results from their physical characteristics. A total of 965 patients have been treated as of December 31, 1984. Dose is expressed in units of cobalt gray equivalent (CGE) which is the dose in Gy multiplied by the RBE (1.1) for modulated protons relative to 60Co radiation. Sixty-seven patients with chordomas or low-grade chondrosarcomas of the base of skull or cervical spine have received proton treatment. Forty-three of these patients have been followed for at least 8 months with a median follow-up of 27 months. The median dose is 69 CGE. The 3-year actuarial local control rate is 89%. Seven patients with gliomas, eight with craniopharyngiomas, and six with meningiomas have also received proton radiation treatments. A total of 615 patients with uveal melanomas have received a median dose of 70 CGE in five fractions. Tumor regression has been seen in 94% with 66% having vision of 20/100 or better</style></abstract><notes><style face="normal" font="default">3003784qmq, 0401246IM0 (Protons)Journal ArticleResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4321</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Austin-Seymour,M.</style></author><author><style face="normal" font="default"> Munzenrider,J.</style></author><author><style face="normal" font="default"> Goitein,M.</style></author><author><style face="normal" font="default"> Verhey,L.</style></author><author><style face="normal" font="default"> Urie,M.</style></author><author><style face="normal" font="default"> Gentry,R.</style></author><author><style face="normal" font="default"> Birnbaum,S.</style></author><author><style face="normal" font="default"> Ruotolo,D.</style></author><author><style face="normal" font="default"> McManus,P.</style></author><author><style face="normal" font="default"> Skates,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Medicine, Massachusetts General Hospital, Boston</style></auth-address><titles><title><style face="normal" font="default">Fractionated proton radiation therapy of chordoma and low-grade chondrosarcoma of the base of the skull</style></title><secondary-title><style face="normal" font="default">Journal of Neurosurgery.70.(1):13-7.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Journal of Neurosurgery.70.(1):13-7.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries</style></keyword><keyword><style face="normal" font="default"> Relative Biological Effectiveness</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Vision Disorders/et [Etiology]</style></keyword></keywords><dates><year Day="0" Month="1" Year="1989">1989/1</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0022-3085</style></isbn><abstract><style face="normal" font="default">Sixty-eight patients with chordoma or low-grade chondrosarcoma at the base of the skull received fractionated high-dose postoperative radiation delivered with a 160-MeV proton beam. Protons have favorable physical characteristics which allow the delivery of high doses of radiation to these critically located tumors. The methods employed for these treatments are described. These patients have been followed for at least 17 months and for a median of 34 months. The median tumor dose was 69 CGE (cobalt Gy equivalent): CGE is the dose in proton Gy multiplied by 1.1, which is the relative biological effectiveness for protons compared to cobalt-60. The daily dose was 1.8 to 2.1 CGE. For this group the 5-year actuarial local control rate is 82% and disease-free survival rate is 76%. The incidence of treatment-related morbidity has been acceptable</style></abstract><notes><style face="normal" font="default">2535872jd3, 0253357AIM, IM0 (Protons)Journal ArticleResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4322</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Austin-Seymour,M.</style></author><author><style face="normal" font="default"> Munzenrider,J.</style></author><author><style face="normal" font="default"> Linggood,R.</style></author><author><style face="normal" font="default"> Goitein,M.</style></author><author><style face="normal" font="default"> Verhey,L.</style></author><author><style face="normal" font="default"> Urie,M.</style></author><author><style face="normal" font="default"> Gentry,R.</style></author><author><style face="normal" font="default"> Birnbaum,S.</style></author><author><style face="normal" font="default"> Ruotolo,D.</style></author><author><style face="normal" font="default"> Crowell,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Medicine, Massachusetts General Hospital, Boston 02114</style></auth-address><titles><title><style face="normal" font="default">Fractionated proton radiation therapy of cranial and intracranial tumors</style></title><secondary-title><style face="normal" font="default">American Journal of Clinical Oncology.13(4):327.-30.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">American Journal of Clinical Oncology.13(4):327.-30.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Brain Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma</style></keyword><keyword><style face="normal" font="default"> Chondrosarcoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Craniopharyngioma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glioma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Meningioma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Computer-Assisted</style></keyword><keyword><style face="normal" font="default"> Relative Biological Effectiveness</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="0" Month="8" Year="1990">1990/8</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0277-3732</style></isbn><abstract><style face="normal" font="default">Since 1973 fractionated proton radiation therapy has been used in the treatment of malignant disease. Protons have favorable physical characteristics that yield dose distributions superior to those of photons in certain clinical situations. As of December 31, 1987, 1,678 patients had been treated. Of these, 110 had chordomas or low-grade chondrosarcomas of the base of skull. The first 68 patients have a minimum follow-up of 17 months. The median dose was 69 Cobalt Gray Equivalent (CGE). (CGE is the dose in proton Gray multiplied by 1.1, which is the relative biological effectiveness for protons relative to 60Cobalt.) The actuarial 5-year local control rate is 82%, and the disease-free survival rate is 76%. Thirteen patients with meningiomas have been treated, following subtotal resection. The median dose was 59.4 CGE. With a median follow-up of 26 months, no patient has had tumor progression. In addition, nine patients with gliomas and 12 with craniopharyngiomas have been treated</style></abstract><notes><style face="normal" font="default">21657393ez, 8207754IM0 (Protons)Journal ArticleResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4376</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vitale,V.</style></author><author><style face="normal" font="default"> Scolaro,T.</style></author><author><style face="normal" font="default"> Andreucci,L.</style></author><author><style face="normal" font="default"> Foppiano,F.</style></author><author><style face="normal" font="default"> Porta,A.</style></author><author><style face="normal" font="default"> Mosci,C.</style></author><author><style face="normal" font="default"> Ravazzoni,L.</style></author><author><style face="normal" font="default"> Brassart,N.</style></author><author><style face="normal" font="default"> Chauvel,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Servizio di Oncologia Radioterapica, Istituto Nazionale per la Ricerca sul Cancro, Genova</style></auth-address><titles><title><style face="normal" font="default">[The proton radiotherapy of melanoma of the uvea. The technic, methodology and first clinical observations]. [Italian]</style></title><secondary-title><style face="normal" font="default">Radiologia Medica.84.(5):630.-5,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Radiologia Medica.84.(5):630.-5,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Cyclotrons/is [Instrumentation]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="0" Month="11" Year="1992">1992/11</year></dates><pub-location><style face="normal" font="default">ITALY</style></pub-location><isbn><style face="normal" font="default">0033-8362</style></isbn><abstract><style face="normal" font="default">Since June 1991, a Cyclotron unit with a proton beam of 65 MeV has been working at the Institute Antoine Lacassagne in Nice, France. An international cooperative group has been founded to guarantee the thorough exploitation of the facility through complete cooperation. From June 17 to December 20, 1991, 47 patients with uveal melanoma were treated; 4 of them entered the study by means of the Italian team and were treated in cooperation with the Cyclotron staff. Treatment modalities and preliminary observations are described</style></abstract><notes><style face="normal" font="default">1335591rbz, 0177625IM0 (Protons)English AbstractJournal ArticleItalian</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4447</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wilkes,S.R.</style></author><author><style face="normal" font="default"> Gragoudas,E.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Regression patterns of uveal melanomas after proton beam irradiation</style></title><secondary-title><style face="normal" font="default">Ophthalmology.89.(7.):840.-4,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ophthalmology.89.(7.):840.-4,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Melanoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Retinal Detachment</style></keyword><keyword><style face="normal" font="default"> Retinal Detachment/co [Complications]</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="0" Month="7" Year="1982">1982/7</year></dates><pub-location><style face="normal" font="default">UNITED STATES</style></pub-location><isbn><style face="normal" font="default">0161-6420</style></isbn><abstract><style face="normal" font="default">Forty-four uveal melanomas were evaluated for patterns of tumor regression after proton beam irradiation. All tumors were followed for a minimum of ten months after treatment. Seven lesions completely disappeared, 33 have decreased in size, and 4 remained unchanged. Associated signs of tumor regression were: resolution of the secondary serous retinal detachments, central apical yellow discoloration of the tumor, destruction of the tumor's vasculature, and elimination of fluorescein leakage. This study demonstrated that regression after proton beam irradiation is a relatively slow process, and the effects of radiation could be observed in some cases more than a year after treatment</style></abstract><notes><style face="normal" font="default">6289219oi5, 7802443IM0 (Protons)Journal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, P.H.SEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4487</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yoshii,Y.</style></author><author><style face="normal" font="default"> Maki,Y.</style></author><author><style face="normal" font="default"> Narushima,A.</style></author><author><style face="normal" font="default"> Takano,S.</style></author><author><style face="normal" font="default"> Hashikawa,M.</style></author><author><style face="normal" font="default"> Nose,T.</style></author><author><style face="normal" font="default"> Nakagawa,K.</style></author><author><style face="normal" font="default"> Kitagawa,T.</style></author><author><style face="normal" font="default"> Inada,T.</style></author><author><style face="normal" font="default"> Oohara,K.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Use of radiotherapy by high-energy protons in the postoperative treatment of brain tumors]. [Japanese]</style></title><secondary-title><style face="normal" font="default">Neurologia Medico-Chirurgica.26.(3):219.-26.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Neurologia Medico-Chirurgica.26.(3):219.-26.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Astrocytoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Astrocytoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Brain</style></keyword><keyword><style face="normal" font="default"> Brain Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Brain Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Brain/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Combined Modality Therapy</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glioblastoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Glioblastoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Postoperative Period</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword></keywords><dates><year Day="0" Month="3" Year="1986">1986/3</year></dates><pub-location><style face="normal" font="default">JAPAN</style></pub-location><isbn><style face="normal" font="default">0470-8105</style></isbn><notes><style face="normal" font="default">2426616nyd, 0400775IM0 (Protons)English AbstractJournal ArticleResearch Support, Non-U.S. Gov'tJapanese</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4488</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yoshii,Y.</style></author><author><style face="normal" font="default"> Takano,S.</style></author><author><style face="normal" font="default"> Tsurushima,H.</style></author><author><style face="normal" font="default"> Hyodo,A.</style></author><author><style face="normal" font="default"> Nose,T.</style></author><author><style face="normal" font="default"> Oohara,K.</style></author><author><style face="normal" font="default"> Kitagawa,T.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Neurological Surgery, University of Tsukuba, Ibaraki, Japan</style></auth-address><titles><title><style face="normal" font="default">Normal brain damage after radiotherapy of brain tumours</style></title><secondary-title><style face="normal" font="default">Clinical Oncology (Royal College of Radiologists).3(5):278.-82.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clinical Oncology (Royal College of Radiologists).3(5):278.-82.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Brain</style></keyword><keyword><style face="normal" font="default"> Brain Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Brain/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Brain/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Brain/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Cobalt Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Cobalt Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Infarction</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="1991">1991/9</year></dates><pub-location><style face="normal" font="default">ENGLAND</style></pub-location><isbn><style face="normal" font="default">0936-6555</style></isbn><abstract><style face="normal" font="default">A total of 106 patients were examined for adverse effects to the brain from 60Co or proton radiotherapy. Radiation induced change (RIC) developed within the irradiated field 40-60 months after doses of 800-1000 neuNSD or 70 TDF and in 10-20 months after doses of more than 1700 neuNSD or 100 TDF. The incidence of RIC increased significantly with increasing age. Furthermore pathological changes like oedema and infarction in the brain tissue may be an important factor for the development of RIC in the central nervous system (CNS)</style></abstract><notes><style face="normal" font="default">1657115ayi, 9002902IM0 (Cobalt Radioisotopes)0 (Protons)Journal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4534</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zografos,L.</style></author><author><style face="normal" font="default"> Gailloud,C.</style></author><author><style face="normal" font="default"> Perret,C.</style></author><author><style face="normal" font="default"> Uffer,S.</style></author><author><style face="normal" font="default"> Raimondi,S.</style></author><author><style face="normal" font="default"> Chamot,L.</style></author><author><style face="normal" font="default"> Carrel,S.</style></author><author><style face="normal" font="default"> Greiner,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinique Ophtalmologique Universitaire de Lausanne</style></auth-address><titles><title><style face="normal" font="default">[Report on the conservative treatment of melanoma of the uvea at the Lausanne University Ophthalmologic Clinic]. [French]</style></title><secondary-title><style face="normal" font="default">Klinische Monatsblatter.fur Augenheilkunde.</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Klinische Monatsblatter.fur Augenheilkunde.</style></abbr-1></periodical><pages end="578" start="572">572-578</pages><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Beta Rays</style></keyword><keyword><style face="normal" font="default"> Brachytherapy/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Gamma Rays</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Laser Therapy</style></keyword><keyword><style face="normal" font="default"> Life Expectancy</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Vision</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword></keywords><dates><year Day="0" Month="5" Year="192">192/5</year></dates><pub-location><style face="normal" font="default">GERMANY, WEST</style></pub-location><isbn><style face="normal" font="default">0023-2165</style></isbn><abstract><style face="normal" font="default">A great number of techniques are currently available for the conservative treatment of uveal melanomas: ocular applicators emitting gamma rays 60Co, 125I) or high-energy beta rays (106Ru/106Rh), light photocoagulation, surgical excision, and accelerated proton beam irradiation. Life expectancy following conservative treatment is equal to or better than that following enucleation. This is demonstrated by nonrandomized comparative studies, and by the authors' own long-term results following the conservative treatment of melanomas by 60Co applicators: mortality due to metastases of small melanomas was 3% (V = smaller than 10 x 10 x 3 mm), with medium-size melanomas it was 12% (V = 10 x 10 x 3-15 x 15 x 5 mm), and with large melanomas 21% (V = larger than 15 x 15 x 5 mm). Accelerated proton beam irradiation of uveal melanomas is currently the method of choice for the conservative treatment of uveal melanomas. The sharp boundaries of the irradiated zone, the uniformly distributed irradiation dose, and beam-splitting are the main advantages of this technique. During the last three years, 310 cases of uveal melanoma have been treated in Switzerland with an accelerated proton beam. Of these, 214 were followed up for more than one year. Eight patients (3.9%) died of metastases. Visual acuity was identical or superior to initial visual acuity in 60.3% of the cases, while 39.6% exhibited a deterioration of vision or a functional loss. Favorable results achieved by conservative treatment of uveal melanomas considerably limited the indications for enucleation, which is now only performed in exceptional situations</style></abstract><notes><style face="normal" font="default">3404968kwa, 0014133IMComparative StudyEnglish AbstractJournal ArticleResearch Support, Non-U.S. Gov'tFrench</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4589</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dendale,R.</style></author><author><style face="normal" font="default"> Lumbroso-Le,Rouic L.</style></author><author><style face="normal" font="default"> Noel,G.</style></author><author><style face="normal" font="default"> Feuvret,L.</style></author><author><style face="normal" font="default"> Levy,C.</style></author><author><style face="normal" font="default"> Delacroix,S.</style></author><author><style face="normal" font="default"> Meyer,A.</style></author><author><style face="normal" font="default"> Nauraye,C.</style></author><author><style face="normal" font="default"> Mazal,A.</style></author><author><style face="normal" font="default"> Mammar,H.</style></author><author><style face="normal" font="default"> Garcia,P.</style></author><author><style face="normal" font="default"> D'Hermies,F.</style></author><author><style face="normal" font="default"> Frau,E.</style></author><author><style face="normal" font="default"> Plancher,C.</style></author><author><style face="normal" font="default"> Asselain,B.</style></author><author><style face="normal" font="default"> Schlienger,P.</style></author><author><style face="normal" font="default"> Mazeron,J.J.</style></author><author><style face="normal" font="default"> Desjardins,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, Curie Institut, Paris, France. remi.dendale@curie.net</style></auth-address><titles><title><style face="normal" font="default">Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO)</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.65.(3):780.-7.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.65.(3):780.-7.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Eye Enucleation/ut [Utilization]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="1" Month="7" Year="2006">2006/7/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: This study reports the results of proton beam radiotherapy based on a retrospective series of patients treated for uveal melanoma at the Orsay Center. METHODS AND MATERIALS: Between September 1991 and September 2001, 1,406 patients with uveal melanoma were treated by proton beam radiotherapy. A total dose of 60 cobalt Gray equivalent (CGE) was delivered in 4 fractions on 4 days. Survival rates were determined using Kaplan-Meier estimates. Prognostic factors were determined by multivariate analysis using the Cox model. RESULTS: The median follow-up was 73 months (range, 24-142 months). The 5-year overall survival and metastasis-free survival rates were 79% and 80.6%, respectively. The 5-year local control rate was 96%. The 5-year enucleation for complications rate was 7.7%. Independent prognostic factors for overall survival were age (p &lt; 0.0001), gender (p &lt; 0.0003), tumor site (p &lt; 0.0001), tumor thickness (p = 0.02), tumor diameter (p &lt; 0.0001), and retinal area receiving at least 30 CGE (p = 0.003). Independent prognostic factors for metastasis-free survival were age (p = 0.0042), retinal detachment (p = 0.01), tumor site (p &lt; 0.0001), tumor volume (p &lt; 0.0001), local recurrence (p &lt; 0.0001), and retinal area receiving at least 30 CGE (p = 0.002). Independent prognostic factors for local control were tumor diameter (p = 0.003) and macular area receiving at least 30 CGE (p = 0.01). Independent prognostic factors for enucleation for complications were tumor thickness (p &lt; 0.0001) and lens volume receiving at least 30 CGE (p = 0.0002). CONCLUSION: This retrospective study confirms that proton beam radiotherapy ensures an excellent local control rate. Further clinical studies are required to decrease the incidence of postirradiation ocular complications</style></abstract><notes><style face="normal" font="default">16647221g97, 7603616IM0 (Protons)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4614</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hasegawa,A.</style></author><author><style face="normal" font="default"> Mizoe,J.E.</style></author><author><style face="normal" font="default"> Mizota,A.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Hospital, Charged Particle Research Center, National Institute of Radiological Sciences, Chiba, Japan. azusa@nirs.go.jp</style></auth-address><titles><title><style face="normal" font="default">Outcomes of visual acuity in carbon ion radiotherapy: analysis of dose-volume histograms and prognostic factors</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.64.(2):396.-401.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.64.(2):396.-401.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Dose-Response Relationship,Radiation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> Head and Neck Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Heavy Ions/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Optic Nerve/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Optic Nerve/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Skull</style></keyword><keyword><style face="normal" font="default"> Skull Base</style></keyword><keyword><style face="normal" font="default"> Vision Disorders/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword><keyword><style face="normal" font="default"> Visual Acuity/ph [Physiology]</style></keyword><keyword><style face="normal" font="default"> Visual Acuity/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="1" Month="2" Year="2006">2006/2/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To analyze the tolerance dose for retention of visual acuity in patients with head-and-neck tumors treated with carbon ion radiotherapy. METHODS AND MATERIALS: From June 1994 to March 2000, 163 patients with tumors in the head and neck or skull base region were treated with carbon ion radiotherapy. Analysis was performed on 54 optic nerves (ONs) corresponding to 30 patients whose ONs had been included in the irradiated volume. These patients showed no evidence of visual impairment due to other factors and had a follow-up period of >4 years. All patients had been informed of the possibility of visual impairment before treatment. We evaluated the dose-complication probability and the prognostic factors for the retention of visual acuity in carbon ion radiotherapy, using dose-volume histograms and multivariate analysis. RESULTS: The median age of 30 patients (14 men, 16 women) was 57.2 years. Median prescribed total dose was 56.0 gray equivalents (GyE) at 3.0-4.0 GyE per fraction per day (range, 48-64 GyE; 16-18 fractions; 4-6 weeks). Of 54 ONs that were analyzed, 35 had been irradiated with &lt;57 GyE (maximum dose [Dmax]) resulting in no visual loss. Conversely, 11 of the 19 ONs (58%) irradiated with >57 GyE (Dmax) suffered a decrease of visual acuity. In all of these cases, the ONs had been involved in the tumor before carbon ion radiotherapy. In the multivariate analysis, a dose of 20% of the volume of the ON (D20) was significantly associated with visual loss. CONCLUSIONS: The occurrence of visual loss seems to be correlated with a delivery of >60 GyE to 20% of the volume of the ON</style></abstract><notes><style face="normal" font="default">16182466g97, 7603616IM0 (Carbon Radioisotopes)Clinical Trial, Phase IClinical Trial, Phase IIJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4615</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hashimoto,T.</style></author><author><style face="normal" font="default"> Tokuuye,K.</style></author><author><style face="normal" font="default"> Fukumitsu,N.</style></author><author><style face="normal" font="default"> Igaki,H.</style></author><author><style face="normal" font="default"> Hata,M.</style></author><author><style face="normal" font="default"> Kagei,K.</style></author><author><style face="normal" font="default"> Sugahara,S.</style></author><author><style face="normal" font="default"> Ohara,K.</style></author><author><style face="normal" font="default"> Matsuzaki,Y.</style></author><author><style face="normal" font="default"> Akine,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Proton Medical Research Center, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan. hashimoto@pmrc.tsukuba.ac.jp</style></auth-address><titles><title><style face="normal" font="default">Repeated proton beam therapy for hepatocellular carcinoma</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.65.(1):196.-202.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.65.(1):196.-202.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Hepatocellular/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation Tolerance</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Rest</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="1" Month="5" Year="2006">2006/5/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To retrospectively evaluate the safety and effectiveness of repeated proton beam therapy for newly developed or recurrent hepatocellular carcinoma (HCC). METHODS AND MATERIALS: From June 1989 through July 2000, 225 patients with HCC underwent their first course of proton beam therapy at the University of Tsukuba. Of them, 27 with 68 lesions who had undergone two or more courses were retrospectively reviewed in this study. Median interval between the first and second course was 24.5 months (range 3.3-79.8 months). Median total dose of 72 Gy in 16 fractions and 66 Gy in 16 fractions were given for the first course and the rest of the courses, respectively. RESULTS: The 5-year survival rate and median survival period from the beginning of the first course for the 27 patients were 55.6% and 62.2 months, respectively. Five-year local control rate for the 68 lesions was 87.8%. Of the patients, 1 with Child-Pugh class B and another with class C before the last course suffered from acute hepatic failure. CONCLUSIONS: Repeated proton beam therapy for HCC is safe when the patient has a target in the peripheral region of the liver and liver function is Child-Pugh class A</style></abstract><notes><style face="normal" font="default">16563656g97, 7603616IM0 (Protons)Evaluation StudiesJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4616</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hata,M.</style></author><author><style face="normal" font="default"> Miyanaga,N.</style></author><author><style face="normal" font="default"> Tokuuye,K.</style></author><author><style face="normal" font="default"> Saida,Y.</style></author><author><style face="normal" font="default"> Ohara,K.</style></author><author><style face="normal" font="default"> Sugahara,S.</style></author><author><style face="normal" font="default"> Kagei,K.</style></author><author><style face="normal" font="default"> Igaki,H.</style></author><author><style face="normal" font="default"> Hashimoto,T.</style></author><author><style face="normal" font="default"> Hattori,K.</style></author><author><style face="normal" font="default"> Shimazui,T.</style></author><author><style face="normal" font="default"> Akaza,H.</style></author><author><style face="normal" font="default"> Akine,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Proton Medical Research Center, University of Tsukuba, Tsukuba, Ibaraki, Japan. mhata@syd.odn.ne.jp</style></auth-address><titles><title><style face="normal" font="default">Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.64.(5):1371.-9,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.64.(5):1371.-9,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Antineoplastic Combined Chemotherapy Protocols/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Antineoplastic Combined Chemotherapy Protocols/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Antineoplastic Combined Chemotherapy Protocols/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Transitional Cell/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Transitional Cell/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Transitional Cell/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Cisplatin</style></keyword><keyword><style face="normal" font="default"> Cisplatin/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Cisplatin/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Combined Modality Therapy/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Cystectomy</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Doxorubicin/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Doxorubicin/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Methotrexate/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Methotrexate/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Salvage Therapy</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urinary Bladder</style></keyword><keyword><style face="normal" font="default"> Urinary Bladder Neoplasms/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default"> Urinary Bladder Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Urinary Bladder Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Urinary Bladder/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Vinblastine/ad [Administration &amp; Dosage]</style></keyword><keyword><style face="normal" font="default"> Vinblastine/ae [Adverse Effects]</style></keyword></keywords><dates><year Day="1" Month="4" Year="2006">2006/4/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To present outcomes of bladder-preserving therapy with proton beam irradiation in patients with invasive bladder cancer. METHODS AND MATERIALS: Twenty-five patients with transitional cell carcinoma of the urinary bladder, cT2-3N0M0, underwent transurethral resection of bladder tumor(s), followed by pelvic X-ray irradiation combined with intra-arterial chemotherapy with methotrexate and cisplatin. Upon completion of these treatments, patients were evaluated by transurethral resection biopsy. Patients with no residual tumor received proton irradiation boost to the primary sites, whereas patients demonstrating residual tumors underwent radical cystectomy. RESULTS: Of 25 patients, 23 (92%) were free of residual tumor at the time of re-evaluation; consequently, proton beam therapy was applied. The remaining 2 patients presenting with residual tumors underwent radical cystectomy. Of the 23 patients treated with proton beam therapy, 9 experienced recurrence at the median follow-up time of 4.8 years: local recurrences and distant metastases in 6 and 2 patients, respectively, and both situations in 1. The 5-year overall, disease-free, and cause-specific survival rates were 60%, 50%, and 80%, respectively. The 5-year local control and bladder-preservation rates were 73% and 96%, respectively, in the patients treated with proton beam therapy. Therapy-related toxicities of Grade 3-4 were observed in 9 patients: hematologic toxicities in 6, pulmonary thrombosis in 1, and hemorrhagic cystitis in 2. CONCLUSIONS: The present bladder-preserving regimen for invasive bladder cancer was feasible and effective. Proton beam therapy might improve local control and facilitate bladder preservation</style></abstract><notes><style face="normal" font="default">16580495g97, 7603616IM0 (M-VAC protocol)0 (Protons)15663-27-1 (Cisplatin)23214-92-8 (Doxorubicin)59-05-2 (Methotrexate)865-21-4 (Vinblastine)Journal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4629</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ishikawa,H.</style></author><author><style face="normal" font="default"> Tsuji,H.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Center for Charged Particle Therapy, National Institute of Radiological Sciences (NIRS)</style></auth-address><titles><title><style face="normal" font="default">[Clinical experience of carbon ion radiotherapy for malignant tumors]. [Review] [13 refs] [Japanese]</style></title><secondary-title><style face="normal" font="default">Gan to Kagaku Ryoho [Japanese Journal of Cancer &amp; Chemotherapy].33(4):444.-9,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Gan to Kagaku Ryoho [Japanese Journal of Cancer &amp; Chemotherapy].33(4):444.-9,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Bone Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Clinical Trials,Phase I as Topic</style></keyword><keyword><style face="normal" font="default"> Clinical Trials,Phase II as Topic</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Energy Transfer</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Head and Neck Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Heavy Ions/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Linear Energy Transfer</style></keyword><keyword><style face="normal" font="default"> Liver Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Relative Biological Effectiveness</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Sarcoma</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword></keywords><dates><year Day="0" Month="4" Year="2006">2006/4</year></dates><pub-location><style face="normal" font="default">Japan</style></pub-location><isbn><style face="normal" font="default">0385-0684</style></isbn><abstract><style face="normal" font="default">The carbon ion (C-ion) beams provide unique advantageous biological and physical properties in radiotherapy (RT) for malignant tumors. C-ion beams have a high relative biological effectiveness (RBE) resulting from the high linear energy transfer (LET). In terms of their physical characteristics, C-ion beams exhibit a spread-out Bragg peak (SOBP) and make for a better dose distribution of the target volume by specified beam modulations. Between June 1994 and August 2005, a total of 2,371 patients with malignant tumors were registered in phase I/II dose-escalation studies and clinical phase II trials using C-ion beams generated at Heavy Ion Medical Accelerator in Chiba (HIMAC). In the initial dose-escalation studies, grade 3 or more late rectal complications had developed in some patients. However, the adverse effects were resolved because of the use of appropriate dose levels and modification of the radiation technique. C-ion beams can carry out hypofractionated radiotherapy with a large fraction dose and reduce the overall treatment times compared with conventional radiotherapy. They can also achieve better local tumor control even for radio-resistant tumors such as malignant melanoma, hepatocellular carcinoma and bone and soft tissue sarcomas with minimal morbidity to the normal surrounding tissues. [References: 13]</style></abstract><notes><style face="normal" font="default">166121517810034, 6t8IM7440-44-0 (Carbon)English AbstractJournal ArticleReviewJapanese</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4639</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kato,S.</style></author><author><style face="normal" font="default"> Ohno,T.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author><author><style face="normal" font="default"> Nakano,T.</style></author><author><style face="normal" font="default"> Mizoe,J.E.</style></author><author><style face="normal" font="default"> Kamada,T.</style></author><author><style face="normal" font="default"> Miyamoto,T.</style></author><author><style face="normal" font="default"> Tsuji,H.</style></author><author><style face="normal" font="default"> Kato,H.</style></author><author><style face="normal" font="default"> Yamada,S.</style></author><author><style face="normal" font="default"> Kandatsu,S.</style></author><author><style face="normal" font="default"> Yoshikawa,K.</style></author><author><style face="normal" font="default"> Ezawa,H.</style></author><author><style face="normal" font="default"> Suzuki,M.</style></author><author><style face="normal" font="default"> Working Group of the Gynecological Tumor</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan. s.kato@nirs.go.jp</style></auth-address><titles><title><style face="normal" font="default">Dose escalation study of carbon ion radiotherapy for locally advanced carcinoma of the uterine cervix</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.65.(2):388.-97.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.65.(2):388.-97.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adenocarcinoma/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Adenocarcinoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Carbon Radioisotopes/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Adenosquamous/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Adenosquamous/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Squamous Cell/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Squamous Cell/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Gastrointestinal Tract/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Intestines</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/co [Complications]</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Uterine Cervical Neoplasms/ra [Radiography]</style></keyword><keyword><style face="normal" font="default"> Uterine Cervical Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="1" Month="6" Year="2006">2006/6/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To evaluate the toxicity and efficacy of carbon ion radiotherapy (CIRT) for locally advanced cervical cancer by two phase I/II clinical trials. METHODS AND MATERIALS: Between June 1995 and January 2000, 44 patients were treated with CIRT. Thirty patients had Stage IIIB disease, and 14 patients had Stage IVA disease. Median tumor size was 6.5 cm (range, 4.2-11.0 cm). The treatment consisted of 16 fractions of whole pelvic irradiation and 8 fractions of local boost. In the first study, the total dose ranged from 52.8 to 72.0 gray equivalents (GyE) (2.2-3.0 GyE per fraction). In the second study, the whole pelvic dose was fixed at 44.8 GyE, and an additional 24.0 or 28.0 GyE was given to the cervical tumor (total dose, 68.8 or 72.8 GyE). RESULTS: No patient developed severe acute toxicity. In contrast, 8 patients developed major late gastrointestinal complications. The doses resulting in major complications were > or =60 GyE. All patients with major complications were surgically salvaged. The 5-year local control rate for patients in the first and second studies was 45% and 79%, respectively. When treated with > or =62.4 GyE, the local control was favorable even for the patients with stage IVA disease (69%) or for those with tumors > or =6.0 cm (64%). CONCLUSIONS: In CIRT for advanced cervical cancer, the dose to the intestines should be limited to &lt;60 GyE to avoid major complications. Although the number of patients in this study was small, the results support continued investigation to confirm therapeutic efficacy</style></abstract><notes><style face="normal" font="default">16626894g97, 7603616IM0 (Carbon Radioisotopes)Clinical Trial, Phase IClinical Trial, Phase IIJournal ArticleResearch Support, Non-U.S. Gov'tEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4641</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kishimoto,R.</style></author><author><style face="normal" font="default"> Mizoe,J.E.</style></author><author><style face="normal" font="default"> Komatsu,S.</style></author><author><style face="normal" font="default"> Kandatsu,S.</style></author><author><style face="normal" font="default"> Obata,T.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center Hospital, National Institute of Radiological Sciences, Chiba, Japan. riwa@nirs.go.jp</style></auth-address><titles><title><style face="normal" font="default">MR imaging of brain injury induced by carbon ion radiotherapy for head and neck tumors</style></title><secondary-title><style face="normal" font="default">Magnetic.Resonance.in Medical Sciences.4(4):159.-64.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Magnetic.Resonance.in Medical Sciences.4(4):159.-64.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Brain</style></keyword><keyword><style face="normal" font="default"> Brain Injuries/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Brain Injuries/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Brain/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Brain/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Edema/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Edema/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> Head and Neck Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Heavy Ions/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Particle Accelerators</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Dosage</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/di [Diagnosis]</style></keyword><keyword><style face="normal" font="default"> Radiation Injuries/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword></keywords><dates><year Day="31" Month="12" Year="2005">2005/12/31</year></dates><pub-location><style face="normal" font="default">Japan</style></pub-location><isbn><style face="normal" font="default">1347-3182</style></isbn><abstract><style face="normal" font="default">To clarify the characteristics of magnetic resonance (MR) imaging of radiation-induced brain injury following carbon ion radiotherapy and to observe the changes in lesions over time, we evaluated 40 patients with radiation-induced brain injury from carbon ion radiotherapy for head and neck tumors. Their primary lesions received a radiation dose of 48 to 70.4 Gray equivalent (GyE) in 16 to 18 fractions. MR imaging of radiation-induced brain injury was graded as follows: Grade 1: change in focal white matter; focal contrast enhancement and surrounding edema; Grade 2: nonenhanced area or cystic lesion in enhanced lesion; Grade 3: focal necrosis with mass effect; and Grade 4: mass effect requiring surgical intervention. Radiation-induced brain injury appeared as early as 2 months and as late as 57 months after carbon ion therapy (mean interval, 22.2 months). MR findings of initial lesion were Grade 1 in 26 cases (65.0%), Grade 2 in 13 (32.5%), and Grade 3 in 1 (2.5%). Brain injury was always found in the radiation field initially, but cystic lesion and edema later extended outside the field in 10 cases (25.0%). In follow-up MR studies, size of edema or enhanced lesion was reduced in 17 patients (42.5%) without treatment. Two cases with large cystic lesions required surgery. Improvement of radiation-induced brain injury was observed more often than had been previously described. Because edema and cystic lesion can occasionally extend outside the radiation field, such findings do not exclude the possibility of radiation-induced brain injury. Careful observation is recommended because cystic lesions can enlarge enough to require surgical treatment in some cases</style></abstract><notes><style face="normal" font="default">16543700101153368IM7440-44-0 (Carbon)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4664</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Marucci,L.</style></author><author><style face="normal" font="default"> Lane,A.M.</style></author><author><style face="normal" font="default"> Li,W.</style></author><author><style face="normal" font="default"> Egan,K.M.</style></author><author><style face="normal" font="default"> Gragoudas,E.S.</style></author><author><style face="normal" font="default"> Adams,J.A.</style></author><author><style face="normal" font="default"> Collier,J.M.</style></author><author><style face="normal" font="default"> Munzenrider,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA</style></auth-address><titles><title><style face="normal" font="default">Conservation treatment of the eye: Conformal proton reirradiation for recurrent uveal melanoma</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.64.(4):1018.-22.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.64.(4):1018.-22.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eye Enucleation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Melanoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Conformal</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Vision</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword></keywords><dates><year Day="15" Month="3" Year="2006">2006/3/15</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To evaluate the outcomes of a second course of proton beam radiation therapy (PBRT) in patients with recurrent uveal melanoma. METHODS AND MATERIALS: Thirty-one patients received a second course of PBRT. The mean interval between the first and the second PBRT course was 50.2 months (range, 8-165 months). Most patients (87%) received 70 cobalt Gray equivalent (CGE) for both courses. Visual acuity was 20/200 or better in 30 patients initially and in 22 patients at the second treatment. The mean follow-up time after the second treatment was 50 months (range, 6-164 months). RESULTS: At the time of the last follow-up, 20 patients were classified as having no evidence of disease, defined as tumor regression or an absence of tumor progression. Nine eyes (29%) were enucleated because of local recurrence (n = 5) or intractable pain (n = 4). The 5-year eye retention rate was 55% (95% confidence interval: 25.2-77.4). Six of the 22 patients who retained the eye (27%) had useful vision (20/200 or better). CONCLUSIONS: A second course of PBRT for recurrent uveal melanoma to total doses between 118 and 140 CGE was associated with a relatively good probability of local control and a low enucleation rate. Although most patients lost vision, the majority were able to retain the reirradiated eye. Further evaluation is needed to assess metastasis-free survival of additional proton irradiation vs. enucleation after local recurrence</style></abstract><notes><style face="normal" font="default">16376492g97, 7603616IM0 (Protons)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4675</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nakano,T.</style></author><author><style face="normal" font="default"> Suzuki,Y.</style></author><author><style face="normal" font="default"> Ohno,T.</style></author><author><style face="normal" font="default"> Kato,S.</style></author><author><style face="normal" font="default"> Suzuki,M.</style></author><author><style face="normal" font="default"> Morita,S.</style></author><author><style face="normal" font="default"> Sato,S.</style></author><author><style face="normal" font="default"> Oka,K.</style></author><author><style face="normal" font="default"> Tsujii,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Center Hospital of Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan. tnakano@med.gunma-u.ac.jp</style></auth-address><titles><title><style face="normal" font="default">Carbon beam therapy overcomes the radiation resistance of uterine cervical cancer originating from hypoxia</style></title><secondary-title><style face="normal" font="default">Clinical Cancer Research.12(7.Pt.1):2185.-90.,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clinical Cancer Research.12(7.Pt.1):2185.-90.,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Carbon</style></keyword><keyword><style face="normal" font="default"> Cell Hypoxia</style></keyword><keyword><style face="normal" font="default"> Cell Hypoxia/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Dose-Response Relationship,Radiation</style></keyword><keyword><style face="normal" font="default"> Electrodes</style></keyword><keyword><style face="normal" font="default"> Energy Transfer</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heavy Ions/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Linear Energy Transfer</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Oxygen</style></keyword><keyword><style face="normal" font="default"> Oxygen/an [Analysis]</style></keyword><keyword><style face="normal" font="default"> Oxygen/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Partial Pressure</style></keyword><keyword><style face="normal" font="default"> Particle Accelerators</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Polarography/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Pressure</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Tolerance/re [Radiation Effects]</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Uterine Cervical Neoplasms/me [Metabolism]</style></keyword><keyword><style face="normal" font="default"> Uterine Cervical Neoplasms/rt [Radiotherapy]</style></keyword></keywords><dates><year Day="1" Month="4" Year="2006">2006/4/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">1078-0432</style></isbn><abstract><style face="normal" font="default">PURPOSE: High linear energy transfer (LET) particles are believed to decrease tumor radiation resistance originating from hypoxia. However, no proof of this effect has been provided by clinical trials and related clinical research. Hence, we investigated the radiation biological aspects of high LET carbon beam therapy on cervical cancer. EXPERIMENTAL DESIGN: This study involved 49 patients with stage IIIb bulky and stage IVa cervical cancer treated with high LET carbon beams between October 1995 and June 2000. Oxygen partial pressure (pO(2)) was measured by using a needle-type polarographic oxygen electrode. RESULTS: The 4-year disease-free survival rates of patients with pO(2) &lt;/= 20 mm Hg (hypoxic tumor) and pO(2) > 20 mm Hg (oxygenated tumor) before treatment were 37% and 21%, respectively. The local control rates of hypoxic and oxygenated tumors before treatment were 58% and 54%, respectively. The disease-free survival rates of hypoxic and oxygenated tumors assessed by oxygen status at the 5th day of irradiation were 33% and 32%, respectively. The local control rates of hypoxic and oxygenated tumors at the 5th day were 60% and 58%, respectively. There was no significant prognostic difference between hypoxic and oxygenated tumors. CONCLUSION: The similar disease-free survival and local control rates between hypoxic and oxygenated tumors before and during treatment indicated that the role of the tumor oxygenation status was not so important in local control in carbon beam therapy. These results indicated that high LET carbon beam irradiation might reduce the radiation-resistant nature stemming from tumor hypoxia</style></abstract><notes><style face="normal" font="default">16609033c2h, 9502500IM7440-44-0 (Carbon)7782-44-7 (Oxygen)Clinical Trial, Phase IClinical Trial, Phase IIJournal ArticleRandomized Controlled TrialEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4678</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nihei,K.</style></author><author><style face="normal" font="default"> Ogino,T.</style></author><author><style face="normal" font="default"> Ishikura,S.</style></author><author><style face="normal" font="default"> Kawashima,M.</style></author><author><style face="normal" font="default"> Nishimura,H.</style></author><author><style face="normal" font="default"> Arahira,S.</style></author><author><style face="normal" font="default"> Onozawa,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Radiation Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba 277-8577, Japan. knihei@east.ncc.go.jp</style></auth-address><titles><title><style face="normal" font="default">Phase II feasibility study of high-dose radiotherapy for prostate cancer using proton boost therapy: first clinical trial of proton beam therapy for prostate cancer in Japan</style></title><secondary-title><style face="normal" font="default">Japanese Journal of Clinical Oncology.35.(12):745.-52,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Japanese Journal of Clinical Oncology.35.(12):745.-52,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adenocarcinoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Adenocarcinoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Dose-Response Relationship,Radiation</style></keyword><keyword><style face="normal" font="default"> Feasibility Studies</style></keyword><keyword><style face="normal" font="default"> Gastrointestinal Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Male Urogenital Diseases/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Staging</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Proctitis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Prostate</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Prostatic Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy Dosage</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Conformal/ae [Adverse Effects]</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,Conformal/mt [Methods]</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Seminal Vesicles</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Urination Disorders/et [Etiology]</style></keyword></keywords><dates><year Day="0" Month="12" Year="2005">2005/12</year></dates><pub-location><style face="normal" font="default">Japan</style></pub-location><isbn><style face="normal" font="default">0368-2811</style></isbn><abstract><style face="normal" font="default">OBJECTIVE: To assess the feasibility of high-dose radiotherapy for prostate cancer using proton boost therapy following photon radiotherapy. METHODS: The primary endpoint was acute grade 3 or greater genitourinary (GU) and gastrointestinal (GI) toxicities. The study included patients with clinical stage T1-3N0M0 prostate cancer. Radiotherapy consisted of 50 Gy/25 fx photon irradiation to the prostate and the bilateral seminal vesicles followed by proton boost of 26 Gy(E)/13 fx to the prostate alone. Hormonal therapy was allowed before and during the radiation therapy. RESULTS: Between January 2001 and January 2003, 30 patients were enrolled in this study. Acute grade 1/2 GU and GI toxicities were observed in 20/4 and 17/0 patients, respectively. With the median follow-up period of 30 months (range 20-45), late grade 1/2 GU and GI toxicities occurred in 2/3 and 8/3 patients, respectively. No grade 3 or greater acute or late toxicities were observed. All patients were alive, but six patients relapsed biochemically after 7-24 months. CONCLUSIONS: Proton boost therapy following photon radiotherapy for prostate cancer is feasible. To evaluate the efficacy and safety of proton beam therapy, a multi-institutional phase II trial is in progress in Japan</style></abstract><notes><style face="normal" font="default">16314345kin, 0313225IMClinical Trial, Phase IIJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4679</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nihei,K.</style></author><author><style face="normal" font="default"> Ogino,T.</style></author><author><style face="normal" font="default"> Ishikura,S.</style></author><author><style face="normal" font="default"> Nishimura,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Radiation Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. knihei@east.ncc.go.jp</style></auth-address><titles><title><style face="normal" font="default">High-dose proton beam therapy for Stage I non-small-cell lung cancer</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.65.(1):107.-11,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.65.(1):107.-11,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Carcinoma,Non-Small-Cell Lung/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Informed Consent</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Lung Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiation Oncology</style></keyword><keyword><style face="normal" font="default"> Radiation Pneumonitis/et [Etiology]</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="1" Month="5" Year="2006">2006/5/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To evaluate retrospectively the safety and efficacy of high-dose proton beam therapy (PBT) for Stage I non-small-cell lung cancer (NSCLC). METHODS AND MATERIALS: Between 1999 and 2003, 37 patients were treated in our institution. The indications for PBT were pathologically proven NSCLC, clinical Stage I, tumor size &lt; or =5 cm, medically inoperable or refusal of surgery, and written informed consent. A total dose of 70-94 Gy(E) was delivered in 20 fractions (3.5-4.9 Gy(E) per fraction). RESULTS: Patient characteristics (number of patients) were as follows: Stage IA/IB, 17 of 20; medically inoperable/refusal of surgery, 23/14; total dose 70/80/88/94 Gy(E), 3/17/16/1. With a median follow-up period of 24 months, the 2-year local progression-free and overall survival rates were 80% and 84%, respectively. The 2-year locoregional relapse-free survival rates in Stage IA and Stage IB were 79% and 60%, respectively. No serious acute toxicity was observed. Late Grades 2 and 3 pulmonary toxicities were observed in 3 patients each. Of these 6 patients, 5 had Stage IB disease. CONCLUSIONS: Proton beam therapy is a promising treatment modality for Stage I NSCLC, though locoregional relapse and late pulmonary toxicities in Stage IB patients were substantial. Further investigation of PBT for Stage I NSCLC is warranted</style></abstract><notes><style face="normal" font="default">16458447g97, 7603616IM0 (Protons)Clinical Trial, Phase IJournal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4685</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Park,L.</style></author><author><style face="normal" font="default"> Delaney,T.F.</style></author><author><style face="normal" font="default"> Liebsch,N.J.</style></author><author><style face="normal" font="default"> Hornicek,F.J.</style></author><author><style face="normal" font="default"> Goldberg,S.</style></author><author><style face="normal" font="default"> Mankin,H.</style></author><author><style face="normal" font="default"> Rosenberg,A.E.</style></author><author><style face="normal" font="default"> Rosenthal,D.I.</style></author><author><style face="normal" font="default"> Suit,H.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiation, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. lilypark@hotmail.com</style></auth-address><titles><title><style face="normal" font="default">Sacral chordomas: Impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor</style></title><secondary-title><style face="normal" font="default">International Journal of Radiation Oncology, Biology, Physics.65.(5):1514.-21,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">International Journal of Radiation Oncology, Biology, Physics.65.(5):1514.-21,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Bone Neoplasms/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Bone Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Bone Neoplasms/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Chordoma</style></keyword><keyword><style face="normal" font="default"> Chordoma/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Chordoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Chordoma/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Combined Modality Therapy</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/mo [Mortality]</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/su [Surgery]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Protons/tu [Therapeutic Use]</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Sacrum</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword></keywords><dates><year Day="1" Month="8" Year="2006">2006/8/1</year></dates><pub-location><style face="normal" font="default">United States</style></pub-location><isbn><style face="normal" font="default">0360-3016</style></isbn><abstract><style face="normal" font="default">PURPOSE: To assess the efficacy of definitive treatment of sacral chordoma by high-dose proton/photon-beam radiation therapy alone or combined with surgery. METHODS AND MATERIALS: The records of 16 primary and 11 recurrent sacral chordoma patients treated from November 1982 to November 2002 by proton/photon radiation therapy alone (6 patients) or combined with surgery (21 patients) have been analyzed for local control, survival, and treatment-related morbidity. The outcome analysis is based on follow-up information as of 2005. RESULTS: Outcome results show a large difference in local failure rate between patients treated for primary and recurrent chordomas. Local control results by surgery and radiation were 12/14 vs. 1/7 for primary and recurrent lesions. For margin-positive patients, local control results were 10 of 11 and 0 of 5 in the primary and recurrent groups, respectively; the mean follow-up on these locally controlled patients was 8.8 years (4 at 10.3, 12.8, 17, and 21 years). Radiation alone was used in 6 patients, 4 of whom received > or =73.0 Gy (E); local control was observed in 3 of these 4 patients for 2.9, 4.9, and 7.6 years. CONCLUSION: These data indicate a high local control rate for surgical and radiation treatment of primary (12 of 14) as distinct from recurrent (1 of 7) sacral chordomas. Three of 4 chordomas treated by > or =73.0 Gy (E) of radiation alone had local control; 1 is at 91 months. This indicates that high-dose proton/photon therapy offers an effective treatment option</style></abstract><notes><style face="normal" font="default">16757128g97, 7603616IM0 (Protons)Journal ArticleResearch Support, N.I.H., ExtramuralEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4744</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wuestemeyer,H.</style></author><author><style face="normal" font="default"> Sauerwein,W.</style></author><author><style face="normal" font="default"> Meller,D.</style></author><author><style face="normal" font="default"> Chauvel,P.</style></author><author><style face="normal" font="default"> Schueler,A.</style></author><author><style face="normal" font="default"> Steuhl,K.P.</style></author><author><style face="normal" font="default"> Bornfeld,N.</style></author><author><style face="normal" font="default"> Anastassiou,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophthalmology, University of Essen, Hufelandstr. 52, 45122, Essen, Germany</style></auth-address><titles><title><style face="normal" font="default">Proton radiotherapy as an alternative to exenteration in the management of extended conjunctival melanoma</style></title><secondary-title><style face="normal" font="default">Graefes Archive.for Clinical &amp; Experimental Ophthalmology.244.(4):438.-46,</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Graefes Archive.for Clinical &amp; Experimental Ophthalmology.244.(4):438.-46,</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Brachytherapy</style></keyword><keyword><style face="normal" font="default"> Cataract</style></keyword><keyword><style face="normal" font="default"> Conjunctival Neoplasms/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Conjunctival Neoplasms/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Dose Fractionation</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eye Enucleation</style></keyword><keyword><style face="normal" font="default"> Eyelids</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Melanoma/pa [Pathology]</style></keyword><keyword><style face="normal" font="default"> Melanoma/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Invasiveness</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local/rt [Radiotherapy]</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Radiotherapy,High-Energy</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword></keywords><dates><year Day="0" Month="4" Year="2006">2006/4</year></dates><pub-location><style face="normal" font="default">Germany</style></pub-location><isbn><style face="normal" font="default">0721-832X</style></isbn><abstract><style face="normal" font="default">BACKGROUND: Diffuse and multifocal patterns of conjunctival melanoma may not be treatable with standard eye-sparing methods. The purpose of this study was to evaluate the usefulness of proton beam radiation therapy as an alternative to exenteration. METHODS: Twenty patients with extended conjunctival melanoma were treated by proton beam irradiation. Most cases were T3 tumours which were not accessible to brachytherapy due to their extension, localisation with fornical or caruncular involvement. Only 2 patients had a tumour limited to the bulbar conjunctiva. Both were recurrent tumours with multiple lesions. Sixteen cases were recurrences after various pre-treatments. The area of the conjunctiva which was suspected to have microscopic disease was treated by 31 Gy in 6 fractions. The "high risk" areas with a clinically detectable tumour (primary target volume) were treated by an additional boost using a smaller beam size and applying 2 fractions up to 45 Gy. An individually shaped compensator was brought into the beam to modify the range of the protons so that the eye was irradiated only at a depth of 2 mm. RESULTS: The mean follow-up time was 38.1+/-26.6 months (median 34 months). Recurrent disease occurred in 6 cases (30%); 2 of them outside the irradiated volume, 3 within the target volume treated by 31 Gy, and just one in the primary target volume treated by 45 Gy. An exenteration followed only in two patients (10%). 6 patients (30%) suffered from metastatic disease and 4 (20%) of them have died by now. During follow up we found no statistically significant association between the occurrence of local recurrence after proton radiotherapy and the development of metastases. Best corrected visual acuity remained stable in 12 cases (60%); in 14 patients the best corrected visual acuity was 0.25 or better. A sicca-syndrome developed in 19/20 patients. However, only 10/20 patients used artificial tears more than 5x/d. A focal cataract developed in 7 patients (35%). There was eyelash loss in the area of irradiated eyelids. In 4 cases a limbal stem cell deficiency occurred with the consequence of corneal vascularisation. CONCLUSIONS: Proton radiotherapy may serve as an alternative to exenteration in case of T3 and diffuse T1 or T2 conjunctival melanomas</style></abstract><notes><style face="normal" font="default">16133022fpr, 8205248IM0 (Protons)Journal ArticleEnglish</style></notes><urls/></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4748</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Egger,E.</style></author><author><style face="normal" font="default"> Schalenbourg,A.</style></author><author><style face="normal" font="default"> Zografos,L.</style></author><author><style face="normal" font="default"> Bercher,L.</style></author><author><style face="normal" font="default"> Boehringer,T.</style></author><author><style face="normal" font="default"> Chamot,L.</style></author><author><style face="normal" font="default"> Goitein,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Radiation Medicine, Paul Scherrer Institute, Villigen, Switzerland. emmanuel.egger@psi.ch</style></auth-address><titles><title><style face="normal" font="default">Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma</style></title><secondary-title><style face="normal" font="default">Int.J Radiat.Oncol.Biol.Phys.</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int.J Radiat.Oncol.Biol.Phys.</style></abbr-1></periodical><pages end="147" start="138">138-147</pages><volume><style face="normal" font="default">51</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> anatomy &amp; histology</style></keyword><keyword><style face="normal" font="default"> Ciliary Body</style></keyword><keyword><style face="normal" font="default"> Eyelids</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Tantalum</style></keyword><keyword><style face="normal" font="default"> therapeutic use</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="1" Month="9" Year="2001">2001/9/1</year></dates><abstract><style face="normal" font="default">PURPOSE: This study reports local tumor control and survival after proton beam radiotherapy (PBRT) of uveal melanoma. It identifies the risk factors for local tumor-control failure and for ocular tumor-related death. It presents the improvements implemented to increase the rate of local tumor control, and compares the survival rate of patients with locally controlled tumors to those of patients who had to receive a second treatment. PATIENTS AND METHODS: We have treated 2,435 uveal melanomas with PBRT between March 1984 and December 1998. Data were analyzed as of September 1999. Patients' age ranged from 9 to 89 years; there were 1,188 men and 1,247 women. The largest tumor diameter ranged from 4 to 26 mm, and tumor thickness from 0.9 to 15.6 mm. Median follow-up time was 40 months. RESULTS: Local tumor control probability at 5 years was improved from 90.6 +/- 1.7% for patients treated before 1988, to 96.3 +/- 0.6% for patients treated between 1989 and 1993, and became 98.9 +/- 0.6% for patients treated after 1993. Among 2,435 treated patients, 73 (3%) had to receive a second treatment because of tumor regrowth. Cause-specific survival at 10 years was calculated to 72.6 +/- 1.9% for patients with controlled tumors compared to 47.5 +/- 6.5% for those with recurrent tumors. CONCLUSION: Reduced safety margins, large ciliary body tumors, eyelids within the treatment field, inadequate positioning of tantalum clips, and male gender were identified to be the main factors impairing local tumor control. The improvement of local tumor control rate after 1993 is attributed to changes implemented in the treatment procedure. Our data strongly support that the rate of death by metastases is influenced by local tumor control failure: improvement of the local tumor control rate results in a better survival rate</style></abstract><notes><style face="normal" font="default">DA - 20010822IS - 0360-3016 (Print)LA - engPT - Journal ArticleRN - 0 (Protons)SB - IM</style></notes><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="11516863">PM:11516863</url></web-urls></urls></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4749</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Egger,E.</style></author><author><style face="normal" font="default"> Zografos,L.</style></author><author><style face="normal" font="default"> Schalenbourg,A.</style></author><author><style face="normal" font="default"> Beati,D.</style></author><author><style face="normal" font="default"> Bohringer,T.</style></author><author><style face="normal" font="default"> Chamot,L.</style></author><author><style face="normal" font="default"> Goitein,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Radiation Medicine, Paul Scherrer Institute, Villigen, Switzerland. EmmanuelEgger@psi.ch</style></auth-address><titles><title><style face="normal" font="default">Eye retention after proton beam radiotherapy for uveal melanoma</style></title><secondary-title><style face="normal" font="default">Int.J Radiat.Oncol.Biol.Phys.</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int.J Radiat.Oncol.Biol.Phys.</style></abbr-1></periodical><pages end="880" start="867">867-880</pages><volume><style face="normal" font="default">55</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> anatomy &amp; histology</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Disease-Free Survival</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eye Enucleation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Intraocular Pressure</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Mortality</style></keyword><keyword><style face="normal" font="default"> Optic Disk</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pressure</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> Quality Control</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Retinal Detachment</style></keyword><keyword><style face="normal" font="default"> Sex Factors</style></keyword><keyword><style face="normal" font="default"> statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> therapeutic use</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Uveal Neoplasms</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="15" Month="3" Year="2003">2003/3/15</year></dates><abstract><style face="normal" font="default">PURPOSE: To analyze the long-term results of eye retention after conservative treatment of uveal melanoma with proton beam radiotherapy, and to analyze the causes leading to enucleation after this conservative treatment approach. MATERIALS AND METHODS: This was a prospective, noncomparative, interventional, consecutive case series. A total of 2645 patients (2648 eyes) with uveal melanoma were treated between 1984 and 1999 with proton beam radiotherapy. Data were analyzed as of February 2001. Patients' age ranged from 9 to 90 years, 1284 were men, and 1361 were women. Largest tumor diameter ranged from 4 to 27.5 mm, and tumor height from 0.9 to 15.6 mm. Median follow-up time was 44 months. RESULTS: The overall eye retention rate at 5, 10, and 15 years after treatment was 88.9%, 86.2%, and 83.7%, respectively. In total, 218 eyes had to be enucleated. Enucleation was related to larger tumor size, mainly tumor height, proximity of posterior tumor margin to optic disc, male gender, high intraocular pressure, and large degree of retinal detachment at treatment time. After optimization of the treatment technique, the eye retention rate at 5 years was increased from 97.1% to 100% for small tumors, from 86.7% to 99.7% for medium, and from 71.1% to 89.5% for large tumors. CONCLUSIONS: The treatment technique as used today results in excellent eye retention rates, even in less favorable cases such as large tumors and tumors located close to the optic disc. The experience and a continuous quality control program allowed us to improve the 5-year eye retention rate for all tumor sizes. These findings demonstrate the positive impact of experience and quality control-based efforts for treatment technique optimization</style></abstract><notes><style face="normal" font="default">DA - 20030227IS - 0360-3016 (Print)LA - engPT - Journal ArticlePT - ReviewRN - 0 (Protons)SB - IM</style></notes><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="12605964">PM:12605964</url></web-urls></urls></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4750</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Damato,B.</style></author><author><style face="normal" font="default"> Kacperek,A.</style></author><author><style face="normal" font="default"> Chopra,M.</style></author><author><style face="normal" font="default"> Campbell,I.R.</style></author><author><style face="normal" font="default"> Errington,R.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Ocular Oncology Service, St. Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom. Bertil@damato.co.uk</style></auth-address><titles><title><style face="normal" font="default">Proton beam radiotherapy of choroidal melanoma: the Liverpool-Clatterbridge experience</style></title><secondary-title><style face="normal" font="default">Int J Radiat.Oncol Biol.Phys</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Radiat.Oncol Biol.Phys</style></abbr-1></periodical><pages end="1411" start="1405">1405-1411</pages><volume><style face="normal" font="default">62</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> Choroid Neoplasms</style></keyword><keyword><style face="normal" font="default"> Cyclotrons</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eye Enucleation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Survival Analysis</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treatment Failure</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vision</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword></keywords><dates><year Day="1" Month="8" Year="2005">2005/8/1</year></dates><abstract><style face="normal" font="default">PURPOSE: To report on outcomes after proton beam radiotherapy of choroidal melanoma using a 62-MeV cyclotron in patients considered unsuitable for other forms of conservative therapy. METHODS AND MATERIALS: A total of 349 patients with choroidal melanoma referred to the Liverpool Ocular Oncology Centre underwent proton beam radiotherapy at Clatterbridge Centre for Oncology (CCO) between January 1993 and December 2003. Four daily fractions of proton beam radiotherapy were delivered, with a total dose of 53.1 proton Gy, and with lateral and distal safety margins of 2.5 mm. Outcomes measured were local tumor recurrence; ocular conservation; vision; and metastatic death according to age, gender, eye, visual acuity, location of anterior and posterior tumor margins, quadrant, longest basal tumor dimension, tumor height, extraocular extension, and retinal invasion. RESULTS: The 5-year actuarial rates were 3.5% for local tumor recurrence, 9.4% for enucleation, 79.1% for conservation of vision of counting fingers or better, 61.1% for conservation of vision of 20/200 or better, 44.8% for conservation of vision of 20/40 or better, and 10.0% for death from metastasis. CONCLUSION: Proton beam radiotherapy with a 62 MeV cyclotron achieves high rates of local tumor control and ocular conservation, with visual outcome depending on tumor size and location</style></abstract><notes><style face="normal" font="default">DA - 20050720IS - 0360-3016 (Print)LA - engPT - Journal ArticleSB - IM</style></notes><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="16029800">PM:16029800</url></web-urls></urls></record><record><database name="forbyronappendixc" path="g:\particle beam radiation therapy 2008\searches\forbyronappendixc">forbyronappendixc</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>4751</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Damato,B.</style></author><author><style face="normal" font="default"> Kacperek,A.</style></author><author><style face="normal" font="default"> Chopra,M.</style></author><author><style face="normal" font="default"> Sheen,M.A.</style></author><author><style face="normal" font="default"> Campbell,I.R.</style></author><author><style face="normal" font="default"> Errington,R.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">St. Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, UK. Bertil@damato.co.uk</style></auth-address><titles><title><style face="normal" font="default">Proton beam radiotherapy of iris melanoma</style></title><secondary-title><style face="normal" font="default">Int J Radiat.Oncol Biol.Phys</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Radiat.Oncol Biol.Phys</style></abbr-1></periodical><pages end="115" start="109">109-115</pages><volume><style face="normal" font="default">63</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Cataract</style></keyword><keyword><style face="normal" font="default"> Ciliary Body</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eye Enucleation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glaucoma</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Iris Neoplasms</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> Methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Neoplasm Recurrence,Local</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Protons</style></keyword><keyword><style face="normal" font="default"> radiation effects</style></keyword><keyword><style face="normal" font="default"> Radiotherapy</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> therapeutic use</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword></keywords><dates><year Day="1" Month="9" Year="2005">2005/9/1</year></dates><abstract><style face="normal" font="default">PURPOSE: To report on outcomes after proton beam radiotherapy of iris melanoma. METHODS AND MATERIALS: Between 1993 and 2004, 88 patients with iris melanoma received proton beam radiotherapy, with 53.1 Gy in 4 fractions. RESULTS: The patients had a mean age of 52 years and a median follow-up of 2.7 years. The tumors had a median diameter of 4.3 mm, involving more than 2 clock hours of iris in 32% of patients and more than 2 hours of angle in 27%. The ciliary body was involved in 20%. Cataract was present in 13 patients before treatment and subsequently developed in another 18. Cataract had a 4-year rate of 63% and by Cox analysis was related to age (p = 0.05), initial visual loss (p &lt; 0.0001), iris involvement (p &lt; 0.0001), and tumor thickness (p &lt; 0.0001). Glaucoma was present before treatment in 13 patients and developed after treatment in another 3. Three eyes were enucleated, all because of recurrence, which had an actuarial 4-year rate of 3.3% (95% CI 0-8.0%). CONCLUSIONS: Proton beam radiotherapy of iris melanoma is well tolerated, the main problems being radiation-cataract, which was treatable, and preexisting glaucoma, which in several patients was difficult to control</style></abstract><notes><style face="normal" font="default">DA - 20050822IS - 0360-3016 (Print)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tRN - 0 (Protons)SB - IM</style></notes><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="16111578">PM:16111578</url></web-urls></urls></record></records></xml>
